<SEC-DOCUMENT>0001683168-22-000663.txt : 20220203
<SEC-HEADER>0001683168-22-000663.hdr.sgml : 20220203
<ACCEPTANCE-DATETIME>20220203173113
ACCESSION NUMBER:		0001683168-22-000663
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		39
FILED AS OF DATE:		20220203
DATE AS OF CHANGE:		20220203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sunshine Biopharma, Inc
		CENTRAL INDEX KEY:			0001402328
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				205566275
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259394
		FILM NUMBER:		22589870

	BUSINESS ADDRESS:	
		STREET 1:		6500 TRANS-CANADA HIGHWAY
		STREET 2:		4TH FLOOR
		CITY:			POINTE-CLAIRE
		STATE:			A8
		ZIP:			H9R 0A5
		BUSINESS PHONE:		514-426-6161

	MAIL ADDRESS:	
		STREET 1:		6500 TRANS-CANADA HIGHWAY
		STREET 2:		4TH FLOOR
		CITY:			POINTE-CLAIRE
		STATE:			A8
		ZIP:			H9R 0A5

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mountain West Business Solutions, Inc
		DATE OF NAME CHANGE:	20071030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	mountain west business solutions,inc
		DATE OF NAME CHANGE:	20070607
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>sunshine_s1a2.htm
<DESCRIPTION>FORM S-1 AMENDMENT 2
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:SBFM="http://sunshinebiopharma.com/20210930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_SBFM_sunshinebiopharma.com_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20210101_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001402328 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DAmendmentDescription_to reflect updates -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityCentralIndexKey">0001402328</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleantrue" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:AmendmentDescription">to reflect updates</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-09-30" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2020-12-31" id="xdx2ixbrl0100" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-09-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-07-012020-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-07-012020-09-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-012020-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-012020-09-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-09-30_us-gaap_ComprehensiveIncomeMember" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-09-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" id="xdx2ixbrl0601" decimals="0" scale="0" unitRef="USD">2000311</ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-09-24_custom_NotePayable5Member" id="xdx2ixbrl0718" decimals="0" scale="0" unitRef="USD">50000</ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="sbfm-20210930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-02-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-04-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_RBCapitalMember_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SBFM:RBCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_NotePayable2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_NotePayable2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-10-01_custom_NotePayable2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-01_custom_NotePayable2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_NotePayable2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_NotePayable2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_NotePayable2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-17_custom_CEBALoanMember_currency_CAD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:CEBALoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-15_custom_CEBALoanMember_currency_CAD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:CEBALoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-27_custom_PPPLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:PPPLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-04-27_custom_PPPLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:PPPLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-04-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-07_custom_NotePayable1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-07-07_custom_NotePayable1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-07-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-05_custom_NotePayable1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-05_custom_NotePayable1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-27_custom_NotePayable2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-07-27_custom_NotePayable2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-07-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-29_custom_NotePayable2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-14_custom_NotePayable3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-08-14_custom_NotePayable3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-08-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-02-22_custom_NotePayable3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-02-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-14_custom_NotePayable4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-14_custom_NotePayable4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-02_custom_NotePayable4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-24_custom_NotePayable5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-24_custom_NotePayable5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-20_custom_NotePayable6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-10-20_custom_NotePayable6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-10-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-02_custom_NotePayable6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-19_custom_NotePayable7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-11-19_custom_NotePayable7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-11-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-19_custom_NotePayable7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-05-19_custom_NotePayable7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-05-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-24_custom_NotePayable8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-11-24_custom_NotePayable8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-11-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-01_custom_NotePayable8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-25_custom_NotePayable9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-11-25_custom_NotePayable9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-02_custom_NotePayable10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-02_custom_NotePayable10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-12_custom_NotePayable11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-12_custom_NotePayable11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-27_custom_NotePayable12Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-27_custom_NotePayable12Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-12_custom_NotePayable12Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-02-12_custom_NotePayable12Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-05_custom_NotePayable13Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-04-05_custom_NotePayable13Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-04-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-20_custom_NotePayable14Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-04-20_custom_NotePayable14Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-06_custom_NotePayable15Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-07-06_custom_NotePayable15Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-18_custom_NotePayable16Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-08-18_custom_NotePayable16Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-08-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-24_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-08-24_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-08-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_OutstandingNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">SBFM:OutstandingNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember_custom_TrtPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:OfficersAndDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:TrtPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="#toc"><span style="font-size: 8pt">Table of Contents</span></a></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed with the Securities and Exchange Commission
on February 3, 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No.&#160;333-259394</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160; </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>FORM <span id="xdx_900_edei--DocumentType_c20210101__20210930_zCxG0E95RPec"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:DocumentType">S-1/A</ix:nonNumeric></span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Amendment No. 2)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_90D_edei--EntityRegistrantName_c20210101__20210930_zvGFw4YCRufl"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityRegistrantName">Sunshine Biopharma,
Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 34%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20210101__20210930_zRpUyReAnv23"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Colorado</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; width: 1%; font-size: 10pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>8731</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%; font-size: 10pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20210101__20210930_zBHgZLslRyv"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityTaxIdentificationNumber">20-5566275</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</p></td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard Industrial</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Classification Code Number)</p></td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20210101__20210930_zptc2QfXvYo1"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressAddressLine1">6500 Trans-Canada Highway</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine2_c20210101__20210930_zDMzYKyPykL3"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressAddressLine2">4th Floor</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20210101__20210930_zJbfhxClfc3f"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressCityOrTown">Pointe-Claire</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20210101__20210930_zfGom8wgd6xa"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Quebec</ix:nonNumeric></span>, Canada <span id="xdx_901_edei--EntityAddressPostalZipCode_c20210101__20210930_z0tSV0IkMyb4"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressPostalZipCode">H9R 0A5</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">(<span id="xdx_90B_edei--CityAreaCode_c20210101__20210930_zTxIW3HV04Y7"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:CityAreaCode">514</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20210101__20210930_zFXDDefKKvjf"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:LocalPhoneNumber">426-6161</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code and telephone number,
including</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">area code, of registrant&#8217;s principal executive
offices) &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Dr. Steve N. Slilaty</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>6500 Trans-Canada Highway</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>4th Floor</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pointe-Claire, Quebec, Canada H9R 0A5</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">(514) 426-6161</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code and telephone
number, including area code, of agent for service)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Copies to:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 45%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Gregory Sichenzia, Esq.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jeff Cahlon, Esq.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Sichenzia Ross Ference LLP</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1185 Avenue of the Americas, 31st Floor</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, New York 10036</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">212-930-9700</p></td>
    <td style="width: 10%; font-size: 10pt; text-align: center">&#160;</td>
    <td style="width: 45%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Anthony W. Basch, Esq.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chenxi Lu, Esq.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Kaufman &amp; Canoles, P.C.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1021 E. Cary St., Suite 1400</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Richmond, Virginia 23219</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">804-771-5700</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Approximate date of commencement of proposed sale
to the public: As soon as practicable after the effective date of the registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If any of the securities being registered on this
form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act, check the following box. <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If this form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If this form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If this form is a post-effective amendment filed
pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 49%"><span style="font-size: 10pt">Large accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td>
    <td><span style="font-size: 10pt">Accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_90D_edei--EntityFilerCategory_c20210101__20210930_zRav2C2e9Ot6"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></span></td>
    <td><span style="font-size: 10pt">Smaller reporting company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--EntitySmallBusiness_c20210101__20210930_zfIlBpcac6ud"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20210101__20210930_z9VSQwXXRGXh"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided to Section 7(a)(2)(B) of the Securities Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityExTransitionPeriod_c20210101__20210930_zGo3DI48hgp2"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CALCULATION OF REGISTRATION FEE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Proposed Maximum<br />
Aggregate Offering Price(1)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Amount of<br />
Registration Fee</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 59%"><span style="font-size: 10pt">Common Units (3)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 14%; text-align: right"><span style="font-size: 10pt">11,500,000 </span></td>
    <td style="width: 8%"><span style="font-size: 10pt">(2)(4)(5)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 14%; text-align: right"><span style="font-size: 10pt">1,066.05 </span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Common stock, par value $0.001, included in the Common Units</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td><span style="font-size: 10pt">(6)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Warrants included in the Common Units (7)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td><span style="font-size: 10pt">(6)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Pre-funded Units (8)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td><span style="font-size: 10pt">(5)(9)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Pre-funded Warrants included in the Pre-funded Units (10)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td><span style="font-size: 10pt">(11)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Warrants included in the Pre-funded Units (7)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td><span style="font-size: 10pt">(11)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Common stock underlying the Pre-funded warrants included in the Pre-funded Units</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Common stock underlying the warrants included in the Common Units and the Pre-funded Units</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">23,000,000</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">(2)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">2,132.10</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">34,500,000 </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">3,198.15</span></td>
    <td style="padding-bottom: 2.25pt"><span style="font-size: 10pt">(12)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">1) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pursuant to Rule 416, the securities being registered hereunder include such indeterminate number of additional securities as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">2) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Calculated pursuant to Rule 457(o) on the basis of the maximum aggregate offering price of all of the securities to be registered.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">3) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Each Common Unit consists of one share of common stock and two warrants, each whole warrant exercisable for one share of common stock. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">4) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes shares and/or warrants representing 15% of the number of shares and warrants included in the Common Units offered to the public that the underwriters have the option to purchase to cover over-allotments, if any. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">5) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The proposed maximum aggregate offering price of Common Units proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-funded Units offered and sold in the offering, and the proposed maximum aggregate offering price of the Pre-funded Units to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Common Units sold in the offering. Accordingly, the proposed maximum aggregate offering price of the Common Units and Pre-funded Units (including the shares of common stock issuable upon exercise of the Pre-funded warrants included in the Pre-funded Units), if any, is $11,500,000. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">6) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Included in the price of the Common Units. No separate registration fee required pursuant to Rule 457(g) under the Securities Act of 1933, as amended. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">7)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The warrants are exercisable at a price per share equal to 100% of the Common Unit offering price. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">8)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Each Pre-funded Unit consists of one Pre-funded warrant to purchase one share of common stock and two warrants, each whole warrant exercisable for one share of common stock. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">9) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes Pre-funded warrants and/or warrants representing 15% of the number of Pre-funded warrants and warrants included in the Pre-funded Units offered to the public that the underwriters have the option to purchase to cover over-allotments, if any </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">10) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Pre-funded warrants are exercisable at an exercise price of $0.001 per share. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">11) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Included in the price of the Pre-funded Units. No separate registration fee required pursuant to Rule 457(g) under the Securities Act of 1933, as amended. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">12)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">$2,509.30 was previously paid on 9/9/2021 in connection with the
    filing of the Registration Statement on Form S-1 (File No. 333-259394).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The registrant hereby amends this registration statement on such
date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically
states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities
Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to said Section&#160;8(a), may determine.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">The information in this prospectus
is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 33%"><span style="font-size: 10pt; color: red"><b>PRELIMINARY PROSPECTUS</b></span></td>
    <td style="width: 34%; text-align: center"><span style="font-size: 10pt; color: red"><b>SUBJECT TO COMPLETION</b></span></td>
    <td style="width: 33%; text-align: right"><span style="font-size: 10pt; color: red"><b>DATED FEBRUARY 3, <span style="font-family: Times New Roman, Times, Serif">2022</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Up to 1,020,408 Common Units, Each Consisting
of One Share of Common Stock and Two Warrants to Purchase Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Up to 1,020,408 Pre-funded Units, Each
Consisting of a Pre-funded Warrant to Purchase One Share of Common Stock and Two Warrants to Purchase Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="image_001.jpg" alt="" style="height: 80px; width: 185px" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sunshine Biopharma, Inc.
is offering 1,020,408 units (the &#8220;Common Units&#8221;), each Common Unit consisting of one&#160;share of our common stock, $0.001
par value, and two warrants (the &#8220;Warrants&#8221;), each whole Warrant exercisable for one share of common stock, at an assumed
public offering price of $9.80 per Common Unit based on the last quoted price of our common stock on February 2, 2022, in a firm commitment
underwritten offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also offering to
those purchasers, if any, whose purchase of Common Units in this offering would otherwise result in the purchaser, together with its
affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding
shares of common stock immediately following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses,
pre-funded units (the &#8220;Pre-funded Units&#8221;) in lieu of Common Units that would otherwise result in the purchaser&#8217;s beneficial
ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock. Each Pre-funded Unit
will consist of a pre-funded warrant to purchase one common share at an exercise price of $0.001 per share (each a &#8220;Pre-funded
Warrant&#8221;) and two Warrants. The purchase price of each Pre-funded Unit is equal to the price per Common Unit being sold to the
public in this offering, minus $0.001. The Pre-funded Warrants will be immediately exercisable and may be exercised at any time until
all of the Pre-funded Warrants are exercised in full. We are offering the Pre-funded Units at an assumed public offering price of $9.979
per Pre-funded Unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
or Pre-funded Warrants, as the case may be, and the Warrants included in the Common Units or the Pre-funded Units, can only be purchased
together in this offering, but the securities included in the Common Units or Pre-funded Units are immediately separable and will be
issued separately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants included
within the Common Units and Pre-Funded Units will be exercisable immediately, have an exercise price per share of common stock of $9.80,
equal to 100% of the public offering price of one Common Unit, and will expire five years from the date of issuance</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is presently
quoted on the OTC Pink under the symbol &#8220;SBFM&#8221;. On February 2, 2022, the last reported sales price of our common stock on
the OTC Pink was $0.049 per share ($9.80 per share assuming a reverse stock split of 1-for-200). We have applied to have our common stock
listed on the Nasdaq Capital Market under the symbol &#8220;SBFM&#8221;. No assurance can be given that our application will be approved.
If our application is not approved, we will not complete this offering. We have applied to list the Warrants on the Nasdaq Capital Market
under the symbol &#8220;SBFMW.&#8221; No assurance can be given that a trading market will develop for the Warrants. There is no established
public trading market for the Pre-Funded Warrants, and we do not expect a market to develop. In addition, we do not intend to apply for
a listing of the Pre-Funded Warrants on any national securities exchange or other nationally recognized trading system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The final public offering
price per Common Unit will be determined through negotiation between us and the underwriters in this offering and will take into account
the recent market price of our common stock, the general condition of the securities market at the time of this offering, the history
of, and the prospects for, the industry in which we compete, and our past and present operations and our prospects for future revenues.
The recent market price used throughout this prospectus may not be indicative of the public offering price per Common Unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise noted and
other than in our financial statements and the notes thereto, the share and per share information in this prospectus reflects a proposed
reverse stock split of the outstanding common stock at an assumed 1-for-200&#160;ratio to occur following the effective date but prior
to the closing of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investing in our securities involves a
high degree of risk. See &#8220;<a href="#s4">Risk Factors</a>&#8221; beginning on page 5 of this prospectus for a discussion of
information that should be considered in connection with an investment in our securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Per</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Unit</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Per</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pre-Funded</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Unit</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Total</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 59%"><span style="font-size: 10pt">Public offering price</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Underwriting discounts and commissions<sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Proceeds to us., before expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Does not include a non-accountable expense allowance equal to 1% of the public offering price. See &#8220;<a href="#s16">Underwriting</a>&#8221; for a description of compensation payable to the underwriters.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
have granted the underwriters a 45-day option to purchase up to 153,061 additional shares of common stock and/or Pre-Funded Warrants,
representing 15% of the shares and Pre-funded Warrants sold in the offering and/or up to 306,122 additional Warrants, representing 15%
of the Warrants sold in the offering, solely to cover over-allotments, if any. The purchase price to be paid per additional share will
be equal to the public offering price of one Common Unit, less the purchase price per Warrant included within the Common Unit and the
underwriting discount. The purchase price to be paid per Pre-funded Warrant will be equal to the public offering price of one Pre-funded
Unit, less the purchase price per Warrant included within the Pre-Funded Unit and the underwriting discount. The purchase price to be
paid per additional Warrant will be $&#160;&#160;&#160;&#160;&#160;&#160;.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters expect to
deliver our securities to purchasers in the offering on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aegis Capital Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="toc"></span><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s1"><span style="font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s2"><span style="font-size: 10pt">The Offering</span></a></td>
    <td style="text-align: center">2</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s4"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center">5</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s5"><span style="font-size: 10pt">Special Note Regarding Forward-Looking Statements</span></a></td>
    <td style="text-align: center">15</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s6"><span style="font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="text-align: center">15</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s7"><span style="font-size: 10pt">Market for Common Stock and Related Stockholder Matters</span></a></td>
    <td style="text-align: center">15</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt"><a href="#s8">Dilution</a></span></td>
    <td style="text-align: center">16</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s9"><span style="font-size: 10pt">Capitalization</span></a></td>
    <td style="text-align: center">17</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s10"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="text-align: center">18</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt"><a href="#s11">Business</a></span></td>
    <td style="text-align: center">23</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt"><a href="#s12">Management</a></span></td>
    <td style="text-align: center">32</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s13"><span style="font-size: 10pt">Transactions with Related Persons</span></a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s14"><span style="font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management</span></a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s15"><span style="font-size: 10pt">Description of Capital Stock</span></a></td>
    <td style="text-align: center">38</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt"><a href="#s16">Underwriting</a></span></td>
    <td style="text-align: center">42</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s17"><span style="font-size: 10pt">Legal Matters</span></a></td>
    <td style="text-align: center">45</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s18">Interests of Named Experts and Counsel</a></td>
    <td style="text-align: center">45</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt"><a href="#s19">Experts</a></span></td>
    <td style="text-align: center">45</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s20"><span style="font-size: 10pt">Where You Can Find More Information</span></a></td>
    <td style="text-align: center">45</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 92%"><span style="font-size: 10pt"><a href="#fsq3">Financial Statements</a></span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information contained in this prospectus, as supplemented and amended. We have not authorized anyone to provide you with information that
is different. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus may only
be accurate on the date of this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any
other information that others may give you. Neither we nor any of the underwriters is making an offer to sell or seeking offers to buy
these securities in any jurisdiction where, or to any person to whom, the offer or sale is not permitted. The information contained in
this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus
or of any sale of our securities. Our business, financial condition, results of operations and future growth prospects may have changed
since those dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For investors outside the
United States: We have not and the underwriters have not done anything that would permit this offering or possession or distribution of
this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United
States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering
of the securities and the distribution of this prospectus outside the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s1"></span><b>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This summary
highlights certain information about us and this offering contained elsewhere in this prospectus. Because it is only a summary, it
does not contain all of the information that you should consider before investing in our securities and it is qualified in its
entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. Before
you decide to invest in our securities, you should read the entire prospectus carefully, including &#8220;<a href="#s4">Risk Factors</a>&#8221; beginning on page 5, and the financial statements and related notes included in this prospectus.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>As used in this prospectus
and unless otherwise indicated, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Sunshine Biopharma,&#8221; or
the &#8220;Company&#8221; refer to Sunshine Biopharma, Inc. and its wholly owned subsidiaries</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
are a pharmaceutical and nutritional supplement company focusing on the research and development of proprietary drugs including our anti-cancer
compound Adva-27a, and  anti-coronavirus lead compound, SBFM-PL4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also, through our wholly
owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;), develop science-based nutritional supplements,
and currently sell one nutritional supplement product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5, and our telephone number is (514) 426-6161.
Our website address is www.sunshinebiopharma.com. Information on our website is not part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s2"></span>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 30%; text-align: justify"><span style="font-size: 10pt"><b>Common Units offered by us:</b></span></td>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="text-align: justify">1,020,408 Common Units, each consisting of one share of common stock and two Warrants, each Warrant
exercisable for one share of common stock. The shares of common stock and Warrants that are part of the Common Units are immediately
separable and will be issued separately in this offering. The Warrants included within the units are exercisable immediately, have an
exercise price of $9.80 per share, equal to 100% of the public offering price of one Common Unit, and expire five years after the date
of issuance.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><b>Pre-Funded Units offered by us</b></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">We are also offering to those purchasers, if any, whose purchase
    of Common Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties,
    beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock
    immediately following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, Pre-funded Units
    in lieu of Common Units that would otherwise result in the purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the
    election of the purchaser, 9.99%) of our outstanding shares of common stock. Each Pre-funded Unit will consist of a Pre-funded
    Warrant to purchase one share of common stock at an exercise price of $0.001 and two Warrants. The purchase price of each Pre-funded
    Unit is equal to the price per Common Unit being sold to the public in this offering, minus $0.001. The Pre-funded Warrants will be
    immediately exercisable and may be exercised at any time until all of the Pre-funded Warrants are exercised in full. For each
    Pre-funded Unit we sell, the number of Common Units we are offering will be decreased on a one-for-one basis. We are offering a
    maximum of 1,020,408 Pre-funded Units. Because we will issue two Warrants as part of each Common Unit or Pre-funded Unit, the number
    of Warrants sold in this offering will not change as a result of a change in the mix of the Common Units and Pre-funded Units sold.
    This prospectus also relates to the offering of the common shares issuable upon exercise of the Pre-funded Warrants.</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Public offering price&#160;</b></p></td>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The assumed public offering price is $9.80
    per Common Unit and $9.799 per Pre-Funded Unit.</p></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Over-allotment option </b></p></td>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted the underwriters a 45-day option to purchase up to
153,061 additional shares of common stock and/or Pre-Funded Warrants, representing 15% of the shares and Pre-funded Warrants sold in the
offering and/or up to 306,122 additional Warrants, representing 15% of the Warrants sold in the offering. The purchase price to be paid
per additional share will be equal to the public offering price of one Common Unit, less the purchase price per Warrant included within
the Common Unit and the underwriting discount. The purchase price to be paid per Pre-funded Warrant will be equal to the public offering
price of one Pre-funded Unit, less the purchase price per Warrant included within the Pre-Funded Unit and the underwriting discount. The
purchase price to be paid per additional Warrant will be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><b>Common stock outstanding before the&#160;offering<sup>(1)</sup></b></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="background-color: white">2,591,241</span> shares of common stock.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-size: 10pt"><b>Common stock to be outstanding after&#160;the offering<sup>(2)</sup></b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">3,611,649 shares of common stock (assuming the exercise of any Pre-Funded Warrants, but no exercise
of the Warrants). If the underwriter&#8217;s over-allotment option is exercised in full, the total number of shares of common stock outstanding
immediately after this offering would be 3,764,710.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Use of proceeds</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">We intend to use the net proceeds of this offering for drug development activities and general corporate purposes, including working capital, and for debt repayment. See &#8220;<a href="#s6">Use of Proceeds</a>.&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Risk factors</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Investing in our securities is highly speculative and involves a high
    degree of risk. You should carefully consider the information set forth in the &#8220;Risk Factors&#8221; section beginning on page
    5 before deciding to invest in our securities.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Trading symbol</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our common stock is currently quoted on the OTC Pink under the trading
    symbol &#8220;SBFM&#8221;. We have applied to have our common stock listed on the Nasdaq Capital Market under the symbol &#8220;SBFM&#8221;.
    No assurance can be given that our application will be approved. If our application is not approved, we will not complete this offering.
    We have applied to list the Warrants on the Nasdaq Capital Market under the symbol &#8220;SBFMW.&#8221; No assurance can be given
    that a trading market will develop for the Warrants. There is no established public trading market for the Pre-Funded Warrants, and
    we do not expect a market to develop. In addition, we do not intend to apply for a listing of the Pre-Funded Warrants on any national
    securities exchange or other nationally recognized trading system.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 6 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 30%"><span style="font-size: 10pt"><b>Reverse stock split</b></span></td>
    <td style="text-align: justify; width: 5%">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">We will effect a reverse stock split of our common stock at a ratio
    of 1-for-200 following the effectiveness of the registration statement of which this prospectus forms a part and prior to
    the closing of this offering. All information presented in this prospectus other than in our consolidated financial statements and
    the notes thereto assumes a 1-for-200 reverse stock split of our outstanding shares of common stock, and unless otherwise
    indicated, all such amounts and, if applicable, corresponding conversion price or exercise price data set forth in this prospectus
    have been adjusted to give effect to such assumed reverse stock split.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Lock-ups</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">We and our directors and executive officers, will agree with the underwriters not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of 180 days after the date of this prospectus. See &#8220;<a href="#s16">Underwriting</a>.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td colspan="3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on shares of common
                    stock outstanding on February 2, 2022 and excludes:</p>

</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 4%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 88%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6,333,333 shares
                                    of common stock issuable upon conversion of convertible notes in the aggregate outstanding principal
                                    amount of $1,900,000, at a fixed conversion price of $0.30 per share, which the Company will repay
                                    upon closing of this offering;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">2,040,816 shares of common stock issuable upon exercise of Warrants that will be issued to investors
in this offering; and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify">1,000,000 outstanding shares of Series B Preferred Stock (10,000 of which will remain outstanding
    following the closing of the offering, and the other 990,000 of which will be redeemed by the Company upon closing of this
    offering),which are not convertible into common stock</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(2) </span></td>
    <td colspan="3"><span style="font-size: 10pt">Based on assumed public offering price of $9.80 per Common Unit. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all information
in this prospectus assumes no exercise by the underwriters of their option to purchase up to 153,061 additional shares of common stock
and/or Pre-Funded Warrants, and/or 306,122 Warrants to cover over-allotments, if any.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s3"></span>Summary Financial Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following consolidated
balance sheet data as of December 31, 2020 and December 31, 2019 and selected consolidated statement of operations data for the years
ended December 31, 2020 and December 31, 2019 have been derived from our audited financial statements included elsewhere in this prospectus.
The consolidated balance sheet data as of  September 30, 2021 and the selected consolidated statements of operations data for the nine months ended September 30, 2021 and September 30, 2020
have been derived from our unaudited condensed consolidated financial statements included elsewhere in this prospectus.
<span style="color: #212529">The unaudited interim condensed consolidated financial statements have been prepared on the same basis as
the audited annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal, recurring
nature that are necessary for a fair statement of the unaudited interim condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary financial
data should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
and the financial statements and related notes included elsewhere in this prospectus. The historical results presented below are not necessarily
indicative of the results that may be expected in any future period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Consolidated Balance Sheet Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="color: #212529; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: #212529; font-weight: bold; text-align: center">September 30,</td><td style="color: #212529; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: #212529; font-weight: bold; text-align: center">December&#160;31,</td><td style="color: #212529; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: #212529; font-weight: bold; text-align: center">December&#160;31,</td><td style="color: #212529; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: #212529; font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Total current assets</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">2,491,683</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">1,025,943</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">65,686</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: #212529; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 20pt">Total assets</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,501,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,045,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">94,142</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #212529; font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: #212529; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 20pt">Total liabilities</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">$</td><td style="color: #212529; text-align: right">3,675,847</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">$</td><td style="color: #212529; text-align: right">2,000,311</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">$</td><td style="color: #212529; text-align: right">833,527</td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #212529; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Total stockholders&#8217; equity / (deficit)</td><td style="color: #212529; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,173,932</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="color: #212529; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(954,837</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="color: #212529; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(735,385</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: #212529; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total liabilities and stockholders&#8217; equity / (deficit)</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,501,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,045,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">98,142</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Consolidated Statement of Operations Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="color: #212529; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: #212529; font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="color: #212529; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: #212529; font-weight: bold; text-align: center">For the Years Ended</td><td style="color: #212529; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 32%; font-weight: bold; padding-bottom: 1pt">Revenue</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">143,308</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">43,397</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">71,410</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">21,121</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #212529; font-weight: bold; text-align: left">Gross Profit</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">86,767</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">28,013</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">45,563</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">10,071</td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: #212529; font-weight: bold; text-align: left">Total General &amp; Administrative Expenses</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">2,247,270</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">261,569</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">622,437</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">651,707</td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: #212529; font-weight: bold; text-align: left">(Loss) from operations</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">(2,160,503</td><td style="color: #212529; text-align: left">)</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">(233,556</td><td style="color: #212529; text-align: left">)</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">(576,874</td><td style="color: #212529; text-align: left">)</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">(641,636</td><td style="color: #212529; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: #212529; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (loss)</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,103,563</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,700,298</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,784,091</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="color: #212529; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,660,291</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s4"></span><b>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Investing in our securities
includes a high degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific
factors discussed below, together with all of the other information contained in this prospectus. Our business, financial condition, results
of operations and prospects could be materially and adversely affected by these risks.<b>&#160;</b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to continue as a going
concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our independent registered
public accounting firm included an explanatory paragraph in their report included herein on our financial statements related to the uncertainty
in our ability to continue as a going concern. The paragraph stated that our limited operations and working capital deficit, raise substantial
doubt about our ability to continue as a going concern. We have an accumulated deficit of $<span style="font: 10pt Times New Roman, Times, Serif">33,322,290
as of September 30, 2021. We incurred a net loss of $13,103,563 for the nine months ended September 30, 2021 and a net loss of $2,784,091
for the year ended December 31, 2020.</span><span style="font: 10pt Times New Roman, Times, Serif"> <span style="color: #212529">We
may never generate significant revenues or achieve profitability. If we fail to continue as a going concern, investors may lose their
entire investment in the Company.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not receive required regulatory approval
for any of our pharmaceutical product candidates. .</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not received
approval for any of our proprietary drug development operations product candidates from the FDA. Any compounds that we discover or
in-license will require extensive and costly development, preclinical testing and/or clinical trials prior to seeking regulatory
approval for commercial sales.&#160;Our most advanced product candidate, Adva-27a, and our potential Covid-19 treatments in
development, may never be approved for commercial sale. We have not made any filings to date with the FDA or other regulatory bodies
in other jurisdictions. The time required to attain product sales and profitability is lengthy and highly uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we expect to
continue to incur significant and increasing operating losses for the foreseeable future.&#160;Because of the numerous risks and uncertainties
associated with our research and product development efforts, we are unable to predict the extent of any future losses or when we will
become profitable, if ever.&#160;If we fail to obtain required regulatory approvals for our pharmaceutical product candidates, we may
be unable to generate significant revenues and our business will be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As we have no approved pharmaceutical products
on the market, we do not expect to generate significant revenues from pharmaceutical product sales in the foreseeable future, if at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have no approved
pharmaceutical products on the market and have generated limited product revenues, solely from our nutritional supplement operations.
We have funded our operations primarily from sales of our securities. We have not received, and do not expect to receive for at least
the next one to two years, if at all, any revenues from the commercialization of our pharmaceutical product candidates. To obtain revenues
from sales of our pharmaceutical product candidates, we must succeed, either alone or with third parties, in developing, obtaining regulatory
approval for, manufacturing, marketing and distributing drugs with commercial potential. We may never succeed in these activities, and
we may not generate sufficient revenues to continue our business operations or achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will require additional funding to satisfy
our future capital needs, which may not be available. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even after we complete this
offering we may require significant additional funding in large part due to our research and development expenses, future preclinical
and clinical testing costs, and the absence of significant revenues in the near future. We do not know whether additional financing will
be available to us on favorable terms or at all.&#160;If we cannot raise additional funds, we may be required to reduce our capital expenditures,
scale back product development programs, reduce our workforce and license to others products or technologies that we may otherwise be
able to commercialize. Our current burn rate is approximately $500,000 per fiscal quarter, and we anticipate that that our burn rate will
increase as we continue and expand our drug development activities. We are currently unable to project when or whether our operations
will generate positive cash flows from operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional equity securities
we issue or issuances of debt we may enter into or undertake may have rights, preferences or privileges senior to those of existing holders
of common stock. To the extent that we raise additional funds through collaboration and licensing arrangements, we may be required
to relinquish some rights to our technologies or product candidates, or grant licenses on terms that are not favorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The FDA may change its approval policies
or requirements, or apply interpretations to its policies or requirements, in a manner that could delay or prevent commercialization
of Adva-27a or our potential Covid-19 treatment in development.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory requirements
may change in a manner that requires us to conduct additional clinical trials, which may delay or prevent commercialization of our Adva-27a
and potential Covid-19 treatment in development. We cannot provide any assurance that the FDA will not require us to repeat existing
studies or conduct new or unforeseen experiments in order to demonstrate the safety and efficacy of any product candidate before considering
the approval of such product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The product candidate we are developing
for the treatment of Covid-19 may not be granted an emergency use authorization by the FDA.</i></b><b><i> If we do not receive such
authorization, or if, once granted, it is terminated, we will be required to pursue the drug approval process, which is lengthy and expensive.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject
to completing and receiving favorable results for clinical trials, we intend to seek emergency use authorization, or EUA, for a potential
Covid-19 treatment, which would allow us to market and sell such product candidate without the need to pursue the lengthy and expensive
drug approval process. The FDA may issue an EUA during a public health emergency if it determines that the potential benefits of a product
outweigh the potential risks and if other regulatory criteria are met. In addition, the FDA may revoke an EUA where it is determined that
the underlying health emergency no longer exists or warrants such authorization. We may not receive EUA for any Covid-19 treatment product
candidate. In addition, even if do we receive EUA for any product candidate, we cannot predict how long such EUA will remain in place.
If we fail to receive an EUA for any Covid-19 product candidate, or such EUA is granted but subsequently terminated, our business, financial
condition and results of operations could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business would be materially harmed
if we fail to obtain FDA approval for&#160;our pharmaceutical product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that
our ability to generate significant product revenues from our drug development business will depend on the successful development
and commercialization of Adva-27a or our potential Covid-19 treatment in development. The FDA may not approve in a timely
manner, or at all, any of our drug candidates. If we are unable to submit a new drug application, or NDA for our product candidates,
we will be unable to commercialize such products and our business will be materially harmed. The FDA can and does reject NDAs,
and often requires additional clinical trials, even when product candidates performed well or achieved favorable results in
large-scale Phase III clinical trials. The FDA imposes substantial requirements on the introduction of pharmaceutical products
through lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming
procedures.&#160;Satisfaction of these requirements typically takes several years and may vary substantially based upon the type and
complexity of the pharmaceutical product. Our product candidates are novel compounds or new chemical entities, which may further
increase the time required for satisfactory testing procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Data obtained from
preclinical and clinical activities are susceptible to varying interpretations, which could delay, limit or prevent regulatory
approval. In addition, delays or rejections may be encountered based on changes in, or additions to, regulatory policies
for drug approval during product development and regulatory review.&#160;Government regulation may delay or prevent the commencement
of clinical trials or marketing of our product candidates, impose costly procedures upon our activities and provide an advantage to
our competitors with greater financial resources or more experience in regulatory affairs. The FDA may not approve our product
candidates for clinical trials or marketing on a timely basis or at all. Delayed or failed approvals would adversely affect the
marketing of our product candidates and our liquidity and capital resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug products and their manufacturers
are subject to continual regulatory review after the product receives FDA approval.&#160;Later discovery of previously unknown problems
with a product or manufacturer may result in additional clinical testing requirements or restrictions on such product or manufacturer,
including withdrawal of the product from the market.&#160;Failure to comply with applicable regulatory requirements can, among other things,
result in fines, injunctions and civil penalties, suspensions or withdrawals of regulatory approvals, product recalls, operating restrictions
or shutdown and criminal prosecution. We may lack sufficient resources and expertise to address these and other regulatory
issues as they arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be sued or become a party to litigation,
which could require significant management time and attention and result in significant legal expenses and may result in an unfavorable
outcome which could have a material adverse effect on our business, financial condition, results of operations and cash flows.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be forced to
incur costs and expenses in connection with defending ourselves with respect to litigation and the payment of any settlement or
judgment in connection therewith if there is an unfavorable outcome. The expense of defending litigation may be
significant. The amount of time to resolve lawsuits is unpredictable and defending ourselves may divert
management&#8217;s attention from the day-to-day operations of our business, which could adversely affect our business, results of
operations and cash flows.&#160;&#160;In addition, an unfavorable outcome in any such litigation could have a material adverse
effect on our business, results of operations and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to attract and retain qualified
scientific, technical and key management personnel, or if our key executive, Dr. Steve N. Slilaty, discontinues his employment with us,
it may delay our research and development efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on the services
of Dr. Slilaty for strategic and operational management, as well as for scientific and/or medical expertise in the development of
our products. The loss of Dr. Slilaty would result in a significant negative impact on our ability to implement our business
plan. We have not entered into an employment agreement with any member of our management, including Dr. Slilaty. In addition, we do
not maintain &#8220;key person&#8221; life insurance covering Dr. Slilaty or any other executive officer. The loss of Dr. Slilaty
will also significantly delay or prevent the achievement of our business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business exposes us to potential product
liability risks and we may be unable to acquire and maintain sufficient insurance to provide adequate coverage against potential liabilities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business exposes us to
potential product liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical products and nutritional
supplements.&#160;The use of our product candidates in clinical trials also exposes us to the possibility of product liability claims
and possible adverse publicity. These risks will increase to the extent our pharmaceutical product candidates receive regulatory approval
and are commercialized.&#160;We do not currently have any product liability insurance, although we plan to obtain product liability insurance
in connection with our nutritional supplement products and future clinical trials of our pharmaceutical product candidates. We intend
to obtain product liability insurance for our nutritional supplements business in the near future. However, our product liability insurance,
once obtained, may not provide adequate coverage against potential liabilities.&#160;On occasion, juries have awarded large judgments
in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims
brought against us would decrease our cash reserves and could cause our stock price to fall significantly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face regulation and risks related to
hazardous materials and environmental laws, violations of which may subject us to claims for damages or fines that could materially affect
our business, cash flows, financial condition and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and
development activities involve the use of controlled and/or hazardous materials and chemicals. The risk of accidental
contamination or injury from these materials cannot be completely eliminated. In the event of an accident, we could be
held liable for any damages or fines that result, and the liability could have a material adverse effect on our business, financial
condition and results of operations. We are also subject to federal, state and local laws and regulations governing the use,
manufacture, storage, handling and disposal of hazardous materials and waste products. If we fail to comply with these laws and
regulations or with the conditions attached to our operating licenses, the licenses could be revoked, and we could be subjected to
criminal sanctions and substantial liability or be required to suspend or modify our operations.&#160;&#160;In addition, we may have
to incur significant costs to comply with future environmental laws and regulations. We do not currently have a pollution and
remediation insurance policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third party manufacturers may not be able
to manufacture our pharmaceutical product candidates, which would prevent us from commercializing our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our
pharmaceutical product candidates is approved by the FDA or other regulatory agencies for commercial sale, we will need third
parties to manufacture the product in larger quantities. If we are able to reach an agreement with any collaborator or third party
manufacturer in the future, of which there can be no assurance due to factors beyond our control, these collaborators and/or third
party manufacturers may not be able to increase their manufacturing capacity for any of our product candidates in a timely or
economic manner, or at all. Significant scale-up of manufacturing may require additional validation studies, which the FDA must
review and approve. If we are unable to increase the manufacturing capacity for a product candidate successfully, the regulatory
approval or commercial launch of that product candidate may be delayed or there may be a shortage in the supply of the product
candidate. Our product candidates require precise, high-quality manufacturing. The failure of collaborators or third
party manufacturers to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors,
could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost
overruns or other problems that could seriously harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to establish sales and
marketing capabilities for our pharmaceutical product candidates or enter into agreements with third parties to sell and market any such
products we may develop, we may be unable to generate revenues from our pharmaceutical business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have
product sales and marketing capabilities for our pharmaceutical operations.&#160;If we receive regulatory approval to commence
commercial sales of any of our pharmaceutical product candidates, we will have to establish a sales and marketing organization with
appropriate technical expertise and distribution capabilities or make arrangements with third parties to perform these services in
other jurisdictions. If we receive approval in applicable jurisdictions to commercialize Adva-27a for the treatment of breast cancer
indication, we intend to engage additional pharmaceutical or health care companies with existing distribution systems and direct
sales organizations to assist us in North America and throughout the world. We may not be able to negotiate favorable distribution
partnering arrangements, if at all. To the extent we enter into co-promotion or other licensing arrangements, any revenues we
receive will depend on the efforts of third parties and will not be under our control. If we are unable to establish adequate sales,
marketing and distribution capabilities, whether independently or with third parties, our ability to generate product revenues, and
become profitable, would be severely limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain required
US and foreign regulatory approvals, as applicable, factors that may inhibit our efforts to commercialize our pharmaceutical product candidates
without strategic partners or licensees include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">difficulty recruiting and retaining adequate numbers of effective sales and marketing personnel;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the inability of sales personnel to obtain access to, or persuade adequate numbers of, physicians to prescribe
our products;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage against companies with broader product lines; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">unforeseen costs associated with creating an independent sales and marketing organization.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we successfully develop and obtain
approval for our proprietary drug product candidates, our business will not be profitable if such products do not achieve and maintain
market acceptance.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our proprietary drug
product candidates are approved for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of our
approved product candidates by physicians, healthcare professionals, patients and third-party payors, and our resulting profitability
and growth, will depend on a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our ability to provide acceptable evidence of safety and efficacy;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">relative convenience and ease of administration;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the prevalence and severity of any adverse side effects;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the availability of alternative treatments;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the details of FDA labeling requirements, including the scope of approved indications and any safety warnings;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">pricing and cost effectiveness;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the effectiveness of our or our collaborators' sales and marketing strategy;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our ability to obtain sufficient third-party insurance coverage or reimbursement; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our ability to have the product listed on insurance company formularies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our proprietary drug product
candidates achieve market acceptance, we may not maintain that market acceptance over time if new products or technologies are introduced
that are received more favorably or are more cost effective.&#160;&#160;Complications may also arise, such as development of new know-how
or new medical or therapeutic capabilities by other parties that render our product obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because the results of preclinical studies
for our preclinical product candidates are not necessarily predictive of future results, our pharmaceutical product candidates may not
have favorable results in later clinical trials or ultimately receive regulatory approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary drug
product candidates have not been tested in clinical trials.&#160;Positive results from preclinical studies are no assurance that
later clinical trials will succeed. Preclinical studies are not designed to establish the clinical efficacy of our
preclinical product candidates. We will be required to demonstrate through clinical trials that our product candidates are safe and
effective for use before we can seek regulatory approvals for commercial sale. There is typically an extremely high rate of failure
as product candidates proceed through clinical trials.&#160;If our product candidates fail to demonstrate sufficient safety and
efficacy in any clinical trial, we would experience potentially significant delays in, or be required to abandon, development of
that product candidate.&#160;This would adversely affect our ability to generate revenues and may damage our reputation in the
industry and in the investment community.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The future clinical testing of our proprietary
drug product candidates could be delayed, resulting in increased costs to us and a delay in our ability to generate revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary drug product
candidates will require additional preclinical testing and extensive clinical trials prior to submitting a regulatory application for
commercial sales. We do not know whether clinical trials will begin on time, if at all.&#160;Delays in the commencement of clinical
testing could significantly increase our product development costs and delay product commercialization. In addition, many of the
factors that may cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to denial of regulatory approval
of a product candidate. Each of these results would adversely affect our ability to generate revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commencement of clinical
trials can be delayed for a variety of reasons, including delays in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr>
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></p></td>
    <td style="text-align: justify"><span style="font-size: 10pt">demonstrating sufficient safety to obtain regulatory approval to commence
a clinical trial;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></p></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reaching agreement on acceptable terms with prospective research organizations
and trial sites;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></p></td>
    <td style="text-align: justify"><span style="font-size: 10pt">manufacturing sufficient quantities of a product candidate;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></p></td>
    <td style="text-align: justify">obtaining institutional review board approvals to conduct clinical trials at prospective sites; and</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></p></td>
    <td style="text-align: justify"><span style="font-size: 10pt">procuring adequate financing to fund the work.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the commencement
of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the
patient population, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments
for the relevant disease, and the eligibility criteria for the clinical trial.&#160;&#160;If we are unable to enroll a sufficient number
of evaluable patients, the clinical trials for our product candidates could be delayed until sufficient numbers are achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face or will face significant competition
from other biotechnology, pharmaceutical and nutritional supplement companies, and our operating results will suffer if we fail to compete
effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have only three
employees involved in our drug development and nutritional supplement program.&#160;Most of our pharmaceutical company competitors,
such as Merck, Bristol-Myers Squibb, Pfizer, Amgen, and others, are large pharmaceutical companies with substantially greater
financial, technical and human resources than we have. The biotechnology and pharmaceutical industries are intensely competitive and
subject to rapid and significant technological change.&#160;The drugs that we are attempting to develop will compete with existing
therapies if we receive marketing approval. Because of their significant resources, our competitors may be able to use discovery
technologies and techniques, or partnerships with collaborators, to develop competing products that are more effective or less
costly than the product candidate we are developing. This may render our technology or product candidate obsolete and
noncompetitive. Academic institutions, government agencies, and other public and private research organizations may seek
patent protection with respect to potentially competitive products or technologies and may establish exclusive collaborative or
licensing relationships with our competitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may
succeed in obtaining FDA or other regulatory approvals for product candidates more rapidly than us. Companies that complete clinical
trials, obtain required regulatory agency approvals and commence commercial sale of their drugs before we do may achieve a
significant competitive advantage, including certain FDA marketing exclusivity rights that would delay or prevent our ability to
market certain products. Any approved drugs resulting from our research and development efforts, or from our joint
efforts with our existing or future collaborative partners, might not be able to compete successfully with our competitors' existing
or future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also face competition in
our nutritional supplements business. The business of marketing nutritional supplements is highly competitive. This market segment includes
numerous manufacturers, marketers, and retailers that actively compete for the business of consumers both in the United States and abroad.
The market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market. Sales
of similar products by competitors may materially and adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market for our potential
Covid-19 treatment in development could be adversely affected if the Covid-19 disease outbreak subsides.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disease outbreaks
are unpredictable. In the event that the Covid-19 outbreak subsides, or Covid-19 is substantially eradicated, there may be reduced demand
or need for our potential Covid-19 treatment in development, which may have a negative effect on the market for such treatment,
even if it is approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Covid-19 pandemic has significantly
impacted worldwide economic conditions and could have a material adverse effect on our operations and business.&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we have been able to
continue to operate, the global Covid-19 pandemic has caused disruptions in supply chains, affecting production and sales across a range
of industries. While the disruptions are currently expected to be temporary, there is considerable uncertainty around the duration and
the impact of these disruptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The extent of the impact of
Covid-19 on our operational and financial performance will depend on the on-going and future impact on our customers, vendors, service
providers, and availability of labor as well as the potential impact of future expanded local, state, or federal restrictions &#8211;
all of which are uncertain and are difficult to predict.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because our proprietary drug product candidates
and our development and collaboration efforts depend on our intellectual property rights, adverse events affecting our intellectual property
rights will harm our ability to commercialize products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success will depend
to a large degree on our own and our licensors&#8217; ability to obtain and defend patents for each party's respective technologies
and the compounds and other products, if any, resulting from the application of such technologies. The patent positions of
pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and technical questions. No consistent
policy regarding the breadth of claims allowed in biotechnology patents has emerged to date.&#160;Accordingly, we cannot predict the
breadth of claims that will be allowed or maintained, after challenge, in our or other companies' patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future protection
for our proprietary rights is uncertain, and we cannot ensure that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">we were the first to make the inventions covered by each of our pending patent applications;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">we were the first to file patent applications for these inventions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">any patents issued to us or our collaborators will provide a basis for commercially viable products, will
provide us with any competitive advantages or will not be challenged by third parties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our pending patent applications will result in issued patents;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">we will develop additional proprietary technologies that are patentable;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the patents of others will not have a negative effect on our ability to do business; or</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our issued patents will have sufficient useful life remaining for commercial viability of our product
candidate.&#160;&#160;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot maintain the
confidentiality of our technology and other confidential information in connection with our collaborations, then our ability to receive
patent protection or protect our proprietary information will be impaired. In addition, some of the technology we have developed
or licensed relies on inventions developed using U.S. and other governments&#8217; resources.&#160;Under applicable law, the U.S. government
has the right to require us to grant a nonexclusive, partially exclusive or exclusive license for such technology to a responsible applicant
or applicants, upon terms that are reasonable under the circumstances, if the government determines that such action is necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Confidentiality agreements with employees
and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our
intellectual property.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on trade secrets to
protect our technology, particularly when we do not believe patent protection is appropriate or obtainable.&#160;However, trade secrets
are difficult to protect.&#160;&#160;In order to protect our proprietary technology and processes, we rely in part on confidentiality
and intellectual property assignment agreements with our employees, consultants, outside scientific collaborators and sponsored researchers
and other advisors.&#160;These agreements may not effectively prevent disclosure of confidential information nor result in the effective
assignment to us of intellectual property, and may not provide an adequate remedy in the event of unauthorized disclosure of confidential
information or other breaches of the agreements. In addition, others may independently discover our trade secrets and proprietary
information, and in such case we could not assert any trade secret rights against such party.&#160;Enforcing a claim that a party illegally
obtained and is using our trade secrets is difficult, expensive and time consuming, and the outcome is unpredictable.&#160;In addition,
courts outside the United States may be less willing to protect trade secrets.&#160;Costly and time-consuming litigation could be necessary
to seek to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could
adversely affect our competitive business position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The implementation of our business plan
may result in a period of rapid growth that will impose a significant burden on our current administrative and operational resources.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to
effectively manage our growth will require us to substantially expand the capabilities of our administrative and operational
resources by attracting, training, managing and retaining additional qualified personnel, including additional members of
management, technicians and others. To successfully develop our products we will need to manage operating, producing, marketing
and selling our products. There can be no assurances that we will be able to do so. Our failure to successfully manage our
growth will have a negative impact on our anticipated results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A significant or prolonged economic downturn
could have a material adverse effect on our results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A significant or prolonged
economic downturn may adversely affect the disposable income of many consumers and may lower demand for our nutritional supplements products.
Any decline in economic conditions in could negatively impact our business. A significant decline in consumer demand, even if only due
in part to general economic conditions, could have a material adverse effect on our revenues and profit margins.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The failure of our service providers and
suppliers to supply quality services and materials in sufficient quantities, at a favorable price, and in a timely fashion could adversely
affect the results of our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our outside manufacturer buys
raw materials for our nutritional supplements business from a limited number of suppliers. The loss of any of our major suppliers or of
any supplier who, through our contract manufacturer, provides us materials that are hard to obtain elsewhere at the same quality could
adversely affect our business operations. Although we believe we could establish alternate manufacturers and sources for most of our raw
materials, any delay in locating and establishing relationships with other sources could result in shortages of products we manufacture
from such raw materials, with a resulting loss of sales and customers. In certain situations we may need to alter our products or with
our customer&#8217;s consent to substitute different materials from alternative sources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shortage of raw materials
or an unexpected interruption of supply could also result in higher prices for those materials. We have experienced increases in various
raw material costs, transportation costs and the cost of petroleum-based raw materials and packaging supplies used in our business. Increasing
cost pricing pressures on raw materials and other products have continued throughout fiscal 2020 as a result of limited supplies of various
ingredients, the effects of higher labor and transportation costs, and impact of Covid-19. We expect these upward pressures to continue
through fiscal 2021. Although we may be able to raise our prices in response to significant increases in the cost of raw materials, we
may not be able to raise prices sufficiently or quickly enough to offset the negative effects such cost increases could have on our results
of operations or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
suppliers will provide the quality raw materials we need in the quantities requested or at a price we are willing to pay. Because we do
not control the actual production of these raw materials, we are also subject to delays caused by interruption in production of materials
including but not&#160;limited to those resulting from conditions outside of our control, such as pandemics, weather, transportation interruptions,
strikes, terrorism, natural disasters, and other catastrophic events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our nutritional supplements business is
subject to the effects of adverse publicity, which could negatively affect our sales and revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business can be affected
by adverse publicity or negative public perception about us, our competitors, our products, or our industry or competitors generally.
Adverse publicity may include publicity about the nutritional supplements industry generally, the efficacy, safety and quality of nutritional
supplements and other health care products or ingredients in general or our products or ingredients specifically, and regulatory investigations,
regardless of whether these investigations involve us or the business practices or products of our competitors, or our customers. Any
adverse publicity or negative public perception could have a material adverse effect on our business, financial condition and results
of operations. Our business, financial condition and results of operations could be adversely affected if any of our products or any similar
products distributed by other companies are alleged to be or are proved to be harmful to consumers or to have unanticipated and unwanted
health consequences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our manufacturing and third party fulfillment
activities are subject to certain risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our nutritional supplements
products are manufactured at third party manufacturing facilities in Canada. As a result, we are dependent on the uninterrupted and efficient
operation of these facilities. Such manufacturing operations, and those of its suppliers, are subject to power failures, blackouts, border
shutdowns, telecommunications failures, computer viruses, cybersecurity vulnerabilities, human error, breakdown, failure or substandard
performance of our facilities, our equipment, the improper installation or operation of equipment, terrorism, pandemics (including Covid-19),
natural or other disasters, intentional acts of violence, and the need to comply with the requirements or directives of governmental agencies,
including the FDA. The occurrence of these or any other operational problems at such facilities may have a material adverse effect on
our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to This Offering and Our Common
Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is a limited market for our common
stock, and investors may find it difficult to buy and sell our shares.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our common stock
is quoted on the OTC Pink, it is an unorganized, inter-dealer, over-the-counter market which provides significantly less liquidity than
the Nasdaq Capital Market or other national securities exchanges. Daily trading volume for our common stock since January 2021 has ranged
from 0 shares to 101,581,664 shares. These factors may have an adverse impact on the trading and price of our common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further,
we have applied to have our common stock listed on the Nasdaq Capital Market. If our application is not approved, we will not complete
this offering. In the event this offering is completed and our common stock is listed on the Nasdaq Capital Market, there is no assurance
an active trading market for our common stock will develop or be sustained or that we will remain eligible for continued listing on the
Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;<b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our chief executive officer,
pursuant to his ownership of our Series B Preferred Stock, owns the majority of the voting power of our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">There
are 1,000,000 shares of Series B Preferred Stock issued and outstanding, all of which are held by</span> our chief executive
officer, <span style="background-color: white">Dr. Steve N. Slilaty. Of these 1,000,000 shares, upon closing of this offering, Mr.
Slilaty will retain 10,000 shares and the remaining 990,000
shares will be redeemed by the Company. The Series B Preferred Stock votes as one class with the holders of the common stock and
entitles the holder to 1,000 votes for each share of Series B Preferred Stock. As a result, upon closing of this offering Dr.
Slilaty will hold approximately 74% of the total voting power of our common stock and will have the ability to control all matters
submitted to shareholders, and his interests may differ from those of other shareholders.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our common stock is, and may in the future
be considered, a &#8220;penny stock&#8221; and thus be subject to additional sale and trading regulations that may make it more difficult
to buy or sell.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock, which is
traded on the OTC Pink is, and may (if it is not then listed on a national securities exchange such as the Nasdaq Capital Market) in the
future be, considered a &#8220;penny stock.&#8221; Securities broker-dealers participating in sales of &#8220;penny stock&#8221; are subject
to the &#8220;penny stock&#8221; regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Securities Exchange Act of 1934,
as amended (the &#8220;Exchange Act&#8221;). Generally, brokers may be less willing to execute transactions in securities subject to the
&#8220;penny stock&#8221; rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the
market value of our stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends on our
common stock for the foreseeable future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have paid no dividends
on our common stock to date and we do not anticipate paying any dividends to holders of our common stock in the foreseeable future. While
our future dividend policy will be based on the operating results and capital needs of the business, we currently anticipate that we will
retain any earnings to finance our future expansion and for the implementation of our business plan. Investors should take note of the
fact that a lack of a dividend can further affect the market value of our common stock and could significantly affect the value of any
investment in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our articles of incorporation allow for
our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights
of the holders of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
the authority to fix and determine the relative rights and preferences of preferred stock. Our board of directors has the authority to
issue up to 30,000,000 shares of our preferred stock without further stockholder approval. 1,000,000 shares of preferred stock are designated
Series B Preferred Stock and are outstanding and held by our chief executive officer (10,000 of which shares will remain outstanding
and held by Dr. Slilaty upon closing of this offering). Our board of directors could authorize the creation of additional series of preferred
stock that would grant to holders of preferred stock the right to our assets upon liquidation, or the right to receive dividend payments
before dividends are distributed to the holders of common stock. In addition, subject to the rules of any securities exchange on which
our stock is then listed, our board of directors could authorize the creation of additional series of preferred stock that has greater
voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting power of our
common stock or result in dilution to our existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Prior to the completion of this offering,
there will have been no public trading market for our Warrants. An active public trading market for the Warrants may not develop, which
may affect the market price and liquidity of the Warrants.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offering under this prospectus
is an initial public offering of our Warrants. Prior to the closing of the offering, there will have been no public market for our Warrants.
An active public trading market for our Warrants may not develop after the completion of the offering. If an active trading market for
our Warrants does not develop after this offering, the market price and liquidity of our Warrants may be materially and adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Warrants are speculative in nature.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants will be exercisable
for five years from the date of initial issuance at an initial exercise price equal to 100% of the public offering price per Common
Unit set forth on the cover page of this prospectus. There can be no assurance that the market price of the common stock will ever
equal or exceed the exercise price of the Warrants. In the event that our common stock price does not exceed the exercise price of the
Warrants during the period when the Warrants are exercisable, a holder of Warrants may be unable to profit from exercising such Warrants
before they expire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Pre-funded Warrants will not be
listed or quoted on any exchange.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no established
public trading market for the Pre-funded Warrants being offered in this offering, and we do not expect a market to develop. In addition,
we do not intend to apply to list the Pre-funded Warrants on any national securities exchange or other nationally recognized trading
system, including Nasdaq. Without an active market, the liquidity of the Pre-funded Warrants will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Except as otherwise provided in the
Warrants and Pre-funded Warrants, holders of Warrants and Pre-funded Warrants purchased in this offering will have no rights as stockholders
until such holders exercise their Warrants or Pre-funded Warrants and acquire our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in the Warrants and Pre-funded Warrants, until holders of Warrants or Pre-funded Warrants acquire our common stock upon exercise of the
Warrants or Pre-funded Warrants, holders of Warrants and Pre-funded warrants will have no rights with respect to our common stock underlying
such Warrants and Pre-funded Warrants. Upon exercise of the Warrants and Pre-funded Warrants, the holders will be entitled to exercise
the rights of a holder of our common stock only as to matters for which the record date occurs after the exercise date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Additional stock offerings in the future
may dilute then-existing shareholders&#8217; percentage ownership of the Company.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given our plans and expectations
that we will need additional capital and personnel, we anticipate that we will need to issue additional shares of common stock or securities
convertible or exercisable for shares of common stock, including convertible preferred stock, convertible notes, stock options or warrants.
The issuance of additional securities in the future will dilute the percentage ownership of then current stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You will experience immediate and substantial
dilution as a result of this offering and may experience additional dilution in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will incur immediate
and substantial dilution as a result of this offering. After giving effect to the sale by us of 1,020,408 shares offered in this offering
at an assumed public offering price of $9.80 per share, and after deducting underwriting discounts and commissions and estimated offering
expenses payable by us, investors in this offering can expect an immediate dilution of approximately $7.31 per share (without assigning
any value to the Warrants). See &#8220;Dilution&#8221; below for a more detailed discussion of the dilution you will incur if you purchase
our common stock in the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management will have broad discretion as
to the use of the proceeds from this offering and may not use the proceeds effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management will have broad
discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that may not improve our results
of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect
on our business and cause the price of our common stock to decline.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s5"></span><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus includes forward-looking
statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange
Act of 1934, or the Exchange Act. Forward-looking statements give current expectations or forecasts of future events or our future financial
or operating performance. We may, in some cases, use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221;
&#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions
that convey uncertainty of future events or outcomes to identify these forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking statements
reflect our management&#8217;s beliefs and views with respect to future events, are based on estimates and assumptions as of the date
of this prospectus and are subject to risks and uncertainties, many of which are beyond our control, that could cause our actual results
to differ materially from those in these forward-looking statements. We discuss many of these risks in greater detail in this prospectus
under &#8220;Risk Factors.&#8221; Moreover, new risks emerge from time to time. It is not possible for our management to predict all risks,
nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should
not place undue reliance on these forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We undertake no obligation
to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as
may be required by applicable laws or regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s6"></span>USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that the net
proceeds from the sale of the securities we are offering will be approximately $8.5 million (or approximately $9.9 million if
the underwriters exercise in full their over-allotment option), after deducting the estimated underwriting discounts and commissions
and estimated offering costs payable by us.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net
proceeds from this offering for our drug development activities and general corporate purposes, including working capital, and for repayment
of third-party debt in the amount of $1.9 million. The debt we intend to repay has maturity dates between July 6, 2023 and August 18,
2023, an annual interest rate of 5%, and is convertible into common stock at a conversion price of $0.30.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This expected use of the net
proceeds from this offering represents our intentions based upon our current plans and business conditions. Pending our use of the net
proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term,
investment grade, interest bearing instruments and U.S. government securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s7"></span><b>MARKET FOR COMMON STOCK AND RELATED STOCKHOLDER
MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is quoted
on the OTC Pink under the symbol &#8220;SBFM.&#8221; We have applied to have our common stock listed on the Nasdaq Capital Market
under the symbol &#8220;SBFM&#8221;. No assurance can be given that our application will be approved. If our application is not approved,
we will not complete this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 31, 2022,
there were approximately 147 holders of record of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Compensation Plan Information </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not have any equity
compensation plans as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any dividends
since our incorporation and do not anticipate paying any dividends in the foreseeable future. At present, our policy is to retain earnings,
if any, to develop and market our products. Our payment of dividends in the future will depend upon, among other factors, our earnings,
capital requirements, and operating financial conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b></b></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s8"></span><b>DILUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you purchase in this
offering, your interest will be diluted to the extent of the difference between the public offering price per Common Unit (without assigning
any value to the Warrants, and assuming the exercise of any Pre-Funded Warrants sold in the offering) and the net tangible book value
per share of our common stock after this offering. Our net tangible book value as of September 30, 2021 was ($1,173,932) or ($0.46) per
share of common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Net tangible book value&#8221;
is total assets minus the sum of liabilities and intangible assets. &#8220;Net tangible book value per share&#8221; is net tangible book
value divided by the total number of shares of common stock outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to (i)
our issuance in October 2021 of 26,250 shares of common stock upon conversion of $346,500 of convertible debt, and (ii) our issuance
in December 2021 of 14,524 shares of common stock upon conversion of $1,361,000 of convertible debt, our pro forma net tangible
book value as of September 30, 2021 would have been approximately $533,568, or $0.21 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pro forma as adjusted
net tangible book value is our net tangible book value after taking into account the effect of the sale of 1,020,408 Common Units in
this offering (assuming the exercise of any Pre-funded Warrants sold in the offering, and without assigning any value to the Warrants)
at the assumed public offering price of $9.80 per Common Unit and after deducting the underwriting discounts and commissions and other
estimated offering expenses payable by us, and the redemption of 990,000 shares of Series B Preferred Stock at the redemption price equal
to the stated value of $0.10 per share that will occur upon closing of this offering. Our pro forma as adjusted net tangible book value
as of September 30, 2021 would have been approximately $9,004,568, or $2.49 per share. This amount represents an immediate increase in
as adjusted net tangible book value of approximately $2.28 per share to our existing stockholders, and an immediate dilution of $7.31
per share to new investors participating in this offering. Dilution per share to new investors is determined by subtracting pro forma
as adjusted net tangible book value per share after this offering from the public offering price per share paid by new investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table illustrates
the dilution:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 87%; text-align: justify"><span style="font-size: 10pt">Assumed public offering price per Common Unit</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; text-align: right"><span style="font-size: 10pt">9.80</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">Net tangible book value per share as of September 30, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(0.46</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt">Pro forma net tangible book value per share as of September 30, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">0.21</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">Increase in net tangible book value per share attributable to this offering</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">2.28</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt">Pro forma as adjusted net tangible book value per share after this offering</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">2.49</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">Dilution per share to new investors</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">7.31</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above table is based
on <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,500,467</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
shares of common stock outstanding as of September 30, 2021, and excludes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">shares
                                            of common stock issuable upon conversion of an outstanding convertible note in the principal
                                            amount of $330,000, as of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
                                            30, 2021, with a conversion price equal to the lower of $60.00 per share or a 35%
                                            discount to the market price;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><p style="margin: 0pt 0">9,114,409
                                            <span style="font: 10pt Times New Roman, Times, Serif">shares of common
                                            stock issuable upon an aggregate of $3,204,215 in principal amount of convertible notes as
                                            of September 30, 2021, at an average fixed conversion price of $0.35 per share;</span></p></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2,040,816
                                            shares of common stock issuable upon exercise of Warrants that will be issued to investors
                                            in this offering; and</p></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1,000,000 outstanding shares of Series B Preferred
Stock, which are not convertible into common stock</p></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the underwriters exercise
in full their over-allotment option, our pro forma as adjusted net tangible book value after giving effect to this offering would be
approximately $10,369,568 or $2.75 per share, which amount represents an immediate increase in net tangible book value of $2.54 per share
to existing stockholders and dilution to new investors of $7.05 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s9"></span>CAPITALIZATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following
table sets forth our cash and our capitalization as of September 30, 2021 on:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an actual basis; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">on a pro forma as adjusted basis to give effect to (i) our issuance
    in October 2021 of 26,250 shares of common stock upon conversion of $346,500 of convertible debt, and (ii) our issuance in December
    2021 of 14,524 shares of common stock upon conversion of $1,361,000 of convertible debt, (iii) the sale by us of 1,020,408 Common
    Units in this offering, at the assumed public offering price of $9.80 per Common Unit (assuming the exercise of any Pre-Funded Warrants
    sold in the offering), after deducting underwriting discounts and commissions and estimated offering expenses payable by us, and
    after giving effect to our use of approximately $1.9 million from the net proceeds of this offering for the repayment of debt, and
    (iv) our redemption of 990,000 shares of Series B Preferred Stock held by Dr. Steve Slilaty at a redemption price equal to the stated
    value of $0.10 per share, which will occur upon the closing of this offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this table
in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and our
financial statements for the period ended September 30, 2021, and the related notes thereto, included in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>As of September 30, 2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Actual</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Pro forma as adjusted</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 72%; text-align: justify"><span style="font-size: 10pt">Cash and cash equivalents</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; width: 11%; text-align: right"><span style="font-size: 10pt">2,386,608</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; width: 11%; text-align: right"><span style="font-size: 10pt">8,917,068</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">Total liabilities</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">3,675,847</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">56,687</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt">Stockholders&#8217; equity:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Series B Preferred Stock, $0.10 par value: 1,000,000 shares authorized, 1,000,000 shares issued and outstanding, actual, 10,000 shares issued and outstanding, pro forma as adjusted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Common Stock, $0.001 par value: 3,000,000,000 shares
    authorized; 2,550,467 shares issued and outstanding, actual; 3,611,649 shares issued and outstanding, pro forma as adjusted</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">510,092</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,611</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">Additional Paid-in Capital</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">31,555,741</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">40,124,721</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt">Accumulated comprehensive income</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(17,475</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(17,475</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">Accumulated (deficit)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(33,322,290</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(33,322,290</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt">Total stockholders&#8217; equity (deficit)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(1,173,932</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9,004,568</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares to be
outstanding immediately after giving effect to this offering as shown above is based on 2,550,467 shares outstanding as of September
30, 2021 and excludes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;&#160;&#160;&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">shares of common stock issuable upon conversion
    of an outstanding convertible note in the principal amount of $330,000, as of September 30, 2021, with a conversion price equal to
    the lower of $0.30 per share or a 35% discount to the market price;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">9,114,409 shares of common stock issuable upon
    an aggregate of $3,204,215 in convertible notes as of September 30, 2021, at an average fixed conversion price of $0.35 per share;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">2,040,816</span><span style="font-size: 10pt">
    shares of common stock issuable upon exercise of Warrants that will be issued to investors in this offering; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">1,000,000 outstanding shares of Series B Preferred
    Stock, which are not convertible into common stock</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s10"></span>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF<br />
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital
resources for the periods described. This discussion should be read in conjunction with our financial statements and the related notes
included in this prospectus. This discussion contains forward-looking statements. Please see &#8220;Cautionary Note Regarding Forward-Looking
Statements&#8221; for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Comparison of Results of
Operations for the Nine Months ended September 30, 2021 and 2020</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">During
the nine months ended September 30, 2021, we generated revenues of $143,308 from the sale of products generated by our science-based
nutritional supplements operations which we launched in March 2019. The direct cost for generating these sales was $56,541 (39.5%). We
generated $43,397 in sales revenues during the comparable period in 2020. The direct cost for generating these sales was $15,384 (35.4%).
The decrease in our gross margin during the nine months ended September 30, 2021, was due to the introduction of new products that have
lower profitability margins.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">General
and administrative expenses during the nine months ended September 30, 2021 was $2,247,270, compared to $261,569 during the nine months
ended September 30, 2020, an increase of $1,985,701. The reason for this relatively large increase was due to a general increase in our
business activities as funding for our drug development projects became available. Specifically, all of our expense categories saw increases
including executive compensation which increased by $1,093,497 due to issuance of common stock to our directors. Similarly, our R&amp;D
expenditures increased by $581,011 and our patenting fees by $14,571. Our other expense categories, including accounting, consulting,
legal and office expenses together increased by a total of $297,591.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
incurred $10,709,843 in losses arising from debt conversion during the nine months ended September 30, 2021, compared to $1,416,313 in
losses from debt conversion during the similar period in 2020. This large increase was due to more costly convertible debt financing
that we took on in order to fund our R&amp;D activities. The other contributing factor is related to recent volatility in our stock price.
We also incurred $292,191 in interest expense during the nine months ended September 30, 2021, compared to $62,669 in interest expense
during the similar period in 2020. The increase was a result of the aforementioned more costly debt financing we took on.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a result, we incurred a net loss of $13,103,563 ($3.00 per share) during the nine month period ended September 30, 2021, compared to
a net loss of $1,700,298 ($1.00 per share) during the nine month period ended September 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Comparison of Results of
Operations for the Three Months Ended September 30, 2021 and 2020</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">During
the three months ended September 30, 2021, we generated $50,376 in revenues, compared to $17,150 in revenues for the same three month
period in 2020, an increase of $33,226. The increase is attributable to an enhanced advertising campaign we initiated in 2021. All of
these revenues were generated from our science-based nutritional supplements operations which we launched in March 2019. The direct cost
for generating these revenues was $19,506 (38.7%) for the period ended September 30, 2021, compared to $6,340 (37.0%) for the same period
in 2020. Our gross profit increased to $30,870 for the period ended September 30, 2021, compared to a gross profit of $10,810 for the
same period in 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">General
and administrative expenses during the three month period ended September 30, 2021 were $527,120, compared to general and administrative
expenses of $78,098 incurred during the three month period ended September 30, 2020, an increase of $449,031. Nearly all categories of
our general and administrative expenses saw an increase during the three month period ended September 30, 2021, compared to the same
period in 2020. Specifically, the increases included R&amp;D expenditures by $222,465, consulting fees by $16,775, office expenses by
$38,993, and legal fees by $50,028. These increases were due to expansion of our drug development and nutritional supplements operations.
Overall, we incurred a loss of $496,259 from our operations in the three month period ended September 30, 2021, compared to a loss of
$67,288 in the similar period of 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, we incurred $46,850 in interest expense during the three months ended September 30, 2021, compared to $22,094 in interest expense
during the similar period in 2020. We also incurred $3,504,000 in losses arising from debt conversion during the three months ended September
30, 2021, compared to $608,899 in losses from debt conversion during the similar period in 2020. These increases were due to increased,
more costly borrowings to fund our expanded drug development and nutritional supplements operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result,
we incurred a net loss of $4,039,383 ($1.00 per share) for the three month period ended September 30, 2021, compared to a net loss of
$698,595 ($0.00 per share) during the three month period ended September 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Comparison of Results of Operations for the
fiscal years ended December 31, 2020 and 2019</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During our fiscal year ended
December 31, 2020, we generated revenues of $71,410, compared to revenues of $21,121 in 2019. All of these revenues were generated from
our nutritional supplements operations which we launched in the first quarter of 2019. The cost of sales in 2020 and 2019 for generating
these revenues was $25,847 and $11,050, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses for our fiscal year ended December 31, 2020 were $622,437, compared to $651,707 during our fiscal year ended December 31, 2019,
a decrease of $29,270. The expense categories that saw a decrease included accounting, which decreased by $7,729, legal fees, which decreased
by $17,609, consulting, which decreased by $58,764, research and development, which decreased by $13,476, and executive compensation,
which decreased by $5,322. The only general and administrative category that saw an increase was office expenses which increased by $73,338
due to expenses related to expansion of our nutritional supplements operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also incurred $168,105
in interest expense and $2,057,513 in losses from debt conversion during the year ended December 31, 2020, compared to $115,901 in interest
expense and $314,752 in losses from debt conversion during the similar period in 2019. The increase in interest expense and losses from
debt conversion in 2020 was due to an increase in issuance of convertible debt instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result,
we incurred a net loss of $2,784,091 (approximately $1.00 per share) for the year ended December 31, 2020, compared to a net loss of
$1,660,291 (approximately $15.00 per share) during the year ended December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">As
of September 30, 2021, we had cash and cash equivalents of $2,386,608.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
discussed in Note 2 to the consolidated financial statements included in this prospectus for going concern, we have incurred significant
continuing losses in 2021 and 2020. Our total accumulated deficits as of September 30, 2021 and December 31, 2020 were $33.3 million
and $20.2 million, respectively. Our ability to continue operating is highly dependent upon continued funding from the debt and/or equity
markets. Our historical and ongoing dependence on proceeds from debt and/or equity issuances to fund operating expenses could raise substantial
doubt about our ability to continue as a going concern. We believe that this offering, if successfully completed, will fully mitigate
the afore expressed doubt about our ability to continue as a going concern. The consolidated financial statements included in this prospectus
have been prepared assuming that we will continue as a going concern and, accordingly, do not include any adjustments relating to any
going concern uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash used in operating activities was $1,517,015 during the nine month period ended September 30, 2021, compared to $233,627 for the
nine month period ended September 30, 2020. We anticipate that overhead costs and other expenses will increase in the future as we move
forward with our proprietary drug development activities and our science-based nutritional supplements operations discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Cash
flows provided by financing activities were $2,928,339 for the nine month periods ended September 30, 2021, compared to $683,643 during
the nine months ended September 30, 2020. Cash flows used in investing activities were $-0- for both the nine month period ended September
30, 2021 and the same nine month period ended in 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During
the nine month period ended September 30, 2021, we issued a total of 1,036,740 shares of our common stock valued at $11,981,072 for the
conversion of outstanding notes payable, reducing debt by $1,233,028 and interest payable by $38,201 and generating a loss on conversion
of $10,709,843.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During
the nine months ended September 30, 2020, we issued a total of 2,690,993 shares of our common stock valued at $1,831,816 for the conversion
of outstanding notes payable, reducing the debt by $373,269 and interest payable by $42,233 and generating a loss on conversion of $1,416,314.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During
the nine months ended September 30, 2021, we did not sell any of our capital stock for cash; however we entered into the following new
debt arrangements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On January 12, 2021, we issued a note in the principal amount of
    $150,000 with interest accruing at 5% per year, due January 12, 2023. The note is convertible after 180 days from issuance into common
    stock at a price of $0.30 per share.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On January 27, 2021, we issued a note in the principal amount of
    $300,000 with interest accruing at 5% per year, due January 27, 2023. The note is convertible after 180 days from issuance into common
    stock at a price equal to $0.50 per share.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On February 12, 2021, we issued a note in the principal amount of
    $700,000 with interest accruing at 5% per year, due February 12, 2023. The Note is convertible after 180 days from issuance into
    common stock at a price of $0.60 per share.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On April 5, 2021, we issued a note in the principal amount of $330,000
    with interest accruing at 10% per year, due January 5, 2022. The note was convertible after 180 days from issuance into common stock
    at a price 35% below market value. On October 13, 2021, the noteholder converted $330,000 in principal and $16,500 in accrued interest
    into 26,250 shares of common stock leaving a principal balance of $0.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On April 20, 2021, we issued a note in the principal amount of $500,000
    with interest accruing at 5% per year, due February April 20, 2023. The note is convertible after 180 days from issuance into common
    stock at a price of $0.30 per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, we issued a note in
        the principal amount of $900,000 with interest accruing at 5% per year, due July 6, 2023. The note is convertible after 180 days
        from issuance into common stock at a price of $0.30 per share. In connection with this debt financing, we agreed to allow the
        lender, who is also the holder of a note dated November 25, 2020, to convert a total of $240,000 in principal into 120,000
        shares of common stock leaving a principal balance of $10,000 and accrued interest of $7,750. On July 6, 2021, we paid off
        the remaining principal balance of this note and received forgiveness of the accrued interest.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On August 18, 2021, we issued a note in the principal amount of
    $500,000 with interest accruing at 5% per year, due August 18, 2023. The note is convertible after 180 days from issuance into
    common stock at a price equal to $0.30 per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September
8, 2020, we executed a financing agreement with RB Capital Partners, Inc., La Jolla, CA, who agreed to provide us with a minimum of $2
million in convertible debt financing during the ensuing three to six month period pursuant to the terms and conditions included in relevant
promissory note. The notes bear interest at the rate of 5% per year and have a maturity date of two years from the date of issuance.
We have the right to pay off all or any part of the notes at any time without penalty. As of September 30, 2021, the total outstanding
principal amounts of the notes was $3,204,215.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of
December 31, 2020, we had cash and cash equivalents of $989,888.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $657,299 during our fiscal year ended December 31, 2020, compared to $495,798 during our fiscal year ended December 31,
2019. We anticipate that our cash requirements for our operations will increase in the future before we reach profitability
levels, of which there is no assurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash flows used in investing
activities were $1,191 during our fiscal year ended December 31, 2020.&#160;&#160;For the fiscal year ended December 31, 2019, cash flows
used in investing activities were $15,276 arising primarily out of the purchase of computer and related equipment.&#160;&#160;Net cash
flows provided by financing activities totaled $1,608,253 in 2020, compared to $442,255 during our fiscal year ended December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are not generating adequate revenues from our operations to fully implement our business plan as set forth herein. As a result, our future
success will depend on the future availability of financing, among other things. Such financing will be required to enable us to implement
our drug development program and further develop our science-based nutritional supplements operations. We estimate that we will require
approximately $10 million (approximately $9 million for our proprietary drug development projects and $1 million for our science-based
nutritional supplements operations) (including funds from this offering) to implement our business plan over the next approximately 18
months and there are no assurances that we will be able to raise this capital, including funds from this financing. Our inability
to obtain sufficient funds from external sources when needed will have a material adverse effect on our plan of operation, results of
operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
cost of operations is expected to increase as we move forward with implementation of our business plan. We do not have sufficient funds
to cover the anticipated increase in the relevant expenses. We need to raise additional capital (which we may receive through this offering)
in order to continue our existing operations and finance our expansion plans for the next year. If we are successful in raising additional
funds, we expect our operations and business efforts to continue and expand. There are no assurances this will occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies and Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Critical Accounting Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussion and analysis
of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States.&#160;The preparation of these financial statements requires us to make
estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that
are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.&#160;&#160;Actual results may differ from these estimates
under different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We follow the guidance in
ASC 842 &#8220;<i>Accounting for Leases</i>,&#8221; as amended, which requires us to evaluate the lease agreements we enter into to determine
whether they represent operating or capital leases at the inception of the lease. Our Company is not party to any lease agreements. Our
corporate offices in Pointe-Claire, Quebec (Canada) are on a month-to-month, pay-per-use basis under a contract with Regus. Our arrangement
in connection with this office has no short-term or long-term asset or liability value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recently Adopted Accounting Standards</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the FASB
issued ASU 2019-12 &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; This guidance removes certain
exceptions to the general principles in Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing
guidance. The effective date of the new guidance for public companies is for fiscal years beginning after December&#160;15, 2020 and interim
periods within those fiscal years. Early adoption is permitted. We are currently evaluating the timing of adoption and impact of the updated
guidance on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, the FASB
issued ASU 2020-02,&#160;<i>Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant
to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02,
Leases (Topic 842)&#160;</i>which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13
and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022.
The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material
impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
August 2020, the FASB issued ASU 2020-06,&#160;<i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</i>, (&#8220;ASU 2020-06&#8221;). ASU 2020-06 simplifies
the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and
contracts on an entity&#8217;s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023,
and interim periods within those fiscal years.&#160;</span>Early adoption is permitted, but no earlier than fiscal years beginning after
December 15, 2020, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not entered into any
off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes
in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be
considered material to investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s11"></span><b>BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in the
State of Colorado on August 31, 2006 under the name &#8220;Mountain West Business Solutions, Inc.&#8221; Until October 2009, our business
was to provide management consulting services to small and home-office based companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2009, we acquired
Sunshine Biopharma, Inc., a Colorado corporation holding an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a.
As a result of this transaction we changed our name to &#8220;Sunshine Biopharma, Inc.&#8221; and our officers and directors resigned
their positions with us and were replaced by Sunshine Biopharma, Inc.&#8217;s management at the time, including our current chief executive
officer, Dr. Steve N. Slilaty, and our current chief financial officer, Camille Sebaaly each of whom remain part of our current management.
Our principal business became that of a pharmaceutical company focusing on the development of our licensed Adva-27a anticancer compound.
In December 2015 we acquired all issued and pending patents pertaining to our Adva-27a technology and terminated the license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2012, we published
the results of our initial preclinical studies of Adva-27a in the peer-reviewed journal, ANTICANCER RESEARCH. The preclinical studies
were conducted in collaboration with Binghamton University, a State University of New York. The publication is entitled &#8220;Adva-27a,
a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells&#8221; [ANTICANCER RESEARCH Volume
32, Pages 4423-4432 (2012)].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2014, we formed a
wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;), for the purposes of offering generic
pharmaceutical products in Canada and elsewhere around the world. Sunshine Pharma has since terminated its generic pharmaceuticals operations
to focus on development and marketing of science-based nutritional supplements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, we formed NOX
Pharmaceuticals, Inc., a Colorado corporation and wholly owned subsidiary of the Company, and assigned all of our interest in our Adva-27a
anticancer compound to that company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018, we completed
the development of a new nutritional supplement which we have branded Essential 9&#8482;. This new supplement is an over-the-counter tablet
comprised of the nine amino acids which the human body cannot make. Essential 9&#8482; has been authorized for marketing by Health Canada
under NPN 80089663. On March 12, 2019, Essential 9&#8482; became available for sale on Amazon.ca and shortly thereafter on Amazon.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2019, we received
Health Canada approval for a new Calcium-Vitamin D supplement. Health Canada issued NPN 80093432 through which it authorized us to manufacture
and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin D&#8482;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 22, 2020, we filed
a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19. Our patent application covers
composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential
for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty,
our chief executive officer. The patent application has a priority date of May 22, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective October 6, 2020,
we entered into a sponsored research agreement with the University of Georgia Research Foundation, Inc. (&#8220;UGARF&#8221;), representing
the University of Georgia (&#8220;UGA&#8221;). The purpose of the agreement is to memorialize the terms of our working together with UGA
to conduct the necessary research and development to advance our Anti-Coronavirus lead compound, SBFM-PL4 (or derivatives thereof) through
various stages of preclinical development, animal studies and clinical trials for Coronavirus infections. Under the agreement, we agreed
to fund research conducted by UGA for a research project relating to creation and testing of peptide-based coronavirus PLpro inhibitors.
In connection with the sponsored research agreement, we also entered into a license agreement with UGA pursuant to which we were granted
a worldwide exclusive license, for a term of five years (subject to earlier termination under certain conditions), to commercialize results
of such research.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 26, 2021, we received
a Notice of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued
patent contains new subject matter and extends the proprietary protection of Adva-27a in Canada until 2034.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On
February 4, 2021, we entered into an additional sponsored research agreement with the University of Georgia (&#8220;UGA&#8221;) for two
Anti-Coronavirus compounds which UGA had previously developed and patented. Under the agreement, we agreed to fund research conducted
by UGA relating to these two compounds. In connection with this agreement, we also entered into an additional license agreement with
UGA (&#8220;UGA License&#8221;) pursuant to which we were granted a worldwide exclusive license to commercialize results of such research.
In December 2021, we were informed by the University of Georgia that preliminary results of the mice study taking place indicated these
two compounds have no significant effect on mice infected with SARS-CoV-2. As a result, we no longer plan to pursue the UGA License or
further development of these two compounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 9,
2021, we received a Notice of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued
patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2034. The equivalent patent in the
United States was issued in 2019 (US Patent Number 10,272,065).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are
in discussions with a university regarding a new research agreement for the development of additional potential treatments for Covid-19.
There is no assurance such an agreement will be completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proprietary Drug Development Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>SBFM-PL4 Anti-Coronavirus Treatment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Viruses carry minimal genetic
information as they rely, for the most part, on host cellular machinery to multiply. Coronavirus has a positive-sense RNA genome consisting
of approximately 30,000 nucleotides, a genome size that places it among the larger sized viruses. A positive-sense RNA genome is effectively
a messenger RNA which allows the virus to express its genes immediately upon gaining entry into the host cell without the need for any
prior replication or transcription steps as is the case with negative-sense RNA or DNA viruses. This is part of what makes Coronavirus
a highly aggressive pathogen. Many of the causative agents of serious human diseases are positive-sense RNA viruses, including Hepatitis
C, Zeka, Polio, West Nile, Dengue, Cardiovirus, and many others. Some positive-sense RNA viruses, such as the rhinoviruses that cause
the common cold, are less clinically serious but they are responsible for widespread morbidity on a yearly basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The initial genome expression
products of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Covid-19, are two large polyproteins,
referred to as pp1a and pp1ab. These two polyproteins are cleaved at 15 specific sites by two virus encoded proteases (Mpro and PLpro)
to generate 16 different non-structural proteins essential for viral replication. Mpro and PLpro represent attractive anti-viral drug
development targets as they play a central role in the early stages of viral replication. The crystal structure of Mpro shows the presence
of an active site Cysteine (Cys145) and a coordinated active site Histidine (His41), both of which are essential for the enzyme&#8217;s
proteolytic activity. Similarly, PLpro, also a Cysteine Protease, has an active site Cysteine at position 112 and a Histidine at 273.
The following is a summary of the development to date of our Coronavirus Treatment project:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">On May 22, 2020, we filed a patent application in the United States for a new treatment for Coronavirus
infections. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the Coronavirus main
protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer
modelled and designed by Dr. Steve N. Slilaty, our chief executive officer. The patent application has a priority date of May 22, 2020.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">In August 2020, we completed the synthesis of four different potential inhibitors of Coronavirus protease.
These compounds are based on the technology described in our patent application filed on May 22, 2020.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">In September 2020, we completed the screening of our four compounds and subsequently identified a lead
Anti-Coronavirus drug candidate (SBFM-PL4). The screening which pinpointed the lead compound was performed at the University of Georgia,
College of Pharmacy under the leadership of Dr. Scott D. Pegan, Director of the Center for Drug Discovery and Interim Associate Head of
Pharmaceutical and Biomedical Sciences.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">In October 2020, we expanded our collaboration with Dr.
Scott Pegan&#8217;s group by entering into a research agreement with the University of Georgia to further develop our Anti-Coronavirus
lead compound, SBFM-PL4. We will proceed by conducting the in vitro studies followed by cell culture assays and assessment in Coronavirus
infected mice before entering human clinical trials.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adva-27a Anticancer Drug</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, our proprietary
drug development activities has focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of
cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including
Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH,
Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to
Adva-27a including U.S. Patents Number 8,236,935 and 10,272,065.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="image_007.jpg" alt="" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: Black"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Figure 1</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adva-27a is a GEM-difluorinated
C-glycoside derivative of Podophyllotoxin (see Figure 1). Another derivative of Podophyllotoxin called Etoposide is currently on the market
and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer,
bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Etoposide is one of the most widely used
anticancer drugs. Adva-27a and Etoposide are similar in that they both attack the same target in cancer cells, namely the DNA unwinding
enzyme, Topoisomerase II. Unlike Etoposide however, Adva-27a is able to penetrate and destroy Multidrug Resistant Cancer cells. Adva-27a
is the only compound known today that is capable of destroying Multidrug Resistant Cancer. In addition, Adva-27a has been shown to have
distinct and more desirable biological and pharmacological properties compared to Etoposide. In side-by-side studies using Multidrug Resistant
Breast Cancer cells and Etoposide as a reference, Adva-27a showed markedly greater cell killing activity (see Figure 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="image_008.jpg" alt="" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Figure 2</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our preclinical studies to
date have shown that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Adva-27a is effective at killing different types of Multidrug Resistant cancer cells, including Pancreatic
Cancer Cells (Panc-1), Breast Cancer Cells (MCF-7/MDR), Small-Cell Lung Cancer Cells (H69AR), and Uterine Sarcoma Cells (MES-SA/Dx5).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to
anti-tumor drugs.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability
studies and pharmacokinetics data in rats.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic
intermediates.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar (this number
has recently been reduced to 1.44 micromolar as a result of resolving the two isomeric forms of Adva-27a).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Adva-27a does not inhibit tubulin assembly.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other preclinical
data have been published in ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment. The publication
which is entitled &#8220;Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells&#8221;
[ANTICANCER RESEARCH 32: 4423-4432 (2012)] is available on our website at www.sunshinebiopharma.com. Information on our website is not
part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been delayed in our
clinical development program due to lack of funding. Our fund raising efforts are continuing and as soon as adequate financing is in place
we will continue our clinical development program of Adva-27a by conducting the following next sequence of steps:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">GMP Manufacturing of 2 kilogram for use in IND-Enabling Studies and Phase I Clinical Trials</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">IND-Enabling Studies</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Regulatory Filing (Fast-Track Status Anticipated)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Phase I Clinical Trials (Pancreatic Cancer Indication)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adva-27a&#8217;s initial indication
will be pancreatic cancer for which there are currently little or no treatment options available. We are planning to conduct our clinical
trials at McGill University&#8217;s Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will employ
FDA standards at all levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the American
Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year. While particularly effective against Multidrug
Resistant Cancer, we believe Adva-27a can potentially treat all cancer types, particularly those in which Topoisomerase II has been amplified.
We believe that upon successful completion of Phase I Clinical Trials we may receive one or more offers from large pharmaceutical companies
to purchase or license our drug. However, there are no assurances that our Phase I Trials will be successful, or if successful, that any
pharmaceutical companies will make an acceptable offer to us. In the event we do not consummate such a transaction, we will require significant
capital in order to manufacture and market our new drug on our own. The following, Figure 3, is a space-filling molecular model of our
Adva-27a.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="image_009.jpg" alt="" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Figure 3</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nutritional Supplements Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sunshine Canada has recently
terminated its generic pharmaceuticals operations and shifted its focus to the development and marketing of science-based nutritional
supplements. In December 2018, we completed the development of Essential 9<span style="font-variant: small-caps"><sup>&#8482;</sup></span>.
On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized us to manufacture and sell the Essential 9&#8482;
product. Our Essential 9&#8482; nutritional supplement tablets contain a balanced formula of the 9 Essential Amino Acids that the human
body cannot make. Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all
body functions &#8211; From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids
cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead
to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Our Essential 9&#8482; provides all
9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9&#8482; is currently available on
Amazon.com and Amazon.ca. Figure 4 below shows our 60-Tablet Essential 9&#8482; product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img src="image_010.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Figure 4</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2019, we received
Health Canada approval for another nutritional supplement, a new Calcium-Vitamin D tablets. Health Canada issued NPN 80093432 through
which it authorized us to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin D&#8482;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vitamin D is a group of steroid-like
molecules responsible for increasing intestinal absorption of calcium, magnesium, and phosphate. They are also involved in multiple other
biological functions, including proper functioning of the immune system, promoting healthy growth of bone, and reduction of inflammation.
The most important compounds in this group are Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol). Sunshine Biopharma&#8217;s
Essential Calcium-Vitamin D&#8482; tablets contain both of these compounds as well as calcium for optimum health benefits. We do not plan
to launch our Essential Calcium-Vitamin D&#8482; product in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also developing additional
nutritional supplement products. We may launch additional nutritional supplement products within approximately 1-2 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Essential 9&#8482; nutritional
supplement is manufactured under contract by Inov Pharma Inc., an independent third party based in Montreal (Canada). Inov Pharma Inc.
operates a GMP certified manufacturing facility and all of our nutritional supplements products are manufactured under such conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have any
pharmaceutical products on the market. Research quantities of our drug candidates are currently manufactured at the University of Georgia,
Athens, GA (Anti-Coronavirus compounds) and WuXi App Tech (Adva-27a compound) in China.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Marketing and Sales</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Essential 9&#8482; nutritional
supplement is currently sold through Amazon only. Company personnel and outside consultants develop and place ads on Google, YouTube and
Amazon, and the same team manages the Company&#8217;s account with Amazon.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While particularly effective
against Multidrug Resistant Cancer, we believe Adva-27a can potentially treat all cancer types, particularly those in which Topoisomerase
II has been amplified. Similarly, we believe there is potentially a large market for our Anti-Coronavirus treatment currently under development
at the University of Georgia. We believe that upon successful completion of Phase I Clinical Trials, we may receive one or more offers
from large pharmaceutical companies to purchase or license these drugs. However, there are no assurances that our Phase I Trials will
be successful, or if successful, that any pharmaceutical companies will make an acceptable offer to us. If we do not consummate such a
transaction, and we receive required regulatory approvals, we will require significant capital in order to manufacture and market our
new drugs on our own.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are the exclusive owner
of all worldwide rights pertaining to Adva-27a covered by PCT/FR2007/000697 and PCT/CA2014/000029.&#160;The patent applications filed
under PCT/FR2007/000697 have been issued in the United States (US Patent Number 8,236,935), Europe, and Canada.&#160;The patent applications
filed under PCT/CA2014/000029 have recently been issued in the United States (US Patent Number 10,272,065), and allowed in Europe, and
Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2018 we completed the
development of Essential 9&#8482;, our first nutritional supplement. On December 14, 2018, Health Canada issued NPN 80089663 through which it
authorized Sunshine Biopharma Inc. to manufacture and sell the Essential 9&#8482;<span style="font-variant: small-caps"> </span>product. We
are currently preparing the necessary documents for registration of our Essential 9&#8482;<span style="font-variant: small-caps"> </span>trademark
in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2019, we received
Health Canada approval for another nutritional supplement, a new Calcium-Vitamin D tablets. Health Canada issued NPN 80093432 through
which it authorized us to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin D<span style="font-variant: small-caps"><sup>&#8482;</sup></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 22, 2020, the Company
filed a provisional patent application in the United States for a new treatment for Coronavirus infections. The Company&#8217;s patent
application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an
enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company
filed a PCT application containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro.
The priority date of May 22, 2020 has been maintained in the newly filed PCT application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our business operations,
including our proprietary drug development operations, and nutritional supplements operations are subject to extensive and frequently
changing federal, state, provincial and local laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
Federal Government agency responsible for regulating drugs and nutritional supplements is the U.S. Food and Drug Administration (&#8220;FDA&#8221;).
The Canadian counterpart to the FDA is Health Canada. Though the FDA and Health Canada have generally similar requirements for drugs and
nutritional supplements to be approved or allowed to be marketed, approval in one jurisdiction does not automatically result in approval
in the other. In Canada, drugs and nutritional supplements are authorized through the issuance by Health Canada of a Drug Identification
Number (DIN) for pharmaceutical products and a Natural Product Number (NPN) for nutritional supplements. In the United States, the marketing
of nutritional supplements does not require prior approval from the FDA. In both the U.S. and Canada, the ingredients, manufacturing processes
and facilities for all drugs and supplements must meet the guidelines for Good Manufacturing Practices (&#8220;GMP&#8221;). Moreover,
all drug manufacturers must perform a series of tests, both during and after production, to show that every drug or supplement batch made
meets the regulatory requirements for that product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with nutritional
supplements, the FDA regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution and sale of such
products, while the Federal Trade Commission (&#8220;FTC&#8221;) regulates marketing and advertising claims. In August 2007, a rule issued
by the FDA went into effect requiring companies that manufacture, package, label, distribute or hold nutritional supplements to meet certain
GMP requirements to ensure such products are of the quality specified and are properly packaged and labeled. We are committed to meeting
or exceeding the standards set by the FDA and the FTC and we believe we are currently operating within both the FDA and FTC mandates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the area of drug development
where our Anti-Coronavirus and Anti-Cancer compounds fall, we will be subject to significant regulations in the U.S. in order to obtain
approval of the FDA to offer our products for sale. The approximate&#160;procedure for obtaining FDA approval involves an initial
filing of an IND application following which the FDA would review and allow for the drug developer to proceed with Phase I clinical trials.&#160;Following
completion of Phase I, the results are filed with the FDA and a request is made to proceed to Phase II.&#160;Similarly, following completion
of Phase II the data are filed with the FDA and a request is made to proceed to Phase III.&#160;Following completion of Phase III, a new
drug application, or NDA is submitted and a request is made for marketing approval. Depending on various issues and considerations,
the FDA could provide &#8220;emergency use authorization&#8221; or limited approval for &#8220;compassionate-use&#8221; if the drug treats
terminally ill patients with limited other treatment options available.&#160;&#160;As of the date of this prospectus we have not made
any filings with the FDA or other regulatory bodies in other jurisdictions.&#160; We anticipate filing an initial IND application for
an anti-Covid-19 compound within approximately one year and filing an initial IND for our anti-cancer compound within approximately two
years. We have however had discussions with clinicians and as a result we believe that the FDA and Health Canada&#160;are likely to grant
us a so-called &#8220;fast-track&#8221; process on the basis of the ongoing Covid-19 pandemic and the terminal nature of the cancer type
we are planning to treat.&#160;There are no assurances this will occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus
we have three employees, comprised of our management team. Presently, most of our development and marketing activities are subcontracted
out to specialized service providers. As our business activities expand, we anticipate that we will need additional employees in the areas
of accounting, regulatory affairs, marketing, sales and laboratory personnel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition &#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our
Anti-Coronavirus drug development project is in direct competition with over 34 companies in the U.S. and abroad that are developing
or that have developed vaccine or treatment options for Covid-19. Among the companies that have or are developing vaccines are Pfizer,
Moderna, AstraZeneca, and Johnson &amp; Johnson. The companies focused on treatments include Pfizer, Merck, Gilead, Eli Lilly, and Regeneron.
To date, three vaccines (Pfizer&#8217;s, Moderna&#8217;s, and Johnson &amp; Johnson&#8217;s) and two (2) antibody treatments (Regeneron&#8217;s,
and Eli Lilly&#8217;s) have been approved by the FDA for emergency use, and Pfizer&#8217;s vaccine has received full FDA approval. Gilead&#8217;s
Remdesivir, an antiviral injectable, was approved by the FDA for treatment of Covid-19 in October 2020. In addition, in December 2021,
Pfizer received Emergency Use Authorization (&#8220;EUA&#8221;), for its antiviral pill, Paxlovid, and, in the same month, the FDA granted
Merck EUA for its antiviral pill, Molnupiravir. While the approved vaccines, pills and injectable treatments are effective, we believe
that additional treatment options such as the one we are developing could potentially form an important component of the range of anti-coronavirus
tools available to attending physicians.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the area of anticancer
drug development, we compete with large publicly and privately held companies engaged in developing new cancer therapies. There are numerous
other entities engaged in oncology therapeutics development that have greater resources, both financial and otherwise, than the resources
presently available to us.&#160;&#160;Nearly all major pharmaceutical companies including Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb
and Novartis, to name a few, have on-going anticancer drug development programs and some of the drugs they may develop could be in direct
competition with our own. In addition, a number of smaller companies are working in the area of cancer therapy and could develop
drugs that may be in competition with ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, our Essential
9&#8482; and Essential Calcium-Vitamin D&#8482; fall directly within a very crowded and highly competitive product sector. As of the
date of this prospectus, we believe Essential 9&#8482; is the only Essential Amino Acid product that comprises all 9 essential amino acids in
tablet form. We believe this may provide us with a competitive advantage, at least for the near future but there are no assurances that
this will occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal place of business
is located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. We pay a monthly fee of $261 (Canadian), including
applicable taxes for use of the available space and services. We are not party to a lease agreement in connection with this service. Additional
office space and conference rooms are available to us on a pay-per-use basis. We believe that our existing facilities and equipment
are adequate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not party to, and our property is not the
subject of, any material legal proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><br />
</p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s12"></span><b>MANAGEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors and Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table and biographical summaries
set forth information, including principal occupation and business experience about our directors and executive officers:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 23%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-size: 10pt">&#160; <b>Age</b> &#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 67%"><span style="font-size: 10pt"><b>Position(s)</b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Dr. Steve N. Slilaty</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">69</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">President, Chief Executive Officer and Chairman</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Dr. Abderrazzak Merzouki</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">57</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Operating Officer and Director</span></td></tr>

<tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Camille Sebaaly</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">60</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Financial Officer and Secretary</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Andrew I. Telsey</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">James (JD) Kish</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">67</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Dr. Rabi Kiderchah</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom">David Natan</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">68</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">Director nominee&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom">Dr. Andrew Keller</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">68</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">Director nominee&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dr. Steve N.
Slilaty</i></b> was appointed as our chief executive officer and chairman of our board of directors on October 15, 2009.&#160;Dr.
Slilaty is an accomplished scientist and business executive. His scientific publications are widely cited. Sunshine Biopharma is the
third in a line of biotechnology companies that Dr. Slilaty founded and managed. The first, <i>Quantum Biotechnologies Inc.</i>
later known as <i>Qbiogene Inc.</i>, was founded in 1991 and is now a member of a family of companies owned by <i>MP
Biomedicals</i>, one of the largest international suppliers of biotechnology reagents and other research products.&#160;The second
company which Dr. Slilaty founded, <i>Genomics One Corporation</i>, conducted an initial public offering of its capital stock in
1999 and, on the basis of its ownership of Dr. Slilaty&#8217;s patented TrueBlue Technology, <i>Genomics One</i> became one of the
key participants in the Human Genome Project and reached a market capitalization of $1 billion in 2000. Formerly, Dr. Slilaty was a
research team leader at the <i>Biotechnology Research Institute (Montreal)</i>, a division of the <i>National Research Council of
Canada</i>. Dr. Slilaty is one of the pioneers of Gene Therapy having developed the first gene delivery system applicable to humans
in 1983 [<i>Science <b>220:</b> 725-727 (1983)</i>]. Dr. Slilaty's other distinguished scientific career accomplishments was the
discovery of a new class of enzymes, the S24 Family of Proteases (IUBMB Enzyme: EC 3.4.21.88) [<i>Proc. Natl. Acad. Sci. U.S.A. <b>84:</b>
3987-3991 (1987)</i>]. In addition, Dr. Slilaty (i) developed the first site-directed mutagenesis system applicable to
double-stranded DNA [<i>Analyt. Biochem. <b>185:</b> 194-200 (1990)</i>], (ii) cloned the gene for the first yeast-lytic enzyme
(lytic b-1,3-glucanase) [<i>J. Biol. Chem. <b>266:</b> 1058-1063 (1991)</i>], (iii) developed a new molecular strategy for
increasing the rate of enzyme reactions [<i>Protein Engineering <b>4:</b> 919-922 (1991)</i>], and (iv) constructed a powerful new
cloning system for genomic sequencing (TrueBlue&#174; Technology) [<i>Gene <b>213:</b> 83-91 (1998)</i>]. Most recently, Dr.
Slilaty, in collaboration with Institut National des Sciences Appliqu&#233;e (France), State University of New York at Binghamton
(USA) and &#201;cole Polytechnique, Universit&#233; de Montr&#233;al (Canada), designed, patented, and advanced the development the
first, and currently the only known anticancer compound (Adva-27a) capable of destroying multidrug resistant cancer cells
[<i>Anticancer Res. <b>32:</b> 4423 (2011) and US Patent Numbers: 8,236,935 and 10,272,065</i>]. These and other works of Dr.
Slilaty are cited in research papers, editorials, review articles and textbooks. Dr. Slilaty is the author of 18 original research
papers and 10 issued and pending. These and other works of Dr. Slilaty are cited in research papers, editorials, review articles and
textbooks. Dr. Slilaty received his Ph.D. degree in Molecular Biology from the University of Arizona in 1983 and Bachelor
of Science degree in Genetics and Biochemistry from Cornell University in 1976. Dr. Slilaty has received research grants from the
NIH and NSF and he is the recipient of the 1981 University of Arizona Foundation award for Meritorious Performance in Teaching.  Dr. Slilaty&#8217;s scientific knowledge and experience qualifies him
to serve on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dr. Abderrazzak
Merzouki</i></b> was appointed as a director and our chief operating officer in February 2016. In addition to his
positions with our Company since January 2016 he has been self-employed as a consultant in the fields of biotechnology and
pharmacology. From July 2007 through December 2016, Dr. Merzouki worked at the Institute of Biomedical Engineering in the
Department of Chemical Engineering at Ecole Polytechnique de Montreal, where he taught and acted as a senior scientist involved in
the research and development of plasmid and siRNA-based therapies. Dr. Merzouki is a molecular biologist and an immunologist
with extensive experience in the area of gene therapy where he performed several preclinical studies for pharmaceutical companies
involving the use of adenoviral vectors&#160;for cancer therapy and plasmid vectors for the treatment of peripheral arterial
occlusions. Dr. Merzouki also has extensive expertise in the design of expression vectors, and production and purification of
recombinant proteins. He developed technologies for production of biogeneric therapeutic proteins for the treatment of various
diseases including cancer, diabetes, hepatitis and multiple sclerosis. Dr. Merzouki obtained his Ph.D. in Virology and
Immunology from Institut Armand-Frappier in Quebec and received his post-doctoral training at the University of British Columbia and
the BC Center for Excellence in HIV/AIDS research. Dr. Merzouki has over 30 publications and 70 communications in various, highly
respected scientific journals in the field of cellular and molecular biology.  Dr. Merzouki&#8217;s scientific knowledge and experience qualifies him to serve on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Camille
Sebaaly</i></b> was appointed as our chief financial officer, secretary and a director of our Company on October 15, 2009. He
resigned as a director of the Company in October 2021. Since 2001, Mr. Sebaaly has been self-employed as a business consultant,
primarily in the biotechnology and biopharmaceutical sectors. He held a number of senior executive positions in various areas
including financial management, business development, project management and finance. As an executive and an entrepreneur, he
combines expertise in strategic planning and finance with strong skills in business development and deal structure and
negotiations.&#160;In addition, Mr. Sebaaly worked in operations, general management, investor relations, marketing and business
development with emphasis on international business and marketing of advanced technologies including hydrogen generation and energy
saving. In the area of marketing, Mr. Sebaaly has evaluated market demands and opportunities, created strategic marketing
and business development plans, designed marketing communications and launched market penetration programs. Mr. Sebaaly graduated
from State University of New York at Buffalo with an Electrical and Computer Engineering Degree in 1987. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Andrew
I. Telsey</i></b> has served as a director of the Company since October 2021 and will resign as a director upon the earlier of completion
of this offering or when the Company&#8217;s director and officer insurance coverage will be in effect. Mr. Telsey is an &#8220;AV&#8221;
rated attorney licensed to practice law in the State of Colorado since 1980. Since 1984, Mr. Telsey has been President and sole shareholder
of Andrew I. Telsey, P.C., Centennial, Colorado, a law firm emphasizing securities law, business transactions, mergers and acquisitions
and general corporate matters for public and privately held development stage and emerging growth companies throughout both the US and
internationally, including Russia, China, England, Italy, Mexico, Canada, Switzerland, Germany and several other countries. He has been
our legal counsel since our inception. Mr. Telsey received a Juris Doctor degree from Syracuse University College of Law in 1979 and
a Bachelor of Arts degree Magna Cum Laude, majoring in politics, from Ithaca College in 1975. He was also named as one of Denver&#8217;s
Top Lawyers by the Denver Post in 2015-2019. Mr. Telesey&#8217;s experience as our legal counsel qualifies him to serve on our board
of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>James
(JD) Kish</i></b> has served as a director of the Company since October 2021 and will resign as a director upon the earlier of the
completion of this offering or when the Company&#8217;s director and officer insurance coverage will be in effect. Mr. Kish has been
a licensed Certified Public Accountant and President of KLA PC, Centennial, CO, an accounting firm, since 1982. He has worked with
our Company since our inception. Mr. Kish received a Bachelor of Business Administration degree from Ohio University in 1976, and an
MBA degree from DePaul University in 1981. He is a licensed certified accountant in Colorado, Kansas, &amp; Florida. Mr.
Kish&#8217;s accounting knowledge and experience qualifies him to serve on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dr.
Rabi Kiderchah </i></b>has served as a director of the Company since October 2021. Dr. Kiderchah is a licensed physician in Canada. From
2000 until August 2021, he was working at Argenteuil Hospital, Lachute, Quebec, Canada, as an emergency room physician. He has also worked
as what is referred to in Canada as a &#8220;medecins depanneurs&#8221;, working in rural areas where there are not enough ER doctors.
Since August 2011 he has worked at Rabi Kiderchah Medecin Inc. as a freelance physician in the Quebec, Canada area. He received a Bachelor
of Science degree in 1994 and an MD degree in 1998 from the University of Montreal. Dr. Kiderchah&#8217;s medical and scientific knowledge
and experience qualifies him to serve on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>David
Natan</i></b> has been appointed to serve on our board of directors, effective upon the earlier of completion of
this offering or when the Company&#8217;s director and officer insurance coverage will be in effect. Since 2007, Mr. Natan has served
as President and Chief Executive Officer of Natan &amp; Associates, LLC, Parkland, Florida, a privately held consulting firm offering
chief financial officer services to public and private companies in a variety of industries. In addition, since April 2020 Mr. Natan
has served as Executive Vice President and Chief Financial Officer for Airborne Motorworks, Inc., Spokane, WA, a privately-held aerospace
transportation company, Since February 2021, Mr. Natan has also been a director and Chairperson of the Audit Committee of Global Diversified
Marketing Group, Inc. (OTCMKTS: GDMK), a manufacturer, marketer and distributor of food and snack products. From February 2010 to May
2020, Mr. Natan served as Chief Executive Officer of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on the solar industry
and LED lighting products. He was also Chairman of the Board of this company from April 2015 to May 2020. Additionally, Mr. Natan served
in various roles of increasing responsibility with Deloitte &amp; Touche LLP, a global consulting firm, as well as a member of the Board
of Directors of various companies. Mr. Natan holds a B.A. in Economics from Boston University. Mr. Natan&#8217;s experience as business
executive and as a director of public companies qualify him to serve on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dr.
Andrew M. Keller</i></b> has been appointed to serve on our board of directors, effective upon the earlier of completion
of this offering or when the Company&#8217;s director and officer insurance coverage will be in effect. From 2016 through November 2019,
Dr. Keller was the Chief Medical Officer at the Western Connecticut Medical Group, Bethel CT, a multispecialty organization. He was employed
by this group beginning in 1989, and in 2003 became Chief &#8211; Section of Cardiovascular Diseases. In 2014 he was appointed Chief
Medical Informatics Officer. Previously, Dr. Keller was an Assistant Professor of Medicine/Radiology at Columbia University, The College
of Physicians and Surgeons, NY, NY. Dr. Keller retired as a practicing physician in 2019 and in 2020, became a full time student at Quinnipiac
University College of Law, where he is currently in his second year. Dr. Keller received a Doctor of Medicine degree in 1979 from The
Ohio State University and a Bachelor of Arts degree in Physics, Magna Cum Laude from Ithaca College in 1975. Dr. Keller&#8217;s medical
and scientific knowledge and experience qualify him to serve on our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors Term of Office</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors are elected at our
annual meeting of shareholders and serve for one year until the next annual meeting of shareholders or until their successors are elected
and qualified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.
Telsey, Mr. Kish, and Dr. Kidershah are independent as defined under Nasdaq Marketplace Rules. Upon completion of this offering, our
independent directors will consist of Dr. Kidershah, Mr. Natan and Dr. Keller.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of our Board of
Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
Company has established an audit committee, a compensation committee, and a corporate governance and nominating committee of our board
of directors. Upon the completion of this offering, each committee will be comprised of each of our independent directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>No Family Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no family relationship
between any director and executive officer or among any directors or executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Involvement in Certain Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors and executive
officers have not been involved in any of the following events during the past ten years:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">being found by a court of competent jurisdiction in a civil action, the SEC or the CFTC to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a Code of
Ethics that applies to our principal executive officer, principal financial officer, and principal accounting officer. Our Code of Ethics
is available on our website at www.sunshinebiopharma.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
compensation information for services rendered by our executive officers in all capacities during the last two completed fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt"><b>Name and Principal Position</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Salary
    ($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Bonus
    ($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Stock
    Awards ($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>All
    Other Compensation ($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Total
    ($)</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt"><b>Dr. Steve N. Slilaty</b></span></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Chief Executive Officer and Director&#160;</span></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 28%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">2021</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">156,380(1)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#8211;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">306,000(2)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#8211;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">462,380</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2020</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">177,000(1)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">50,000(3)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">227,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt"><b>Camille Sebaaly</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Chief Financial Officer and Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">40,000&#160;&#160;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">306,000<span style="font-size: 10pt">(2)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">346,000</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2020</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">20,000&#160;&#160;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">- &#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">20,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt"><b>Dr. Abderrazzak Merzouki</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Chief Operating Officer and Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">109,927&#160;&#160;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">306,000<span style="font-size: 10pt">(2)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">415,927</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2020</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">24,930&#160;&#160;&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8211; <span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">24,930</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">________________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 27px; font-size: 10pt"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Portions of these amounts were
    paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by Dr. Slilaty.</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 27px; font-size: 10pt"><span style="font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Represents stock award valued at $3.06 per
    share, the closing price of the common stock on the date of grant of January 6, 2021.</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 27px; font-size: 10pt"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">In consideration for services
    valued at $50,000, Dr. Slilaty was issued 500,000 shares of Series B Preferred Stock, valued based on the stated value of $0.10.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Agreements&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not party to any employment
agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at 2021 Fiscal Year-End</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not have any outstanding
equity awards as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not pay any compensation
to our directors during the year ended December 31, 2021, except as set forth in the summary compensation table above.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s13"></span><b>TRANSACTIONS WITH RELATED PERSONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had
an outstanding note dated December 31, 2019 held by Dr. Steve N. Slilaty, our chief executive officer, with a principal amount of $128,269,
accruing interest at 12% per year, which was due December 31, 2020. On December 31, 2020, we renewed this note together with accrued
interest of $15,392 for a 12-month period. The new note had a principal amount of $143,661, accrued interest at 12% per year, and had
a maturity date of December 31, 2021. On August 24, 2021, the Company paid off the entire principal balance of this note, together with
accrued interest of $12,929 by making a cash payment of $156,590.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the
year ended December 31, 2020, we issued to Dr. Slilaty 500,000 shares of Series B Preferred Stock for services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Andrew
Telsey, who was elected a director of the Company in October 2021, is the sole shareholder of Andrew I. Telsey, P.C., a law firm that
provides legal services to the Company. During the years ended December 31, 2020 and 2019, the Company paid the firm $36,042 and $26,648
in legal fees and expenses. During the year ended December 31, 2021, the Company paid the firm $35,281 in legal fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">James (JD) Kish, who was
elected a director of the Company in October 2021, provides accounting services to the Company. During the year ended December 31, 2020
the Company paid Mr. Kish $20,000 in fees for accounting services. During the year ended December 31, 2019 issued to Mr. Kish 1,150
shares of common stock for accounting services. During the year ended December 31, 2021, the Company paid Mr. Kish $27,000 in fees
for accounting services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Rabi Kiderchah, who was
elected a director of the Company in October 2021, has previously been a consultant to the Company. During the year ended December 31,
2019, the Company issued to Dr. Kiderchah 1,625 shares of common stock for services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon closing of this offering,
we will redeem 990,000 shares of Series B Preferred Stock held by Dr. Steve Slilaty at a redemption price equal to the stated
value of $0.10 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s14"></span>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth certain information, as of February 2, 2022, with respect to the
beneficial ownership of the outstanding common stock and Series B Preferred Stock by (i) any holder of more than five (5%) percent;
(ii) each of our executive officers and directors; and (iii) our directors and executive officers as a group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined beneficial
ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who
possess sole or shared voting power or investment power with respect to those securities. The table lists applicable percentage ownership
based on 2,591,241 shares of common stock and 1,000,000 shares of Series B Preferred Stock outstanding as of January 28, 2022.
In addition, under SEC rules, beneficial ownership of common stock include shares of our common stock issuable pursuant to the conversion
or exercise of securities that are either immediately exercisable or convertible into common stock or exercisable or convertible into
common stock within 60 days of January 28, 2022. These shares are deemed to be outstanding and beneficially owned by the person
holding those securities for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding
for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified
in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable
community property laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: left; font-weight: bold">Title of
    Class</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Address of Beneficial Owner</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Amount and Nature of
    Beneficial Ownership</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="color: #212529; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Percent of Common Class</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; width: 11%; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Common</b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 57%; text-align: left"><p style="margin-top: 0; margin-bottom: 0">Dr. Steve N. Slilaty</p>
                                                             <p style="margin-top: 0; margin-bottom: 0">579 Rue Lajeunesse <br />Laval,
                                            Quebec <br />Canada H7X 3K4</p></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">121,024</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">4.7%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Common</b></span></td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">Camille Sebaaly <br />14464 Gouin West, #B <br />Montreal, Quebec <br />Canada H9H 1B1</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">119,465</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">4.6%</td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Common</b></span></td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">Dr. Abderrazzak Merzouki <br />731 Place de l&#8217;Eeau Vive <br />Laval, Quebec <br />Canada
    H7Y 2E1</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">116,720</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">4.5%</td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="2" style="vertical-align: top; text-align: left"><b>Common</b>&#160;</td>
    <td style="color: #212529; text-align: left">Andrew Telsey <br />6198 South Moline Court <br />Englewood, CO 80111</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">15</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right"><span style="font-size: 10pt">*</span></td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="vertical-align: top; text-align: left">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">&#160;</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">&#160;</td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="2" style="vertical-align: top; text-align: left"><b>Common</b>&#160;</td>
    <td style="color: #212529; text-align: left">James (JD) Kish <br />c/o Sunshine Biopharma, Inc. <br />6500 Trans-Canada Highway <br />4th
    Floor, Pointe-Claire, <br />Quebec H9R 0A5, Canada</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">1,448</td><td style="color: #212529; text-align: left">(2)</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right"><span style="font-size: 10pt">*</span></td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="vertical-align: top; text-align: left">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">&#160;</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">&#160;</td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td colspan="2" style="vertical-align: top; text-align: left"><b>Common</b>&#160;</td>
    <td style="color: #212529; text-align: left">Dr. Rabi Kiderchah <br />c/o Sunshine Biopharma, Inc. <br />6500 Trans-Canada Highway
    <br />4th Floor, Pointe-Claire, <br />Quebec H9R 0A5, Canada</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">1,625</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right"><span style="font-size: 10pt">*</span></td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="vertical-align: top; text-align: left">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">&#160;</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">&#160;</td><td style="color: #212529; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">All Officers and Directors As Group (6 persons):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">360,297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.9%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Common</b></span></td><td>&#160;</td>
    <td><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Robert K. Beathard, 3<sup>rd</sup>/Angela R. Beathard
        (3)</span></p>
        <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">24915 Falling Water Estates Ln <br />Katy, TX 77494</span></p></td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">196,159</td><td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529">&#160;</td>
    <td style="color: #212529; text-align: left">&#160;</td><td style="color: #212529; text-align: right">7.6%</td><td style="color: #212529; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">____________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Less than 1%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 2pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 20pt; text-align: left">(1)</td><td style="text-align: justify">Includes 4,306 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            held in the name of Advanomics Corporation (now known as TRT Pharma Inc.). <span style="color: #212529">Dr.
                                            Slilaty is an officer, director and principal shareholder of TRT Pharma Inc. and, as a result,
                                            controls the disposition of these shares. Dr. Slilaty also owns all of our 1,000,000 outstanding
                                            shares of Series B Preferred Stock. Each share of Series B Preferred Stock entitles the holder
                                            to 1,000 votes. Upon closing of this offering, 990,000 shares of Series B Preferred
                                            Stock will be redeemed by the Company and Dr. Slilaty will retain 10,000 shares of
                                            Series B Preferred Stock.</span></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 2pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 20pt; text-align: left">(2)</td><td style="text-align: justify">Includes 13 shares
                                            held by Mr. Kish&#8217;s spouse.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 2pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 20pt; text-align: left">(3)</td><td style="text-align: justify">Based on Schedule 13G filed with the SEC on July 29, 2021.</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s15"></span>DESCRIPTION OF CAPITAL STOCK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized capital stock
consists of 3,000,000,000 shares of common stock, par value of $0.001 per share, and 30,000,000 shares of preferred stock, par value $0.10
per share. 1,000,000 shares of our preferred stock are designated as Series B Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of February 2, 2022,
there were 2,591,241 shares of our common stock and 1,000,000 shares of our Series B Preferred Stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common</b><b> Units</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Common Unit consists
of one share of common stock and two Warrants, each exercisable for one share of common stock, each as described further below. The Common
Units will not be issued or certificated. Purchasers of Common Units will receive only shares of common stock and Warrants. The common
stock and Warrants may be transferred separately immediately upon issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-Funded Units</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each
Pre-funded Unit consists of one Pre-Funded Warrant and two Warrants, each exercisable for one share of common stock,
each as described further below. The Pre-Funded Units will not be issued or certificated. Purchasers of Pre-Funded Units will
receive only Pre-Funded Warrants and Warrants. The Pre-Funded Warrants and Warrants may be transferred separately immediately upon
issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of common stock do not have cumulative
voting rights. Therefore, holders of a majority of the voting power of our stockholders for the election of directors can elect all of
the directors. Holders of the majority of the voting power of the Company&#8217;s stockholders, outstanding and entitled to vote, represented
in person or by proxy, are necessary to constitute a quorum at any meeting of stockholders. A vote by the holders of a majority of the
voting power of the Company&#8217;s stockholders is required to effectuate certain fundamental corporate changes such as liquidation,
merger or an amendment to the Company&#8217;s certificate of incorporation. Our chief executive officer, through his ownership of Series
B Preferred Stock and common stock, currently holds the majority of the voting power of our stockholders (see &#8220;Security Ownership
of Certain Beneficial Ownership and Management&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
are entitled to share in all dividends that the board of directors, in its discretion, declares from legally available funds. In the
event of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that
remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. The
Company&#8217;s common stock has no pre-emptive rights, no conversion rights and there are no withdrawal provisions applicable to the
Company&#8217;s common stock.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-Funded Warrants to be issued in this
offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary
of certain terms and provisions of the Pre-funded Warrants that are being offered hereby is not complete and is subject to, and qualified
in its entirety by the provisions of, the Pre-funded Warrant. Prospective investors should carefully review the terms and provisions
of the form of Pre-funded Warrant for a complete description of the terms and conditions of the Pre-funded Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8220;pre-funded&#8221;
refers to the fact that the purchase price of our common stock in this offering includes almost the entire exercise price that will be
paid under the Pre-funded Warrants, except for a nominal remaining exercise price of $0.001. The purpose of the Pre-funded Warrants is
to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, upon election of the holder,
9.99%) of our outstanding shares of common stock following the consummation of this offering the opportunity to make an investment in
the Company without triggering their ownership restrictions, by receiving Pre-funded Warrants in lieu of our common stock which would
result in such ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their option to purchase the shares underlying
the Pre-funded Warrants at such nominal price at a later date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Duration</i>. The Pre-funded
Warrants offered hereby will entitle the holders thereof to purchase our shares of common stock at a nominal exercise price of $0.001
per share, commencing immediately on the date of issuance. There is no expiration date for the Pre-funded Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exercise Limitation</i>.
A holder will not have the right to exercise any portion of the Pre-funded Warrant if the holder (together with its affiliates) would
beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of our shares of common stock outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-funded
Warrants. However, any holder may increase or decrease such percentage (up to 9.99%), provided that any increase will not be effective
until the 61st day after such election. It is the responsibility of the holder to determine whether any exercise would exceed the exercise
limitation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exercise Price</i>.
The Pre-funded Warrants will have an exercise price of $0.001 per share. The exercise price is subject to appropriate adjustment in the
event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our
common stock and also upon any distributions of assets, including cash, stock or other property to our shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Transferability</i>.
Subject to applicable laws, the Pre-funded Warrants may be offered for sale, sold, transferred or assigned without our consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Absence of Trading
Market</i>. There is no established trading market for the Pre-funded Warrants and we do not expect a market to develop. In addition,
we do not intend to apply for the listing of the Pre-funded Warrants on any national securities exchange or other trading market. Without
an active trading market, the liquidity of the Pre-funded Warrants will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Fundamental Transactions</i>.
In the event of a fundamental transaction, generally including any reorganization, recapitalization or reclassification of our common
stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation, merger, amalgamation
or arrangement with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group
becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holder will have the right
to receive, for each share of common stock that would have been issuable upon such exercise immediately prior to the occurrence of such
fundamental transaction, the number of shares of the successor or acquiring corporation or of us if we are the surviving corporation,
and any additional consideration receivable as a result of such fundamental transaction by a holder of the number of shares for which
the Pre-funded Warrant was exercisable immediately prior to such fundamental transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>No Rights as a Shareholder</i>.
Except as otherwise provided in the Pre-funded Warrants or by virtue of such holder&#8217;s ownership of our shares of common stock,
the holder of Pre-funded Warrants does not have the rights or privileges of a holder of our common stock, including any voting rights,
until the holder exercises the Pre-funded Warrant.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants to be issued in this offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary of
certain terms and provisions of the Warrants included in the Common Units and Pre-Funded Units offered hereby is not complete
and is subject to, and qualified in its entirety by the provisions of the form of Warrant, which is filed as an exhibit to the registration
statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the
form of Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exercisability</i>. The
Warrants are exercisable immediately and at any time up to the date that is five years after their original issuance. The Warrants
will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any
time a registration statement registering the issuance of the shares of common stock underlying the Warrants under the Securities Act
is effective and available for the issuance of such shares, or an exemption from registration under the Securities Act is available for
the issuance of such shares, by payment in full in immediately available funds for the number of shares of common stock purchased upon
such exercise. If a registration statement registering the issuance of the shares of common stock underlying the Warrants under the Securities
Act is not effective or available and an exemption from registration under the Securities Act is not available for the issuance of such
shares, the holder may elect to exercise the Warrant through a cashless exercise, in which case the holder would receive upon such exercise
the net number of shares of common stock determined according to the formula set forth in the warrant. No fractional shares of common
stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, we will pay the holder an amount in
cash equal to the fractional amount multiplied by the exercise price.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exercise Limitation</i>.
A holder will not have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially
own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such
percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage
to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days following
notice from the holder to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exercise Price</i>. The
exercise price per whole share of common stock purchasable upon exercise of the warrants is $9.80 per share or 100% of the public
offering price of the Common Unit. The exercise price is subject to appropriate adjustment in the event of certain stock dividends
and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any
distributions of assets, including cash, stock or other property to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Transferability</i>. Subject
to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exchange Listing</i>. We
have applied to have the Warrants offered in this offering listed on the Nasdaq Capital Market under the symbol &#8220;SBFMW&#8221;. No
assurance can be given that such listing will be approved or that a trading market will develop.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Warrant Agent</i>. The
Warrants will be issued in registered form under a warrant agency agreement between Equiniti, as warrant agent, and us. The Warrants shall
initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository
Trust Company (DTC) and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Fundamental Transactions</i>.
In the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or
reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets,
our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person
or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the warrants
will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property that the holders would
have received had they exercised the warrants immediately prior to such fundamental transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Rights as a Stockholder</i>.
Except as otherwise provided in the Warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of
a Warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises
the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Governing Law</i>. The
Warrants and the warrant agency agreement are governed by New York law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Blank Check Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our articles of incorporation
authorize the issuance of 30,000,000 shares of preferred stock, par value $0.10 per share, in one or more series, subject to any limitations
prescribed by law, without further vote or action by the stockholders.&#160;Each such series of preferred stock shall have such number
of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as shall be determined
by our board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights
and preemptive rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series B Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1,000,000 shares of our authorized
preferred stock have been designated Series B Preferred Stock and are outstanding and held by our chief executive officer, Dr. Steve
N. Slilaty. Upon closing of this offering, 990,000 of such shares will be redeemed by the Company at a redemption price equal
to the stated value of $0.10 per share and 10,000 will be retained by Dr. Slilaty.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series B Preferred Stock
votes together with the common stock on all matters submitted to a vote of the Company&#8217;s stockholders. Each share of Series B Preferred
Stock entitles the holder to 1,000 votes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon any liquidation or dissolution
of the Company, the Series B Preferred Stock will be entitled to a payment equal to the stated value of $0.10 per share, prior to any
payments being made with respect to the common stock. The Series B Preferred Stock is not redeemable by the Company and is entitled to
dividends when, as and if declared by the board of directors in its sole discretion.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s16"></span>UNDERWRITING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aegis Capital Corp. is acting
as representative of the underwriters of the offering. We have entered into an underwriting agreement dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2022 with the representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter
named below, and each underwriter named below has severally agreed to purchase, at the public offering price less the underwriting discounts
set forth on the cover page of this prospectus, the number of Common Units and Pre-Funded Units listed next to its name
in the following table:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"><span style="font-size: 10pt">Underwriter</span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: center"><span style="font-size: 10pt">Number of <br />
Common Units</span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: center"><span style="font-size: 10pt">Number of<br />
Pre-funded Units</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Aegis Capital Corp.</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters are committed
to purchase all the Common Units and Pre-funded Units offered by us, other than those covered by the over-allotment option to
purchase additional shares of common stock and/or warrants described below, if they purchase any units. The obligations of the underwriters
may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting
agreement, the underwriters&#8217; obligations are subject to customary conditions, representations and warranties contained in the underwriting
agreement, such as receipt by the underwriters of officers&#8217; certificates and legal opinions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify
the underwriters against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters
may be required to make in respect thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters are offering
the Common Units, Pre-funded Units, shares of common stock, Pre-Funded Warrants and Warrants subject to prior sale, when,
as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the
underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in
whole or in part.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
have granted the underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus,
permits the underwriters to purchase up to an aggregate of up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
additional shares of common stock and/or Pre-Funded Warrants, representing 15% of the shares and Pre-funded Warrants sold in the offering
and/or up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; additional Warrants, representing 15% of
the Warrants sold in the offering. The purchase price to be paid per additional share will be equal to the public offering price of one
Common Unit, less the purchase price per Warrant included within the Common Unit and the underwriting discount. The purchase price to
be paid per Pre-funded Warrant will be equal to the public offering price of one Pre-funded Unit, less the purchase price per Warrant
included within the Pre-Funded Unit and the underwriting discount. The purchase price to be paid per additional Warrant will be $&#160;&#160;&#160;&#160;&#160;&#160;.
If this option is exercised in full to purchase shares of common stock and/or Pre-Funded Warrants only, the total price to the public
will be $ and the total net proceeds, before expenses, to us will be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;. If this option is exercised
in full to purchase Warrants only, the total price to the public will be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and the total
net proceeds, before expenses, to us will be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; .</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Discounts, Commissions and Reimbursement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table shows
the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full
exercise by the underwriters of their over-allotment option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Per Common Unit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Per Pre- <br />funded Unit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total with no Over-Allotment</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total with Over-Allotment</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 48%">Public offering price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8239;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8239;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8239;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8239;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Underwriting discounts and commissions (8.0%)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 10pt">Non-accountable expense allowance (1.0%)<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds, before expenses, to us</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8239;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) We have agreed to pay a non-accountable expense
allowance to the representative equal to 1.0% of the gross proceeds received in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters propose
to offer the Common Units and Pre-Funded Units to the public at the public offering price set forth on the cover of this prospectus.
In addition, the underwriters may offer some of the Common Units and Pre-Funded Units to other securities dealers at such price less
a concession not in excess of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per Common Unit or Pre-Funded Units.
If all of the Common Units and Pre-Funded Units offered by us are not sold at the public offering price, the representative may change
the offering price and other selling terms by means of a supplement to this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also agreed to pay
up to $125,000 of the representative&#8217;s expenses relating to the offering, including for road show, diligence, and legal expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that the total
expenses of the offering payable by us, excluding the discount and non-accountable expense allowance, will be approximately $565,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Discretionary Accounts</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters do not intend
to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Lock-Up Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to &#8220;lock-up&#8221;
agreements, we and our executive officers and directors have agreed, subject to limited exceptions, without the prior written consent
of the representative not to directly or indirectly offer to sell, sell, pledge or otherwise transfer or dispose of any of shares of (or
enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person
at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to another, in whole
or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right
or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common
stock or securities convertible into or exercisable or exchangeable for common stock or any of our other securities or publicly disclose
the intention to do any of the foregoing, subject to customary exceptions, for a period of 180 days from the date of this prospectus,
in the case of our directors and executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Right of First Refusal and Tail Financing </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have granted the representative
a right of first refusal, for a period of 18 months from the consummation of this offering, to act as sole book-runner, sole manager,
sole placement agent, sole agent, sole book-runner, sole book-running manger and/or sole underwriter, at the representative&#8217;s sole
discretion, for each and every future public and private equity or debt offering or debt refinancing, including all equity linked financings
(each, a &#8220;Subject Transaction&#8221;), during such 18 month period, of the Company, or any successor to or subsidiary of the Company,
on terms and conditions customary to the representative for such Subject Transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have agreed
to pay the above cash compensation to the extent that any fund which the representative contacted or introduced to us during the term
of our engagement agreement with the underwriter provides financing or capital in any public or private offering or capital raising transaction
during the eighteen-month period following expiration or termination of our engagement letter with the underwriter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Electronic Offer, Sale and Distribution of
Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A prospectus in electronic
format may be made available on the websites maintained by one or more of the underwriters or selling group members. The representative
may agree to allocate a number of securities to underwriters and selling group members for sale to its online brokerage account holders.
Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same
basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of, nor incorporated
by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed
by us, and should not be relied upon by investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stabilization</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this offering,
the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids and
purchases to cover positions created by short sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stabilizing transactions permit
bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing
or retarding a decline in the market price of the shares while the offering is in progress.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over-allotment transactions
involve sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase. This creates
a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number
of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment option.
In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters
may close out any short position by exercising their over-allotment option and/or purchasing shares in the open market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Syndicate covering transactions
involve purchases of shares in the open market after the distribution has been completed in order to cover syndicate short positions.
In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of
shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the
over-allotment option. If the underwriters sell more shares than could be covered by exercise of the over-allotment option and, therefore,
have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely
to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the
open market that could adversely affect investors who purchase in the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Penalty bids permit the representative
to reclaim a selling concession from a syndicate member when the shares originally sold by that syndicate member are purchased in stabilizing
or syndicate covering transactions to cover syndicate short positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These stabilizing transactions,
syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our shares of common
stock or preventing or retarding a decline in the market price of our shares of common stock. As a result, the price of our common stock
in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make
any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These
transactions may be effected in the&#160;over-the-counter&#160;market or otherwise and, if commenced, may be discontinued at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Passive market making</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this offering,
underwriters and selling group members may engage in passive market making transactions in our common stock on the Nasdaq Capital Market
in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the
shares and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess
of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#8217;s bid,
then that bid must then be lowered when specified purchase limits are exceeded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of the underwriters
and their affiliates may in the future provide various investment banking, commercial banking and other financial services for us and
our affiliates for which they may in the future receive customary fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Offer restrictions outside the United States</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than in the United States,
no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in
any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly
or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such
securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable
rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about
and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute
an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer
or a solicitation is unlawful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s17"></span><b>LEGAL MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are being represented
by Sichenzia Ross Ference LLP, New York, New York, with respect to certain legal matters as to United States federal securities and New
York State law. The enforceability of the Pre-Funded Warrants and Warrants will be passed upon for us by Sichenzia Ross Ference LLP,
New York, New York. The validity of the securities being offered by this prospectus, including the shares, Common Units, Pre-Funded Units,
Pre-Funded Warrants, Warrants, and shares underlying the Pre-Funded Warrants and Warrants, will be passed upon for us by Andrew I. Telsey,
P.C. Certain legal matters in connection with this offering have been passed upon for the underwriters by Kaufman &amp; Canoles, P.C.,
Richmond, Virginia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s18"></span><b>INTERESTS OF NAMED EXPERTS AND COUNSEL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Andrew Telsey holds 15
shares of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s19"></span><b>EXPERTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of Sunshine Biopharma, Inc. at December 31, 2020 and 2019, and for each of the two years in the period ended December 31, 2020,
included in this prospectus have been audited by B F Borgers CPA PC, independent registered public accounting firm, as set forth in their
report thereon, appearing therein, and are included in reliance upon such report given on the authority of such firm as experts in accounting
and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s20"></span>WHERE YOU CAN FIND MORE INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, which constitutes
a part of the registration statement on Form S-1 that we have filed with the SEC under the Securities Act, does not contain all of the
information in the registration statement and its exhibits. For further information with respect to us and the securities offered
by this prospectus, you should refer to the registration statement and the exhibits filed as part of that document. Statements contained
in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance,
we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements
is qualified in all respects by this reference.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the reporting
requirements of the Exchange Act, and file annual, quarterly and current reports, and other information with the SEC. The SEC maintains
an Internet site that contains these reports and other information filed electronically by us with the SEC, which are available on the
SEC&#8217;s website at http://www.sec.gov. We also maintain a website at https://sunshinebiopharma.com, at which you may access these
materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information
contained in, or that can be accessed through, our website is not part of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sunshine Biopharma, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fsq3"></span>CONSOLIDATED FINANCIAL STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">At September 30, 2021 and December
31, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; width: 85%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#q3">Unaudited Condensed Consolidated Balance Sheet</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#q4">Unaudited Condensed Consolidated Statement of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#q5">Unaudited Condensed Consolidated Statement of Cash Flows</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><a href="#q6">Unaudited Condensed Consolidated Statement of Shareholders&#8217; Equity</a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a12">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED FINANCIAL STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">With Independent Accountant&#8217;s Audit Report</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">At December 31, 2020 and 2019</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; width: 85%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs10k_001">Independent Accountant&#8217;s Audit Report</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-12</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs10k_002">Consolidated Balance Sheet</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-13</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs10k_003">Consolidated Statement of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-14</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs10k_004">Consolidated Statement of Cash Flows</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-15</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs10k_005">Consolidated Statement of Shareholders&#8217; Equity</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-16</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#fs10k_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-17</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 50; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sunshine Biopharma, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q3"></span><b>Unaudited Condensed Consolidated Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_zJu8Al8bsOp9" summary="xdx: Statement - Unaudited Condensed Consolidated Balance Sheets" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210930" style="text-align: right; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_494_20201231" style="text-align: right; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">September 30,</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">December 31,</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zJwMiMQUUEY4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt"><span style="text-decoration: underline">ASSETS</span></td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_iB_zFQY0WufpK7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">Current Assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maCzgjv_zWnH3NcTw9Q5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,386,608</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">989,888</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsReceivableNetCurrent_i01I_maCzgjv_zY6lCXxxeZx1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts receivable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,129</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,916</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InventoryNet_i01I_maCzgjv_z9oUJQO804da" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">Inventory</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,310</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,771</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidExpenseCurrent_i01I_maCzgjv_zfbMpWX1FPU9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Prepaid expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,046</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,778</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DepositsAssetsCurrent_i01I_maCzgjv_zcqMIBy8zta8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt">Deposits</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,590</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,590</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrent_i01TI_mtCzgjv_maCz8bf_z94S3izsxTIl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Current Assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,491,683</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,025,943</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCz8bf_zMd9wIq5ozYg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
  <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Equipment (net of $<span id="xdx_902_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pp0p0_c20210930_zhuESBFLsuFg" title="Equipment depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,774</ix:nonFraction> </span>and $<span id="xdx_903_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c20201231_pp0p0" title="Equipment depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,485</ix:nonFraction></span> depreciation)</td>
  <td style="font-size: 10pt">&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,232</ix:nonFraction></td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td style="font-size: 10pt">&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,531</ix:nonFraction></td>
  <td style="font-size: 10pt; text-align: left">&#160;&#160;</td>
</tr>
<tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_d0_maCz8bf_zFKzWrO4pPgb" style="vertical-align: bottom; background-color: White">
  <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Patents (net of $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20210930_zvF1hn0xkKZ3" title="Patent amortization"><span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_pp0p0" title="Patent amortization"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,918</ix:nonFraction></ix:nonFraction></span></span> amortization and $<span id="xdx_90D_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_c20210101__20210930_zQnkLGuJngGk" title="Patent impairment"><span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20200101__20201231_pp0p0" title="Patent impairment"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">556,120</ix:nonFraction></ix:nonFraction></span> </span>impairment)</td>
  <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
  <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td>
  <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
  <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td>
  <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td>
  <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Assets_i01TI_mtCz8bf_z4gIgKtWmNia" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,501,915</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,045,474</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAbstract_iB_zRIoKCRIgzP3" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">LIABILITIES AND SHAREHOLDERS' EQUITY</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_iB_zzwp7IjGLQa" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">Current Liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NotesPayableCurrent_i01I_maCzlMT_z0p8KhXN10Ye" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Notes payable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">330,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">820,454</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_i01I_d0_maCzlMT_zDbcSvvCercj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Notes payable - related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="AsOf2021-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,661</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableCurrent_i01I_maCzlMT_zJ5om0Xzx5na" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts payable &amp; accrued expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,687</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,870</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestPayableCurrent_i01I_maCzlMT_znVnfod9e0N5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Interest payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,945</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,320</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrent_i01TI_mtCzlMT_maCzDvP_z0pjK9YrV2l3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Current Liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471,632</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,051,305</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermNotesPayable_i01I_maCzDvP_zHZIFY918O8d" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Long-term portion of notes payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,204,215</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">949,006</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Liabilities_i01TI_mtCzDvP_maCz5Zn_z3sW8R4ZBNMf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,675,847</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,311</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommitmentsAndContingencies_i01I_zHvFs03dFGBi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left">COMMITMENTS AND CONTINGENCIES</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0100">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_iB_zn719cL3uVkg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">SHAREHOLDERS' EQUITY (DEFICIT)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
  <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt">Preferred Stock, Series B $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRkS9w7rvpXk" title="Preferred stock, par value"><span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjONw0toJFxk" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></ix:nonFraction></span></span> par value per share; Authorized
  <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCdzgv03o25i" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdCiZ2PLyiI5" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> Shares; Issued and outstanding <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zeoaIrjQfGy5" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhxiAgI1wJd4" title="Preferred stock, shares outstanding"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z3nZy5Okr8i7" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8A2BhopSVek" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares.</td>
  <td style="font-size: 10pt">&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td id="xdx_98C_eus-gaap--PreferredStockValue_i01I_maCzovC_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8UlDY7GrQTg" title="Preferred stock value" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td style="font-size: 10pt">&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td id="xdx_984_eus-gaap--PreferredStockValue_i01I_maCzovC_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTRdx37akjmk" title="Preferred stock value" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td>
  <td style="font-size: 10pt; text-align: left">&#160;&#160;</td>
</tr>
  <tr id="xdx_402_eus-gaap--CommonStockValue_i01I_maCzovC_zydG7DqJ2o3g" style="vertical-align: bottom; background-color: White">
  <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt">Common Stock, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20210930_pdd" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>
  par value per share; Authorized <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20210930_pdd" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000,000</ix:nonFraction></ix:nonFraction></span></span>
  Shares; Issued and outstanding <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20210930_pdd" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20210930_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">510,093,265</ix:nonFraction></ix:nonFraction></span></span>
  and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_c20201231_pdd" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">346,419,296</ix:nonFraction></ix:nonFraction></span></span>
  at September 30, 2021 and December 31, 2020 respectively</td>
  <td style="font-size: 10pt">&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">510,092</ix:nonFraction></td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td style="font-size: 10pt">&#160;&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;&#160;</td>
  <td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,418</ix:nonFraction></td>
  <td style="font-size: 10pt; text-align: left">&#160;&#160;&#160;</td>
</tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapital_i01I_maCzovC_zR4cYZ1XX74k" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt">Capital paid in excess of par value</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,555,741</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,820,343</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maCzovC_zDlxEvTuUOha" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accumulated comprehensive income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,475</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,871</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzovC_zG41pWsRthPj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated (Deficit)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,322,290</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,218,727</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i01TI_mtCzovC_maCz5Zn_z4VdnVVGKlbk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">TOTAL SHAREHOLDERS' EQUITY (DEFICIT)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,173,932</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">954,837</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCz5Zn_ztN3eObokC88" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,501,915</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,045,474</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes To These Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sunshine Biopharma, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q4"></span><b>Unaudited Condensed Consolidated Statements of Operations and Comprehensive
Loss</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_zsh7BEkwTTA8" summary="xdx: Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49B_20210701_20210930" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_499_20200701_20200930" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20210101_20210930" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_493_20200101_20200930" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">3 Months</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">3 Months</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">9 Months</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">9 Months</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">Ended</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">Ended</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">Ended</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">Ended</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">September 30,</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">September 30,</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">September 30,</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">September 30,</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Revenues_maCzOkE_zc3OxVvDD1Rg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 44%; font-size: 10pt">Revenue:</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,376</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,150</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,308</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,397</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_msCzOkE_zAGznPYQIKuf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Cost of sales</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,506</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,340</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,541</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,384</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_iT_mtCzOkE_maCzhYP_zqg7qklSao0b" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left">Gross profit</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,870</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,810</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,767</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,013</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zBcXeAEs6O65" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left">General &amp; Administrative Expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProfessionalFees_i01_maCzY80_z6KaiMXHPR0h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">Accounting</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,290</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,200</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,490</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ConsultingExpense_i01_maCzY80_z6kc5DnFgknb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt">Consulting</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">20,598</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,823</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">53,168</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">7,731</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LegalFees_i01_maCzY80_zieS63z8jxZj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">Legal</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,923</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,895</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,074</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,970</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--OfficeExpense_i01_maCzY80_zDFMBiGr3Ic6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt">Office</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">58,959</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">19,966</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">159,762</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">55,422</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--OfficerAndDirectorRemuneration_i01_maCzY80_zZBNRsTtrXH4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Officer &amp; director remuneration</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">130,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">24,600</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,173,927</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">80,430</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PatentingFees_i01_d0_maCzY80_zv1B4v2yrl5l" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Patent fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14,571</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_d0_maCzY80_zHlOp0ZEgcta" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">R&amp;D</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,465</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-07-012020-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">581,011</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Depreciation_i01_maCzY80_zFNrrYfmxER9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt">Depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,183</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,524</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,557</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,526</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01T_mtCzY80_msCzhYP_zBGS8srGwY9d" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total General&#160;&amp;&#160;Administrative Expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527,129</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,098</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,247,270</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">261,569</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_i01T_mtCzhYP_maCz6FL_zYnLPsXZbP" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">(Loss) from operations</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">496,259</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">67,288</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,160,503</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">233,556</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zlF1RASkLx4j" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other Income (Expense):</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzDc8_ze9g4pMfsmEi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Foreign exchange</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,598</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,404</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_i01N_di_msCzDc8_z1URE1qLpNYb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,849</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,094</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,188</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,669</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherNonoperatingIncome_i01_d0_maCzDc8_zQuNgSmKROll" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2021-07-012021-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2020-07-012020-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2021-01-01to2021-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maCzDc8_zTNaaQ45j41j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Debt release</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,688</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,284</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,940</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,836</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InducedConversionOfConvertibleDebtExpense_i01N_di_msCzDc8_zmvkUsJIcdU3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Loss on debt conversions</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,504,000</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">608,899</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,709,843</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,416,313</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzDc8_maCz6FL_z5NTKePXV2me" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total Other Income (Expense)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,543,124</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">631,307</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,943,060</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,466,742</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i01T_mtCz6FL_maCzx8R_zZm4hdkFZl0c" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net (loss) before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,039,383</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">698,595</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,103,563</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,700,298</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_i01N_di0_msCzx8R_zXIiFBbcS2Y4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Provision for income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-07-012021-09-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-07-012020-09-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-09-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-09-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01T_mtCzx8R_maCz7dV_zyZHh60te05f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,039,383</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">698,595</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,103,563</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,700,298</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_i01B_zcdtl1m1Ow2f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other comprehensive income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_i02_maCz7dV_zJ6LWndIqmAh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Unrealized loss from foreign exchange translation</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,839</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">144</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,604</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,009</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_i02T_mtCz7dV_zcGTN54G0iEc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Comprehensive (loss)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,045,222</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">698,739</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,118,167</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,701,307</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_i02_z2bxmGqhS6l6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted (loss) per common share</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i02_zEJJh8WxZdL5" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; padding-bottom: 2.5pt">Weighted Average Common Shares Outstanding (Basic &amp; Diluted)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">508,528,048</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">280,873,792</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,536,409</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,133,885</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes To These Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sunshine Biopharma, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q5"></span><b>Unaudited Condensed Consolidated Statements of Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_zxLbywOPtaC3" summary="xdx: Statement - Unaudited Condensed Consolidated Statements of Cash Flows" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_498_20210101__20210930_zvrUu41yixfj" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20200101__20200930_zQ4ryK8QPrj7" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">9 Months</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">9 Months</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">Ended</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">Ended</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">September 30,</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">September 30,</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z4nbwCFN20rh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left"><b>Cash Flows From Operating Activities:</b></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_maCzCV1_zrtKKoANxlOe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; font-size: 10pt; text-align: left">Net (Loss)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,103,563</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 13%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,700,298</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zgvNF2Cei5j" style="vertical-align: bottom; background-color: White">
  <td style="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td>
  <td style="font-size: 10pt">&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td style="font-size: 10pt; text-align: right">&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td style="font-size: 10pt">&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;</td>
  <td style="font-size: 10pt; text-align: right">&#160;</td>
  <td style="font-size: 10pt; text-align: left">&#160;&#160;</td>
</tr>
  <tr id="xdx_407_eus-gaap--DepreciationAndAmortization_i02_maCzCV1_zJwEns26Az5c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Depreciation and amortization</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,557</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,505</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_i02N_di_msCzCV1_zbu7d0tYoyTl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Foreign exchange (gain) loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,404</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maCzCV1_zuEQFKSsn0w8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Stock issued for services</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">918,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedForPaymentInterestOnNotesPayable_i02_maCzCV1_zTFWvoqU4NNc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Stock issued for payment interest</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">38,201</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">42,233</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InducedConversionOfConvertibleDebtExpense_i02_maCzCV1_ztuvqXJWb37d" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Loss on debt conversion</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,709,843</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,416,313</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msCzCV1_zA5WRAWlfeMk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Debt &amp; interest release</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,940</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,836</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msCzCV1_zxGx9AtunJkd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Decrease in accounts receivable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">787</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">430</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msCzCV1_zkzbUSNiYSm9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">(Increase)  in inventory</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,539</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,291</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzCV1_zIFt8ZIKCB5g" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">(Increase) in prepaid expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,268</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,850</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maCzCV1_zOQVDiYkJ5Kh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">(Decrease) in Accounts Payable &amp; accrued expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,778</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,029</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_maCzCV1_zcmgGKP40Bv2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Increase in interest payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,716</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,600</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCzCV1_maCzQG1_zQuh4ECn3jxg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><b>Net Cash Flows (used) in operations</b></td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,517,015</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">233,627</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_i02B_zcXNF0Y8f7R2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><b>Cash Flows From Investing Activities:</b></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di0_msCz4jK_zttKd6GXo5hl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; padding-left: 10pt; font-size: 10pt">Purchase of equipment</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-01to2021-09-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01_d0_mtCz4jK_maCzQG1_zae9npL22Ry2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><b>Net Cash Flows (used) in Investing activities</b></td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">800</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zSL1nbXnGe22" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><b>Cash Flows From Financing Activities:</b></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromNotesPayable_i01_maCzRpL_zMgLkak1LOL" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Proceeds from notes payable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,318,500</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,643</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromOtherShortTermDebt_i01_maCzRpL_zjSrgEgFFXcd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Note payable to pay fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,500</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msCzRpL_zojbiLeIj39f" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Payments of notes payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,661</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzRpL_maCzQG1_zPffFwOtDZM9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><b>Net Cash Flows provided by financing activities</b></td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,928,339</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,643</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Cash_i01S_zgnFxvwlfeh3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><b>Cash and Cash Equivalents at Beginning of Period</b></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">989,888</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,501</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_i01T_mtCzQG1_zf0Rb6Na5Oy8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Net increase in cash and cash equivalents</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,411,324</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,216</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectOfExchangeRateOnCashAndCashEquivalents_i01_zKsuKAk968O8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,604</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,009</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--Cash_i01E_ztlBvtHqZV59" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><b>Cash and Cash Equivalents at End of Period</b></td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,386,608</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,708</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zkpujZJvTrN3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-size: 10pt; text-align: left"><b>Supplementary Disclosure Of Cash Flow Information:</b></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ConversionOfStockAmountConverted1_i01_zWauwl5kKZ38" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Stock issued for note conversions including interest</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,981,072</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,831,816</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPaidNet_i01_d0_zzrNtF0tV0Lb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,081</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-012020-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxesPaidNet_i01_d0_zjAWjh94cmu1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for income taxes</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-01to2021-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-012020-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes To These Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sunshine Biopharma, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q6"></span><b>Unaudited Condensed Consolidated Statement of Shareholders' Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zEHBX4jCT3li" summary="xdx: Statement - Unaudited Condensed Consolidated Statement of Shareholders&apos; Equity" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zZCtCbij5q0d" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z9mpeXlX0Z6e" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zlJCgKVvifkg" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--ComprehensiveIncomeMember_zkbYmy1sG8ij" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zU8SdFi8BTlf" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_4BF_z2RgAdSKxZQj" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">Number Of</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">Capital Paid</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">Number Of</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">Common</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">Common</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">in Excess</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">Preferred</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">Preferred</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">Comprehensive</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: center">Accumulated</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">Shares Issued</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">Stock</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">of Par Value</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">Shares Issued</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">Stock</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">Income</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt"><b>Three Month Period</b></td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="2" style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt">&#160;</td></tr>
  <tr id="xdx_43A_c20210701__20210930_eus-gaap--StockholdersEquity_iS_zq7kwVjyU8G" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; width: 20%; font-size: 8pt; font-weight: bold; text-indent: -5pt">Balance June 30, 2021</td><td style="width: 1%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIn7cvTU0AMc" title="Begining balance, shares" style="width: 7%; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">486,093,265</ix:nonFraction></td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 7%; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,092</ix:nonFraction></td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 7%; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,835,741</ix:nonFraction></td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSp9HGWjIgsj" title="Begining balance, shares" style="width: 7%; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 7%; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 7%; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,636</ix:nonFraction></td><td style="width: 1%; font-size: 8pt; text-align: left">)</td><td style="width: 1%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 7%; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,282,907</ix:nonFraction></td><td style="width: 1%; font-size: 8pt; text-align: left">)</td><td style="width: 1%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 7%; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">872,710</ix:nonFraction></td><td style="width: 1%; font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; text-indent: -5pt">Common stock issued for the reduction of note payable and payment of interest</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkBxLhFymTS9" title="Common stock issued for the reduction of note payable and payment of interest, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,000,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,720,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#8211;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,744,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProfitLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt">Net (loss)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-012021-09-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,839</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,039,383</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,045,222</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20210701__20210930_eus-gaap--StockholdersEquity_iE_zdJoTMwAczsd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -5pt">Balance at September 30, 2021</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOZLYpJXeCfb" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">510,093,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">510,092</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,555,741</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zklaRqVa7Khd" style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,475</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,322,290</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,173,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt"><b>Nine Month Period</b></td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20210101__20210930_eus-gaap--StockholdersEquity_iS_zLG2xzB0XDGa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; font-weight: bold; text-indent: -5pt">Balance December 31, 2020</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx9tGaMdyaLd" title="Begining balance, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">346,419,296</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,418</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,820,343</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWCmRmnUF862" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,871</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,218,727</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">954,837</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueOther_zGGkMApvX95g" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; text-indent: -5pt">Common stock issued for the reduction of note payable and payment of interest</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7peEHcD3tp5" title="Common stock issued for the reduction of note payable and payment of interest, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,673,969</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,674</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,877,398</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#8211;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,981,072</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_iP3us-gaap--StockIssuedDuringPeriodSharesOther_zlcYnz3qF2t5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; text-indent: -5pt">Common stock issued for management compensation</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_iP3us-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOGjPVV4kB4k" title="Common stock issued for services, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">858,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">918,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_ziW4PGlRn1n" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt">Net (loss)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-09-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,604</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,103,563</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,118,167</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20210101__20210930_eus-gaap--StockholdersEquity_iE_zceGzFjoOspl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -5pt">Balance at September 30, 2021</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8NJxaZprvR8" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">510,093,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">510,092</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,555,741</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWs5nHHc1Ko5" style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,475</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,322,290</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,173,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt"><b>Three Months Period</b></td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20200701__20200930_eus-gaap--StockholdersEquity_iS_zoBa7tWj6Z1k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; font-weight: bold; text-indent: -5pt">June 30, 2020</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrfXxXpUWRp4" title="Begining balance, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">269,821,248</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,820</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,542,616</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCWnc7RDpI69" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,360</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,436,339</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">577,263</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueOther_zW3RLKZjiTm7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; text-indent: -5pt">Common stock issued for the reduction of note payable and payment of interest</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzPhR95Ut1kd" title="Common stock issued for the reduction of note payable and payment of interest, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,598,048</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,599</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636,527</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#8211;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,125</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_iP3us-gaap--StockIssuedDuringPeriodSharesOther_zFisHbb7v9L1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; text-indent: -5pt">Preferred stock issued for management
    compensation</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#8211;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_iP3custom--PreferredStockIssuedForServices_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6PsaNPdI1A8" title="Preferred stock issued for services, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProfitLoss_z0azuCQWc8R2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt">Net (loss)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">144</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">698,595</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">698,739</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20200701__20200930_eus-gaap--StockholdersEquity_iE_z3ATORKhNmp8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -5pt">Balance at September 30, 2020</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7OEHiHpXjJd" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,419,296</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,419</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,179,143</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6qSYxphHey5" style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,504</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,134,934</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">554,876</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt"><b>Nine Months Period</b></td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20200101__20200930_eus-gaap--StockholdersEquity_iS_z7MRSpndHBaa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; font-weight: bold; text-indent: -5pt">Balance December 31, 2019</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCy99qMISnCe" title="Begining balance, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,319,990</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,320</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,616,426</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_ztAaJnP7NwQf" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,495</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,434,636</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">735,385</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueOther_zcyRS25Zztxh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; text-indent: -5pt">Common stock issued for the reduction of note payable and payment of interest</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztfPVUC9aVG4" title="Common stock issued for the reduction of notes payable and payment of interest, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">269,099,306</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,099</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,562,717</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,831,816</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zS9Uru0INiNi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; text-indent: -5pt">Preferred stock issued for management
    compensation</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#8211;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zUW8oRQB5JWa" title="Preferred stock issued for services, shares" style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-01-012020-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">&#8211;</span></td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_z07XCfZNz0U6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt">Net (loss)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">&#8211;</span></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-09-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,009</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,700,298</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,701,307</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5pt; font-size: 8pt; text-indent: -5pt">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20200101__20200930_eus-gaap--StockholdersEquity_iE_z65lYgSTuh69" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 5pt; font-size: 8pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -5pt">Balance at September 30, 2020</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUVSYmjnoZ66" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,419,296</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,419</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,179,143</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMrKoTurekpi" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_ComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,504</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,134,934</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">554,876</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes To These Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sunshine Biopharma, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a12"></span>Notes to Unaudited Condensed Consolidated Financial
Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>For the Three and Nine Month Interim Periods Ended September 30,
2021 and 2020</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zj5EQMx7t3xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 1 &#8211; <span id="xdx_826_z1xHyG7GlLJ8">Nature of Business and Basis
of Presentation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sunshine Biopharma, Inc. (the &#34;Company&#34;)
was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Until
October 2009, the Company was operating as a business consultancy firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 15, 2009, the Company acquired
Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. was holding an exclusive license
to a new anticancer drug bearing the laboratory name, Adva-27a (the &#8220;License Agreement&#8221;). Upon completion of the reverse acquisition
transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the
development of the licensed Adva-27a anticancer drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2012, the Company published the results
of its initial preclinical studies of Adva-27a in the peer-reviewed journal, ANTICANCER RESEARCH. The studies were conducted in collaboration
with Binghamton University, a State University of New York, and Ecole Polytechnique, Universite de Montreal. The publication is entitled
&#8220;Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells&#8221; [ANTICANCER
RESEARCH Volume 32, Pages 4423-4432 (2012)].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2014, the Company formed a wholly owned
Canadian subsidiary, Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;) for the purposes of offering generic pharmaceutical
products in Canada and elsewhere around the world. Sunshine Canada has recently transitioned its focus to the development and marketing
of Science-Based Nutritional Supplements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, the Company acquired all worldwide
issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a
anticancer compound from Advanomics Corporation, a related party, and terminated the License Agreement. In 2016, the remaining value of
these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2018, the Company formed NOX Pharmaceuticals,
Inc., a wholly owned Colorado corporation and assigned all of the Company&#8217;s interest in the Adva-27a anticancer drug to that company.
NOX Pharmaceuticals Inc.&#8217;s mission is to research, develop and commercialize proprietary drugs including Adva-27a.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2018, the Company launched its first
Science-Based Nutritional Supplements product, Essential 9<span style="font-variant: small-caps"><sup>&#8482;</sup></span>, an over-the-counter
tablet comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9<span style="font-variant: small-caps"><sup>&#8482;
</sup></span>has been authorized for marketing by Health Canada under NPN 80089663.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20190101__20190201" title="Stockholders&apos; Equity, Reverse Stock Split"><ix:nonNumeric contextRef="From2019-01-012019-02-01" name="us-gaap:StockholdersEquityReverseStockSplit">Effective February 1, 2019, the Company completed
a 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400
(the &#8220;First Reverse Stock Split&#8221;). The Company&#8217;s authorized capital of Common Stock remained as previously established
at 3,000,000,000 shares.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20200101__20200406" title="Stockholders&apos; Equity, Reverse Stock Split"><ix:nonNumeric contextRef="From2020-01-012020-04-06" name="us-gaap:StockholdersEquityReverseStockSplit">Effective April 6, 2020, the Company completed
another 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417
(the &#8220;Second Reverse Stock Split&#8221;). The number of Common Shares authorized for issuance remained as previously established
at 3,000,000,000 shares.</ix:nonNumeric></span> All references to the Company&#8217;s Common Stock in this Report, including the Company's financial statements
reflect both the First and Second Reverse Stock Split on a retroactive basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 22, 2020, the Company filed a provisional
patent application in the United States for a new treatment for Coronavirus infections. The Company&#8217;s patent application covers
composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential
for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company filed a PCT application
containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May
22, 2020 has been maintained in the newly filed PCT application.</p>

<ix:exclude><p id="xdx_23B_zZ3ZynPgLhFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zCEBlHGsrVoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zEYAtVUImas3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zfL2dGKhraOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_ziyrzXHhfBm" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2020, the Company filed an amendment
to its Articles of Incorporation (the &#8220;Amendment&#8221;) with the State of Colorado, to eliminate the Series &#8220;A&#8221; Preferred
Shares consisting of Eight Hundred and Fifty Thousand (850,000) shares, par value $0.10 per share, and the designation thereof, which
shares were returned to the status of undesignated shares of Preferred Stock. In addition, the Amendment increased the number of authorized
Series &#8220;B&#8221; Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on June 17, 2020, the Company issued Five
Hundred Thousand (500,000) shares of Series &#8220;B&#8221; Preferred Stock in favor of Dr. Steve N. Slilaty, the Company&#8217;s CEO,
in consideration for the COVID-19 treatment technology he developed. The Series &#8220;B&#8221; Preferred Stock is non-convertible, non-redeemable,
non-retractable and has a superior liquidation value of $0.10 per share. Each share of Series &#8220;B&#8221; Preferred Stock is entitled
to 1,000 votes per share. This issuance brought the total number of Series &#8220;B&#8221; Preferred Stock held by Dr. Slilaty to 1,000,000
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 8, 2020, the Company executed a financing
agreement with RB Capital Partners, Inc., La Jolla, CA, (&#8220;RB Capital&#8221;) who agreed to provide the Company with a minimum of
$2 million in convertible debt financing during the ensuing three to six month period pursuant to the terms and conditions included in
relevant Promissory Notes (the &#8220;Promissory Notes&#8221;). The Promissory Notes bear interest at the rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210930__us-gaap--DebtInstrumentAxis__custom--RBCapitalMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zBe9bJTQH3sb" title="Debt stated rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-09-30_custom_RBCapitalMember_custom_PromissoryNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% per annum and have
a maturity date of two years from the date of issuance. The Company has the right to pay off all or any part of the Promissory Notes at
any time without penalty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 6, 2020, the Company entered
into a Research Agreement (the &#8220;Agreement&#8221;) with the University of Georgia Research Foundation, Inc. (&#8220;UGARF&#8221;),
representing the University of Georgia (&#8220;UGA&#8221;). The purpose of the Agreement is to memorialize the terms of the Company working
together with UGA to conduct the necessary research and development to advance the Company&#8217;s Anti-Coronavirus lead compound, SBFM-PL4
(or derivatives thereof) through various stages of preclinical development, animal studies and clinical trials for Coronavirus infections.
The Agreement grants the Company an exclusive worldwide license for all of the intellectual property developed by UGA, whether developed
alone or jointly with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 26, 2021, the Company received a Notice
of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains
new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 4, 2021, the Company entered into
an exclusive license agreement with the University of Georgia (&#8220;UGA&#8221;) for two Anti-Coronavirus compounds which UGA had previously
developed and patented. The Company and UGA will advance the development of these two compounds in parallel with the Company&#8217;s own
Anti-Coronavirus compound, SBFM-PL4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2021, the Company received a Notice
of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject
matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued
in 2019 (US Patent Number 10,272,065).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 25, 2021, the Company entered into an
engagement agreement with Aegis Capital Corp. (&#8220;Aegis&#8221;), pursuant to which we engaged Aegis to act as lead underwriter in
connection with a proposed public offering of approximately $10 million of common stock and warrants by the Company (the &#8220;Offering&#8221;).
The Offering is contingent on satisfaction of various conditions, including Aegis&#8217;s due diligence examination of the Company, Nasdaq
approval of the listing of the Company&#8217;s Common Stock, and successful completion of a reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2021, the Company filed its Definitive Information Statement
with the SEC to complete the reverse split of the Company&#8217;s Common Stock in part to meet the Nasdaq listing requirement concerning
minimum price per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's financial statements reflect both
the First and Second Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and
its subsidiaries (Sunshine Biopharma Canada Inc. and NOX Pharmaceuticals Inc.) herein collectively referred to as the &#34;Company&#34;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_230_ztT0aSF85UZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zOAaWijVHjNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_z9Z8pG7J2769" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zpVv1jiPBTyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p id="xdx_84B_ecustom--ImpactOfCoronavirusPandemicPolicyTextBlock_z0KiM2ZTYp3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B4_zfGehxDTYLFl"><b><i>Impact
of Coronavirus (COVID-19) Pandemic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, the World Health Organization declared
Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak have been and are
continuing to evolve rapidly. Government authorities in the U.S. and around the world have implemented emergency measures to mitigate
the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on
the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of
the adverse conditions of the outbreak and their effects on the Company&#8217;s business or ability to raise funds. No adjustments have
been made to the amounts reported in the Company's financial statements as a result of this matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zMOgnXzFJPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_znHHq3vFqa0g">Basis of Presentation of Unaudited Financial
Information</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited financial statements of the Company
for the three and nine month periods ended September 30, 2021 and 2020 have been prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q
and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted
in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely
of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position
and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full
fiscal year. The balance sheet information as of December 31, 2020 was derived from the audited financial statements included in the Company's
financial statements as of and for the year ended December 31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 30, 2021. These financial statements should be read in conjunction
with that report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0quiwBf4kBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_z8XZZadL6vOf">Recently Issued Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2019, the FASB issued ASU 2019-12 &#8220;Income Taxes
(Topic 740): Simplifying the Accounting for Income Taxes.&#8221; This guidance removes certain exceptions to the general principles in
Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new
guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early
adoption is permitted. There was no impact of the updated guidance on the Company&#8217;s financial statements for the year ended December
31, 2020. The Company is currently evaluating the impact of the updated guidance on its financial statements for 2021 and going forward.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, the FASB issued ASU 2020-02,&#160;<i>Financial
Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842)&#160;</i>which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective
for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will
modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The
Company is in the process of determining the effects adoption will have on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In August
2020, the FASB issued ASU 2020-06,&#160;<i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</i>, (&#8220;ASU 2020-06&#8221;). ASU 2020-06 simplifies the
accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts
on an entity&#8217;s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim
periods within those fiscal years.&#160;</span>Early adoption is permitted, but no earlier than fiscal years beginning after December
15, 2020, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zBP56Z9LPIl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 2 &#8211; <span id="xdx_82A_z6XYaTzUM7yb">Going Concern and Liquidity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and December 31,
2020, the Company had <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_c20210930_pp0p0" title="Cash and cash equivalents">$<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,386,608</ix:nonFraction></span>
and <span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_c20201231_pp0p0" title="Cash and cash equivalents">$<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">989,888</ix:nonFraction></span>
in cash on hand, respectively, and limited revenue-producing business. Additionally, as of September 30, 2021 and December 31, 2020,
the outstanding liabilities of the Company totaled <span id="xdx_90F_eus-gaap--Liabilities_c20210930_pp0p0" title="Outstanding liabilities">$<ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,675,847</ix:nonFraction> </span>and <span id="xdx_900_eus-gaap--Liabilities_c20201231_pp0p0" title="Outstanding liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0601">$2,000,311,</span></span>
respectively. These factors raise substantial doubts about the Company&#8217;s ability to continue as a going concern. On June 25,
2021, the Company entered into an Engagement agreement with Aegis Capital for the purposes of raising <span id="xdx_903_eus-gaap--Capital_iI_c20210625_zHmKb77hr6Vk" title="Capital">$<ix:nonFraction name="us-gaap:Capital" contextRef="AsOf2021-06-25" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span>
in equity financing in a proposed public offering and, in connection therewith, the Company filed a preliminary prospectus of Form
S-1 with the SEC on September 9, 2021. The Company believes that the afore expressed doubt about the Company&#8217;s ability to
continue as a going concern will be fully mitigated if the financing were to close. There is no
assurance the offering will be completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_z85AC3GFfAgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zATauWV5ADR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_z2v8JlRM4rm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zN1MwYL5cwVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_z7Jwv2g7uRb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements included
in this Report have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities
and commitments in the normal course of business. The consolidated financial statements included in this Report do not include any adjustments
that may result from the outcome of any going concern uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no assurance that these events will be
satisfactorily completed. The issuance of equity securities in connection with the Offering (see Note 1), if accomplished, could cause
substantial dilution to existing stockholders. Any failure by the Company to successfully implement these plans would have a material
adverse effect on its business, including the possible inability to continue operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zL6yBtq348Th" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 3 &#8211; <span id="xdx_822_zQmHd2l9WI91">Notes Payable</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s Notes Payable at September
30, 2021 consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Note Payable dated December 31, 2018 having
a Face Value of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_c20181231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2018-12-31_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">136,744</ix:nonFraction></span> and accruing interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20180101__20181231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_zEDMO8ip8aSf" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2018-01-012018-12-31_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% was due <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20180101__20181231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_zFkmxlZG1PGh" title="Maturity Date"><ix:nonNumeric contextRef="From2018-01-012018-12-31_custom_NotePayable2018Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 31, 2019</ix:nonNumeric></span>. On October 1, 2019, the holder of this note requested
to convert $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20190101__20191001__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2019-01-012019-10-01_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000</ix:nonFraction></span> in principal amount into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20190101__20191001__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pdd" title="Debt converted, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2019-01-012019-10-01_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span> shares of Common Stock, leaving a principal balance $<span id="xdx_909_eus-gaap--NotesPayable_c20191001__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Note payable balance"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2019-10-01_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,744</ix:nonFraction></span>. On December 31, 2019,
the Company renewed the remaining principal balance of this Note, together with accrued interest of $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_c20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Interest accrued"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2019-12-31_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,509</ix:nonFraction></span> for a 12-month period. The
new Note has a Face Value of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2019-12-31_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">122,253</ix:nonFraction></span> and accrues interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_zhdavqww6961" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2019-01-012019-12-31_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%. This Note matured on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_z3fBHVcsw0mg" title="Maturity Date"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_NotePayable2018Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 31, 2020</ix:nonNumeric></span>. On August 27, 2020, the holder
of this Note transferred all of its interest therein to RB Capital and in connection with a financing agreement with RB Capital, the Company
agreed to render the Note convertible at $0.001 per share. Through September 30, 2021, the entire principal amount of $<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-09-30_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">122,253</ix:nonFraction></span> of this
Note and all accrued interest of $<span id="xdx_90A_ecustom--DebtConvertedInterestConverted_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, interest converted">14,247</span> was converted into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pdd" title="Debt converted, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-01-012021-09-30_custom_NotePayable2018Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136,500,000</ix:nonFraction></span> shares of Common Stock valued at $<span id="xdx_90F_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, shares converted value">7,884,100</span> resulting in a loss
of $<span id="xdx_903_ecustom--GainLossOnDebtConversion_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Gain (Loss) on debt conversion">7,747,600</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2020, the Company&#8217;s Canadian
subsidiary received a CEBA Loan (Canada Emergency Business Account Loan) from CIBC (Canadian Imperial Bank of Commerce) in the principal
amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20200417__us-gaap--LongtermDebtTypeAxis__custom--CEBALoanMember__srt--CurrencyAxis__currency--CAD_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-04-17_custom_CEBALoanMember_currency_CAD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span> Canadian ($29,352 US) as part of the Canadian government&#8217;s COVID-19 relief program. The CEBA Loan is non-interest
bearing if repaid on or before December 31, 2022 (the &#8220;Termination Date&#8221;). The CEBA Loan is considered repaid in full if the
borrower repays 75% of the Principal Amount on or before the Termination Date. On June 15, 2021, the Company paid 75% <span id="xdx_90C_eus-gaap--RepaymentsOfNotesPayable_pp0p0_c20210101__20210615__us-gaap--LongtermDebtTypeAxis__custom--CEBALoanMember__srt--CurrencyAxis__currency--CAD_zH9D8ZjO5so9" title="Repayments of notes payable" style="display: none"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-012021-06-15_custom_CEBALoanMember_currency_CAD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000</ix:nonFraction></span> of this loan and
the remaining 25% <span id="xdx_90F_ecustom--GainLossOnDebtConversion_c20210101__20210615__us-gaap--LongtermDebtTypeAxis__custom--CEBALoanMember__srt--CurrencyAxis__currency--CAD_pp0p0" style="display: none">20,000</span> was forgiven.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 27, 2020, the Company received a Paycheck
Protection Program loan (&#34;PPP Loan&#34;) in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_c20200427__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-04-27_custom_PPPLoanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,655</ix:nonFraction></span> from the US Small Business Administration (&#8220;SBA&#8221;)
as part of the US government&#8217;s COVID-19 relief program. This loan accrues interest at the rate of<span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200427__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_zDviKoZhCJFf" title="Interest Rate"> <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-04-27_custom_PPPLoanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% per annum. The Company is obligated
to make payments of principal and interest totaling $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20200101__20200427__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_pp0p0" title="Periodic Payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2020-01-012020-04-27_custom_PPPLoanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,133</ix:nonFraction></span> each month commencing on November 27, 2020, with any remaining balances due
and payable on or before April 27, 2022. The proceeds derived from this loan may only be used for payroll costs, interest on mortgages,
rent and utilities (&#8220;Admissible Expenses&#8221;). In addition, the Paycheck Protection Program provides for conditional loan forgiveness
if the Company utilizes at least 75% of the proceeds from the loan to pay Admissible Expenses. On December 15, 2020, the Company applied
to the funding bank for forgiveness of this loan per SBA guidance. On December 18, 2020, the Company received notification that the funding
bank has approved forgiveness of the loan in its entirety and that it has submitted a request to the SBA for final approval. On February
22, 2021, the funding bank informed the Company that the SBA has fully forgiven the loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 7, 2020, the Company received monies in
exchange for a Note Payable having a Face Value of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20200707__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-07-07_custom_NotePayable1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,000</ix:nonFraction></span> with interest accruing at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200707__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_zNhXvJ1X394" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-07-07_custom_NotePayable1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% is due <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200707__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_zjVedKQLOiF7" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-07-07_custom_NotePayable1Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">July 7, 2021</ix:nonNumeric></span>. The Note is convertible after
180 days from issuance into Common Stock at a price 35% below market value. On January 5, 2021, the Company paid off the entire principal
balance of this Note, together with accrued interest and prepayment penalties of $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210105__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Interest accrued"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-01-05_custom_NotePayable1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,271</ix:nonFraction></span> by issuing cash payment of $<span id="xdx_90E_eus-gaap--RepaymentsOfNotesPayable_c20210101__20210105__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Repayments of notes payable"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-012021-01-05_custom_NotePayable1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,271</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_c20200727__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-07-27_custom_NotePayable2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,000</ix:nonFraction></span> with interest accruing at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200727__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_zXOVBslYiu7g" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-07-27_custom_NotePayable2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% is due <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200727__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_zqGr6wMovZ99" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-07-27_custom_NotePayable2Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">July 27, 2021</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price 30% below market value. On January 29, 2021, the entire principal amount of
$<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-01-29_custom_NotePayable2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,000</ix:nonFraction></span> of this Note plus accrued interest of $<span id="xdx_90A_ecustom--DebtConvertedInterestConverted_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Debt converted, interest converted">4,171</span> was converted into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pdd" title="Debt converted, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-01-012021-01-29_custom_NotePayable2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,044,456</ix:nonFraction></span> shares of Common Stock valued at $<span id="xdx_909_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Debt converted, shares converted value">484,268</span> resulting
in a loss of $<span id="xdx_902_ecustom--GainLossOnDebtConversion_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Gain (Loss) on debt conversion">378,097</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20200814__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-08-14_custom_NotePayable3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,000</ix:nonFraction></span> with interest accruing at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200814__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_zb0YDi5pLNdc" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-08-14_custom_NotePayable3Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% is due <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200814__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_z1ioZeBy69qb" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-08-14_custom_NotePayable3Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August 14, 2021</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price 30% below market value. On February 22, 2021, the entire principal amount of
$<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-02-22_custom_NotePayable3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,000</ix:nonFraction></span> of this Note plus accrued interest of $<span id="xdx_900_ecustom--DebtConvertedInterestConverted_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Debt converted, interest converted">2,680 </span>was converted into<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pdd" title="Debt converted, shares issued"> <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-01-012021-02-22_custom_NotePayable3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">542,173</ix:nonFraction> </span>shares of Common Stock valued at $<span id="xdx_90C_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Debt converted, shares converted value">119,169</span> resulting in
a loss of $<span id="xdx_90E_ecustom--GainLossOnDebtConversion_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Gain (Loss) on debt conversion">49,489</span>.</p>

<ix:exclude><p id="xdx_232_zRgaEEbnFfq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zYvHAHr3IBe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_z5eaFm2Dq2Z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zhuKDshmJ7g3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zwvwnZygga67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zs5dKGZ08bDg" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-09-14_custom_NotePayable4Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>
with interest accruing at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zrSJ8YXNqKnb" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-09-14_custom_NotePayable4Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
which was due <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zw3piTPyZD2g" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-09-14_custom_NotePayable4Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">September
14, 2022</ix:nonNumeric></span>. The Note was convertible after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-09-14_custom_NotePayable4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction> </span>per
share. On June 2, 2021, the entire principal amount of $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-06-02_custom_NotePayable4Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>
of this Note plus all accrued interest of $<span id="xdx_905_ecustom--DebtConvertedInterestConverted_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Debt converted, interest converted">8,850</span>
converted into <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pdd" title="Debt converted, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-01-012021-06-02_custom_NotePayable4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">862,833</ix:nonFraction></span>
shares of Common Stock valued at $<span id="xdx_90B_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Debt converted, shares converted value">170,841</span>
resulting in a gain of $<span id="xdx_90D_ecustom--GainLossOnDebtConversion_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Gain (Loss) on debt conversion">88,009</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zF0hLsrNrVKh" title="Face Value"><span style="-sec-ix-hidden: xdx2ixbrl0718">50,000,</span></span> with interest accruing at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zLWpTfKngd3" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-09-24_custom_NotePayable5Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%, which due <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zJTUbHnCYINg" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-09-24_custom_NotePayable5Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">September 24, 2022</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-09-24_custom_NotePayable5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction></span> per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date on March 23, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 20, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zhwwbKzxfcUg" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-10-20_custom_NotePayable6Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>
with interest accruing at<span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zIcfQDfqiTZh" title="Interest Rate">
<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-10-20_custom_NotePayable6Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% whic was due <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zNX9IYNIpRC3" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-10-20_custom_NotePayable6Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">October
20, 2022</ix:nonNumeric></span>. The Note was convertible after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zZpLGSmSXbRb" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-10-20_custom_NotePayable6Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction></span>
per share. On June 2, 2021, the entire principal amount of $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-06-02_custom_NotePayable6Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>
of this Note plus all accrued interest of $<span id="xdx_90A_ecustom--DebtConvertedInterestConverted_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Debt converted, interest converted">7,600</span>
was converted into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pdd" title="Debt converted, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-01-012021-06-02_custom_NotePayable6Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">858,666</ix:nonFraction></span>
shares of Common Stock valued at $<span id="xdx_909_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Debt converted, shares converted value">170,016</span>
resulting in a gain of $<span id="xdx_902_ecustom--GainLossOnDebtConversion_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Gain (Loss) on debt conversion">87,584</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 19, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20201119__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-11-19_custom_NotePayable7Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>
with interest accruing at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201119__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_zZzH4B4mDPHe" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-11-19_custom_NotePayable7Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
which was due <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201119__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_zi1TN5bx1fg" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-11-19_custom_NotePayable7Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August
19, 2021</ix:nonNumeric></span>. The Note was convertible after 180 days from issuance into Common Stock at a price 35% below market value. On May
19, 2021, the Company paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of
$<span id="xdx_90D_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210519__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Interest accrued"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-05-19_custom_NotePayable7Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">126,881</ix:nonFraction></span>
by issuing cash payment of $<span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20210101__20210519__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Repayments of notes payable"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-012021-05-19_custom_NotePayable7Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">376,881</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 24, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20201124__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-11-24_custom_NotePayable8Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,000</ix:nonFraction></span>
with interest accruing at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201124__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_z6xvrFpjEuA5" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-11-24_custom_NotePayable8Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
which was due <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dp_c20200101__20201124__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_zjeTo3APb0Lj" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-11-24_custom_NotePayable8Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November
24, 2021</ix:nonNumeric></span>. The Note was convertible after 180 days from issuance into Common Stock at a price 30% below market value. On June
1, 2021, the entire principal amount of $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-06-01_custom_NotePayable8Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,000</ix:nonFraction></span>
of this Note plus all accrued interest of $<span id="xdx_90B_ecustom--DebtConvertedInterestConverted_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Debt converted, interest converted">10,428</span>
was converted into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pdd" title="Debt converted, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-01-012021-06-01_custom_NotePayable8Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,865,841</ix:nonFraction></span>
shares of Common Stock valued at $<span id="xdx_906_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Debt converted, shares converted value">695,078,</span>
resulting in a loss of $<span id="xdx_901_ecustom--GainLossOnDebtConversion_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Gain (Loss) on debt conversion">424,650</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 25, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_c20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-11-25_custom_NotePayable9Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span> with interest accruing at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_zIjbvs9zAeka" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-11-25_custom_NotePayable9Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% is due <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_zDD7Pz9RCw13" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-11-25_custom_NotePayable9Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November 25, 2022</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-11-25_custom_NotePayable9Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction> </span>per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date on May 24, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 2, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-12-02_custom_NotePayable10Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,215</ix:nonFraction> </span>with interest accruing at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_z9JyVfukcBtj" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-01-012020-12-02_custom_NotePayable10Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% is due <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_zhjs9KC1ryjb" title="Maturity Date"><ix:nonNumeric contextRef="From2020-01-012020-12-02_custom_NotePayable10Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 2, 2022</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-12-02_custom_NotePayable10Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction></span> per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date on May 31, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_c20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-01-12_custom_NotePayable11Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span> with interest accruing at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_zXelRL6xjDuc" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-01-012021-01-12_custom_NotePayable11Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% is due<span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_zKWE5c44uBH9" title="Maturity Date"> <ix:nonNumeric contextRef="From2021-01-012021-01-12_custom_NotePayable11Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">January 12, 2023</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-01-12_custom_NotePayable11Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction> </span>per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date of July 11, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-01-27_custom_NotePayable12Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span> with interest accruing at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_znz9M9nvZNUj" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-01-012021-01-27_custom_NotePayable12Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% is due <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_zBqsSnh4HJAi" title="Maturity Date"><ix:nonNumeric contextRef="From2021-01-012021-01-27_custom_NotePayable12Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">January 27, 2023</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-01-27_custom_NotePayable12Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date of July 26, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_c20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-02-12_custom_NotePayable12Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">700,000</ix:nonFraction></span> with interest accruing at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_zQhol8cn6FEf" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-01-012021-02-12_custom_NotePayable12Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% is due<span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_zpKD0yK1wejh" title="Maturity Date"> <ix:nonNumeric contextRef="From2021-01-012021-02-12_custom_NotePayable12Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">February 12, 2023</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-02-12_custom_NotePayable12Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.60</ix:nonFraction></span> per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date of August&#160;11, 2021, which is 180 days after the issuance date, and
determined that there was no beneficial conversion feature on September 30, 2021.</p>

<ix:exclude><p id="xdx_233_z0hXZ6YWxFY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zq4lPlK0hdGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zFdRTtwvHjj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zj8aJygloLFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_znrJcddYfnWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 5, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-04-05_custom_NotePayable13Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">330,000</ix:nonFraction> </span>with interest accruing at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_zykLR6I8qgJe" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-01-012021-04-05_custom_NotePayable13Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% is due <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_zK2C7oNzGGVd" title="Maturity Date"><ix:nonNumeric contextRef="From2021-01-012021-04-05_custom_NotePayable13Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">January 5, 2022</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-04-05_custom_NotePayable13Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction></span> per share or 35% below market value, whichever is lower. The Company
will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on October 2, 2021, which is
180 days after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-04-20_custom_NotePayable14Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction> </span>with interest accruing at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_z2IDWSem2fh8" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-01-012021-04-20_custom_NotePayable14Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% is due <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_z3K0qdJwCsU4" title="Maturity Date"><ix:nonNumeric contextRef="From2021-01-012021-04-20_custom_NotePayable14Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">April 20, 2023</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-04-20_custom_NotePayable14Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction></span> per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date of October 17, 2021, which is 180 days after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company received monies in
exchange for a Note Payable having a Face Value of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-07-06_custom_NotePayable15Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">900,000</ix:nonFraction></span> with interest accruing at <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_zV64WnpCfgng" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-01-012021-07-06_custom_NotePayable15Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% is due <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_zhgHSKYFk69a"><ix:nonNumeric contextRef="From2021-01-012021-07-06_custom_NotePayable15Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">July 6, 2023</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-07-06_custom_NotePayable15Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction></span> per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date of January 2, 2022, which is 180 days after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_pp0p0" title="Face Value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-08-18_custom_NotePayable16Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> with interest accruing at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_zfVrqpxjwz1i" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-01-012021-08-18_custom_NotePayable16Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% is due <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_zGJlX1iOlaxh" title="Maturity Date"><ix:nonNumeric contextRef="From2021-01-012021-08-18_custom_NotePayable16Member" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August 18, 2023</ix:nonNumeric></span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_pdd" title="Conversion Price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2021-08-18_custom_NotePayable16Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction></span> per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date of February 14, 2022, which is 180 days after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2021 and December 31, 2020, total
accrued interest on Notes Payable was $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20210930_zDOg3t4z8jpf" title="Interest accrued"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,945</ix:nonFraction> </span>and $<span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20201231_zR7erHBKJVKl" title="Interest accrued"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,320</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_80B_ecustom--DebtDisclosureRelatedEntityTextBlock_zvvmCXBAZeVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 4 &#8211; <span id="xdx_827_z6dLz3oZPntd">Notes Payable - Related Party</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outstanding Notes Payable at September 30, 2021
held by related parties consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Note Payable dated December 31, 2019 held by
the CEO of the Company having a Face Value of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableRelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Face value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">128,269</ix:nonFraction> </span>and accruing interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableRelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_ziTvg9GXGcV5" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% was due December 31, 2020. On <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableRelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zF2tdvfhsoc" title="Debt Instrument, Maturity Date"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 31, 2020</ix:nonNumeric></span>, the
Company renewed the Note together with accrued interest of $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableRelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Interest accrued"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,392</ix:nonFraction></span> for a 12-month period. The new Note has a face Value of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableRelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Face value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,661</ix:nonFraction></span>, accrues
interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableRelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLRAMQAtTzjh" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum, and has a maturity date of<span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayableRelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zMgfFmJ1ItPj" title="Debt Instrument, Maturity Date"> <ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 31, 2021</ix:nonNumeric></span>. On August 24, 2021, the Company paid off the entire principal
balance of this Note, together with accrued interest of $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_c20210824__us-gaap--LongtermDebtTypeAxis__custom--NotePayableRelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Accrued interest"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-08-24_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,929</ix:nonFraction></span> by issuing cash payment of $<span id="xdx_900_eus-gaap--RepaymentsOfNotesPayable_c20210101__20210824__us-gaap--LongtermDebtTypeAxis__custom--NotePayableRelatedPartyMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Repayment of notes payable"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-012021-08-24_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">156,590</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zmsPrI6Gxbac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 5 &#8211; <span id="xdx_822_zpR8R5juXnz">Shareholders&#8217; Equity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September 30,
2021, the Company issued a total of <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_zJNb1u7s8cg" title="Debt converted, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2021-01-012021-09-30_custom_OutstandingNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,673,969</ix:nonFraction></span>
shares of Common Stock valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueOther_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_z4aneKSlkvne"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_custom_OutstandingNotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,981,072</ix:nonFraction></span> for the conversion of outstanding notes payable, reducing the debt by $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_pp0p0" title="Debt converted, amount converted"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-09-30_custom_OutstandingNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,233,028</ix:nonFraction></span>
and interest payable by $<span id="xdx_908_ecustom--DebtConvertedInterestConverted_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_pp0p0" title="Debt converted, interest converted">38,201</span>
and generating a loss on conversion of $<span id="xdx_906_ecustom--GainLossOnDebtConversion_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_pp0p0" title="Gain (Loss) on debt conversion">10,709,843</span>.
In addition, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pdd" title="Common stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000,000</ix:nonFraction></span>
shares of Common Stock valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pp0p0" title="Common stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">918,000</ix:nonFraction> </span>to
its Officers and Directors as compensation for their services to the Company. The fair value of the stock was based on the closing price of the stock
on the date of the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company declared <span id="xdx_906_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_pp0p0_do_c20210930_z4MGShsO4Uua" title="Dividends Payable"><ix:nonFraction name="us-gaap:DividendsPayableCurrentAndNoncurrent" contextRef="AsOf2021-09-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> dividends through September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_808_ecustom--ManagementCompensationDisclosureTextBlock_zP6afK3Flc77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note
6 &#8211; <span id="xdx_82A_zm8ldgMa6M0k"><span id="xdx_820_zbSPamgJcZ7f">Management Compensation</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid its Officers and Directors cash compensation totaling $<span id="xdx_907_eus-gaap--SalariesWagesAndOfficersCompensation_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pp0p0" title="Salary and Wage, Excluding Cost of Good and Service Sold"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">130,000</ix:nonFraction></span>
and $<span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pp0p0" title="Salary and Wage, Excluding Cost of Good and Service Sold"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2020-01-012020-09-30_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">255,927</ix:nonFraction> </span>for
the nine months ended September 30, 2021 and 2020, respectively. Of these amounts, $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember__srt--CounterpartyNameAxis__custom--TrtPharmaMember_pp0p0" title="Salary and Wage, Excluding Cost of Good and Service Sold"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember_custom_TrtPharmaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span> was paid to Advanomics Corporation (now
known as TRT Pharma Inc.), a company controlled by the CEO of the Company. In addition, the Company issued<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zsZjUvM0PTc9" title="Common stock issued for services, shares"> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000,000</ix:nonFraction></span> shares of
Common Stock valued at $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zl4Odf8ZG4O1" title="Common stock issued for services, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">918,000</ix:nonFraction></span> to its Officers and Directors during the nine months ended September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zHfPRvbLECvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 7 &#8211; <span id="xdx_824_zwejI9ctrvmg">Subsequent Events</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2021, the holder of a Note Payable
dated April 5, 2021 elected to convert a total of $330,000 in principal and $16,500 in accrued interest into 5,250,000 shares of Common
Stock leaving a principal balance of $-0-.</p>

</ix:nonNumeric><p id="xdx_81F_z9GXCiVBlK75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="fs10k_001"></span>Report of Independent Registered Public Accounting
Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the shareholders and the board of directors
of Sunshine Biopharma, Inc.:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Sunshine Biopharma, Inc. (the &#34;Company&#34;) as of December 31, 2020 and 2019, the related consolidated statements
of operations and comprehensive income (loss), shareholders' equity, and cash flows for each of the two years in the period ended December
31, 2020, and the related notes (collectively referred to as the &#34;financial statements&#34;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its
operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles
generally accepted in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern Uncertainty</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has
suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue
as a going concern.&#160;Management&#8217;s plans in regard to these matters are also described in Note 3. The financial statements do
not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#34;PCAOB&#34;) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ B F Borgers CPA PC</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company's auditor since
2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lakewood, CO</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 30, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Sunshine Biopharma, Inc.</p>

<p style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="fs10k_002"></span>Consolidated Balance Sheets</p>



<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; background-color: White; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">989,888</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">40,501</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,916</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,771</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,910</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,778</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,255</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Deposits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,590</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,590</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Total Current Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,025,943</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">65,686</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Equipment (net of $51,485 and $37,109 depreciation, respectively)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,456</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Patents (net of $58,918 amortization and $556,120 impairment)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,045,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">98,142</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">820,454</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">586,307</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143,661</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,261</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accounts payable &amp; accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,882</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Interest payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,320</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,077</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Total Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,051,305</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">833,527</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Long-term portion of notes payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">949,006</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">TOTAL LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,000,311</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">833,527</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">SHAREHOLDERS' EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Preferred Stock, Series B $0.10 par value per share; Authorized 1,000,000 Shares;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Issued and outstanding 1,000,000 and 500,000 shares at December 31, 2020 and December 31, 2019, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Common Stock, $0.001 value per share; Authorized 3,000,000,000 Shares;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Issued and outstanding 346,419,296 and 35,319,990 at December 31, 2020 and December 31, 2019, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,418</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,320</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Capital paid in excess of par value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,820,343</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,616,426</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accumulated comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,871</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,495</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Accumulated (Deficit)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(20,218,727</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(17,434,636</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">TOTAL SHAREHOLDERS' EQUITY (DEFICIT)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(954,837</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(735,385</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-align: left">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,045,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">98,142</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes to These Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold">Sunshine Biopharma, Inc.</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold"><span id="fs10k_003"></span>Consolidated Statement of Operations and Comprehensive Income (Loss)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2020</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">71,410</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">21,121</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cost of sales</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,847</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,050</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">45,563</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,071</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">General &amp; Administrative Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Accounting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,524</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,253</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Consulting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,360</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,124</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Legal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,587</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,196</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Office</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,904</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Officer &amp; director remuneration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,930</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,252</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>R&amp;D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,948</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,204</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,066</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,774</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Total General &amp; Administrative Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">622,437</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">651,707</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Income (Loss) from Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(576,874</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(641,636</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other Income (Expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on debt conversions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,057,513</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(314,752</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign exchange gain (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,099</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(168,105</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(115,901</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Miscellaneous income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt release</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,967</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Interest forgiveness</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,836</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,367</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Total Other Income (Expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,207,217</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(436,418</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss) before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,784,091</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,078,054</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Provision for income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss) from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,784,091</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,078,054</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: left">Net income (loss) on discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(582,237</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Net Income (Loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,784,091</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,660,291</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Unrealized gain (loss) from foreign exchange translation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">376</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,243</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-align: left">Comprehensive Income (Loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,783,715</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,659,048</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic income (loss) from continuing operations per common share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.10</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic income (loss) from discontinued operations per common share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic income (loss) per common share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.15</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Weighted Average Common Shares Outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,096,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,932,813</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes to These Financial
Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold">Sunshine Biopharma, Inc.</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold"><span id="fs10k_004"></span>Consolidated Statement of Cash Flows</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Net Income (Loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(2,784,091</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,660,291</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Adjustments to reconcile net income (loss) to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,774</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign exchange (gain) loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,891</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,099</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">261,690</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Stock issued for payment interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,197</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on debt conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,057,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,752</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Gain on interest and debt forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,510</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,334</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on disposition of subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">582,237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">(Increase) in accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,486</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(430</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Increase) decrease in inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,861</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,910</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">(Increase) in prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,523</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,676</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Increase) in deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">(Decrease) in Accounts Payable &amp; accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35,012</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,692</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Increase in interest payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,243</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,786</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Net Cash Flows (Used) in Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(657,299</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(495,798</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advances to discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,416</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Purchase of equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,191</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(860</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Net Cash Flows (Used) in Investing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,191</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,276</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows from Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Proceeds from notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,674,246</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">441,230</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payments of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(106,600</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(53,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Note payable - interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,795</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Note payable used to pay note origination fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,230</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Net Cash Flows Provided by Financing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,608,253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">442,255</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash and Cash Equivalents at Beginning of Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,501</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,216</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Increase (Decrease) In Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">949,763</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(68,819</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(376</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,896</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Cash and Cash Equivalents at End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">989,888</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40,501</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplementary Disclosure of Cash Flow Information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-align: left">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,963</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Cash paid for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; text-align: left">Stock issued for note conversions</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,515,015</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">717,726</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes to These Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="33" style="font-weight: bold"><span style="font-size: 8pt"><b>Sunshine Biopharma, Inc.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="33" style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 8pt"><b><span id="fs10k_005"></span>Consolidated
Statement of Shareholders' Equity</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>Number
                                            of Common Shares Issued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>Common
                                            Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>Capital
                                            Paid in Excess</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>of
                                            Par Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>Number
                                            of Preferred</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>Shares
                                            Issued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>Preferred
                                            Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>Comprehensive
                                            Income</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>Accumulated
                                            Deficit</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 28%; font-weight: bold"><span style="font-size: 8pt">Balance at December 31, 2018</span></td><td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">4,282,620</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">4,283</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">15,668,047</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">500,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">50,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">(3,738</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">(15,774,345</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">(55,753</span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; text-align: left"><span style="font-size: 8pt">Common stock issued to directors</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">9,150,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">9,150</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">195,150</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">204,300</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; text-align: left"><span style="font-size: 8pt">Common stock issued for services</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,455,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">1,455</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">55,935</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">57,390</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; text-align: left"><span style="font-size: 8pt">Common stock issued for the
    reduction of notes payable and payment of interest</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">20,432,370</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">20,432</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">697,294</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">717,726</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt; text-align: left"><span style="font-size: 8pt">Net (loss)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">1,243</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(1,660,291</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(1,659,048</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-size: 8pt">Balance at December 31, 2019</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">35,319,990</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">35,320</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">16,616,426</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">50,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(2,495</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(17,434,636</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(735,385</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; text-align: left"><span style="font-size: 8pt">Common stock issued for the
    reduction of notes payable and payment of interest</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">311,098,985</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">311,098</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">2,203,917</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">2,515,015</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; text-align: left"><span style="font-size: 8pt">Adjustment for Reverse-Split</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">321</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; text-align: left"><span style="font-size: 8pt">Preferred stock issued for services</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">500,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">50,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">50,000</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-indent: -5pt; padding-left: 5pt; text-align: left"><span style="font-size: 8pt">Net (loss)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(376</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(2,784,091</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(2,784,467</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -5pt; padding-left: 5pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-size: 8pt">Balance at December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">346,419,296</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">346,418</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">18,820,343</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">1,000,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">100,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(2,871</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(20,218,727</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(954,837</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See Accompanying Notes to These Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sunshine Biopharma, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="fs10k_006"></span>Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 31, 2020 and 2019</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 1 &#8211; Description of Business</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sunshine Biopharma, Inc. (the &#34;Company&#34;)
was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006 in the State of Colorado. Until October
2009, the Company was operating as a business consultancy firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 15, 2009, the Company acquired
Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. was holding an exclusive license
to a new anticancer drug bearing the laboratory name, Adva-27a (the &#8220;License Agreement&#8221;). Upon completion of the reverse acquisition
transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the
development of the licensed Adva-27a anticancer drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2012, the Company published the results
of its initial preclinical studies of Adva-27a in the peer-reviewed journal, ANTICANCER RESEARCH. The preclinical studies were conducted
in collaboration with Binghamton University, a State University of New York. The publication is entitled &#8220;Adva-27a, a Novel Podophyllotoxin
Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells&#8221; [ANTICANCER RESEARCH Volume 32, Pages 4423-4432
(2012)].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2014, the Company formed a wholly owned
Canadian subsidiary, Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;) for the purposes of offering generic pharmaceutical
products in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs
for treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, the Company acquired all worldwide
issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a
anticancer compound from Advanomics Corporation, a related party, in exchange for an aggregate of 803,264 shares of Common Stock valued
at $835,394 and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing
development of the Adva-27a anticancer drug covered by these patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2018, the Company acquired all of
the issued and outstanding shares of Atlas Pharma Inc. (&#8220;Atlas&#8221;), a Canadian privately held analytical chemistry company.
The purchase price for the shares was Eight Hundred Forty-Eight Thousand Dollars $848,000 Canadian ($676,748 US). The purchase price included
cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 50,000 shares of the Company&#8217;s Common Stock valued at $238,000,
and a promissory note (&#8220;Atlas Debt&#8221;) in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at
the rate of 3% per annum. Effective April 1, 2019, the Company re-assigned all of its stock in Atlas back to the original owner in exchange
for the Atlas Debt. The loss on the disposition was $580,125. See Note 11, below for a more detailed explanation of this disposition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2018, the Company formed NOX Pharmaceuticals,
Inc., a wholly owned Colorado corporation and assigned all of the Company&#8217;s interest in the Adva27a anticancer drug to that company.
NOX Pharmaceuticals Inc.&#8217;s mission is to research, develop and commercialize proprietary drugs including Adva-27a.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2018, the Company launched its first
over-the-counter product, Essential 9&#8482;, a nutritional supplement comprised of the nine (9) essential amino acids that the human
body cannot make. Essential 9<span style="font-variant: small-caps">tm</span> has been authorized for marketing by Health Canada under
NPN 80089663.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 1, 2019, the Company completed
a 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400
(the &#8220;First Reverse Stock Split&#8221;). The Company&#8217;s authorized capital of Common Stock remained as previously established
at 3,000,000,000 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2019, the Company received Health
Canada approval for a new Calcium-Vitamin D supplement. Health Canada issued NPN 80093432 through which it authorized the Company to manufacture
and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin D<span style="font-variant: small-caps">tm</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective April 6, 2020, the Company completed
another 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417
(the &#8220;Second Reverse Stock Split&#8221;). The Company&#8217;s authorized capital of Common Stock remained as previously established
at 3,000,000,000 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 22, 2020, the Company filed a patent application
in the United States for a new treatment for Coronavirus infections. The Company&#8217;s patent application covers composition subject
matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication.
The patent application has a priority date of May 22, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2020, the Company filed an amendment
to its Articles of Incorporation (the &#8220;Amendment&#8221;) with the State of Colorado, to eliminate the Series &#8220;A&#8221; Preferred
Shares consisting of Eight Hundred and Fifty Thousand (850,000) shares, par value $0.10 per share, and the designation thereof, which
shares were returned to the status of undesignated shares of Preferred Stock. In addition, the Amendment increased the number of authorized
Series &#8220;B&#8221; Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on June 17, 2020, the Company issued Five
Hundred Thousand (500,000) shares of Series &#8220;B&#8221; Preferred Stock in favor of Dr. Steve N. Slilaty, the Company&#8217;s CEO,
in consideration for the COVID-19 treatment technology he developed. The Series &#8220;B&#8221; Preferred Stock is non-convertible, non-redeemable,
non-retractable and has a superior liquidation value of $0.10 per share. Each share of Series &#8220;B&#8221; Preferred Stock is entitled
to 1,000 votes per share. This issuance brought the total number of Series &#8220;B&#8221; Preferred Stock held by Dr. Slilaty to 1,000,000
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 8, 2020, the Company executed a financing
agreement with RB Capital Partners, Inc., La Jolla, CA, who has agreed to provide the Company with a minimum of $2 million in convertible
debt financing over the next three to six months pursuant to the terms and conditions included in relevant Promissory Notes (the &#8220;Promissory
Notes&#8221;). The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of shares
of the Company&#8217;s Common Stock at a conversion price equal to the market value of the Company&#8217;s Common Stock on the applicable
conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of
issuance and must be fully converted on or before the maturity date. The Company has the right under these Promissory Notes to pay off
all or any part of the Promissory Notes at any time without penalty. As of December 31, 2020, the Company has received a total of $1,350,000
in funding under this agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 6, 2020, the Company entered
into a Research Agreement (the &#8220;Agreement&#8221;) with the University of Georgia Research Foundation, Inc. (&#8220;UGARF&#8221;),
representing the University of Georgia (&#8220;UGA&#8221;). The purpose of the Agreement is to memorialize the terms of the Company working
together with UGA to conduct the necessary research and development to advance the Company&#8217;s Anti-Coronavirus lead compound, SBFM-PL4
(or derivatives thereof) through various stages of preclinical development, animal studies and clinical trials for Coronavirus infections.
The Agreement grants the Company an exclusive worldwide license for all of the intellectual property developed by UGA, whether alone or
jointly with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's financial statements reflect both
the First and Second Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and
its subsidiaries (Sunshine Biopharma Canada Inc. and NOX Pharmaceuticals Inc.) herein collectively referred to as the &#34;Company&#34;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the last twelve month period the Company
has continued to raise money through the issuance of convertible debt. The Company&#8217;s activities are subject to significant risks
and uncertainties, including failing to secure additional funding to operationalize the Company&#8217;s proprietary drug development program
and other business activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 2 &#8211; Summary of Significant Accounting
Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary of significant accounting policies
is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes
are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform
to Generally Accepted Accounting Principles and have been consistently applied in the preparation of the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>IMPACT OF CORONAVIRUS (COVID-19) PANDEMIC</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, the World Health Organization declared
Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak are evolving rapidly
and government authorities around the world have implemented emergency measures to mitigate the spread of the virus. The outbreak and
related mitigation measures have had and will continue to have a material adverse impact on the world economies and the Company's business
activities. It is not possible for the Company to predict the duration or magnitude of the adverse conditions of the outbreak and their
effects on the Company&#8217;s business or ability to raise funds. No adjustments have been made to the amounts reported in the Company's
financial statements as a result of this matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>PRINCIPLES OF CONSOLIDATION</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated
in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>USE OF ESTIMATES</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation
of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those
estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>CASH AND CASH EQUIVALENTS</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Balance Sheets and Statements of Cash
Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance
of $989,888 and $40,501 as of December 31, 2020 and December 31, 2019, respectively. At times such cash balances may be in excess of the
FDIC limit of $250,000 or the equivalent in Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>PROPERTY AND EQUIPMENT</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is reviewed for recoverability
when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31,
2020 and 2019, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and
improvements and renewals are capitalized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is calculated using the straight-line method for financial reporting purposes and accelerated methods for tax purposes. Their estimated
useful lives are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="width: 48%; text-align: justify"><span style="font-size: 10pt">Office Equipment:</span></td>
    <td style="width: 52%; text-align: justify"><span style="font-size: 10pt">5-7 Years</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">Laboratory Equipment:</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">5 Years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt">Vehicles:</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">5 Years</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>EARNINGS PER SHARE</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted the Financial Accounting
Standards Board (FASB) ASC Topic 260 regarding earnings / loss per share, which provides for calculation of &#8220;basic&#8221; and &#8220;diluted&#8221;
earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available
to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the
potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>INCOME TAXES</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 740 &#8211; Income Taxes,
the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by
applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities
and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect
changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not
be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to recognize the financial
statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position
in an examination. For tax positions meeting a &#34;more-likely-than-not&#34; threshold, the amount to be recognized in the financial
statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold,
no financial statement benefit is recognized. As of December 31, 2020 the Company had no uncertain tax positions. The Company recognizes
interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no
federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred
any interest or tax penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Canadian and US tax purposes, the Company&#8217;s
2017 through 2019 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>FUNCTIONAL CURRENCY</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. dollar is the functional currency of
the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company translates its Canadian subsidiary's
financial statements into U.S. dollars as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.5in">&#160;</td>
  <td style="width: 0.25in">&#9679;</td>
  <td>Assets and liabilities are translated
at the exchange rate in effect as of the financial statement date.</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#9679;</td>
  <td>Income statement accounts are translated
using the weighted average exchange rate for the period.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company includes translation adjustments from
currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate
component of shareholders&#8217; equity. There are currently no transactions of a long-term investment nature, nor any gains or losses
from non U.S. currency transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>CONCENTRATION OF CREDIT RISKS</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash
equivalents with high credit quality financial institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL
INSTRUMENTS</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the provisions of accounting
guidance, FASB Topic ASC 825, Financial Instruments. ASC 825 requires all entities to disclose the fair value of financial instruments,
both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and
defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties. As of December 31, 2020 and 2019, the fair value of cash, accounts receivable and notes receivable, accounts payable,
accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or
interest rates which fluctuate with market rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company defines fair value as the price that
would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels
and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.5in">&#160;</td>
  <td style="width: 0.25in">&#9679;</td>
  <td>Level 1 &#8211; Level 1 inputs are quoted
prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement
date.</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#9679;</td>
  <td>Level 2 &#8211; Level 2 inputs are inputs
other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the
asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset
or liability.</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#9679;</td>
  <td>Level 3 &#8211; Level 3 inputs are unobservable
inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying value of financial assets and liabilities
recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring
basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried
and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are
those that are adjusted to fair value each time a financial statement is prepared.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>NOTES PAYABLE</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrowings are recognized initially at fair value,
net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of
transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective
interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>ACCOUNTING FOR DERIVATIVES LIABILITIES</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates stock options, stock warrants
or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted
for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity&#8217;s Own Equity. The result
of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market
at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair
value is recorded in the statement of operations as other income or other expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon conversion or exercise of a derivative instrument,
the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments
that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability
account at the fair value of the instrument on the reclassification date. The Company determined that none of the Company&#8217;s financial
instruments meet the criteria for derivative accounting as of December 31, 2020 and 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>EQUITY INSTRUMENTS ISSUED TO&#160; EMPLOYEES
OR NON-EMPLOYEES FOR AQUIRING GOODS OR SERVICES</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock-based compensation expense for both
employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. The
Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, Stock Based Compensation.
Stock-based compensation to employees consisting of stock option grants and restricted shares are recognized in the statement of operations
based on their fair values at the date of grant. The Company accounts for equity instruments issued to non-employees in accordance with
the provisions of ASC Topic 718, based upon the fair-value of the underlying instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>BASIC AND DILUTED NET GAIN (LOSS) PER SHARE</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes loss per share in accordance
with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the
face of the income statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net income (loss) per share is calculated
by dividing net (loss) by the weighted-average common shares outstanding. Diluted net income per share is calculated by dividing net income
by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever
is more dilutive. As the Company incurred net losses for the year ended December 31, 2020 no potentially dilutive securities were included
in the calculation of diluted earnings per share as the impact would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therefore, basic and dilutive net (loss) per share
were the same as of December 31, 2020 and 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>REVENUE RECOGNITION</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 1, 2018, the Company adopted ASU
No. 201409, &#8220;Revenue from Contracts with Customers&#8221; (ASC 606). Under the new guidance, an entity will recognize revenue to
depict the transfer of promised goods or services to customers at an amount that the entity expects to be entitled to in exchange for
those goods or services. A five-step model has been introduced for an entity to apply when recognizing revenue. The new guidance also
includes enhanced disclosure requirements. The guidance was effective January 1, 2018 and was applied on a modified retrospective basis.
The adoption did not have an impact on the Company's financial statements. All of the revenues of the Company are the Company's wholly
owned Canadian subsidiary, which sells nutritional supplements through Amazon.com and Amazon.ca.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In Canada, governmental regulations require that
companies recognize revenues upon completion of the work by issuing an invoice and remitting the applicable sales taxes (GST and QST)
to the appropriate government agency. The Company&#8217;s wholly owned Canadian subsidiary's revenue recognition policy is in compliance
with these local regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12
&#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; This guidance removes certain exceptions to the general
principles in Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date
of the new guidance for public companies is for fiscal years beginning after December&#160;15, 2020 and interim periods within those fiscal
years. Early adoption is permitted. The Company is currently evaluating the timing of adoption and impact of the updated guidance on its
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>LEGAL FEES</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2020 and 2019,
the legal fees incurred were related to services provided to the Company to assist with its regulatory requirements with the Securities
and Exchange Commission, patenting costs and one ongoing litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>DATE OF MANAGEMENT&#8217;S REVIEW</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent events have been evaluated through
March 29, 2021, which is the date the Financial Statements were available to be issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 3 &#8211; Going Concern</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. In the course of its life, the Company has had limited operations
and Working Capital deficit. This raises substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company
believes it can raise capital through equity sales and borrowing to fund its operations. Management believes this will contribute toward
its subsequent profitability. The accompanying Financial Statements do not include any adjustments that might be necessary if the Company
is unable to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 4 &#8211; Patents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the patents held
by the Company at December 31, 2020 and 2019:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, the Company acquired all worldwide
issued (US Patent Number 8,236,935, and US Patent Number 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029
for the Adva-27a anticancer compound from Advanomics Corporation, a related party, in exchange for an aggregate of 803,264 shares of Common
Stock valued at $835,394 and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company
is however continuing development of the Adva-27a anticancer drug covered by these patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 22, 2020, the Company filed a patent application
in the United States for a new treatment for Coronavirus infections. The Company&#8217;s patent application covers composition subject
matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication.
The patent application has a priority date of May 22, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 5 &#8211; Capital Stock</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s authorized capital is comprised
of 3,000,000,000 shares of $0.001 par value Common Stock and 30,000,000 shares of $0.10 par value Preferred Stock, to have such rights
and preferences as the Directors of the Company have or may assign from time to time. Out of the authorized Preferred Stock, the Company
had designated 850,000 shares as Series &#8220;A&#8221; Preferred Stock (&#8220;Series A&#8221;). At December 31, 2020 and December 31,
2019, the Company had no issued and outstanding shares of Series A. On June 17, 2020, the Company filed an amendment to its Articles of
Incorporation (the &#8220;Amendment&#8221;) eliminating the Series A shares and the designation thereof, which shares were returned to
the status of undesignated shares of Preferred Stock. In addition to eliminating the Series A shares, the Amendment also increased the
number of authorized Series B Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2015, the Company
authorized 500,000 shares of $0.10 par value Series &#8220;B&#8221; Preferred Stock (&#8220;Series B&#8221;). The Series B Preferred Stock
is non-convertible, non-redeemable and non-retractable. It has superior liquidation rights to the Common Stock at $0.10 per share and
gives the holder the right to 1,000 votes per share. All shares of the Series B Preferred Stock are held by the CEO of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2020, the Company issued Five Hundred
Thousand (500,000) shares of Series &#8220;B&#8221; Preferred Stock in favor of the Company&#8217;s CEO, in consideration for the COVID-19
treatment technology he developed. This issuance brought the total number of Series B Preferred Stock held by the Company&#8217;s CEO
to 1,000,000 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through December 31, 2020 and December 31, 2019,
the Company has issued and outstanding a total of 346,419,296 and 35,319,990 shares of Common Stock, respectively. Through the same periods,
the Company has issued and outstanding a total of -0- and -0- shares of Series A Preferred Stock and 1,000,000 and 500,000 shares of Series
B Preferred Stock, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended December 31, 2020,
the Company issued an aggregate of 311,098,985 shares of its Common Stock valued at $2,515,015 in connection with the conversion of $415,269
in debt and interest of $ 42,233 resulting in a $2,057,513 loss on conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended December 31, 2019,
the Company issued an aggregate of 31,037,370 shares of its Common Stock as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.5in">&#160;</td>
  <td style="width: 0.25in">&#9679;</td>
  <td>9,150,000 shares valued at $204,300
as compensation to the Company&#8217;s Directors and Officers</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#9679;</td>
  <td>1,455,000 shares for services rendered
to the Company by third parties valued at $57,390</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#9679;</td>
  <td>20,432,370 shares valued at $717,726
in connection with the conversion of $385,778 in debt and interest of $6,689 resulting in a $314,751 loss on conversion</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has declared no dividends since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 6 &#8211; Earnings Per Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation
of basic and diluted net income per share for the years ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Net gain (loss) attributable to Common Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(2,784,091</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,660,291</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Basic weighted average outstanding shares of Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,096,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,392,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Dilutive effects of common share equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Dilutive weighted average outstanding shares of Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,096,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,932,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net gain (loss) per share attributable to Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.15</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 7 &#8211; Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company files a United States federal income
tax return and a Canadian branch return on a calendar year basis. The Company and its wholly-owned subsidiaries, Sunshine Biopharma Canada
Inc., have not generated taxable income since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes arise from the temporary
differences between financial statement and income tax recognition of net operating losses and other items. These loss carryovers are
limited under the Internal Revenue Code should a significant change in ownership occur. The Company accounts for income taxes pursuant
to ASC 740, &#8220;Accounting for Income Taxes&#8221;, which requires, among other things, an asset and liability approach to calculating
deferred income taxes. The components of the deferred income tax assets and liabilities arising under ASC No. 740 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; background-color: White; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31, 2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31, 2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Amount</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Tax
                                            Effect</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Amount</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Tax Effect</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: justify">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,784,091</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">683,773</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,660,291</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">407,767</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Other differences</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26,786</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(686,984</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(168,723</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,810,877</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">690,352</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">973,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">239,044</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,810,877</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(690,352</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(973,307</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(239,044</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes arise from the temporary
differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the
Internal Revenue Code should a significant change in ownership occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, the Company had net operating
loss carry forwards of $10,611,921 that may be available to reduce future years&#8217; taxable income through 2037 and $5,329,161 may
be available to reduce future years&#8217; taxable income indefinitely.&#160;At December 31, 2020 and December 31, 2019, a deferred tax
asset at each date of approximately $690,352 and $239,044, respectively, resulting from the loss carryforwards has been offset by a 100%
valuation allowance. The change in the valuation allowance for the period ended December 31, 2020 and December 31, 2019 was approximately
$(451,307) and $149,054, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the U.S. statutory federal
income tax rate to the effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">U.S. Federal statutory graduated income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.00%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.00%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: justify">State income tax rate, net of federal benefit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3.56%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3.56%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.56%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.56%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net operating loss used</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net operating loss for which no tax benefit is currently available</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Canada Federal statutory rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.00%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.00%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: justify">Canada Provincial rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11.80%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11.80%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net Canada rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.80%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.80%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net operating loss used (Canada)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net operating loss for which no tax benefit is currently available (Canada)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-26.80%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-26.80%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s income tax filings are subject
to audit by various taxation authorities. The Company&#8217;s open audit periods are 2018, 2019, and 2020, although, the statute of limitations
for the 2018 tax year will expire effective October 15, 2020. In evaluating the Company&#8217;s provisions and accruals, future taxable
income, and reversal of temporary differences, interpretations and tax planning strategies are considered. The Company believes its estimates
are appropriate based on current facts and circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 8 &#8211; Notes Payable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s Notes Payable at December
31, 2020 consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2017, the Company received monies
in exchange for a Note Payable having a Face Value of $100,000 Canadian ($74,970 US at September 30, 2020) with interest payable quarterly
at 9%, which Note was due April 1, 2019. The Note is convertible any time after issuance into $0.001 par value Common Stock at a price
of $0.015 Canadian (approximately $0.011 US) per share. The Company estimates that the fair value of this convertible debt approximates
the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion.
In June 2018, the Company filed an action in the Superior Court of the Province of Quebec in the District of Montreal (Canada) against
the holder of this Note. The complaint alleges among other things, claims of misrepresentations and misleading conduct resulting in damages
to the Company in an amount of approximately $200,000 Canadian (approximately $143,000 US). A date for the hearings to commence was set
for November 16, 2020. On November 10, 2020, the Company elected to pay off the Note together with accrued interest of $14,696 Canadian
(approximately $10,500 US) and terminate the proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2018, the Company issued two
Notes Payable having an aggregate Face Value of $36,500 with interest accruing at 8%. The two Notes were issued for services rendered
to the Company and had maturity dates in June 2019. The Company was unable to pay the notes and on November 30, 2019 the Company issued
a new Note which included accrued interest and accelerated interest of $7,059 for a total Face Value of $43,559. The new Note accrues
interest at 8% and is convertible after 180 days from issuance into Common Stock at a price 35% below market value. The new Note was due
August 31, 2020. During the year ended December 31, 2020, the entire principal amount of $43,559 of this Note plus accrued interest of
$2,523 was converted into 14,198,048 shares of Common Stock valued at $86,685 resulting in a loss of $40,603.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 24, 2018, the Company received monies
in exchange for a Note Payable having a Face Value of $87,000 with interest accruing at 8% was due December 24, 2019. The Note is convertible
after 180 days from issuance into $0.001 par value Common Stock at a price 35% below market value. As of December 31, 2020, the entire
principal amount of $87,000 of this Note plus accrued interest of $9,639 was converted into 43,986,317 shares of Common Stock valued at
$276,396 resulting in a loss of $161,036.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 8, 2019, the Company received monies
in exchange for a Note Payable having a Face Value of $54,000 with interest accruing at 8% was due January 8, 2020. The Note is convertible
after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire
principal amount of $54,000 of this Note plus accrued interest of $9,814 was converted into 44,931,640 shares of Common Stock valued at
$365,787 resulting in a loss of $301,973.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 5, 2019, the Company received monies
in exchange for a Note Payable having a Face Value of $37,450 with interest accruing at 8% was due October 10, 2019. The Note is convertible
after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire
principal amount of $37,450 of this Note plus accrued interest of $2,996 was converted into 38,263,409 shares of Common Stock valued at
$217,971 resulting in a loss of $182,790.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2019, the Company received monies in
exchange for a Note Payable having a Face Value of $40,000 with interest accruing at 8% was due April 30, 2020. The Note is convertible
after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire
principal amount of $40,000 of this Note plus accrued interest of $1,600 was converted into 13,099,359 shares of Common Stock valued at
$58,684 resulting in a loss of $17,084.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 26, 2019, the Company received monies
in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 8%, which became due July 26, 2020. The Note is
convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020,
the entire principal of $50,000 of this Note plus accrued interest of $4,909 was converted into 43,522,363 shares of Common Stock valued
at $131,370 resulting in a loss of $76,461.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2019, the Company received monies
in exchange for a Note Payable having a Face Value of $43,000 with interest accruing at 8% is due July 15, 2020. The Note is convertible
after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020, the entire
principal amount of $43,000 of this Note plus accrued interest of $1,720 was converted into 38,855,726 shares of Common Stock valued at
$117,177 resulting in a loss of $72,457.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 14, 2019, the Company received monies
in exchange for a Note Payable having a Face Value of $42,800 with interest accruing at 8% and which is due December 14, 2020. The Note
is convertible after 180 days from issuance into Common Stock at a price 35% below market value. During the year ended December 31, 2020,
the entire principal amount of $42,800 of this Note plus accrued interest of $1,712 was converted into 18,592,605 shares of Common Stock
valued at $81,796 resulting in a loss of $37,284.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Note Payable dated December 31, 2019 having
a Face Value of $30,120 and accruing interest at 12% was due December 31, 2020. On December 1, 2020, the Company paid off the entire principal
balance of this Note, together with accrued interest of $3,614 by issuing cash payment of $33,734.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Note Payable dated December 31, 2018 having
a Face Value of $136,744 and accruing interest at 12% was due December 31, 2019. On October 1, 2019, the holder of this note requested
to convert $30,000 in principal amount into 1,500,000 shares of Common Stock, leaving a principal balance $106,744. On December 31, 2019,
the Company renewed the remaining principal balance of this Note, together with accrued interest of $15,509 for a 12-month period. The
new Note has a Face Value of $122,253 and accrues interest at 12%. This Note matures on December 31, 2020. On August 27, 2020, the holder
of this Note transferred all of its interest therein to a third party and on September 4, 2020, the Company agreed to render the Note
convertible at $0.001 per share. During the year ended December 31, 2020, an aggregate principal amount of $58,225 of this Note plus accrued
interest of $9,775 was converted into 68,000,000 shares of Common Stock valued at $1,286,400 resulting in a loss of $1,218,400. This note
is currently past due and the Company is in discussion with the holder to extend the due date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2020, the Company&#8217;s Canadian
subsidiary received a CEBA Loan (Canada Emergency Business Account Loan) from CIBC (Canadian Imperial Bank of Commerce) in the principal
amount of $40,000 Canadian ($29,352 US) as part of the Canadian government&#8217;s COVID-19 relief program. The CEBA Loan is non-interest
bearing if repaid on or before December 31, 2022 (the &#8220;Termination Date&#8221;). The CEBA Loan is considered repaid in full if the
borrower repays 75% of the Principal Amount on or before the Termination Date. If the CEBA Loan is not repaid in full on or before the
Termination Date, the lender will automatically extend the term of the loan by three years until December 31, 2025 (the &#8220;Extension
Period&#8221;). During the Extension Period, interest will be charged, and will accrue on the outstanding amount of the CEBA Loan at a
fixed rate of 5% per year, calculated daily and compounded monthly. The outstanding balance of the CEBA Loan and all accrued interest
will be due at the end of the Extension Period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 27, 2020, the Company received a Paycheck
Protection Program loan (&#34;PPP Loan&#34;) in the principal amount of $50,655 from the US Small Business Administration (&#8220;SBA&#8221;)
as part of the US government&#8217;s COVID-19 relief program. This loan accrues interest at the rate of 1% per annum. The Company is obligated
to make payments of principal and interest totaling $2,133 each month commencing on November 27, 2020, with any remaining balances due
and payable on or before April 27, 2022. The proceeds derived from this loan may only be used for payroll costs, interest on mortgages,
rent and utilities (&#8220;Admissible Expenses&#8221;). In addition, the Paycheck Protection Program provides for conditional loan forgiveness
if the Company utilizes at least 75% of the proceeds from the loan to pay Admissible Expenses. On December 15, 2020, the Company applied
to the funding bank for forgiveness of this loan per SBA guidance. On December 18, 2020, the Company received notification that the funding
bank has approved forgiveness of the loan in its entirety and that it has submitted a request to the SBA for final approval. On February
22, 2021, the funding bank informed the Company that the SBA has fully forgiven the loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2020, the Company received monies in
exchange for a Note Payable having a Face Value of $42,000 with interest accruing at 8% is due June 1, 2021. The Note is convertible after
180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, the Company paid off the entire principal
balance of this Note, together with accrued interest and prepayment penalties of $13,435 by issuing payment of $55,435.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 9, 2020, the Company received monies in
exchange for a Note Payable having a Face Value of $37,000 with interest accruing at 8% is due June 9, 2021. The Note is convertible after
180 days from issuance into Common Stock at a price 35% below market value. On December 2, 2020, the Company paid off the entire principal
balance of this Note, together with accrued interest and prepayment penalties of $11,779 by issuing payment of $48,779.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 7, 2020, the Company received monies in
exchange for a Note Payable having a Face Value of $48,000 with interest accruing at 8% is due July 7, 2021. The Note is convertible after
180 days from issuance into Common Stock at a price 35% below market value. The Company will analyze the conversion feature of the note
for a beneficial conversion feature on the commitment date on January 3, 2021 which is 180 days after the issuance date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $102,000 with interest accruing at 8% is due July 27, 2021. The Note is convertible
after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the
note for a beneficial conversion feature on the commitment date on January 23, 2021 which is 180 days after the issuance date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $67,000 with interest accruing at 8% is due August 14, 2021. The Note is convertible
after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the
note for a beneficial conversion feature on the commitment date on February 10, 2021 which is 180 days after the issuance date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due September 14, 2022. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date on March 13, 2021 which is 180 days after the issuance date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $50,000 with interest accruing at 5% is due September 24, 2022. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date on March 23, 2021 which is 180 days after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 20, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due October 20, 2022. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date on April 18, 2021 which is 180 days after the issuance date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 19, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 8% is due August 19, 2021. The Note is convertible
after 180 days from issuance into Common Stock at a price 35% below market value. The Company will analyze the conversion feature of the
note for a beneficial conversion feature on the commitment date on May 18, 2021 which is 180 days after the issuance date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 24, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $260,000 with interest accruing at 8% is due November 24, 2021. The Note is convertible
after 180 days from issuance into Common Stock at a price 30% below market value. The Company will analyze the conversion feature of the
note for a beneficial conversion feature on the commitment date on May 23, 2021 which is 180 days after the issuance date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 25, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $250,000 with interest accruing at 5% is due November 25, 2022. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date on May 24, 2021 which is 180 days after the issuance date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 2, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $104,215 with interest accruing at 5% is due December 2, 2022. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $0.30 per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date on May 31, 2021 which is 180 days after the issuance date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2020 and December 31, 2019, total
accrued interest on Notes Payable was $24,320 and $21,077, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 9 &#8211; Notes Payable - Related Party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outstanding Notes Payable at December 31, 2020
held by related parties consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Note Payable dated December 31, 2019 held by
the CEO of the Company having a Face Value of $128,269 and accruing interest at 12% was due December 31, 2020. On December 31, 2020, the
Company renewed the Note together with accrued interest of $15,392 for a 12-month period. The new Note has a face Value of $143,661, accrues
interest at 12% per annum, and has a maturity date of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 10 &#8211; Related Party Transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the transactions specified under
Note 9 above, during the period ended December 31, 2020, the Directors and Officers of the Company were paid $221,930 in cash. Of this
amount, $177,000 was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by the CEO of the Company. In
addition, during the period ended December 31, 2020, the Company issued to its CEO 500,000 shares of Series B Preferred Stock valued at
$50,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the period ended December 31, 2019, the Company
issued to the Board of Directors 1,950,000 shares of Common Stock valued at $74,100, 3,300,000 shares of Common Stock valued at $99,000,
and 3,900,000 shares of Common Stock valued at $31,200. The Company also issued 550,000 shares of Common Stock valued at $16,500 to the
CFO for consulting services rendered to the Company in 2019. During the year ended December 31, 2019 the Directors and officers were paid
$72,916 in cash. Of this amount, $28,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 11 &#8211; Acquisition and Disposition
of Atlas Pharma Inc.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2018 the Company acquired all of
the issued and outstanding shares of Atlas Pharma Inc. (&#8220;Atlas&#8221;), a privately held Canadian company providing analytical chemistry
testing services (&#8220;Atlas Business&#8221;). The purchase price for the shares was $848,000 Canadian ($676,748 US). The purchase price
included cash payment of $100,500 Canadian ($80,289 US), plus the issuance of 50,000 shares of the Company&#8217;s Common Stock valued
at $238,000, and a promissory note in the principal amount of $450,000 Canadian ($358,407 US), with interest payable at the rate of 3%
per annum (&#8220;Atlas Note&#8221;). The following table summarizes the allocation of the purchase price as of the acquisition date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,942</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">79,508</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Prepaids</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,428</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">62,990</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">665,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: justify">Liabilities assumed ($172,899 Canadian)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(137,817</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">Total consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">676,748</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective April 1, 2019, the Company disposed
of Atlas by re-assigning all of its stock in Atlas back to the original owner in exchange for the Atlas Note. As a consequence of the
sale, the operating results and the assets and liabilities of the discontinued Atlas Business are presented separately in the Company's
financial statements. Summarized financial information for the discontinued Atlas Business is shown below. Prior period balances have
been reclassified to present the operations of the Atlas Business as discontinued operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discontinued Operations Income Statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Audited</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2020</b></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Audited</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2019</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">119,522</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: justify">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">81,920</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: justify">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37,602</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,196</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Gain (Loss) from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,406</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt; text-align: justify">Other income (expense) &#8211; Interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,518</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: justify">Net Income (Loss) from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,112</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Loss on Disposal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(580,125</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: justify">Net Income (Loss) from Discontinued Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(582,237</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The individual assets and liabilities of the discontinued
Atlas Business are in the captions &#34;Assets of Discontinued Operation&#34; and &#34;Liabilities of Discontinued Operation&#34;
in the Consolidated Balance Sheet. The carrying amounts of the major classes of assets and liabilities included part of the discontinued
business are presented in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discontinued Operations Balance Sheets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; background-color: White; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Audited</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Audited</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2019</b></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Total Current Assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Equipment (net of $ 0 and $34,959 depreciation)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">TOTAL ASSETS</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Notes payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Related party advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accounts payable &amp; accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Total Current Liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">TOTAL LIABILITIES</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discontinued Operations Cash Flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash flows used in discontinued operations for
the period ended December 31, 2020 and 2019 were $-0-and $8,510, respectively. There were no cash flows used in or provided by investing
or financing activities during those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 12 &#8211; Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's arrangement in connection with its
office space located in Pointe-Claire, Quebec, Canada has no short-term or long-term asset or liability value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 13 &#8211; Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company paid off a Note
Payable dated July 7, 2020 by issuing cash payment in the amount of $63,271 comprised of $48,000 in principal and $15,271 in accrued interest
and prepayment penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $150,000 with interest accruing at 5%. The Note is convertible after 180 days from
issuance into Common Stock at a price equal to $0.30 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12 and 28, and on March 3, 2021, the
holder of a Note Payable dated December 31, 2019 elected to convert a total of $53,000 in principal into 53,000,000 shares of Common Stock
leaving a principal balance of $11,028.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $300,000 with interest accruing at 5%. The Note is convertible after 180 days from
issuance into Common Stock at a price equal to $0.50 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 29, 2021, the holder of a Note Payable
dated July 27, 2020 elected to convert the entire principal amount of $102,000 and accrued interest of $4,171 into 5,044,456 shares of
Common Stock leaving a balance of $-0-.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $700,000 with interest accruing at 5%. The Note is convertible after 180 days from
issuance into Common Stock at a price equal to $0.60 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 22, 2021, the holder of a Note Payable
dated August 14, 2020 elected to convert the entire principal amount of $67,000 and accrued interest of $2,680 into 542,173 shares of
Common Stock leaving a balance of $-0-.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 22, 2021, the funding bank informed
the Company that the SBA has fully forgiven the Company's PPP Loan dated April 27, 2020 in the amount of $50,655.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"></td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="image_001.jpg" alt="" style="height: 80px; width: 185px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Up to 1,020,408 Common
Units, Each Consisting of One Share of Common Stock and Two Warrants to Purchase Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Up to 1,020,408 Pre-funded
Units, Each Consisting of a Pre-funded Warrant to Purchase One Share of Common Stock and Two Warrants to Purchase Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aegis Capital Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.75in">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>,
2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 81 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;13. Other Expenses of Issuance and Distribution. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
all costs and expenses paid or payable by us in connection with the sale of the securities being registered, other than underwriting discounts
and commissions. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the Nasdaq
listing fee, and the FINRA filing fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Expense</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount<br /> Paid or<br /> to be Paid</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 82%; text-align: left">SEC registration fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">3,198</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FINRA filing fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,225</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Nasdaq Listing Fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Miscellaneous expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Expense reimbursement to underwriters</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">125,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">565,423</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;14. Indemnification of Directors
and Officers. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7-108-402 of the Colorado
Business Corporation Act (the &#8220;CBCA&#8221;) provides, generally, that the articles of incorporation may contain a provision eliminating
or limiting the personal liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty
as a director, except that any such provision shall not eliminate or limit the liability of a director for (i) any breach of the director&#8217;s
duty of loyalty to the corporation or its shareholders, (ii) acts or omissions not in good faith or which involve intentional misconduct
or a knowing violation of law, (iii) acts specified in Section 7-108-403 of the CBCA, or (iv) any transaction from which the director
directly or indirectly derived an improper personal benefit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#160;7-109-102(1)&#160;of
the CBCA permits indemnification of a director of a Colorado corporation, in the case of a third party action, if the director (a)&#160;conducted
himself or herself in good faith, (b)&#160;reasonably believed that (i)&#160;in the case of conduct in his or her official capacity, his
or her conduct was in the corporation&#8217;s best interest, or (ii)&#160;in all other cases, his or her conduct was not opposed to the
corporation&#8217;s best interest, and (c)&#160;in the case of any criminal proceeding, had no reasonable cause to believe that his conduct
was unlawful. Section&#160;7-109-103 further provides for mandatory indemnification of directors and officers who are successful on the
merits or otherwise in litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#160;7-109-102(4)&#160;of
the CBCA limits the indemnification that a corporation may provide to its directors in two key respects.&#160; A corporation may not indemnify
a director in a derivative action in which the director is held liable to the corporation, or in any proceeding in which the director
is held liable on the basis of his improper receipt of a personal benefit.&#160;Sections 7-109-104 of the CBCA permits a corporation to
advance expenses to a director, and Section&#160;7-109-107(1)(c)&#160;of the CBCA permits a corporation to indemnify and advance litigation
expenses to officers, employees and agents who are not directors to a greater extent than directors if consistent with law and provided
for by the bylaws, a resolution of directors or shareholders, or a contract between the corporation and the officer, employee or agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 82; Section: 1; Options: NewSection -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws include provisions
that require the company to indemnify our directors or officers against monetary damages for actions taken as a director or officer of
our Company. We are also expressly authorized to carry directors&#8217; and officers&#8217; insurance to protect our directors, officers,
employees and agents for certain liabilities. Our articles of incorporation do not contain any limiting language regarding director immunity
from liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing
provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities
Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by us is against public policy as expressed hereby in the Securities Act and we will be governed
by the final adjudication of such issue.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;15. Recent Sales of Unregistered
Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019, the
Company issued an aggregate of 155,187 shares of common stock as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">45,750</span><span style="font-size: 10pt">
    shares as compensation to the Company&#8217;s directors and officers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify">7,275 <span style="font-size: 10pt">shares for services rendered to the Company;
    and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">102,162</span><span style="font-size: 10pt">
    shares in connection with the conversion of $385,778 in debt and interest of $6,689 resulting in a $314,751 loss on conversion.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 8, 2019, the Company issued a note
in the principal amount of $54,000, convertible after 180 days from issuance into common stock at a price 35% below market value. During
the year ended December 31, 2020, the entire principal amount of $54,000 of this note plus accrued interest of $9,814 was converted into
224,658 shares of common stock valued at $365,787 resulting in a loss of $301,973.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 10, 2019, the Company issued a note
in the principal amount of $40,660, convertible after 180 days from issuance into common stock at a price 35% below market value. The
principal amount of $40,660 of this note plus accrued interest of $1,693 was converted in 2019 into 8,024 shares of common stock
valued at $75,469 resulting in a loss of $33,116.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 5, 2019, the Company issued a note
in the principal amount of $37,450, convertible after 180 days from issuance into common stock at a price 35% below market value. During
the year ended December 31, 2020, the entire principal amount of $37,450 of this note plus accrued interest of $2,996 was converted into
191,317 shares of common stock valued at $217,971 resulting in a loss of $182,790.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 11, 2019, the Company issued a note
in the principal amount of $52,000, convertible after 180 days from issuance common stock at a price 35% below market value. The principal
amount of $52,000 of this note plus accrued interest of $2,080 was converted in 2019 into 11,441 shares of common stock valued
at $81,990 resulting in a loss of $27,910.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2019, the Company issued a note
in the principal amount of $40,660, convertible after 180 days from issuance into common stock at a price 35% below market value. A principal
amount of $38,693 of this note plus accrued interest of $2,046 was converted in 2019 into 19,756 shares of common stock valued
at $74,721 resulting in a loss of $23,474 and a write off of $1,967.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2019, the Company issued a note
in the principal amount of $40,660, convertible after 180 days from issuance into common stock at a price 35% below market value. The
principal amount of $40,660 of this note plus accrued interest of $1,718 was converted in 2019 into 1,751 shares of common stock
valued at $85,700 resulting in a loss of $43,322.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2019, the Company issued a note in
the principal amount of $40,000, convertible after 180 days from issuance into common stock at a price 35% below market value. During
the year ended December 31, 2020, the entire principal amount of $40,000 of this note plus accrued interest of $1,600 was converted into
65,497 shares of common stock valued at $58,684 resulting in a loss of $17,084.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 26, 2019, the Company issued a note in
the principal amount of $50,000, convertible after 180 days from issuance into common stock at a price 35% below market value. During
the year ended December 31, 2020, the entire principal of $50,000 of this note plus accrued interest of $4,909 was converted into 2,176
shares of common stock valued at $131,370 resulting in a loss of $76,461.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2019, the Company issued a note
in the principal amount of $43,000, convertible after 180 days from issuance into common stock at a price 35% below market value. During
the year ended December 31, 2020, the entire principal amount of $43,000 of this note plus accrued interest of $1,720 was converted into
194,279 shares of common stock valued at $117,177 resulting in a loss of $72,457.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 14, 2019, the Company issued a note
in the principal amount of $42,800, convertible after 180 days from issuance into common stock at a price 35% below market value. During
the year ended December 31, 2020, the entire principal amount of $42,800 of this note plus accrued interest of $1,712 was converted into
92,963 shares of common stock valued at $81,796 resulting in a loss of $37,284.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, the
Company issued an aggregate of 1,555,495 shares of common stock valued at $2,515,015 in connection with the conversion of $415,269
in debt and interest of $42,233 resulting in a $2,057,513 loss on conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2020, the Company issued a note in
the principal amount of $42,000, convertible after 180 days from issuance into common stock at a price 35% below market value. On December
2, 2020, we paid off the entire principal balance of this note, together with accrued interest and prepayment penalties of $13,435 by
making a cash payment of $55,435.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 9, 2020, the Company issued a note in
the principal amount of $37,000, convertible after 180 days from issuance into common stock at a price 35% below market value. On December
2, 2020, we paid off the entire principal balance of this note, together with accrued interest and prepayment penalties of $11,779 by
making a cash payment of $48,779.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 7, 2020, the Company
issued a convertible note in the principal amount of $48,000 with interest accruing at 8% per year due July 7, 2021, convertible after
180 days from issuance into common stock at a price 35% below market value. On January 5, 2021, the Company paid off the entire principal
balance of this note, together with accrued interest and prepayment penalties of $15,271 by making a cash payment of $63,271.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2020, the Company issued a note in
the principal amount of $102,000, convertible after 180 days from issuance into common stock at a price 30% below market value. On January
29, 2021, the entire principal amount of $102,000 of this note plus accrued interest of $4,171 was converted into 25,223 shares
of common stock valued at $484,268 resulting in a loss of $378,097.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2020, the Company issued a note
in the principal amount of $67,000, convertible after 180 days from issuance into common stock at a price 30% below market value. On
February 22, 2021, the entire principal amount of $67,000 of this note plus accrued interest of $2,680 was converted into 2,711
shares of common stock valued at $119,169 resulting in a loss of $49,489.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2020, the Company issued a note
in the principal amount of $250,000, convertible after 180 days from issuance into common stock at a price equal to $60.00 per
share. On June 2, 2021, the entire principal amount of $250,000 of this note plus all accrued interest of $8,850 was converted into 4,315
shares of common stock valued at $170,841 resulting in a gain of $88,009.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2020, the Company issued a note
in the principal amount of $50,000, convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. This
note was converted to common stock on December 20, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 20, 2020, the Company issued a note
in the principal amount of $250,000, convertible after 180 days from issuance into common stock at a price equal to $60.00 per
share. On June 2, 2021, the entire principal amount of $250,000 of this note plus all accrued interest of $7,600 was converted into 4,294
shares of common stock valued at $170,016 resulting in a gain of $87,584.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 19, 2020, the Company issued a note
in the principal amount of $250,000, convertible after 180 days from issuance into common stock at a price 35% below market value. On
May 19, 2021, the Company paid off the entire principal balance of this note, together with accrued interest and prepayment penalties
of $126,881 by making a cash payment of $376,881.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 24, 2020, the Company issued a convertible
note in the principal amount of $260,000 with interest accruing at 8% is due November 24, 2021. The note is convertible after 180 days
from issuance into common stock at a price 30% below market value. On June 1, 2021, the entire principal amount of $260,000 of this note
plus all accrued interest of $10,428 was converted into 19,329 shares of common stock valued at $695,078 resulting in a loss of
$424,650.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 25, 2020, the Company
issued a note in the principal amount of $250,000, convertible after 180 days from issuance into common stock at a price equal to $0.30
per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 2, 2020, the Company issued a note
in the principal amount of $104,215, convertible after 180 days from issuance into common stock at a price equal to $0.30 per share.
This note was converted to common stock on December 20, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2021, we issued
a note in the principal amount of $150,000, convertible after 180 days from issuance into common stock at a price equal to $0.30 per share.
This note was converted to common stock on December 20, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2021, we issued
a note in the principal amount of $300,000, convertible after 180 days from issuance into common stock at a price equal to $0.50 per share.
This note was converted to common stock on December 20, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, we issued
a note in the principal amount of $700,000, convertible after 180 days from issuance into common stock at a price equal to $0.60 per
share. This note was converted to common stock on December 20, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 5, 2021, we&#160;issued a note in the
principal amount of $330,000. The note was convertible after 180 days from issuance into common stock at a price equal to the lower of
$60.00 or 35% below market. On October 13, 2021, the noteholder converted $330,000 in principal and $16,500 in accrued interest
into 26,250 shares of common stock leaving a principal balance of $0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2021, we issued a
note in the principal amount of $500,000. The note is convertible after 180 days from issuance into common stock at a price equal to $0.30
per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021, a note holder converted a
total of $11,028 in principal and $4,472 in accrued interest into 77,500 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company issued a note in
the principal amount of $900,000, convertible after 180 days from issuance into common stock at a price of $0.30 per share. In connection
with this debt financing, the Company agreed to allow the lender, who is also the holder of a note dated November 25, 2020 (the &#8220;November
Note&#8221;), to convert a total of $240,000 in principal amount of the November Note into 120,000 shares of common stock leaving
a principal balance of $10,000 and accrued interest of $7,750.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 85; Section: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2021, the Company issued a issued
a note in the principal amount of $500,000, convertible after 180 days from issuance into common stock at a price of $0.30 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September 30, 2021,
the Company issued a total of 518,370 shares of common stock valued at $11,981,072 for the conversion of outstanding notes, reducing
the debt by $1,233,028 and interest payable by $38,201 and generating a loss on conversion of $10,709,843.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September 30, 2021,
the Company issued 300,000 shares of common stock to its officers and directors as compensation for their services to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">On December 20, 2021, the Company
issued 14,524 shares of common stock upon conversion of $1,361,000 in convertible debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The notes, and shares of common stock issued upon
conversion thereof, listed above were issued to various accredited investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the foregoing, we relied upon
the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving
a public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;16. Exhibits and Financial Statement
Schedules. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Exhibits. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; width: 6%; text-align: left">1.1</td><td style="width: 2%">&#160;</td>
    <td style="width: 92%; text-align: justify">Form of Underwriting Agreement*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">3.1</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000107997407000547/mountainwsb2ex31_10182007.htm" style="-sec-extract: exhibit">Articles of Incorporation</a> (1)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">3.2</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000101359609000030/exh3-3.htm" style="-sec-extract: exhibit">Certificate of Amendment to Articles of Incorporation filed November 2, 2009</a> (2)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">3.3</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000101359610000075/exh3-4.htm" style="-sec-extract: exhibit">Statement of Share and Equity Capital Exchange</a> (3)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">3.4</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000101359610000075/exh3-5.htm" style="-sec-extract: exhibit">Articles of Amendment to Articles of Incorporation filed July 13, 2010</a> (3)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">3.5</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000135448815002794/sbfm_ex35.htm" style="-sec-extract: exhibit">Articles of Amendment to Articles of Incorporation filed May 27, 2015</a> (4)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">3.5</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000165495420006915/sbfm_ex36.htm" style="-sec-extract: exhibit">Articles of Amendment to Articles of Incorporation</a> (5)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">3.5</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000107997407000547/mountainwsb2ex32_10182007.htm" style="-sec-extract: exhibit">Bylaws</a> (1)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">5.1</td><td>&#160;</td>
    <td style="text-align: justify">Opinion of Andrew I. Telsey, P.C.*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">5.2</td><td>&#160;</td>
    <td style="text-align: justify">Opinion of Sichenzia Ross Ference LLP *</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">10.1</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000135448815004592/sbfm_ex109.htm" style="-sec-extract: exhibit">Patent Purchase Agreement with Advanomics Corporation</a> (6)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">10.2</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000135448815005669/sbfm_ex109.htm" style="-sec-extract: exhibit">Second Patent Purchase Agreement with Advanomics Corporation</a> (7)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">10.3</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000165495416000160/sbfm_ex1010.htm" style="-sec-extract: exhibit">Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated October 8, 2016, including Secured Convertible Promissory Note</a> (8)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">10.4</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000165495416000160/sbfm_ex1011.htm" style="-sec-extract: exhibit">Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated December 28, 2016, including Secured Convertible Promissory Note</a> (8)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 86; Section: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; width: 6%">10.5</td><td style="width: 2%">&#160;</td>
    <td style="text-align: justify; width: 92%">Form of Warrant for offering *</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">10.6</td><td>&#160;</td>
    <td style="text-align: justify">Form of Pre-Funded Warrant for offering *</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">10.6</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000165495420010083/sbfm_ex1015.htm" style="-sec-extract: exhibit">Financing Agreement with RB Capital Partners, Inc.</a> (9)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="vertical-align: top; text-align: left">10.7</td><td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822000418/sunshine_ex1007.htm" style="-sec-extract: exhibit">Sponsored Research Agreement, dated October 6, 2020, between the Company and the University of
    Georgia Research Foundation, Inc. </a>(previously filed) **</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">21</td><td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316821004175/sunshine_ex2100.htm">Subsidiaries </a>(previously filed)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">23.1</td><td>&#160;</td>
    <td style="text-align: justify"><a href="sunshine_ex2301.htm">Consent of B F Borgers CPA PC</a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">23.2</td><td>&#160;</td>
    <td style="text-align: justify">Consent of Andrew I. Telsey, P.C. (included in Exhibit 5.1) *</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">23.3</td><td>&#160;</td>
    <td style="text-align: justify">Consent of Sichenzia Ross Ference LLP (included in Exhibit 5.2)*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">99.1</td><td>&#160;</td>
    <td style="text-align: justify"><a href="sunshine_ex9901.htm">Consent to be named as a director nominee of David Natan</a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">99.2</td><td>&#160;</td>
    <td style="text-align: justify"><a href="sunshine_ex9902.htm">Consent to be named as a director nominee of Dr. Andrew Keller</a></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">107</td><td>&#160;</td>
    <td style="text-align: justify"><a href="sunshine_ex107.htm">Filing Fee Table</a></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; background-color: rgb(238,238,238)"><td style="width: 10%">EX-101.INS</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 89%; text-align: justify">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</td></tr>
  <tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>EX-101.SCH</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Schema Document</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>EX-101.CAL</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>EX-101.DEF</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>EX-101.LAB</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>EX-101.PRE</td>
    <td>&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="white-space: nowrap; vertical-align: top">EX-104</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* To be filed by amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">** Portions of the exhibit have been omitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Incorporated by reference to SB-2 filed with
the SEC on October 19, 2007.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Incorporated by reference to 8-K filed
with the SEC on November 6, 2009.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Incorporated by reference to 10-Q filed with
the SEC on August 4, 2010.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Incorporated by reference to 8-K filed with
the SEC on June 1, 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Incorporated by reference to 8-K filed with
the SEC on June 24, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Incorporated by reference to 8-K filed with
the SEC on October 9, 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Incorporated by reference to 8-K filed with
the SEC on December 28, 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) Incorporated by reference to 8-K filed with
the SEC on March 14, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Incorporated by reference to 8-K filed with
the SEC on September 15, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Financial statement schedule. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 87; Section: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;17. Undertakings. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The undersigned registrant hereby undertakes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the registrant is relying on Rule 430B (&#167;230.430B of this chapter):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(A)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) (&#167;230.424(b)(3) of this chapter) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(B)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) (&#167;230.424(b)(2), (b)(5), or (b)(7) of this chapter) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) (&#167;230.415(a)(1)(i), (vii), or (x) of this chapter) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 88; Section: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the registrant is subject to Rule 430C (&#167;230.430C of this chapter), each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A (&#167;230.430A of this chapter), shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (&#167;230.424 of this chapter);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 89; Section: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Point-Claire, Quebec, on February 3, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt"><b>SUNSHINE BIOPHARMA, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 62%">&#160;</td>
    <td style="width: 3%; text-align: justify">&#160;</td>
    <td style="width: 35%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Dr. Steve N. Slilaty</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dr. Steve N. Slilaty</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each person whose signature
appears below constitutes and appoints Dr. Steve N. Slilaty, his true and lawful attorney-in-fact and agent, with full power of substitution
and re-substitution for him and in his name, place and stead, and in any and all capacities, to sign for him and in him name in the capacities
indicated below any and all amendments (including post-effective amendments) to this registration statement (or any other registration
statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended),
and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite or necessary
to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming
all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates
indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 30%; text-align: center"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">/s/ Dr. Steve N. Slilaty</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center">February 3, 2022</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dr. Steve N. Slilaty</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">/s/ Camille Sebaaly</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer </span></td>
    <td>&#160;</td>
    <td style="text-align: center">February 3, 2022</td></tr>
  <tr style="vertical-align: top">
    <td>Camille Sebaaly</td>
    <td>&#160;</td>
    <td>(Principal Financial and Accounting Officer)</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">/s/ Dr. Abderrazzak Merzouki</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center">February 3, 2022</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dr. Abderrazzak Merzouki</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">/s/ Andrew I. Telsey</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director </span></td>
    <td>&#160;</td>
    <td style="text-align: center">February 3, 2022</td></tr>
  <tr>
    <td><span style="font-size: 10pt">Andrew I. Telsey</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid">/s/ James (JD) Kish</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director </span></td>
    <td>&#160;</td>
    <td style="text-align: center">February 3, 2022</td></tr>
  <tr>
    <td><span style="font-size: 10pt">James (JD) Kish</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">/s/ Dr. Rabi Kiderchah</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director </span></td>
    <td>&#160;</td>
    <td style="text-align: center">February 3, 2022</td></tr>
  <tr>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Dr. Rabi Kiderchah</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 90; Section: 1; Options: Last -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLMdKLg3HSriFBkivlYXpbg1I61TP8m/tG6IIRCSe0+uEAOxpIWpkOE4K3LYY91U2iMUeEFGe8bgyFbrFMIs8GqcZ219t/7AjAKDgRnFk1O4d87WOCxTkJOhVMNEgRynSsJ0I6KvnpG9mBKtN7oCbUvYMTVs0Gt+9R/2+kmW6leXdEB2hmwKKpa9/IZEqgS21OoH8c1BnmciGnQViSXTvfnG3J2nGuYV1iHL9ei/ow/We0kL -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sunshine_ex9901.htm
<DESCRIPTION>CONSENT TO BE NAMED AS A DIRECTOR NOMINEE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent to be Named as a Director Nominee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the filing by Sunshine Biopharma,
Inc. of the Registration Statement on Form&nbsp;S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;),&nbsp;I hereby consent, pursuant to Rule&nbsp;438 under the Securities Act, to being named as a nominee
to the board of directors of Sunshine Biopharma, Inc.in the Registration Statement and any and all amendments and supplements thereto.
I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated:&nbsp;&nbsp;February 3, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ David Natan</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Natan</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>sunshine_ex9902.htm
<DESCRIPTION>CONSENT TO BE NAMED AS A DIRECTOR NOMINEE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.2</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent to be Named as a Director Nominee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the filing by Sunshine
Biopharma, Inc. of the Registration Statement on Form&nbsp;S-1 with the Securities and Exchange Commission under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;), I hereby consent, pursuant to Rule&nbsp;438 under the Securities Act, to
being named as a nominee to the board of directors of Sunshine Biopharma, Inc.in the Registration Statement and any and all
amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and
any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated:&nbsp;&nbsp;February 3, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Dr. Andrew Keller</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Andrew Keller</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>sunshine_ex107.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Exhibit 107</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proposed Maximum<BR>
Aggregate Offering Price(1)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount of<BR>
Registration Fee</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 59%"><FONT STYLE="font-size: 10pt">Common Units (3)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">11,500,000 </FONT></TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">(2)(4)(5)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">1,066.05 </FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Common stock, par value $0.001, included in the Common Units</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-size: 10pt">Warrants included in the Common Units (7)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Pre-funded Units (8)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(5)(9)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-size: 10pt">Pre-funded Warrants included in the Pre-funded Units (10)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(11)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Warrants included in the Pre-funded Units (7)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(11)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-size: 10pt">Common stock underlying the Pre-funded warrants included in the Pre-funded Units</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Common stock underlying the warrants included in the Common Units and the Pre-funded Units</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">23,000,000</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,132.10</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">34,500,000 </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,198.15</FONT></TD>
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-size: 10pt">(12)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">1) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant to Rule 416, the securities being registered hereunder include such indeterminate number of additional securities as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">2) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Calculated pursuant to Rule 457(o) on the basis of the maximum aggregate offering price of all of the securities to be registered.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each Common Unit consists of one share of common stock and two warrants, each whole warrant exercisable for one share of common stock. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">4) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes shares and/or warrants representing 15% of the number of shares and warrants included in the Common Units offered to the public that the underwriters have the option to purchase to cover over-allotments, if any. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">5) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The proposed maximum aggregate offering price of Common Units proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-funded Units offered and sold in the offering, and the proposed maximum aggregate offering price of the Pre-funded Units to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Common Units sold in the offering. Accordingly, the proposed maximum aggregate offering price of the Common Units and Pre-funded Units (including the shares of common stock issuable upon exercise of the Pre-funded warrants included in the Pre-funded Units), if any, is $11,500,000. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Included in the price of the Common Units. No separate registration fee required pursuant to Rule 457(g) under the Securities Act of 1933, as amended. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The warrants are exercisable at a price per share equal to 100% of the Common Unit offering price. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each Pre-funded Unit consists of one Pre-funded warrant to purchase one share of common stock and two warrants, each whole warrant exercisable for one share of common stock. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">9) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes Pre-funded warrants and/or warrants representing 15% of the number of Pre-funded warrants and warrants included in the Pre-funded Units offered to the public that the underwriters have the option to purchase to cover over-allotments, if any </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">10) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Pre-funded warrants are exercisable at an exercise price of $0.001 per share. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">11) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Included in the price of the Pre-funded Units. No separate registration fee required pursuant to Rule 457(g) under the Securities Act of 1933, as amended. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">12)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$2,509.30 was previously paid on 9/9/2021 in connection with the
    filing of the Registration Statement on Form S-1 (File No. 333-259394).</FONT></TD></TR>
  </TABLE>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sbfm-20210930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOa+IeaPty5526YkxvmR6fQlqLyArCeWZtSsghCmmQZoF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:SBFM="http://sunshinebiopharma.com/20210930" elementFormDefault="qualified" targetNamespace="http://sunshinebiopharma.com/20210930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets" id="UnauditedCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - Unaudited Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" id="UnauditedCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" id="UnauditedCondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity" id="UnauditedCondensedConsolidatedStatementOfShareholdersEquity">
	  <link:definition>00000006 - Statement - Unaudited Condensed Consolidated Statement of Shareholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation" id="NatureOfBusinessAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/GoingConcernAndLiquidity" id="GoingConcernAndLiquidity">
	  <link:definition>00000008 - Disclosure - Going Concern and Liquidity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000009 - Disclosure - Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/FaceValue" id="FaceValue">
	  <link:definition>00000010 - Disclosure - Face value</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/ShareholdersEquity" id="ShareholdersEquity">
	  <link:definition>00000011 - Disclosure - Shareholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold" id="SalaryAndWageExcludingCostOfGoodAndServiceSold">
	  <link:definition>00000012 - Disclosure - Salary and Wage, Excluding Cost of Good and Service Sold</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000013 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" id="NatureOfBusinessAndBasisOfPresentationPolicies">
	  <link:definition>00000014 - Disclosure - Nature of Business and Basis of Presentation (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" id="NatureOfBusinessAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000015 - Disclosure - Nature of Business and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative" id="GoingConcernAndLiquidityDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Going Concern and Liquidity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000017 - Disclosure - Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
	  <link:definition>00000018 - Disclosure - Shareholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="SBFM_RBCapitalMember" name="RBCapitalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PromissoryNotesMember" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable2018Member" name="NotePayable2018Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_CEBALoanMember" name="CEBALoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PPPLoanMember" name="PPPLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable1Member" name="NotePayable1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable2Member" name="NotePayable2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable3Member" name="NotePayable3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable4Member" name="NotePayable4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable5Member" name="NotePayable5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable6Member" name="NotePayable6Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable7Member" name="NotePayable7Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable8Member" name="NotePayable8Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable9Member" name="NotePayable9Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable10Member" name="NotePayable10Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable11Member" name="NotePayable11Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable12Member" name="NotePayable12Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable13Member" name="NotePayable13Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable14Member" name="NotePayable14Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable15Member" name="NotePayable15Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayable16Member" name="NotePayable16Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NotePayableRelatedPartyMember" name="NotePayableRelatedPartyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_OutstandingNotesPayableMember" name="OutstandingNotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_TrtPharmaMember" name="TrtPharmaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sbfm-20210930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/Cover" xlink:href="sbfm-20210930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedStatementOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="sbfm-20210930.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/GoingConcernAndLiquidity" xlink:href="sbfm-20210930.xsd#GoingConcernAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayable" xlink:href="sbfm-20210930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/FaceValue" xlink:href="sbfm-20210930.xsd#FaceValue" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:href="sbfm-20210930.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold" xlink:href="sbfm-20210930.xsd#SalaryAndWageExcludingCostOfGoodAndServiceSold" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:href="sbfm-20210930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:href="sbfm-20210930.xsd#NatureOfBusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="sbfm-20210930.xsd#NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative" xlink:href="sbfm-20210930.xsd#GoingConcernAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:href="sbfm-20210930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="sbfm-20210930.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Unaudited Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaapProceedsFromOtherShortTermDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity" xlink:title="00000006 - Statement - Unaudited Condensed Consolidated Statement of Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Nature of Business and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/GoingConcernAndLiquidity" xlink:title="00000008 - Disclosure - Going Concern and Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayable" xlink:title="00000009 - Disclosure - Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/FaceValue" xlink:title="00000010 - Disclosure - Face value" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:title="00000011 - Disclosure - Shareholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold" xlink:title="00000012 - Disclosure - Salary and Wage, Excluding Cost of Good and Service Sold" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="00000013 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:title="00000014 - Disclosure - Nature of Business and Basis of Presentation (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000015 - Disclosure - Nature of Business and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative" xlink:title="00000016 - Disclosure - Going Concern and Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000017 - Disclosure - Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000018 - Disclosure - Shareholders&#8217; Equity (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sbfm-20210930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/Cover" xlink:href="sbfm-20210930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedStatementOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="sbfm-20210930.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/GoingConcernAndLiquidity" xlink:href="sbfm-20210930.xsd#GoingConcernAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayable" xlink:href="sbfm-20210930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/FaceValue" xlink:href="sbfm-20210930.xsd#FaceValue" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:href="sbfm-20210930.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold" xlink:href="sbfm-20210930.xsd#SalaryAndWageExcludingCostOfGoodAndServiceSold" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:href="sbfm-20210930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:href="sbfm-20210930.xsd#NatureOfBusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="sbfm-20210930.xsd#NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative" xlink:href="sbfm-20210930.xsd#GoingConcernAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:href="sbfm-20210930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="sbfm-20210930.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Unaudited Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapInventoryNet_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPrepaidExpenseCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapDepositsAssetsCurrent_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssetsCurrent_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssets_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapNotesPayableCurrent_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccountsPayableCurrent_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapInterestPayableCurrent_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapLongTermNotesPayable_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapLiabilities_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapCommitmentsAndContingencies_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapPreferredStockValue_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommonStockValue_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapAdditionalPaidInCapital_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_50" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity" xlink:title="00000006 - Statement - Unaudited Condensed Consolidated Statement of Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaapComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Nature of Business and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/GoingConcernAndLiquidity" xlink:title="00000008 - Disclosure - Going Concern and Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayable" xlink:title="00000009 - Disclosure - Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/FaceValue" xlink:title="00000010 - Disclosure - Face value">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayableRelatedPartyMember" xlink:label="loc_SBFMNotePayableRelatedPartyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayableRelatedPartyMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:title="00000011 - Disclosure - Shareholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold" xlink:title="00000012 - Disclosure - Salary and Wage, Excluding Cost of Good and Service Sold">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_OfficersAndDirectorsMember" xlink:label="loc_SBFMOfficersAndDirectorsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMOfficersAndDirectorsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_TrtPharmaMember" xlink:label="loc_SBFMTrtPharmaMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMTrtPharmaMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="00000013 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:title="00000014 - Disclosure - Nature of Business and Basis of Presentation (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000015 - Disclosure - Nature of Business and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_RBCapitalMember" xlink:label="loc_SBFMRBCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SBFMRBCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_PromissoryNotesMember" xlink:label="loc_SBFMPromissoryNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMPromissoryNotesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative" xlink:title="00000016 - Disclosure - Going Concern and Liquidity (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000017 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable2018Member" xlink:label="loc_SBFMNotePayable2018Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable2018Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_CEBALoanMember" xlink:label="loc_SBFMCEBALoanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMCEBALoanMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_PPPLoanMember" xlink:label="loc_SBFMPPPLoanMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMPPPLoanMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable1Member" xlink:label="loc_SBFMNotePayable1Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable1Member_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable2Member" xlink:label="loc_SBFMNotePayable2Member_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable2Member_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable3Member" xlink:label="loc_SBFMNotePayable3Member_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable3Member_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable4Member" xlink:label="loc_SBFMNotePayable4Member_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable4Member_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable5Member" xlink:label="loc_SBFMNotePayable5Member_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable5Member_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable6Member" xlink:label="loc_SBFMNotePayable6Member_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable6Member_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable7Member" xlink:label="loc_SBFMNotePayable7Member_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable7Member_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable8Member" xlink:label="loc_SBFMNotePayable8Member_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable8Member_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable9Member" xlink:label="loc_SBFMNotePayable9Member_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable9Member_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable10Member" xlink:label="loc_SBFMNotePayable10Member_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable10Member_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable11Member" xlink:label="loc_SBFMNotePayable11Member_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable11Member_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable12Member" xlink:label="loc_SBFMNotePayable12Member_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable12Member_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable13Member" xlink:label="loc_SBFMNotePayable13Member_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable13Member_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable14Member" xlink:label="loc_SBFMNotePayable14Member_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable14Member_480" xlink:type="arc" order="481" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable15Member" xlink:label="loc_SBFMNotePayable15Member_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable15Member_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable16Member" xlink:label="loc_SBFMNotePayable16Member_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable16Member_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD" xlink:label="loc_currencyCAD_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyCAD_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_570" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_570" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_570" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_570" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_570" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable_570" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_570" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_570" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_570" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_570" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000018 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionLineItems" xlink:label="loc_us-gaapDebtConversionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionTable" xlink:label="loc_us-gaapDebtConversionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapDebtConversionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaapDebtConversionByUniqueDescriptionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtConversionTable" xlink:to="loc_us-gaapDebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaapDebtConversionNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtConversionByUniqueDescriptionAxis" xlink:to="loc_us-gaapDebtConversionNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaapDebtConversionNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtConversionByUniqueDescriptionAxis" xlink:to="loc_us-gaapDebtConversionNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_OutstandingNotesPayableMember" xlink:label="loc_SBFMOutstandingNotesPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionNameDomain" xlink:to="loc_SBFMOutstandingNotesPayableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtConversionTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_OfficersAndDirectorsMember" xlink:label="loc_SBFMOfficersAndDirectorsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMOfficersAndDirectorsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapDividendsPayableCurrentAndNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapDividendsPayableCurrentAndNoncurrent_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_40" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sbfm-20210930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeMember" xlink:to="us-gaap_ComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl" xml:lang="en-US">Comprehensive Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_RBCapitalMember" xlink:label="SBFM_RBCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_RBCapitalMember" xlink:to="SBFM_RBCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_RBCapitalMember_lbl" xml:lang="en-US">R B Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_PromissoryNotesMember" xlink:label="SBFM_PromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PromissoryNotesMember" xlink:to="SBFM_PromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PromissoryNotesMember_lbl" xml:lang="en-US">Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable2018Member" xlink:label="SBFM_NotePayable2018Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable2018Member" xlink:to="SBFM_NotePayable2018Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable2018Member_lbl" xml:lang="en-US">Note Payable 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_CEBALoanMember" xlink:label="SBFM_CEBALoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_CEBALoanMember" xlink:to="SBFM_CEBALoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_CEBALoanMember_lbl" xml:lang="en-US">C E B A Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD" xlink:label="currency_CAD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CAD" xlink:to="currency_CAD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CAD_lbl" xml:lang="en-US">Canada, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_PPPLoanMember" xlink:label="SBFM_PPPLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PPPLoanMember" xlink:to="SBFM_PPPLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PPPLoanMember_lbl" xml:lang="en-US">P P P Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable1Member" xlink:label="SBFM_NotePayable1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable1Member" xlink:to="SBFM_NotePayable1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable1Member_lbl" xml:lang="en-US">Note Payable 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable2Member" xlink:label="SBFM_NotePayable2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable2Member" xlink:to="SBFM_NotePayable2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable2Member_lbl" xml:lang="en-US">Note Payable 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable3Member" xlink:label="SBFM_NotePayable3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable3Member" xlink:to="SBFM_NotePayable3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable3Member_lbl" xml:lang="en-US">Note Payable 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable4Member" xlink:label="SBFM_NotePayable4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable4Member" xlink:to="SBFM_NotePayable4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable4Member_lbl" xml:lang="en-US">Note Payable 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable5Member" xlink:label="SBFM_NotePayable5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable5Member" xlink:to="SBFM_NotePayable5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable5Member_lbl" xml:lang="en-US">Note Payable 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable6Member" xlink:label="SBFM_NotePayable6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable6Member" xlink:to="SBFM_NotePayable6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable6Member_lbl" xml:lang="en-US">Note Payable 6 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable7Member" xlink:label="SBFM_NotePayable7Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable7Member" xlink:to="SBFM_NotePayable7Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable7Member_lbl" xml:lang="en-US">Note Payable 7 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable8Member" xlink:label="SBFM_NotePayable8Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable8Member" xlink:to="SBFM_NotePayable8Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable8Member_lbl" xml:lang="en-US">Note Payable 8 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable9Member" xlink:label="SBFM_NotePayable9Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable9Member" xlink:to="SBFM_NotePayable9Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable9Member_lbl" xml:lang="en-US">Note Payable 9 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable10Member" xlink:label="SBFM_NotePayable10Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable10Member" xlink:to="SBFM_NotePayable10Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable10Member_lbl" xml:lang="en-US">Note Payable 10 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable11Member" xlink:label="SBFM_NotePayable11Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable11Member" xlink:to="SBFM_NotePayable11Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable11Member_lbl" xml:lang="en-US">Note Payable 11 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable12Member" xlink:label="SBFM_NotePayable12Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable12Member" xlink:to="SBFM_NotePayable12Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable12Member_lbl" xml:lang="en-US">Note Payable 12 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable13Member" xlink:label="SBFM_NotePayable13Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable13Member" xlink:to="SBFM_NotePayable13Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable13Member_lbl" xml:lang="en-US">Note Payable 13 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable14Member" xlink:label="SBFM_NotePayable14Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable14Member" xlink:to="SBFM_NotePayable14Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable14Member_lbl" xml:lang="en-US">Note Payable 14 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable15Member" xlink:label="SBFM_NotePayable15Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable15Member" xlink:to="SBFM_NotePayable15Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable15Member_lbl" xml:lang="en-US">Note Payable 15 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable16Member" xlink:label="SBFM_NotePayable16Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayable16Member" xlink:to="SBFM_NotePayable16Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayable16Member_lbl" xml:lang="en-US">Note Payable 16 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayableRelatedPartyMember" xlink:label="SBFM_NotePayableRelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NotePayableRelatedPartyMember" xlink:to="SBFM_NotePayableRelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NotePayableRelatedPartyMember_lbl" xml:lang="en-US">Note Payable Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_OutstandingNotesPayableMember" xlink:label="SBFM_OutstandingNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_OutstandingNotesPayableMember" xlink:to="SBFM_OutstandingNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_OutstandingNotesPayableMember_lbl" xml:lang="en-US">Outstanding Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_OfficersAndDirectorsMember" xlink:label="SBFM_OfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_OfficersAndDirectorsMember" xlink:to="SBFM_OfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers And Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_TrtPharmaMember" xlink:label="SBFM_TrtPharmaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_TrtPharmaMember" xlink:to="SBFM_TrtPharmaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_TrtPharmaMember_lbl" xml:lang="en-US">Trt Pharma [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment (net of $60,774 and $51,485 depreciation)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patents (net of $58,918 amortization and $556,120 impairment)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Notes payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable &amp; accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Long-term portion of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS' EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 510,093,265 and 346,419,296 at September 30, 2021 and December 31, 2020 respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Capital paid in excess of par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Equipment depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Patent amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Patent impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General &amp; Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total General&#160;&amp;&#160;Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">(Loss) from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Debt release</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="us-gaap_InducedConversionOfConvertibleDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense_lbl" xml:lang="en-US">Loss on debt conversions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Net (loss) before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xml:lang="en-US">Unrealized loss from foreign exchange translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted (loss) per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Outstanding (Basic &amp; Diluted)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_lbl" xml:lang="en-US">Foreign exchange (gain) loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Stock issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="us-gaap_InducedConversionOfConvertibleDebtExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense_2_lbl" xml:lang="en-US">Loss on debt conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Debt &amp; interest release</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">(Increase) in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">(Increase) in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">(Decrease) in Accounts Payable &amp; accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Increase in interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Flows (used) in operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Flows (used) in Investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xml:lang="en-US">Note payable to pay fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash and Cash Equivalents at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplementary Disclosure Of Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Stock issued for note conversions including interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Begining balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Common stock issued for the reduction of note payable and payment of interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common stock issued for the reduction of notes payable and payment of interest, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Preferred stock issued for management compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Preferred stock issued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Face value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayment of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Common stock issued for services, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation of Unaudited Financial Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt stated rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Outstanding liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Capital" xlink:label="us-gaap_Capital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Capital" xlink:to="us-gaap_Capital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Capital_lbl" xml:lang="en-US">Capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Face Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_2_lbl" xml:lang="en-US">Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt converted, amount converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt converted, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Note payable balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_3_lbl" xml:lang="en-US">Repayments of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Periodic Payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionTable" xlink:label="us-gaap_DebtConversionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_DebtConversionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionTable_lbl" xml:lang="en-US">Debt Conversion [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionLineItems" xlink:label="us-gaap_DebtConversionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionLineItems_lbl" xml:lang="en-US">Debt Conversion [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Dividends Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_2_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sbfm-20210930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/Cover" xlink:href="sbfm-20210930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity" xlink:href="sbfm-20210930.xsd#UnauditedCondensedConsolidatedStatementOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="sbfm-20210930.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/GoingConcernAndLiquidity" xlink:href="sbfm-20210930.xsd#GoingConcernAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayable" xlink:href="sbfm-20210930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/FaceValue" xlink:href="sbfm-20210930.xsd#FaceValue" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:href="sbfm-20210930.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold" xlink:href="sbfm-20210930.xsd#SalaryAndWageExcludingCostOfGoodAndServiceSold" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:href="sbfm-20210930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:href="sbfm-20210930.xsd#NatureOfBusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="sbfm-20210930.xsd#NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative" xlink:href="sbfm-20210930.xsd#GoingConcernAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:href="sbfm-20210930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="sbfm-20210930.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Unaudited Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaapProceedsFromOtherShortTermDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity" xlink:title="00000006 - Statement - Unaudited Condensed Consolidated Statement of Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaapComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Nature of Business and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/GoingConcernAndLiquidity" xlink:title="00000008 - Disclosure - Going Concern and Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayable" xlink:title="00000009 - Disclosure - Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/FaceValue" xlink:title="00000010 - Disclosure - Face value">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayableRelatedPartyMember" xlink:label="loc_SBFMNotePayableRelatedPartyMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayableRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquity" xlink:title="00000011 - Disclosure - Shareholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold" xlink:title="00000012 - Disclosure - Salary and Wage, Excluding Cost of Good and Service Sold">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaapCompensationRelatedCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationRelatedCostsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_OfficersAndDirectorsMember" xlink:label="loc_SBFMOfficersAndDirectorsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_TrtPharmaMember" xlink:label="loc_SBFMTrtPharmaMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMTrtPharmaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="00000013 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:title="00000014 - Disclosure - Nature of Business and Basis of Presentation (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000015 - Disclosure - Nature of Business and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_RBCapitalMember" xlink:label="loc_SBFMRBCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SBFMRBCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_PromissoryNotesMember" xlink:label="loc_SBFMPromissoryNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative" xlink:title="00000016 - Disclosure - Going Concern and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Capital" xlink:label="loc_us-gaapCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCapital" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000017 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable2018Member" xlink:label="loc_SBFMNotePayable2018Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable2018Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_CEBALoanMember" xlink:label="loc_SBFMCEBALoanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMCEBALoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_PPPLoanMember" xlink:label="loc_SBFMPPPLoanMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMPPPLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable1Member" xlink:label="loc_SBFMNotePayable1Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable2Member" xlink:label="loc_SBFMNotePayable2Member" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable3Member" xlink:label="loc_SBFMNotePayable3Member" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable4Member" xlink:label="loc_SBFMNotePayable4Member" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable5Member" xlink:label="loc_SBFMNotePayable5Member" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable6Member" xlink:label="loc_SBFMNotePayable6Member" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable7Member" xlink:label="loc_SBFMNotePayable7Member" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable7Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable8Member" xlink:label="loc_SBFMNotePayable8Member" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable8Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable9Member" xlink:label="loc_SBFMNotePayable9Member" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable9Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable10Member" xlink:label="loc_SBFMNotePayable10Member" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable10Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable11Member" xlink:label="loc_SBFMNotePayable11Member" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable11Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable12Member" xlink:label="loc_SBFMNotePayable12Member" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable12Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable13Member" xlink:label="loc_SBFMNotePayable13Member" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable13Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable14Member" xlink:label="loc_SBFMNotePayable14Member" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable14Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable15Member" xlink:label="loc_SBFMNotePayable15Member" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable15Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_NotePayable16Member" xlink:label="loc_SBFMNotePayable16Member" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SBFMNotePayable16Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD" xlink:label="loc_currencyCAD" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyCAD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000018 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionTable" xlink:label="loc_us-gaapDebtConversionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapDebtConversionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionLineItems" xlink:label="loc_us-gaapDebtConversionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionTable" xlink:to="loc_us-gaapDebtConversionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaapDebtConversionByUniqueDescriptionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionTable" xlink:to="loc_us-gaapDebtConversionByUniqueDescriptionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaapDebtConversionNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionByUniqueDescriptionAxis" xlink:to="loc_us-gaapDebtConversionNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_OutstandingNotesPayableMember" xlink:label="loc_SBFMOutstandingNotesPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionNameDomain" xlink:to="loc_SBFMOutstandingNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20210930.xsd#SBFM_OfficersAndDirectorsMember" xlink:label="loc_SBFMOfficersAndDirectorsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapDividendsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapDividendsPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtConversionLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !? -L# 2(  A$! Q$!_\0
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MG<]%C+J Q/L37J55*$Z;M-6)A4A45X._H%%%%06%%%% !1110 4444 %%%%
M!1110 4444 %%%% 'Q%_P4R^-,_AOPCI/P]TRX:&YUW-UJ#(<'[*AP$^COU]
MEK\\?!OA:[\<>+-&\/6*-)=ZI=QVD:H,G+L!_*O9_P!N[Q5+XH_:?\6*[9BT
ML0Z=$,\!4C#'_P >=JA_8=\.W7B+]I#PX+-E2>RBN+Q6;H"L1 /0]V%?73G+
M+LIJ5Z<7*482E:*O)NUTDGN]DKGP=9_7<Q5.3T<E'Y7L?I=X5T_4?!OAO2]"
MTSPU'%I^G6Z6T*_9#G:H R?<]3[FM7^UM?\ ^A?C_P# 0U>_LCQC_P!!&/\
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M.G[*&G_'[6M$U#7O&&OV:Z-A[*VT_P"SI'%+\I:7F(DL2BGK@8XQ6O\ %_\
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M^ ;?X5^)'PG^*NO_  9\<6'BGPY<>3?6K;9(7SY=Q$?OQ2#NI_0X(Y%?K_\
M O\ :&T'X_>$4UGP\A^TQ82^TZ25!-:28^ZPSR#V;H:^3SS*:^%K.O1FE3D]
ME2<FO5I_<[+L>IE.8PQ%-4:GQKSM?^NIW']L6'_0/N/_  #;_"C^V+#_ *!]
MQ_X!M_A6A]KNO^?%O^_J_P"-8'BKXD:9X+MS+JS);OC*P"9&E?Z*#FOF(T<3
M4?+"=W_V#S_S/>G4ITX\T]%_B1;N/$6E6=O)//9S0P1J6>22T(50.I)Q7RO\
M5/&[?$CQ<O\ 9T)^PQ'[/90JF&DR?O8]6./PQ6C\3?C-J?Q&E&G64,EEI+,
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M4Y4[8)QB^ST?^0+!U(U+XY2DNZ=U\^I]6^ _@_X?\!;9K: WFH8YO+G#./\
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $$ .8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V/6-8U*UU
MFQTO2].M+N>ZMY[AFNKQH%18FB7 VQN229AV'0U']L\8?] +0_\ P<S?_(M%
MY_R4/1O^P5?_ /HVTKH* .?^V>,/^@%H?_@YF_\ D6C[9XP_Z 6A_P#@YF_^
M1:Z"B@#G_MGC#_H!:'_X.9O_ )%H^V>,/^@%H?\ X.9O_D6N@HH Y_[9XP_Z
M 6A_^#F;_P"1:/MGC#_H!:'_ .#F;_Y%KH*Q]6U.]L;H1P6R21M;O(&&YWW!
MD'W .0 Q. <G&!B@"O\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+6
MEI%^=1TY;AAA@[QG]VR9*L5SM;E<XS@]*O4 <_\ ;/&'_0"T/_P<S?\ R+1]
ML\8?] +0_P#P<S?_ "+7044 <_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P
M<S?_ "+7044 <_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+7044
M<_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+7044 <_\ ;/&'_0"T
M/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+7044 <_\ ;/&'_0"T/_P<S?\ R+1]
ML\8?] +0_P#P<S?_ "+7044 <_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P
M<S?_ "+7044 <_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+7044
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M[:_5;R$9Z[F;$[=21F;@X_A&VN@HH Q[%_$D=Y'!?P:5/:C.^]@FDB=N"1B
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M02H'CDC8,KJ1D$$<$$<YJ2@ HHHH :[I&NYV55R!ECCDG _6A71F9592R'#
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M $4U '04444 <_>?\E#T;_L%7_\ Z-M*Z"N?O/\ DH>C?]@J_P#_ $;:5T%
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M:X+,&V"!!/  2X8G>!N)7/<:;IL.F6[1QM)+)(YDGN)2#)/(0 7<@ 9P
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M964MQO+A0M8^GZ@_AW41I?\ 9U\MU-$TD6CVA:YA(4K\]O<2;$BC56"M$^P
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M-XZTFX6*0P)IEZCR!3M5FEM2H)Z D*Q [[3Z4 6;72/LNL3WXO)W$RD&%U3
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M!T%%<_\ \)#JG_0F:Y_W^LO_ )(H_P"$AU3_ *$S7/\ O]9?_)% '045S_\
MPD.J?]"9KG_?ZR_^2*/^$AU3_H3-<_[_ %E_\D4 =!17/_\ "0ZI_P!"9KG_
M '^LO_DBC_A(=4_Z$S7/^_UE_P#)% '05YA/\-M=N=$U*1M>,>L76HG4DA01
MFU$JN#'ES%YO"JHX/X8Z]?\ \)#JG_0F:Y_W^LO_ )(H_P"$AU3_ *$S7/\
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M2*R_$NH:UK/A75]+M_!^LK/>V4UO&TD]D%#.A4$XN"<9/H: .THHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #U 7<# 2(  A$! Q$!_\0
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M[)WL+5G:WC+,T*DD[1R>*M_V/IG_ $#K/_OPO^%&C_\ ($L/^O:/_P!!%7:
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M:W<$K+&X92/4$<5,"",CD4 4O['TS_H'6?\ WX7_  H_L?3/^@=9_P#?A?\
M"KA95QD@9.!D]34#7]FMZMFUW +IAD0&0;R/7;G- $7]CZ9_T#K/_OPO^%']
MCZ9_T#K/_OPO^%7:* *7]CZ9_P! ZS_[\+_A1_8^F?\ 0.L_^_"_X5<W L5R
M,CDBH8[VTENI+6.ZA>XB&9(ED!=/J.HH A_L?3/^@=9_]^%_PH_L?3/^@=9_
M]^%_PJ[10!2_L?3/^@=9_P#?A?\ "C^Q],_Z!UG_ -^%_P *NU!#>VEQ/+!#
M=0R30G$L:2 LG^\!R/QH A_L?3/^@=9_]^%_PH_L?3/^@=9_]^%_PI\FI6,-
MU]FDO+=+@LB^4T@#9;.T8Z\[6QZX/I4MS=6]G;O<74T<,*8W22,%4<XY)]Z
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MS L..@ ^;.?:@"+PMHNJVWBPZMJEC/#)=:3;Q.5O&E2.5&?<K;F))P4(//\
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MC SEA&2",@':3[#% $7A[2=9BO\ 6;K5+Z\:21EBM=\V8@GDQY=8P<*3)O\
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M/ .<@5U-% '.P^"=%MI(V@BEB6.;SD19#M4_9_LX 'IY?;UYIMEX&T:P:V,
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M[%9274"7<P+10-( [@=2%ZD"K%<EK^F7]SXV\/ZA9Z7YD-IYHN+L21JP5T*
M8)W':3N_'CF@#:/B+1!%<RG5['R[9PD[?:%Q$Q. &YX.01^%:$,T5Q"DT,B2
M12*&1T8%6!Z$$=17D=CX&\1V6H^']0:PA?\ L*"*V:W2X7_3=IES(I/ QO#
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M4L@*K\V.N#MQGVHMV%U%YL%[*\>2 P5<''''R\CWHL!<HJ#R)/\ GZE_)/\
MXFCR)/\ GZE_)/\ XF@">BH/(D_Y^I?R3_XFCR)/^?J7\D_^)H GHJ#R)/\
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M<^)X6[7%LR?BI!_D36K6=+1-=F_\_P!1(YBX\"Z/<R7$AMHH6< 0^0FP1>^
M>23U]N*F7P7HP1<PS*^!N,=S*HSWQ\U=#16_M)]RKLY__A#-)[&]7Z7LH_\
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M4?;(?^FG_?MO\* )ZK:A:"^L)K8G&]< ^A['\\4[[9#_ --/^_;?X4?;(?\
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M6Y_[=O\ [*KGE7/_ #]#_OV*/*N?^?H?]^Q1[)=W]["Q2^SZW_T$+7_P'/\
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M(Z<GF,5NIC>.L@!_Y;((P@!;^ [N"<U[=110 4444 0W91;*<R3FW01L6F!
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M_P#ZAG_D?_[&BB@ _P"$_P#^H9_Y'_\ L:/^$_\ ^H9_Y'_^QHHH /\ A/\
M_J&?^1__ +&C_A/_ /J&?^1__L:** #_ (3_ /ZAG_D?_P"QH_X3_P#ZAG_D
M?_[&BB@ _P"$_P#^H9_Y'_\ L:/^$_\ ^H9_Y'_^QHHH /\ A/\ _J&?^1__
M +&C_A/_ /J&?^1__L:** #_ (3_ /ZAG_D?_P"QH_X3_P#ZAG_D?_[&BB@
M_P"$_P#^H9_Y'_\ L:/^$_\ ^H9_Y'_^QHHH HZSXQ_M+2IK3[!Y?F;?F\[.
+,,#TV^U%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y > # 2(  A$! Q$!_\0
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M9H8)S5YZ(\@LOA'X@N&87$MG;*!P2Y?)].*9?_"7Q):;VMQ;7B*F[,;[6)]
M#WKW= ,4^OFUQ9F//S/EMVY?^#<]!9=1:ZGRMJ6DZAH\_D:C9S6TG82+@'OP
M>AZCI5.OJZ[LK6_MV@O+:*XA;JDJ!@?P/TKQ/XA?#X>'MVJZ82VFN^'B.2T!
M/OW7Z]*^FRGB:EC)JC6CR3>W9OMW3]?O.+$Y?*DN:#NCSVBBBOJ#S@HHHH W
M_"?AX^(=6$4N];2/YI67K[*#[U]'^';"VT^QAM[6%(88QA40<"O)?AQ%'%H7
MGJN'EG;>V>N.!_.O7=*G&P<UXF,JN=1QZ(]C"TU"FGU9M44R2:.&%I975(U&
M69C@ 5A27.HZPY6R'V:TP1YC\-)_4"N0Z34NM3M;1@LDF7)QM09(^M<=XSTR
MU\9:4UJ]JD5P@S;W3<O$WIQ_">A_/J!700>' B@O<?-CG"\5/_8Y0?)*&^HQ
M51DXOFCN3**DK,\ OOAIJVF SRO'<VRC+M!G<OX'M[T6EE;VR_NHU'OU)_&O
M>9;0H"DL8*L,$$9!![5Y+XAT<Z+JSP 'R'^>$_[/I^'2N+,ZU>HDW+W>W0^F
MX8CA82E3Y%S[I];=5KM;RZ&;%$\TJQ1J6=SM51W-=38>"+BXC5[JX6'<N=BK
MN8'T/:JG@^.-]6D=URT<>5/H2<5Z/:X=E4'K66 P=.K#GJ:GKYIF%6A+V=/3
MS/.=7^&+3JSP-',>W&Q_\#7E^K:/<:5.R2(VP-C)&"I]#Z&OJ>:W\E0<YS7$
M>.M!@U#3)+L1J)8Q^\/0NG^(KUJ<Y85<])MQ6Z>NGEV:^X^8JTJ.9^Y424WM
M)*VO:5MT^^ZW/GVBK-_:-97;PMT'*GU%5J]Z$XU(J<=F?'5J4Z-25.HK-.S"
MBBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+/_ (\;?_KF
MO\JGJ"S_ ./&W_ZYK_*IZF'P+T7Y%3^)A1115$FMHNBSZH9IEPL4"%BS="0,
MXK1LR, UTWA-8[73[51R'0.<]R>37.3QFSU*YMV96*2,"5Z'FODLXFZDU+HM
M#]'X;HQP]+EZNS?]>1I1GBIHW>*19(V*.IRK*<$'VJG#)D"K(.:\)GV*M)';
M>'/%6KI(L,EYYT?/$XW=??K^M:NK>-=5L3MB%HV1UV'_ !KB=+T^^NG1HE\N
M(_\ +1N!CV]:ZZRT&U'S7.;E\=9.GY5Z5#V\X66GF?+9A++J%;FDE)]DOSV2
M.;&JW5_?"[O9C+,P +' X'8 =*Z&2Y#:/=COY#_^@FJ?B;23 Z7UO$H@VA7"
MC 4] ?QKF-5UE[;2W@5\2S?+PV"%[G^GXUWM\E+7HCCPU2-:HG!63>W;4S(7
MRHJ<5F03< 5>20$5\\T?9PFI(U=,NKA+F.*V4M+(P1%'4D]*]@TGPY;V2+-=
M*ES>GEI67(4XZ*#TKS7P'Y(\1B6503%$60GL<XS^1->Q1RK(@8$<UZF!IWAS
ML^0XAQ3C6]A#335][]/0'ABDC\MXT9,8VE01BO)O&G@6P@NVN 6CM3L>",'C
M?N^9/IMR1Z8KURN7\>/ N@JLB@RM*HB.,X/4_3C-=&);A3=2+M);/\/U/GX5
MIQA*G]F2LU^/Z'+:2551@8^E=5:ME17%:=. 0#74V<X('(KX3$1=S-&VAXJ>
M./>*I1R9 JRDA X-9T)TXSO45T=$7=:"LNTXJ&X@BNK>2WF0/%(I1U/<'@U*
M6S29J)R7->&A=M-3Y@\3:*WA_P 17FFD-LB?,188W(>A_P ^E9-=Y\6HE7QK
MYBS([26Z9C7.Y,>OUZBN+2SF?'R[1ZFOV;*95<9A*56UVXJ_J?,5Z?+5E&/<
MKT5U_ASX;ZWXE!DMS#!;8RL\Y(5CG&!@$FNTG^ \@M6-OKZM<8^59+;:A/N0
MQ./PK6K6IT9\DW9_UV".'JR5TC+^'UQ')X>>%2?,AG;?QP-W(_E7H5AJ:6T9
M>:0(B#+,QX KRM]#UWX::JMQJ5OYVG3'RFF@;<C>AYZ'T!QG%=!/?6^LSV4%
MK(LEN_[UF!ZCT]CUKR,5#W^>.J9Z6'E[B@]&CNK.]N/$$Z2W"%+13F.W/_H3
M>I_E77P*%C %<=HL@0@=J["W<-&.:Y3H)J*** $90ZE6&0>U<%\0]'WZ6EY&
MI9K=LDA>=AZY/H.M=]5+5K9+S2KF"1 ZNA&UAD'TS6=6FJD'$Z<'B'AZ\*RZ
M/\.OX'AVE:@=-OTN,,R8(=0<9%>DV5\DT231ME&&5->4,IBE>)F!:-BA(Z$@
MXJU9ZC=6#$VTQ3<,$=1^1KS,+BW0]V2T/O<=@(XI*<7K^:/7_MK2*-S9Q6-X
MFO8X]!N@[8,B;%'J37'?\)=J.W 2 '&,[3_C45K:ZMXIOD7<SA1@RL,(@[].
M,_2NVKF$9P<*:;;/+I95["7M:TE&,==S&'A&7Q%YUU "Q@PKHIPQSDC&?H>/
M>LN3PM;PRM%+]H213AE8@$'\J]WTO2H-*T^.T@&0OWG( +GN367XD\/Q:G:/
M-%&!>1KE&'\6/X3ZTT\53HJ-.HU9;?TCREBLNKXR3KT(N,G\5M>BN]=OQ7GJ
M>(3^&'&3;S@CGY7&/UK'NK*XLVVSQE<]#V-=]@CJ,5#<6T5U"T4R!E/Z4\-G
M=>FTJWO+\3MQ_">$K1<L-[DNFMU_P/D>?T5?U33'TZ8#.Z)ONM_0U0KZJE5A
M6@JD'=,_.\3AJN&JNC55I(****T, HHHH **** "BBB@ HHHH **** "BBB@
M""S_ ./&W_ZYK_*IZ@L_^/&W_P"N:_RJ>IA\"]%^14_B844451)W'AK41/IZ
M1%QYT'RD< [>QJKKPVZH9@JJLJ@\=SW)KF+2[GLIQ-;OLD QG&>*U)]8_M)H
MO,0)(B[>#D,?:O!S/!RY'."NMS[#(\TIN4:51V>WD^WS-"R:2>9(88VDE<X5
M%&237I_AGX>S7$:7.K-Y:L,B #+#Z^]0_#[P_'86Z74\:F[E&68CE%/1:]3A
M $8Q7DT,)%6G,]',,ZJRO1HNRZOJ_3LOQ,RW\-:=!&J['<C^(N1_*GMH< !\
MIW0]@>0*U**[CY\P;C1C<VTUG<INBE0HQ4]0?3TKP+Q/HUUH.O3V%W.)W3!6
M4?Q*1D?0X[5]-UY]\2-,AD:VO)(P\<@,,F<8'<$=\]?R%8UJ7M%YG?@,:\+/
M57B]SQ&.0H>M7(KKW%;-QX52;YK*X"$G[DO(_.J;>$M7#D1Q1R*#PPE !_/F
MO.GAI]CZ>AFN'DKJ=O70T- U6.RU$/(X5'787S]WWKTZPUYXT4D[U[,IR#7D
MJ>$]9#JKK;Q D99YUX'KC.:VM(\*Q&55OM9^3=A8K8L WXD<?E^-;X>52FN1
MK]#S\SI8?%R]O&>MM;)RO]W^9ZO%XECE?RH\/,!DH#R![^E8/BV62]T])I&Q
MY3@A0..>*MZ;IUI8PB"UB5 @P><M_P ")Y/XT[7+99=$N!G;L'F9QGISBNNK
M3]K3<)=3YJ5D]-CA(93&^<\5O65[T&:S4LHYQP2C>HZ5,FE7<?,3I(,\#.#7
MS>(RRNME?T ZFVO 0.:T4N >]<I!#J*N$^RR,?\ 8^85JI#J2CYK*<?5:\BI
M@JR?PO[F-.QM"8>M,EN%1268#CO67NO00/LTH)]13TM[C>LEQMV*<^7US]:>
M'RW$5I\JC\^Q3J,\F^(B[_&DDC#YFMXCR.G!KG *ZGXDE3XVE*D$&VA(QZ8-
M<M7]!Y+1C1R^C3CLHH\FK\;/6OAKXPTNUTN/1KV5;6:,GRY)#A9=S9QGL<GI
M7J=?*\2[V"GO7;Z0^OZ=9BYL=3N$0'>49]R$XQR#7D9GDM.51U:<^5R>SVOZ
MF]*L[6:/9-6TVWU?2;K3[I \-Q&48$XZ^_:OGOPS"VD:Y)8RO'*(IV17C/WS
MRI(]N!6AJ_C7Q)J$+6EUJ++$<AEB01[@>,$CM7-([1.KH<,O(Q4T,AG]7G"I
M)7>JMW7^8IU8\ZDEL>O6<_DRCFNNT^^! &:\ZTJ_^WV<<C*5D*@D'^+W%;5G
M?/ P!)(KY647%M/='9OJCT-6##((-.KG+/5A@?/TK6CU&-AR12 NU6OY_L]C
M-*,95>,^M-;4(5&<]*Y#7_$2W+_9XF'E(?F/J: /-O%!-OXDN<E<2XD4+V!'
M3Z\53M1-=R".WB>5_1!FMR]TZTU;51=3F1SM"!%. <?KWKJ-*TJ2*$FQT]TC
M)^;RX\ FO.E@G*;;=D?44N(51P\(1C>2279?YF7HOA#S&675'PN?]0AZCW8?
MTKU#3K*VM[&*&"-4B08"*.!7-+;W<"AI+:55Z9*U>M=2:(8&#[5V4J,*2M%'
MAXS'U\7*]67RZ+Y?TS6NXUC Q5%CQ3);YICEC4+S9%:G$<CXBTNVB>68$*\A
MW8KCVX-=/XSE(NK8B5>4(* \]>OTKEBU>)BK*HTC]#R=SEA(3D[W7Y:?H4]6
MM1=6$B;2S ;D ZY'2N'KT%SD&O/SU->_P]4;A.'1-/[_ /ACY/C2C&-6E56[
M33^5K?F)1117T1\0%%%% !1110 4444 %%%% !1110 4444 06?_ !XV_P#U
MS7^53U!9_P#'C;_]<U_E4]33^!>B_(J?Q,***NZ9ILNJ78A1UC4#=)(YX1>Y
MIRDHKFEL.$)5)*$%=LI=*UM!L&GU[3X[F"40R3*#E2N>_6NGM!I^G9CTRSB<
MXVFZN$WNWK@'A15VWO)6OX)KF627;("=S9]OH*\&OGM)/DIJ_2^Q]=AN$:[I
M^UJS2:5[)7OUMT/1](GVOSUS796L@>,5YW!,89-PKJM-U 8&36!YYT5%1QS+
M(!SS4E !61XGL?[1\/7< 4L^W<F.NX=*UZS];NOLFDS.&"LPVKGOGM^6: /%
M(;Y8D+2.%"]23TJ&37KJ8E;8^3'V;^(_X5EZW=07>NSFU_X]U;C!X+=R/:GP
MXQT[5Y>*Q4K\L-$?7Y/D]/E56NKM]'LO^"=SH&D0&-+JY037#C=OD^;&?3-=
MG;H, #I7!:!K\,,:V]XVS;PLAY!'OZ5W%C=12!'C=9%X.5.>*]/!SI."Y/\
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M[ID5VI<#;-V<=_8T#-/3KL%0":U@<BN!M+V6UE,4NY64X(:NDL]4#*,MD>]
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M64J->3^;-EB3D _PCVK'M)#,V]B3GIN["MZTQQ7T66Y;'"7E+63_  %<T+:
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M&**XUWQ!=6D90?N+9OWG?[S'@'IV-=7)\+/#%P%:\BO+J7 W2RW<F6(&,G!
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M8U>&5=Q&=N>1_C6K#?RPD G(%<5X5T:PG\.6LHED:1P2SJ_^K;/('TKM=/\
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M1(N7^4?K4".+B]=S@Y;MW%;:#"#% &5/X9TJX8,]MANY5BN?RJE=>#+"5/\
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M=/I[&N#'47.*E'H=N#JJ+<9=3VG3-1!4#=7017"2+P>:\YAG>%LJ:VK/6-N
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M(VI&I^5%'0#_ ![UDU[N&H^RA9[GC8BK[2=UL%%%%=!@%%%% $%G_P >-O\
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DH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $L ) # 2(  A$! Q$!_\0
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MA.A)&<U4(NY,F:-O!':VT5O"-L<2A%&<X &!4E%%;$!115&^O?*S!"<SL/\
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M-3X;6ZK_ ,@N8?[NJ _SCKTDF@=!4NA3[%K,L3_._O/.%^', ZZ==_AJ,?\
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M$6X;=*,Y/'//'3VK#O='>7Q!>W5M<O&S2J94W$!L*./R]OQK;T\3BQB%R<S
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MJ@$CTS6?K[F/3BZP37##>1##_K'.QN%SW/:J?A>3+2QK//<Q"")EED=SL^4
MQD-QD$$Y'4'GI6EJ<8FBCC(8AV9<+U.48<570YYIJ5F[GG5Q?^(K^5KF'P=9
MV>1_K]4O@>O&2BD>GIZU/X?759/'>AOJ^M)>NMQ\EI8Q;+>+Y&Y)ZL1V_G6C
M&^DB.0V^G7MV[K\\;  8SVQT^[_.C3KFY;Q5I45ND$,$=[&"L"YRIR,,1G&,
M]^3Z4B6=]>SSIXI,7D*;=U'[P]0^TGC\!BM-*AN #JL_'3:1^53+UJQ#J#NP
M2,X[TM<WJRW4.J76H01V[_9K1"K2[RT9)?)4#@CN<^E '0%0WWE!R,<C-((H
MP,"-!@@C"CJ.E8FEZG>WEQ=1M-;SQ6T9VR1QX\]MS@,,' 'R]!GG/-4(-8DL
M[.S2WEGO[V\2*1FF9I(U+*Y.U4&1RC# '''H:5PN=1Y$.\OY,>\D,6VC)(Z$
MGU%1_8;,;L6L(W*4;"#E3C(/MP/RK$D\2W-M"]S<Z<(X%RI3>?-5Q$),$8QC
MJO7/M4B>(+@N$DLHX=B2/+))*R(%3;RN4R0=X'08P>M*Y7,S0&FV,;W)2S@4
MW/$Y"#]X/]KUI;C3[*\Q]IM(9L  >8@. #D"LO2];DU35!'M\I4299(^3ET9
M &!(!QA^X'6MT4P4G>]RA-I.FR2H[V%JSHI56:%20#G(''N?S-/CM;:WMQ;1
MP0Q0 <1*@"X^G2L[Q,]R\$=I97,J7$H8&.!<R,I4C<#_  X)!R2 <8S7CVJ^
M++&RO);,Z3/<S)<,)7N[HAF8/\RJ%!.W(Z<CWI72)E4MHV>[K;0!G?R(MTF"
MYV#+'U/K2/U-<KX8MKO3DAN;X7UK%<*6\B=Q(J,W0,1]WMC*C'3/45U3]30K
M,=[D3DGJ2?K5&_CB>VWS32Q+"?,WQ-AA@'/;T)JZU4[\0FPN!.6$/EG>5Z@8
MZCWJA'.IJ/AR:01+*;B<MM2.8N[,W/&UN!C!SQQBL[3]=DU7Q7HD%A:206:7
M:^9(0 .!G: .!SQ[YK1$OARQ;SHB9KB/<>2SNI/7/89/)]Z9I5V)O%^DQ067
MEV+R"<MLQ\Y5O3@$$+4C9V=]J,=MK=RDZLB#8%?&0>!5Z":.>-98G#HW1AWK
M+U-KI_$4JPI;S6ZJJSQMRPR!SCZ'^5:D<:1($C7:HZ 50B:J]Y<+:6DURREE
MB1G*KU( R:G/I44\2SV\L+?=D1D/T(Q0!3EU33K255>>"-=C$R[E5$"E1@GL
M<N./>JB_V#)<W-I]DM07;?*WE*J.0%8,6^D@P?<UDIX+F@16COP\B")QUCWR
M@YD8L,D;OEZ9QCO4Z^%I$'EKY'D?(/*9B^ !$,9(Y_U;=?44A*YO?8]/EB5/
M)MWC?+*."&^7:2/7Y>/I49TO3_*:/R5="C1D,[-\K8R,DD_PC\JPW\-3KJR3
M[ ;<2%HUA=$,(\UG&,C(!##(4CIBH1H-W%:QI#IT>ZWG+6RRF-@5(&?.QPQX
MX8?-QS[H:.@M=+L[.0RV\&V0[LN69F.[&<DDYSM7\JN"GL !Q3!3&>7ZUXZN
MM#\5ZAIUS;;[4.'DN(!MD$3A4C ).,JY<=.@X&:Y'4?$/AVYU=-:T?24L-2W
MQAKV\D\VWMLMM$KQKG+8 YYP2,C->OZSI%LKW6J)#:>;Y8:X6Y@$B2K'E@3W
M!')!'Y5ST?B/21:SE=*T@1*C^8RN FS[S$@QY*Y.>G)/<U/J0VKZH@B^)$UQ
MYMK'I4%V8XV\R;[3LCD"X#-@KP#G(&2<?CCNXP1!&#G.T=>M9.BSPZVD\I:
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,R-R[GW-7Z**T$?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624361177128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">to reflect updates<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sunshine Biopharma,
Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001402328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5566275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6500 Trans-Canada Highway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pointe-Claire<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H9R 0A5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">426-6161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624358501432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,386,608<span></span>
</td>
<td class="nump">$ 989,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">71,310<span></span>
</td>
<td class="nump">23,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">25,046<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">7,590<span></span>
</td>
<td class="nump">7,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">2,491,683<span></span>
</td>
<td class="nump">1,025,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment (net of $60,774 and $51,485 depreciation)</a></td>
<td class="nump">10,232<span></span>
</td>
<td class="nump">19,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents (net of $58,918 amortization and $556,120 impairment)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">2,501,915<span></span>
</td>
<td class="nump">1,045,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="nump">820,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Notes payable - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">143,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable &amp; accrued expenses</a></td>
<td class="nump">56,687<span></span>
</td>
<td class="nump">62,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">84,945<span></span>
</td>
<td class="nump">24,320<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">471,632<span></span>
</td>
<td class="nump">1,051,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term portion of notes payable</a></td>
<td class="nump">3,204,215<span></span>
</td>
<td class="nump">949,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">3,675,847<span></span>
</td>
<td class="nump">2,000,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 510,093,265 and 346,419,296 at September 30, 2021 and December 31, 2020 respectively</a></td>
<td class="nump">510,092<span></span>
</td>
<td class="nump">346,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital paid in excess of par value</a></td>
<td class="nump">31,555,741<span></span>
</td>
<td class="nump">18,820,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated comprehensive income</a></td>
<td class="num">(17,475)<span></span>
</td>
<td class="num">(2,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated (Deficit)</a></td>
<td class="num">(33,322,290)<span></span>
</td>
<td class="num">(20,218,727)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="num">(1,173,932)<span></span>
</td>
<td class="num">(954,837)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="nump">2,501,915<span></span>
</td>
<td class="nump">1,045,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624358476392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Equipment depreciation</a></td>
<td class="nump">$ 60,774<span></span>
</td>
<td class="nump">$ 51,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Patent amortization</a></td>
<td class="nump">58,918<span></span>
</td>
<td class="nump">58,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Patent impairment</a></td>
<td class="nump">$ 556,120<span></span>
</td>
<td class="nump">$ 556,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">510,093,265<span></span>
</td>
<td class="nump">346,419,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">510,093,265<span></span>
</td>
<td class="nump">346,419,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624355856920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue:</a></td>
<td class="nump">$ 50,376<span></span>
</td>
<td class="nump">$ 17,150<span></span>
</td>
<td class="nump">$ 143,308<span></span>
</td>
<td class="nump">$ 43,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">19,506<span></span>
</td>
<td class="nump">6,340<span></span>
</td>
<td class="nump">56,541<span></span>
</td>
<td class="nump">15,384<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">30,870<span></span>
</td>
<td class="nump">10,810<span></span>
</td>
<td class="nump">86,767<span></span>
</td>
<td class="nump">28,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General &amp; Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Accounting</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">19,290<span></span>
</td>
<td class="nump">96,200<span></span>
</td>
<td class="nump">56,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal</a></td>
<td class="nump">56,923<span></span>
</td>
<td class="nump">6,895<span></span>
</td>
<td class="nump">159,074<span></span>
</td>
<td class="nump">50,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D</a></td>
<td class="nump">222,465<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">581,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,183<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">9,557<span></span>
</td>
<td class="nump">10,526<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total General&#160;&amp;&#160;Administrative Expenses</a></td>
<td class="nump">527,129<span></span>
</td>
<td class="nump">78,098<span></span>
</td>
<td class="nump">2,247,270<span></span>
</td>
<td class="nump">261,569<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) from operations</a></td>
<td class="num">(496,259)<span></span>
</td>
<td class="num">(67,288)<span></span>
</td>
<td class="num">(2,160,503)<span></span>
</td>
<td class="num">(233,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(1,598)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(46,849)<span></span>
</td>
<td class="num">(22,094)<span></span>
</td>
<td class="num">(292,188)<span></span>
</td>
<td class="num">(62,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt release</a></td>
<td class="nump">7,688<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">58,940<span></span>
</td>
<td class="nump">2,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Loss on debt conversions</a></td>
<td class="num">(3,504,000)<span></span>
</td>
<td class="num">(608,899)<span></span>
</td>
<td class="num">(10,709,843)<span></span>
</td>
<td class="num">(1,416,313)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="num">(3,543,124)<span></span>
</td>
<td class="num">(631,307)<span></span>
</td>
<td class="num">(10,943,060)<span></span>
</td>
<td class="num">(1,466,742)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Net (loss) before income taxes</a></td>
<td class="num">(4,039,383)<span></span>
</td>
<td class="num">(698,595)<span></span>
</td>
<td class="num">(13,103,563)<span></span>
</td>
<td class="num">(1,700,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss)</a></td>
<td class="num">(4,039,383)<span></span>
</td>
<td class="num">(698,595)<span></span>
</td>
<td class="num">(13,103,563)<span></span>
</td>
<td class="num">(1,700,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Unrealized loss from foreign exchange translation</a></td>
<td class="num">(5,839)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="num">(14,604)<span></span>
</td>
<td class="num">(1,009)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss)</a></td>
<td class="num">$ (4,045,222)<span></span>
</td>
<td class="num">$ (698,739)<span></span>
</td>
<td class="num">$ (13,118,167)<span></span>
</td>
<td class="num">$ (1,701,307)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted (loss) per common share</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Outstanding (Basic &amp; Diluted)</a></td>
<td class="nump">508,528,048<span></span>
</td>
<td class="nump">280,873,792<span></span>
</td>
<td class="nump">475,536,409<span></span>
</td>
<td class="nump">162,133,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624359984280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss)</a></td>
<td class="num">$ (13,103,563)<span></span>
</td>
<td class="num">$ (1,700,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9,557<span></span>
</td>
<td class="nump">10,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Foreign exchange (gain) loss</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(6,404)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock issued for services</a></td>
<td class="nump">918,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Loss on debt conversion</a></td>
<td class="nump">10,709,843<span></span>
</td>
<td class="nump">1,416,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt &amp; interest release</a></td>
<td class="num">(58,940)<span></span>
</td>
<td class="num">(2,836)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in accounts receivable</a></td>
<td class="nump">787<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) in inventory</a></td>
<td class="num">(47,539)<span></span>
</td>
<td class="num">(10,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">(Increase) in prepaid expenses</a></td>
<td class="num">(22,268)<span></span>
</td>
<td class="num">(3,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">(Decrease) in Accounts Payable &amp; accrued expenses</a></td>
<td class="num">(13,778)<span></span>
</td>
<td class="num">(40,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Increase in interest payable</a></td>
<td class="nump">52,716<span></span>
</td>
<td class="nump">10,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Flows (used) in operations</a></td>
<td class="num">(1,517,015)<span></span>
</td>
<td class="num">(233,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Flows (used) in Investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">3,318,500<span></span>
</td>
<td class="nump">676,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherShortTermDebt', window );">Note payable to pay fees</a></td>
<td class="nump">61,500<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments of notes payable</a></td>
<td class="num">(451,661)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Flows provided by financing activities</a></td>
<td class="nump">2,928,339<span></span>
</td>
<td class="nump">683,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">989,888<span></span>
</td>
<td class="nump">40,501<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">1,411,324<span></span>
</td>
<td class="nump">449,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Foreign currency translation adjustment</a></td>
<td class="num">(14,604)<span></span>
</td>
<td class="num">(1,009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">2,386,608<span></span>
</td>
<td class="nump">488,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary Disclosure Of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Stock issued for note conversions including interest</a></td>
<td class="nump">11,981,072<span></span>
</td>
<td class="nump">1,831,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">155,081<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624354883128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statement of Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Comprehensive Income [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 35,320<span></span>
</td>
<td class="nump">$ 16,616,426<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="num">$ (2,495)<span></span>
</td>
<td class="num">$ (17,434,636)<span></span>
</td>
<td class="num">$ (735,385)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Begining balance, shares at Dec. 31, 2019</a></td>
<td class="nump">35,319,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for the reduction of note payable and payment of interest</a></td>
<td class="nump">$ 269,099<span></span>
</td>
<td class="nump">1,562,717<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,831,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for the reduction of notes payable and payment of interest, shares</a></td>
<td class="nump">269,099,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 304,419<span></span>
</td>
<td class="nump">18,179,143<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="num">(3,504)<span></span>
</td>
<td class="num">(19,134,934)<span></span>
</td>
<td class="num">(554,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Preferred stock issued for management compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,009)<span></span>
</td>
<td class="num">(1,700,298)<span></span>
</td>
<td class="num">(1,701,307)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="nump">304,419,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Preferred stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 269,820<span></span>
</td>
<td class="nump">17,542,616<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="num">(3,360)<span></span>
</td>
<td class="num">(18,436,339)<span></span>
</td>
<td class="num">(577,263)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Begining balance, shares at Jun. 30, 2020</a></td>
<td class="nump">269,821,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for the reduction of note payable and payment of interest</a></td>
<td class="nump">$ 34,599<span></span>
</td>
<td class="nump">636,527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">671,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for the reduction of notes payable and payment of interest, shares</a></td>
<td class="nump">34,598,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 304,419<span></span>
</td>
<td class="nump">18,179,143<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="num">(3,504)<span></span>
</td>
<td class="num">(19,134,934)<span></span>
</td>
<td class="num">(554,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Preferred stock issued for management compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="num">(698,595)<span></span>
</td>
<td class="num">(698,739)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="nump">304,419,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Preferred stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 346,418<span></span>
</td>
<td class="nump">18,820,343<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">(2,871)<span></span>
</td>
<td class="num">(20,218,727)<span></span>
</td>
<td class="num">(954,837)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Begining balance, shares at Dec. 31, 2020</a></td>
<td class="nump">346,419,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for the reduction of note payable and payment of interest</a></td>
<td class="nump">$ 103,674<span></span>
</td>
<td class="nump">11,877,398<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,981,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for the reduction of notes payable and payment of interest, shares</a></td>
<td class="nump">103,673,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 510,092<span></span>
</td>
<td class="nump">31,555,741<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="num">(17,475)<span></span>
</td>
<td class="num">(33,322,290)<span></span>
</td>
<td class="num">(1,173,932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Preferred stock issued for management compensation</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">858,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">918,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,604)<span></span>
</td>
<td class="num">(13,103,563)<span></span>
</td>
<td class="num">(13,118,167)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="nump">510,093,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Preferred stock issued for services, shares</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 486,092<span></span>
</td>
<td class="nump">27,835,741<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">(11,636)<span></span>
</td>
<td class="num">(29,282,907)<span></span>
</td>
<td class="num">(872,710)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Begining balance, shares at Jun. 30, 2021</a></td>
<td class="nump">486,093,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for the reduction of note payable and payment of interest</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">3,720,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,744,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for the reduction of notes payable and payment of interest, shares</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 510,092<span></span>
</td>
<td class="nump">31,555,741<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="num">(17,475)<span></span>
</td>
<td class="num">(33,322,290)<span></span>
</td>
<td class="num">(1,173,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (5,839)<span></span>
</td>
<td class="num">$ (4,039,383)<span></span>
</td>
<td class="num">$ (4,045,222)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="nump">510,093,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624360860088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text"><p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zj5EQMx7t3xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 1 &#8211; <span id="xdx_826_z1xHyG7GlLJ8">Nature of Business and Basis
of Presentation</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sunshine Biopharma, Inc. (the "Company")
was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Until
October 2009, the Company was operating as a business consultancy firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 15, 2009, the Company acquired
Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. was holding an exclusive license
to a new anticancer drug bearing the laboratory name, Adva-27a (the &#8220;License Agreement&#8221;). Upon completion of the reverse acquisition
transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the
development of the licensed Adva-27a anticancer drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2012, the Company published the results
of its initial preclinical studies of Adva-27a in the peer-reviewed journal, ANTICANCER RESEARCH. The studies were conducted in collaboration
with Binghamton University, a State University of New York, and Ecole Polytechnique, Universite de Montreal. The publication is entitled
&#8220;Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells&#8221; [ANTICANCER
RESEARCH Volume 32, Pages 4423-4432 (2012)].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2014, the Company formed a wholly owned
Canadian subsidiary, Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;) for the purposes of offering generic pharmaceutical
products in Canada and elsewhere around the world. Sunshine Canada has recently transitioned its focus to the development and marketing
of Science-Based Nutritional Supplements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, the Company acquired all worldwide
issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a
anticancer compound from Advanomics Corporation, a related party, and terminated the License Agreement. In 2016, the remaining value of
these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2018, the Company formed NOX Pharmaceuticals,
Inc., a wholly owned Colorado corporation and assigned all of the Company&#8217;s interest in the Adva-27a anticancer drug to that company.
NOX Pharmaceuticals Inc.&#8217;s mission is to research, develop and commercialize proprietary drugs including Adva-27a.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2018, the Company launched its first
Science-Based Nutritional Supplements product, Essential 9<span style="font-variant: small-caps"><sup>&#8482;</sup></span>, an over-the-counter
tablet comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9<span style="font-variant: small-caps"><sup>&#8482;
</sup></span>has been authorized for marketing by Health Canada under NPN 80089663.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20190101__20190201" title="Stockholders' Equity, Reverse Stock Split">Effective February 1, 2019, the Company completed
a 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400
(the &#8220;First Reverse Stock Split&#8221;). The Company&#8217;s authorized capital of Common Stock remained as previously established
at 3,000,000,000 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20200101__20200406" title="Stockholders' Equity, Reverse Stock Split">Effective April 6, 2020, the Company completed
another 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417
(the &#8220;Second Reverse Stock Split&#8221;). The number of Common Shares authorized for issuance remained as previously established
at 3,000,000,000 shares.</span> All references to the Company&#8217;s Common Stock in this Report, including the Company's financial statements
reflect both the First and Second Reverse Stock Split on a retroactive basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 22, 2020, the Company filed a provisional
patent application in the United States for a new treatment for Coronavirus infections. The Company&#8217;s patent application covers
composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential
for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company filed a PCT application
containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May
22, 2020 has been maintained in the newly filed PCT application.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2020, the Company filed an amendment
to its Articles of Incorporation (the &#8220;Amendment&#8221;) with the State of Colorado, to eliminate the Series &#8220;A&#8221; Preferred
Shares consisting of Eight Hundred and Fifty Thousand (850,000) shares, par value $0.10 per share, and the designation thereof, which
shares were returned to the status of undesignated shares of Preferred Stock. In addition, the Amendment increased the number of authorized
Series &#8220;B&#8221; Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on June 17, 2020, the Company issued Five
Hundred Thousand (500,000) shares of Series &#8220;B&#8221; Preferred Stock in favor of Dr. Steve N. Slilaty, the Company&#8217;s CEO,
in consideration for the COVID-19 treatment technology he developed. The Series &#8220;B&#8221; Preferred Stock is non-convertible, non-redeemable,
non-retractable and has a superior liquidation value of $0.10 per share. Each share of Series &#8220;B&#8221; Preferred Stock is entitled
to 1,000 votes per share. This issuance brought the total number of Series &#8220;B&#8221; Preferred Stock held by Dr. Slilaty to 1,000,000
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 8, 2020, the Company executed a financing
agreement with RB Capital Partners, Inc., La Jolla, CA, (&#8220;RB Capital&#8221;) who agreed to provide the Company with a minimum of
$2 million in convertible debt financing during the ensuing three to six month period pursuant to the terms and conditions included in
relevant Promissory Notes (the &#8220;Promissory Notes&#8221;). The Promissory Notes bear interest at the rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210930__us-gaap--DebtInstrumentAxis__custom--RBCapitalMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zBe9bJTQH3sb" title="Debt stated rate">5</span>% per annum and have
a maturity date of two years from the date of issuance. The Company has the right to pay off all or any part of the Promissory Notes at
any time without penalty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 6, 2020, the Company entered
into a Research Agreement (the &#8220;Agreement&#8221;) with the University of Georgia Research Foundation, Inc. (&#8220;UGARF&#8221;),
representing the University of Georgia (&#8220;UGA&#8221;). The purpose of the Agreement is to memorialize the terms of the Company working
together with UGA to conduct the necessary research and development to advance the Company&#8217;s Anti-Coronavirus lead compound, SBFM-PL4
(or derivatives thereof) through various stages of preclinical development, animal studies and clinical trials for Coronavirus infections.
The Agreement grants the Company an exclusive worldwide license for all of the intellectual property developed by UGA, whether developed
alone or jointly with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 26, 2021, the Company received a Notice
of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains
new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 4, 2021, the Company entered into
an exclusive license agreement with the University of Georgia (&#8220;UGA&#8221;) for two Anti-Coronavirus compounds which UGA had previously
developed and patented. The Company and UGA will advance the development of these two compounds in parallel with the Company&#8217;s own
Anti-Coronavirus compound, SBFM-PL4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2021, the Company received a Notice
of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject
matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued
in 2019 (US Patent Number 10,272,065).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 25, 2021, the Company entered into an
engagement agreement with Aegis Capital Corp. (&#8220;Aegis&#8221;), pursuant to which we engaged Aegis to act as lead underwriter in
connection with a proposed public offering of approximately $10 million of common stock and warrants by the Company (the &#8220;Offering&#8221;).
The Offering is contingent on satisfaction of various conditions, including Aegis&#8217;s due diligence examination of the Company, Nasdaq
approval of the listing of the Company&#8217;s Common Stock, and successful completion of a reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2021, the Company filed its Definitive Information Statement
with the SEC to complete the reverse split of the Company&#8217;s Common Stock in part to meet the Nasdaq listing requirement concerning
minimum price per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's financial statements reflect both
the First and Second Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and
its subsidiaries (Sunshine Biopharma Canada Inc. and NOX Pharmaceuticals Inc.) herein collectively referred to as the "Company".</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_84B_ecustom--ImpactOfCoronavirusPandemicPolicyTextBlock_z0KiM2ZTYp3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B4_zfGehxDTYLFl"><b><i>Impact
of Coronavirus (COVID-19) Pandemic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, the World Health Organization declared
Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak have been and are
continuing to evolve rapidly. Government authorities in the U.S. and around the world have implemented emergency measures to mitigate
the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on
the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of
the adverse conditions of the outbreak and their effects on the Company&#8217;s business or ability to raise funds. No adjustments have
been made to the amounts reported in the Company's financial statements as a result of this matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zMOgnXzFJPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_znHHq3vFqa0g">Basis of Presentation of Unaudited Financial
Information</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited financial statements of the Company
for the three and nine month periods ended September 30, 2021 and 2020 have been prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q
and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted
in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely
of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position
and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full
fiscal year. The balance sheet information as of December 31, 2020 was derived from the audited financial statements included in the Company's
financial statements as of and for the year ended December 31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 30, 2021. These financial statements should be read in conjunction
with that report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0quiwBf4kBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_z8XZZadL6vOf">Recently Issued Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2019, the FASB issued ASU 2019-12 &#8220;Income Taxes
(Topic 740): Simplifying the Accounting for Income Taxes.&#8221; This guidance removes certain exceptions to the general principles in
Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new
guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early
adoption is permitted. There was no impact of the updated guidance on the Company&#8217;s financial statements for the year ended December
31, 2020. The Company is currently evaluating the impact of the updated guidance on its financial statements for 2021 and going forward.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, the FASB issued ASU 2020-02,&#160;<i>Financial
Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842)&#160;</i>which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective
for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will
modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The
Company is in the process of determining the effects adoption will have on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In August
2020, the FASB issued ASU 2020-06,&#160;<i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</i>, (&#8220;ASU 2020-06&#8221;). ASU 2020-06 simplifies the
accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts
on an entity&#8217;s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim
periods within those fiscal years.&#160;</span>Early adoption is permitted, but no earlier than fiscal years beginning after December
15, 2020, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624360963864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern and Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern and Liquidity</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zBP56Z9LPIl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Note 2 &#8211; <span id="xdx_82A_z6XYaTzUM7yb">Going Concern and Liquidity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and December 31,
2020, the Company had <span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_c20210930_pp0p0" title="Cash and cash equivalents">$2,386,608</span>
and <span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_c20201231_pp0p0" title="Cash and cash equivalents">$989,888</span>
in cash on hand, respectively, and limited revenue-producing business. Additionally, as of September 30, 2021 and December 31, 2020,
the outstanding liabilities of the Company totaled <span id="xdx_90F_eus-gaap--Liabilities_c20210930_pp0p0" title="Outstanding liabilities">$3,675,847 </span>and <span id="xdx_900_eus-gaap--Liabilities_c20201231_pp0p0" title="Outstanding liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0601">$2,000,311,</span></span>
respectively. These factors raise substantial doubts about the Company&#8217;s ability to continue as a going concern. On June 25,
2021, the Company entered into an Engagement agreement with Aegis Capital for the purposes of raising <span id="xdx_903_eus-gaap--Capital_iI_c20210625_zHmKb77hr6Vk" title="Capital">$10,000,000</span>
in equity financing in a proposed public offering and, in connection therewith, the Company filed a preliminary prospectus of Form
S-1 with the SEC on September 9, 2021. The Company believes that the afore expressed doubt about the Company&#8217;s ability to
continue as a going concern will be fully mitigated if the financing were to close. There is no
assurance the offering will be completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements included
in this Report have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities
and commitments in the normal course of business. The consolidated financial statements included in this Report do not include any adjustments
that may result from the outcome of any going concern uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no assurance that these events will be
satisfactorily completed. The issuance of equity securities in connection with the Offering (see Note 1), if accomplished, could cause
substantial dilution to existing stockholders. Any failure by the Company to successfully implement these plans would have a material
adverse effect on its business, including the possible inability to continue operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624360862248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zL6yBtq348Th" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 3 &#8211; <span id="xdx_822_zQmHd2l9WI91">Notes Payable</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s Notes Payable at September
30, 2021 consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Note Payable dated December 31, 2018 having
a Face Value of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_c20181231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Face Value">136,744</span> and accruing interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20180101__20181231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_zEDMO8ip8aSf" title="Interest Rate">12</span>% was due <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20180101__20181231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_zFkmxlZG1PGh" title="Maturity Date">December 31, 2019</span>. On October 1, 2019, the holder of this note requested
to convert $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20190101__20191001__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, amount converted">30,000</span> in principal amount into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20190101__20191001__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pdd" title="Debt converted, shares issued">1,500,000</span> shares of Common Stock, leaving a principal balance $<span id="xdx_909_eus-gaap--NotesPayable_c20191001__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Note payable balance">106,744</span>. On December 31, 2019,
the Company renewed the remaining principal balance of this Note, together with accrued interest of $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_c20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Interest accrued">15,509</span> for a 12-month period. The
new Note has a Face Value of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Face Value">122,253</span> and accrues interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_zhdavqww6961" title="Interest Rate">12</span>%. This Note matured on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_z3fBHVcsw0mg" title="Maturity Date">December 31, 2020</span>. On August 27, 2020, the holder
of this Note transferred all of its interest therein to RB Capital and in connection with a financing agreement with RB Capital, the Company
agreed to render the Note convertible at $0.001 per share. Through September 30, 2021, the entire principal amount of $<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, amount converted">122,253</span> of this
Note and all accrued interest of $<span id="xdx_90A_ecustom--DebtConvertedInterestConverted_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, interest converted">14,247</span> was converted into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pdd" title="Debt converted, shares issued">136,500,000</span> shares of Common Stock valued at $<span id="xdx_90F_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, shares converted value">7,884,100</span> resulting in a loss
of $<span id="xdx_903_ecustom--GainLossOnDebtConversion_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Gain (Loss) on debt conversion">7,747,600</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2020, the Company&#8217;s Canadian
subsidiary received a CEBA Loan (Canada Emergency Business Account Loan) from CIBC (Canadian Imperial Bank of Commerce) in the principal
amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20200417__us-gaap--LongtermDebtTypeAxis__custom--CEBALoanMember__srt--CurrencyAxis__currency--CAD_pp0p0" title="Face Value">40,000</span> Canadian ($29,352 US) as part of the Canadian government&#8217;s COVID-19 relief program. The CEBA Loan is non-interest
bearing if repaid on or before December 31, 2022 (the &#8220;Termination Date&#8221;). The CEBA Loan is considered repaid in full if the
borrower repays 75% of the Principal Amount on or before the Termination Date. On June 15, 2021, the Company paid 75% <span id="xdx_90C_eus-gaap--RepaymentsOfNotesPayable_pp0p0_c20210101__20210615__us-gaap--LongtermDebtTypeAxis__custom--CEBALoanMember__srt--CurrencyAxis__currency--CAD_zH9D8ZjO5so9" style="display: none" title="Repayments of notes payable">30,000</span> of this loan and
the remaining 25% <span id="xdx_90F_ecustom--GainLossOnDebtConversion_c20210101__20210615__us-gaap--LongtermDebtTypeAxis__custom--CEBALoanMember__srt--CurrencyAxis__currency--CAD_pp0p0" style="display: none">20,000</span> was forgiven.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 27, 2020, the Company received a Paycheck
Protection Program loan ("PPP Loan") in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_c20200427__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_pp0p0" title="Face Value">50,655</span> from the US Small Business Administration (&#8220;SBA&#8221;)
as part of the US government&#8217;s COVID-19 relief program. This loan accrues interest at the rate of<span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200427__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_zDviKoZhCJFf" title="Interest Rate"> 1</span>% per annum. The Company is obligated
to make payments of principal and interest totaling $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20200101__20200427__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_pp0p0" title="Periodic Payment">2,133</span> each month commencing on November 27, 2020, with any remaining balances due
and payable on or before April 27, 2022. The proceeds derived from this loan may only be used for payroll costs, interest on mortgages,
rent and utilities (&#8220;Admissible Expenses&#8221;). In addition, the Paycheck Protection Program provides for conditional loan forgiveness
if the Company utilizes at least 75% of the proceeds from the loan to pay Admissible Expenses. On December 15, 2020, the Company applied
to the funding bank for forgiveness of this loan per SBA guidance. On December 18, 2020, the Company received notification that the funding
bank has approved forgiveness of the loan in its entirety and that it has submitted a request to the SBA for final approval. On February
22, 2021, the funding bank informed the Company that the SBA has fully forgiven the loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 7, 2020, the Company received monies in
exchange for a Note Payable having a Face Value of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20200707__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Face Value">48,000</span> with interest accruing at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200707__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_zNhXvJ1X394" title="Interest Rate">8</span>% is due <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200707__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_zjVedKQLOiF7" title="Maturity Date">July 7, 2021</span>. The Note is convertible after
180 days from issuance into Common Stock at a price 35% below market value. On January 5, 2021, the Company paid off the entire principal
balance of this Note, together with accrued interest and prepayment penalties of $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210105__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Interest accrued">15,271</span> by issuing cash payment of $<span id="xdx_90E_eus-gaap--RepaymentsOfNotesPayable_c20210101__20210105__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Repayments of notes payable">63,271</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_c20200727__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Face Value">102,000</span> with interest accruing at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200727__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_zXOVBslYiu7g" title="Interest Rate">8</span>% is due <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200727__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_zqGr6wMovZ99" title="Maturity Date">July 27, 2021</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price 30% below market value. On January 29, 2021, the entire principal amount of
$<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Debt converted, amount converted">102,000</span> of this Note plus accrued interest of $<span id="xdx_90A_ecustom--DebtConvertedInterestConverted_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Debt converted, interest converted">4,171</span> was converted into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pdd" title="Debt converted, shares issued">5,044,456</span> shares of Common Stock valued at $<span id="xdx_909_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Debt converted, shares converted value">484,268</span> resulting
in a loss of $<span id="xdx_902_ecustom--GainLossOnDebtConversion_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Gain (Loss) on debt conversion">378,097</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20200814__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Face Value">67,000</span> with interest accruing at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200814__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_zb0YDi5pLNdc" title="Interest Rate">8</span>% is due <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200814__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_z1ioZeBy69qb" title="Maturity Date">August 14, 2021</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price 30% below market value. On February 22, 2021, the entire principal amount of
$<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Debt converted, amount converted">67,000</span> of this Note plus accrued interest of $<span id="xdx_900_ecustom--DebtConvertedInterestConverted_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Debt converted, interest converted">2,680 </span>was converted into<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pdd" title="Debt converted, shares issued"> 542,173 </span>shares of Common Stock valued at $<span id="xdx_90C_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Debt converted, shares converted value">119,169</span> resulting in
a loss of $<span id="xdx_90E_ecustom--GainLossOnDebtConversion_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Gain (Loss) on debt conversion">49,489</span>.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zs5dKGZ08bDg" title="Face Value">250,000</span>
with interest accruing at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zrSJ8YXNqKnb" title="Interest Rate">5</span>%
which was due <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zw3piTPyZD2g" title="Maturity Date">September
14, 2022</span>. The Note was convertible after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pdd" title="Conversion Price">0.30 </span>per
share. On June 2, 2021, the entire principal amount of $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Debt converted, amount converted">250,000</span>
of this Note plus all accrued interest of $<span id="xdx_905_ecustom--DebtConvertedInterestConverted_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Debt converted, interest converted">8,850</span>
converted into <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pdd" title="Debt converted, shares issued">862,833</span>
shares of Common Stock valued at $<span id="xdx_90B_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Debt converted, shares converted value">170,841</span>
resulting in a gain of $<span id="xdx_90D_ecustom--GainLossOnDebtConversion_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Gain (Loss) on debt conversion">88,009</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zF0hLsrNrVKh" title="Face Value"><span style="-sec-ix-hidden: xdx2ixbrl0718">50,000,</span></span> with interest accruing at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zLWpTfKngd3" title="Interest Rate">5</span>%, which due <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zJTUbHnCYINg" title="Maturity Date">September 24, 2022</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_pdd" title="Conversion Price">0.30</span> per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date on March 23, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 20, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zhwwbKzxfcUg" title="Face Value">250,000</span>
with interest accruing at<span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zIcfQDfqiTZh" title="Interest Rate">
5</span>% whic was due <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zNX9IYNIpRC3" title="Maturity Date">October
20, 2022</span>. The Note was convertible after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zZpLGSmSXbRb" title="Conversion Price">0.30</span>
per share. On June 2, 2021, the entire principal amount of $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Debt converted, amount converted">250,000</span>
of this Note plus all accrued interest of $<span id="xdx_90A_ecustom--DebtConvertedInterestConverted_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Debt converted, interest converted">7,600</span>
was converted into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pdd" title="Debt converted, shares issued">858,666</span>
shares of Common Stock valued at $<span id="xdx_909_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Debt converted, shares converted value">170,016</span>
resulting in a gain of $<span id="xdx_902_ecustom--GainLossOnDebtConversion_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Gain (Loss) on debt conversion">87,584</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 19, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20201119__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Face Value">250,000</span>
with interest accruing at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201119__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_zZzH4B4mDPHe" title="Interest Rate">8</span>%
which was due <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201119__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_zi1TN5bx1fg" title="Maturity Date">August
19, 2021</span>. The Note was convertible after 180 days from issuance into Common Stock at a price 35% below market value. On May
19, 2021, the Company paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of
$<span id="xdx_90D_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210519__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Interest accrued">126,881</span>
by issuing cash payment of $<span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20210101__20210519__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Repayments of notes payable">376,881</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 24, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20201124__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Face Value">260,000</span>
with interest accruing at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201124__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_z6xvrFpjEuA5" title="Interest Rate">8</span>%
which was due <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dp_c20200101__20201124__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_zjeTo3APb0Lj" title="Maturity Date">November
24, 2021</span>. The Note was convertible after 180 days from issuance into Common Stock at a price 30% below market value. On June
1, 2021, the entire principal amount of $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Debt converted, amount converted">260,000</span>
of this Note plus all accrued interest of $<span id="xdx_90B_ecustom--DebtConvertedInterestConverted_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Debt converted, interest converted">10,428</span>
was converted into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pdd" title="Debt converted, shares issued">3,865,841</span>
shares of Common Stock valued at $<span id="xdx_906_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Debt converted, shares converted value">695,078,</span>
resulting in a loss of $<span id="xdx_901_ecustom--GainLossOnDebtConversion_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Gain (Loss) on debt conversion">424,650</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 25, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_c20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_pp0p0" title="Face Value">250,000</span> with interest accruing at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_zIjbvs9zAeka" title="Interest Rate">5</span>% is due <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_zDD7Pz9RCw13" title="Maturity Date">November 25, 2022</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_pdd" title="Conversion Price">0.30 </span>per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date on May 24, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 2, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_pp0p0" title="Face Value">104,215 </span>with interest accruing at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_z9JyVfukcBtj" title="Interest Rate">5</span>% is due <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_zhjs9KC1ryjb" title="Maturity Date">December 2, 2022</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_pdd" title="Conversion Price">0.30</span> per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date on May 31, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_c20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_pp0p0" title="Face Value">150,000</span> with interest accruing at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_zXelRL6xjDuc" title="Interest Rate">5</span>% is due<span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_zKWE5c44uBH9" title="Maturity Date"> January 12, 2023</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_pdd" title="Conversion Price">0.30 </span>per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date of July 11, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pp0p0" title="Face Value">300,000</span> with interest accruing at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_znz9M9nvZNUj" title="Interest Rate">5</span>% is due <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_zBqsSnh4HJAi" title="Maturity Date">January 27, 2023</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pdd" title="Conversion Price">0.50</span> per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date of July 26, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_c20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pp0p0" title="Face Value">700,000</span> with interest accruing at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_zQhol8cn6FEf" title="Interest Rate">5</span>% is due<span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_zpKD0yK1wejh" title="Maturity Date"> February 12, 2023</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pdd" title="Conversion Price">0.60</span> per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date of August&#160;11, 2021, which is 180 days after the issuance date, and
determined that there was no beneficial conversion feature on September 30, 2021.</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 5, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_pp0p0" title="Face Value">330,000 </span>with interest accruing at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_zykLR6I8qgJe" title="Interest Rate">10</span>% is due <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_zK2C7oNzGGVd" title="Maturity Date">January 5, 2022</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_pdd" title="Conversion Price">0.30</span> per share or 35% below market value, whichever is lower. The Company
will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on October 2, 2021, which is
180 days after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_pp0p0" title="Face Value">500,000 </span>with interest accruing at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_z2IDWSem2fh8" title="Interest Rate">5</span>% is due <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_z3K0qdJwCsU4" title="Maturity Date">April 20, 2023</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_pdd" title="Conversion Price">0.30</span> per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date of October 17, 2021, which is 180 days after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company received monies in
exchange for a Note Payable having a Face Value of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_pp0p0" title="Face Value">900,000</span> with interest accruing at <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_zV64WnpCfgng" title="Interest Rate">5</span>% is due <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_zhgHSKYFk69a">July 6, 2023</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_pdd" title="Conversion Price">0.30</span> per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date of January 2, 2022, which is 180 days after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 18, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_pp0p0" title="Face Value">500,000</span> with interest accruing at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_zfVrqpxjwz1i" title="Interest Rate">5</span>% is due <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_zGJlX1iOlaxh" title="Maturity Date">August 18, 2023</span>. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_pdd" title="Conversion Price">0.30</span> per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date of February 14, 2022, which is 180 days after the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2021 and December 31, 2020, total
accrued interest on Notes Payable was $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20210930_zDOg3t4z8jpf" title="Interest accrued">84,945 </span>and $<span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20201231_zR7erHBKJVKl" title="Interest accrued">24,320</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624358859224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Face value - USD ($)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 24, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 451,661<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayableRelatedPartyMember', window );">Note Payable Related Party [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,661<span></span>
</td>
<td class="nump">$ 128,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued interest</a></td>
<td class="nump">$ 12,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="nump">$ 156,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayableRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayableRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624360932872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zmsPrI6Gxbac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 5 &#8211; <span id="xdx_822_zpR8R5juXnz">Shareholders&#8217; Equity</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September 30,
2021, the Company issued a total of <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_zJNb1u7s8cg" title="Debt converted, shares issued">103,673,969</span>
shares of Common Stock valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueOther_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_z4aneKSlkvne">11,981,072</span> for the conversion of outstanding notes payable, reducing the debt by $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_pp0p0" title="Debt converted, amount converted">1,233,028</span>
and interest payable by $<span id="xdx_908_ecustom--DebtConvertedInterestConverted_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_pp0p0" title="Debt converted, interest converted">38,201</span>
and generating a loss on conversion of $<span id="xdx_906_ecustom--GainLossOnDebtConversion_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_pp0p0" title="Gain (Loss) on debt conversion">10,709,843</span>.
In addition, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pdd" title="Common stock issued for services, shares">60,000,000</span>
shares of Common Stock valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pp0p0" title="Common stock issued for services, amount">918,000 </span>to
its Officers and Directors as compensation for their services to the Company. The fair value of the stock was based on the closing price of the stock
on the date of the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company declared <span id="xdx_906_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_pp0p0_do_c20210930_z4MGShsO4Uua" title="Dividends Payable">no</span> dividends through September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624358820584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Salary and Wage, Excluding Cost of Good and Service Sold - Officers And Directors [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salary and Wage, Excluding Cost of Good and Service Sold</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 255,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services, shares</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services, amount</a></td>
<td class="nump">$ 918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_OfficersAndDirectorsMember', window );">Trt Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salary and Wage, Excluding Cost of Good and Service Sold</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SBFM_TrtPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SBFM_TrtPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624360966408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zHfPRvbLECvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Note 7 &#8211; <span id="xdx_824_zwejI9ctrvmg">Subsequent Events</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2021, the holder of a Note Payable
dated April 5, 2021 elected to convert a total of $330,000 in principal and $16,500 in accrued interest into 5,250,000 shares of Common
Stock leaving a principal balance of $-0-.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624360998472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation of Unaudited Financial Information</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zMOgnXzFJPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_znHHq3vFqa0g">Basis of Presentation of Unaudited Financial
Information</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited financial statements of the Company
for the three and nine month periods ended September 30, 2021 and 2020 have been prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q
and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted
in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely
of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position
and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full
fiscal year. The balance sheet information as of December 31, 2020 was derived from the audited financial statements included in the Company's
financial statements as of and for the year ended December 31, 2020 included in the Company&#8217;s Annual Report on Form 10-K filed with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 30, 2021. These financial statements should be read in conjunction
with that report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0quiwBf4kBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_z8XZZadL6vOf">Recently Issued Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2019, the FASB issued ASU 2019-12 &#8220;Income Taxes
(Topic 740): Simplifying the Accounting for Income Taxes.&#8221; This guidance removes certain exceptions to the general principles in
Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new
guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early
adoption is permitted. There was no impact of the updated guidance on the Company&#8217;s financial statements for the year ended December
31, 2020. The Company is currently evaluating the impact of the updated guidance on its financial statements for 2021 and going forward.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, the FASB issued ASU 2020-02,&#160;<i>Financial
Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842)&#160;</i>which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective
for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will
modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The
Company is in the process of determining the effects adoption will have on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In August
2020, the FASB issued ASU 2020-06,&#160;<i>Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</i>, (&#8220;ASU 2020-06&#8221;). ASU 2020-06 simplifies the
accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts
on an entity&#8217;s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim
periods within those fiscal years.&#160;</span>Early adoption is permitted, but no earlier than fiscal years beginning after December
15, 2020, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624359912488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">Effective February 1, 2019, the Company completed
a 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400
(the &#8220;First Reverse Stock Split&#8221;). The Company&#8217;s authorized capital of Common Stock remained as previously established
at 3,000,000,000 shares.<span></span>
</td>
<td class="text">Effective April 6, 2020, the Company completed
another 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417
(the &#8220;Second Reverse Stock Split&#8221;). The number of Common Shares authorized for issuance remained as previously established
at 3,000,000,000 shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SBFM_RBCapitalMember', window );">R B Capital [Member] | Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt stated rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SBFM_RBCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SBFM_RBCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624358828856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Going Concern and Liquidity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,386,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Outstanding liabilities</a></td>
<td class="nump">$ 3,675,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Capital', window );">Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Capital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624340193160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">4 Months Ended</th>
<th class="th" colspan="3">5 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="2">7 Months Ended</th>
<th class="th" colspan="2">8 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="4">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2021</div></th>
<th class="th"><div>Jan. 05, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Jan. 27, 2021</div></th>
<th class="th"><div>Feb. 22, 2021</div></th>
<th class="th"><div>Apr. 05, 2021</div></th>
<th class="th"><div>Apr. 20, 2021</div></th>
<th class="th"><div>Apr. 27, 2020</div></th>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>May 19, 2021</div></th>
<th class="th"><div>Jul. 06, 2021</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
<th class="th"><div>Jul. 07, 2020</div></th>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th"><div>Jul. 27, 2020</div></th>
<th class="th"><div>Aug. 18, 2021</div></th>
<th class="th"><div>Sep. 14, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
<th class="th"><div>Oct. 01, 2019</div></th>
<th class="th"><div>Oct. 20, 2020</div></th>
<th class="th"><div>Dec. 02, 2020</div></th>
<th class="th"><div>Nov. 25, 2020</div></th>
<th class="th"><div>Nov. 24, 2020</div></th>
<th class="th"><div>Nov. 19, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451,661<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable2018Member', window );">Note Payable 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,253<span></span>
</td>
<td class="nump">$ 136,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_CEBALoanMember', window );">C E B A Loan [Member] | Canada, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_PPPLoanMember', window );">P P P Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable1Member', window );">Note Payable 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  07,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable2Member', window );">Note Payable 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 27,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,044,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable3Member', window );">Note Payable 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 14,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable4Member', window );">Note Payable 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 14,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">862,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable5Member', window );">Note Payable 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 24,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable6Member', window );">Note Payable 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 20,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable7Member', window );">Note Payable 7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 19,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable8Member', window );">Note Payable 8 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 24,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,865,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable9Member', window );">Note Payable 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 25,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable10Member', window );">Note Payable 10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  02,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable11Member', window );">Note Payable 11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Jan. 12,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable12Member', window );">Note Payable 12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 12,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 27,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable13Member', window );">Note Payable 13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable14Member', window );">Note Payable 14 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 20,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable15Member', window );">Note Payable 15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  06,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable16Member', window );">Note Payable 16 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 18,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_CEBALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_CEBALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable11Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable11Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable12Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable12Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable13Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable13Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable14Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable14Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SBFM_NotePayable16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140624358872568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock Issued During Period, Value, Other</a></td>
<td class="nump">$ 3,744,000<span></span>
</td>
<td class="nump">$ 671,125<span></span>
</td>
<td class="nump">$ 11,981,072<span></span>
</td>
<td class="nump">$ 1,831,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_OfficersAndDirectorsMember', window );">Officers And Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salary and Wage, Excluding Cost of Good and Service Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 255,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=SBFM_OutstandingNotesPayableMember', window );">Outstanding Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt converted, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,673,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock Issued During Period, Value, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,981,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted, amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,233,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=SBFM_OutstandingNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=SBFM_OutstandingNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>sunshine_s1a2_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SBFM="http://sunshinebiopharma.com/20210930"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sbfm-20210930.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2019-01-012019-02-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-04-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-04-06</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_RBCapitalMember_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SBFM:RBCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2021-06-25</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_NotePayable2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_NotePayable2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-10-01_custom_NotePayable2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2019-10-01_custom_NotePayable2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-01</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_NotePayable2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_NotePayable2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_NotePayable2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-17_custom_CEBALoanMember_currency_CAD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:CEBALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-17</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-15_custom_CEBALoanMember_currency_CAD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:CEBALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-27_custom_PPPLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-27</instant>
        </period>
    </context>
    <context id="From2020-01-012020-04-27_custom_PPPLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-04-27</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-07_custom_NotePayable1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-07</instant>
        </period>
    </context>
    <context id="From2020-01-012020-07-07_custom_NotePayable1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-07-07</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-05_custom_NotePayable1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-05</instant>
        </period>
    </context>
    <context id="From2021-01-012021-01-05_custom_NotePayable1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-05</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-27_custom_NotePayable2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-27</instant>
        </period>
    </context>
    <context id="From2020-01-012020-07-27_custom_NotePayable2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-29_custom_NotePayable2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-29</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-14_custom_NotePayable3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-14</instant>
        </period>
    </context>
    <context id="From2020-01-012020-08-14_custom_NotePayable3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-02-22_custom_NotePayable3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-22</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-14_custom_NotePayable4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-14</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-14_custom_NotePayable4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-14</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-02_custom_NotePayable4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-24_custom_NotePayable5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-24_custom_NotePayable5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="AsOf2020-10-20_custom_NotePayable6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-20</instant>
        </period>
    </context>
    <context id="From2020-01-012020-10-20_custom_NotePayable6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-10-20</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-02_custom_NotePayable6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-19_custom_NotePayable7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="From2020-01-012020-11-19_custom_NotePayable7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-19_custom_NotePayable7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-19</instant>
        </period>
    </context>
    <context id="From2021-01-012021-05-19_custom_NotePayable7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-05-19</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-24_custom_NotePayable8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-24</instant>
        </period>
    </context>
    <context id="From2020-01-012020-11-24_custom_NotePayable8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-11-24</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-01_custom_NotePayable8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-25_custom_NotePayable9Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-25</instant>
        </period>
    </context>
    <context id="From2020-01-012020-11-25_custom_NotePayable9Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-11-25</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-02_custom_NotePayable10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-02</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-02_custom_NotePayable10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-12_custom_NotePayable11Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable11Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-12</instant>
        </period>
    </context>
    <context id="From2021-01-012021-01-12_custom_NotePayable11Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable11Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-27_custom_NotePayable12Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-27</instant>
        </period>
    </context>
    <context id="From2021-01-012021-01-27_custom_NotePayable12Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-27</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-12_custom_NotePayable12Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="From2021-01-012021-02-12_custom_NotePayable12Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-05_custom_NotePayable13Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable13Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-05</instant>
        </period>
    </context>
    <context id="From2021-01-012021-04-05_custom_NotePayable13Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable13Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-05</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_NotePayable14Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable14Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="From2021-01-012021-04-20_custom_NotePayable14Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable14Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="AsOf2021-07-06_custom_NotePayable15Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-06</instant>
        </period>
    </context>
    <context id="From2021-01-012021-07-06_custom_NotePayable15Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-18_custom_NotePayable16Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable16Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-18</instant>
        </period>
    </context>
    <context id="From2021-01-012021-08-18_custom_NotePayable16Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayable16Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-08-18</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-24_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-24</instant>
        </period>
    </context>
    <context id="From2021-01-012021-08-24_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SBFM:NotePayableRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-08-24</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_OutstandingNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">SBFM:OutstandingNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember_custom_TrtPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:TrtPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-09-30">0001402328</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-09-30">true</dei:AmendmentFlag>
    <dei:AmendmentDescription contextRef="From2021-01-01to2021-09-30">to reflect updates</dei:AmendmentDescription>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0100"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-09-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-07-012020-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-07-012020-09-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-09-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-09-30_us-gaap_ComprehensiveIncomeMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-09-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="xdx2ixbrl0601"
      unitRef="USD">2000311</us-gaap:Liabilities>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-09-24_custom_NotePayable5Member"
      decimals="0"
      id="xdx2ixbrl0718"
      unitRef="USD">50000</us-gaap:DebtInstrumentFaceAmount>
    <dei:DocumentType contextRef="From2021-01-01to2021-09-30">S-1/A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-09-30">Sunshine Biopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-09-30">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-09-30">20-5566275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-09-30">6500 Trans-Canada Highway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-09-30">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-09-30">Pointe-Claire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-09-30">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-09-30">H9R 0A5</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-09-30">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-09-30">426-6161</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-09-30">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-01-01to2021-09-30">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2386608</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">989888</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1129</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1916</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">71310</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">23771</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">25046</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2778</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">7590</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7590</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2491683</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1025943</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">60774</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">51485</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">10232</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">19531</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">58918</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">58918</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">556120</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">556120</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2501915</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1045474</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">330000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">820454</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">0</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">143661</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">56687</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">62870</us-gaap:AccountsPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">84945</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">24320</us-gaap:InterestPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">471632</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1051305</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">3204215</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">949006</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">3675847</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2000311</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">510093265</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">510093265</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">346419296</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">346419296</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">510092</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">346418</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">31555741</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">18820343</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-17475</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-2871</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-33322290</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-20218727</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-1173932</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-954837</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2501915</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1045474</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">50376</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">17150</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">143308</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">43397</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">19506</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">6340</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">56541</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">15384</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">30870</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">10810</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">86767</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">28013</us-gaap:GrossProfit>
    <us-gaap:ProfessionalFees
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">35000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">19290</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">96200</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">56490</us-gaap:ProfessionalFees>
    <us-gaap:LegalFees
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">56923</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">6895</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">159074</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">50970</us-gaap:LegalFees>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">222465</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">581011</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Depreciation
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">3183</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">3524</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">9557</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">10526</us-gaap:Depreciation>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">527129</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">78098</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">2247270</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">261569</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-496259</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-67288</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-2160503</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-233556</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">37</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-1598</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">31</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">6404</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">46849</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">22094</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">292188</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">62669</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">3000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">7688</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">1284</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">58940</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">2836</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">3504000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">608899</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">10709843</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1416313</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-3543124</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-631307</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-10943060</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-1466742</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-4039383</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-698595</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-13103563</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-1700298</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-4039383</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-698595</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-13103563</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-1700298</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-5839</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-144</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-14604</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-1009</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-4045222</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-698739</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-13118167</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-1701307</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Shares">508528048</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Shares">280873792</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">475536409</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="Shares">162133885</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-13103563</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-1700298</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">9557</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">10505</us-gaap:DepreciationAndAmortization>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">31</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">6404</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">918000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">50000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">10709843</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1416313</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">58940</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">2836</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-787</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-430</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">47539</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">10291</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">22268</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">3850</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-13778</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-40029</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">52716</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">10600</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-1517015</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-233627</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">800</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-800</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">3318500</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">676643</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">61500</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">7000</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">451661</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">2928339</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">683643</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:Cash contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">989888</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">40501</us-gaap:Cash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">1411324</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">449216</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-14604</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-1009</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:Cash contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2386608</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">488708</us-gaap:Cash>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">11981072</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1831816</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">155081</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">486093265</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">486092</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">27835741</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-11636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-29282907</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-872710</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">24000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3720000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">3744000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-5839</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4039383</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-4045222</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">510093265</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">510092</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">31555741</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-17475</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-33322290</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-1173932</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">346419296</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">346418</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18820343</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-2871</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-20218727</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-954837</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">103673969</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">103674</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">11877398</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">11981072</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">60000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">60000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">858000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">918000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-09-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-14604</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-13103563</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-13118167</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">510093265</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">510092</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">31555741</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-17475</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-33322290</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-1173932</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">269821248</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">269820</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">17542616</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-3360</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-18436339</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">-577263</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">34598048</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">34599</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">636527</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">671125</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-144</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-698595</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-698739</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">304419296</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">304419</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18179143</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-3504</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-19134934</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-554876</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">35319990</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">35320</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">16616426</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-2495</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-17434636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-735385</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">269099306</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">269099</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1562717</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1831816</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-01-012020-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-09-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-1009</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1700298</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-1701307</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">304419296</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">304419</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18179143</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-3504</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-19134934</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-554876</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zj5EQMx7t3xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 1 &#x2013; &lt;span id="xdx_826_z1xHyG7GlLJ8"&gt;Nature of Business and Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sunshine Biopharma, Inc. (the "Company")
was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Until
October 2009, the Company was operating as a business consultancy firm.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective October 15, 2009, the Company acquired
Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. was holding an exclusive license
to a new anticancer drug bearing the laboratory name, Adva-27a (the &#x201c;License Agreement&#x201d;). Upon completion of the reverse acquisition
transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the
development of the licensed Adva-27a anticancer drug.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2012, the Company published the results
of its initial preclinical studies of Adva-27a in the peer-reviewed journal, ANTICANCER RESEARCH. The studies were conducted in collaboration
with Binghamton University, a State University of New York, and Ecole Polytechnique, Universite de Montreal. The publication is entitled
&#x201c;Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells&#x201d; [ANTICANCER
RESEARCH Volume 32, Pages 4423-4432 (2012)].&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2014, the Company formed a wholly owned
Canadian subsidiary, Sunshine Biopharma Canada Inc. (&#x201c;Sunshine Canada&#x201d;) for the purposes of offering generic pharmaceutical
products in Canada and elsewhere around the world. Sunshine Canada has recently transitioned its focus to the development and marketing
of Science-Based Nutritional Supplements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2015, the Company acquired all worldwide
issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a
anticancer compound from Advanomics Corporation, a related party, and terminated the License Agreement. In 2016, the remaining value of
these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2018, the Company formed NOX Pharmaceuticals,
Inc., a wholly owned Colorado corporation and assigned all of the Company&#x2019;s interest in the Adva-27a anticancer drug to that company.
NOX Pharmaceuticals Inc.&#x2019;s mission is to research, develop and commercialize proprietary drugs including Adva-27a.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2018, the Company launched its first
Science-Based Nutritional Supplements product, Essential 9&lt;span style="font-variant: small-caps"&gt;&lt;sup&gt;&#x2122;&lt;/sup&gt;&lt;/span&gt;, an over-the-counter
tablet comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9&lt;span style="font-variant: small-caps"&gt;&lt;sup&gt;&#x2122;
&lt;/sup&gt;&lt;/span&gt;has been authorized for marketing by Health Canada under NPN 80089663.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20190101__20190201" title="Stockholders' Equity, Reverse Stock Split"&gt;Effective February 1, 2019, the Company completed
a 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400
(the &#x201c;First Reverse Stock Split&#x201d;). The Company&#x2019;s authorized capital of Common Stock remained as previously established
at 3,000,000,000 shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20200101__20200406" title="Stockholders' Equity, Reverse Stock Split"&gt;Effective April 6, 2020, the Company completed
another 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417
(the &#x201c;Second Reverse Stock Split&#x201d;). The number of Common Shares authorized for issuance remained as previously established
at 3,000,000,000 shares.&lt;/span&gt; All references to the Company&#x2019;s Common Stock in this Report, including the Company's financial statements
reflect both the First and Second Reverse Stock Split on a retroactive basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 22, 2020, the Company filed a provisional
patent application in the United States for a new treatment for Coronavirus infections. The Company&#x2019;s patent application covers
composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential
for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company filed a PCT application
containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May
22, 2020 has been maintained in the newly filed PCT application.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 17, 2020, the Company filed an amendment
to its Articles of Incorporation (the &#x201c;Amendment&#x201d;) with the State of Colorado, to eliminate the Series &#x201c;A&#x201d; Preferred
Shares consisting of Eight Hundred and Fifty Thousand (850,000) shares, par value $0.10 per share, and the designation thereof, which
shares were returned to the status of undesignated shares of Preferred Stock. In addition, the Amendment increased the number of authorized
Series &#x201c;B&#x201d; Preferred Shares from Five Hundred Thousand (500,000) to One Million (1,000,000) shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Also on June 17, 2020, the Company issued Five
Hundred Thousand (500,000) shares of Series &#x201c;B&#x201d; Preferred Stock in favor of Dr. Steve N. Slilaty, the Company&#x2019;s CEO,
in consideration for the COVID-19 treatment technology he developed. The Series &#x201c;B&#x201d; Preferred Stock is non-convertible, non-redeemable,
non-retractable and has a superior liquidation value of $0.10 per share. Each share of Series &#x201c;B&#x201d; Preferred Stock is entitled
to 1,000 votes per share. This issuance brought the total number of Series &#x201c;B&#x201d; Preferred Stock held by Dr. Slilaty to 1,000,000
shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 8, 2020, the Company executed a financing
agreement with RB Capital Partners, Inc., La Jolla, CA, (&#x201c;RB Capital&#x201d;) who agreed to provide the Company with a minimum of
$2 million in convertible debt financing during the ensuing three to six month period pursuant to the terms and conditions included in
relevant Promissory Notes (the &#x201c;Promissory Notes&#x201d;). The Promissory Notes bear interest at the rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210930__us-gaap--DebtInstrumentAxis__custom--RBCapitalMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zBe9bJTQH3sb" title="Debt stated rate"&gt;5&lt;/span&gt;% per annum and have
a maturity date of two years from the date of issuance. The Company has the right to pay off all or any part of the Promissory Notes at
any time without penalty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective October 6, 2020, the Company entered
into a Research Agreement (the &#x201c;Agreement&#x201d;) with the University of Georgia Research Foundation, Inc. (&#x201c;UGARF&#x201d;),
representing the University of Georgia (&#x201c;UGA&#x201d;). The purpose of the Agreement is to memorialize the terms of the Company working
together with UGA to conduct the necessary research and development to advance the Company&#x2019;s Anti-Coronavirus lead compound, SBFM-PL4
(or derivatives thereof) through various stages of preclinical development, animal studies and clinical trials for Coronavirus infections.
The Agreement grants the Company an exclusive worldwide license for all of the intellectual property developed by UGA, whether developed
alone or jointly with the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 26, 2021, the Company received a Notice
of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains
new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 4, 2021, the Company entered into
an exclusive license agreement with the University of Georgia (&#x201c;UGA&#x201d;) for two Anti-Coronavirus compounds which UGA had previously
developed and patented. The Company and UGA will advance the development of these two compounds in parallel with the Company&#x2019;s own
Anti-Coronavirus compound, SBFM-PL4.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 9, 2021, the Company received a Notice
of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject
matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued
in 2019 (US Patent Number 10,272,065).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 25, 2021, the Company entered into an
engagement agreement with Aegis Capital Corp. (&#x201c;Aegis&#x201d;), pursuant to which we engaged Aegis to act as lead underwriter in
connection with a proposed public offering of approximately $10 million of common stock and warrants by the Company (the &#x201c;Offering&#x201d;).
The Offering is contingent on satisfaction of various conditions, including Aegis&#x2019;s due diligence examination of the Company, Nasdaq
approval of the listing of the Company&#x2019;s Common Stock, and successful completion of a reverse stock split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 6, 2021, the Company filed its Definitive Information Statement
with the SEC to complete the reverse split of the Company&#x2019;s Common Stock in part to meet the Nasdaq listing requirement concerning
minimum price per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company's financial statements reflect both
the First and Second Reverse Stock Split on a retroactive basis and represent the consolidated activity of Sunshine Biopharma, Inc. and
its subsidiaries (Sunshine Biopharma Canada Inc. and NOX Pharmaceuticals Inc.) herein collectively referred to as the "Company".&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_84B_ecustom--ImpactOfCoronavirusPandemicPolicyTextBlock_z0KiM2ZTYp3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zfGehxDTYLFl"&gt;&lt;b&gt;&lt;i&gt;Impact
of Coronavirus (COVID-19) Pandemic&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2020, the World Health Organization declared
Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak have been and are
continuing to evolve rapidly. Government authorities in the U.S. and around the world have implemented emergency measures to mitigate
the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on
the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of
the adverse conditions of the outbreak and their effects on the Company&#x2019;s business or ability to raise funds. No adjustments have
been made to the amounts reported in the Company's financial statements as a result of this matter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zMOgnXzFJPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_znHHq3vFqa0g"&gt;Basis of Presentation of Unaudited Financial
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unaudited financial statements of the Company
for the three and nine month periods ended September 30, 2021 and 2020 have been prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q
and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted
in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely
of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position
and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full
fiscal year. The balance sheet information as of December 31, 2020 was derived from the audited financial statements included in the Company's
financial statements as of and for the year ended December 31, 2020 included in the Company&#x2019;s Annual Report on Form 10-K filed with
the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 30, 2021. These financial statements should be read in conjunction
with that report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0quiwBf4kBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z8XZZadL6vOf"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In December 2019, the FASB issued ASU 2019-12 &#x201c;Income Taxes
(Topic 740): Simplifying the Accounting for Income Taxes.&#x201d; This guidance removes certain exceptions to the general principles in
Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new
guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early
adoption is permitted. There was no impact of the updated guidance on the Company&#x2019;s financial statements for the year ended December
31, 2020. The Company is currently evaluating the impact of the updated guidance on its financial statements for 2021 and going forward.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February 2020, the FASB issued ASU 2020-02,&#160;&lt;i&gt;Financial
Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842)&#160;&lt;/i&gt;which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective
for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will
modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The
Company is in the process of determining the effects adoption will have on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In August
2020, the FASB issued ASU 2020-06,&#160;&lt;i&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&lt;/i&gt;, (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 simplifies the
accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts
on an entity&#x2019;s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim
periods within those fiscal years.&#160;&lt;/span&gt;Early adoption is permitted, but no earlier than fiscal years beginning after December
15, 2020, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited
consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2019-01-012019-02-01">Effective February 1, 2019, the Company completed
a 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,713,046,242 to 85,652,400
(the &#x201c;First Reverse Stock Split&#x201d;). The Company&#x2019;s authorized capital of Common Stock remained as previously established
at 3,000,000,000 shares.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2020-01-012020-04-06">Effective April 6, 2020, the Company completed
another 20 to 1 reverse split of its Common Stock, reducing the issued and outstanding shares of Common Stock from 1,193,501,925 to 59,675,417
(the &#x201c;Second Reverse Stock Split&#x201d;). The number of Common Shares authorized for issuance remained as previously established
at 3,000,000,000 shares.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_custom_RBCapitalMember_custom_PromissoryNotesMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zMOgnXzFJPi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_znHHq3vFqa0g"&gt;Basis of Presentation of Unaudited Financial
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unaudited financial statements of the Company
for the three and nine month periods ended September 30, 2021 and 2020 have been prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q
and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted
in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely
of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position
and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full
fiscal year. The balance sheet information as of December 31, 2020 was derived from the audited financial statements included in the Company's
financial statements as of and for the year ended December 31, 2020 included in the Company&#x2019;s Annual Report on Form 10-K filed with
the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 30, 2021. These financial statements should be read in conjunction
with that report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z0quiwBf4kBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z8XZZadL6vOf"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In December 2019, the FASB issued ASU 2019-12 &#x201c;Income Taxes
(Topic 740): Simplifying the Accounting for Income Taxes.&#x201d; This guidance removes certain exceptions to the general principles in
Topic 740 and provides consistent application of U.S. GAAP by clarifying and amending existing guidance. The effective date of the new
guidance for public companies is for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years. Early
adoption is permitted. There was no impact of the updated guidance on the Company&#x2019;s financial statements for the year ended December
31, 2020. The Company is currently evaluating the impact of the updated guidance on its financial statements for 2021 and going forward.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February 2020, the FASB issued ASU 2020-02,&#160;&lt;i&gt;Financial
Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842)&#160;&lt;/i&gt;which
amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective
for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will
modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The
Company is in the process of determining the effects adoption will have on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In August
2020, the FASB issued ASU 2020-06,&#160;&lt;i&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging
&#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&lt;/i&gt;, (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 simplifies the
accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts
on an entity&#x2019;s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim
periods within those fiscal years.&#160;&lt;/span&gt;Early adoption is permitted, but no earlier than fiscal years beginning after December
15, 2020, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited
consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zBP56Z9LPIl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 2 &#x2013; &lt;span id="xdx_82A_z6XYaTzUM7yb"&gt;Going Concern and Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021 and December 31,
2020, the Company had &lt;span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_c20210930_pp0p0" title="Cash and cash equivalents"&gt;$2,386,608&lt;/span&gt;
and &lt;span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_c20201231_pp0p0" title="Cash and cash equivalents"&gt;$989,888&lt;/span&gt;
in cash on hand, respectively, and limited revenue-producing business. Additionally, as of September 30, 2021 and December 31, 2020,
the outstanding liabilities of the Company totaled &lt;span id="xdx_90F_eus-gaap--Liabilities_c20210930_pp0p0" title="Outstanding liabilities"&gt;$3,675,847 &lt;/span&gt;and &lt;span id="xdx_900_eus-gaap--Liabilities_c20201231_pp0p0" title="Outstanding liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;$2,000,311,&lt;/span&gt;&lt;/span&gt;
respectively. These factors raise substantial doubts about the Company&#x2019;s ability to continue as a going concern. On June 25,
2021, the Company entered into an Engagement agreement with Aegis Capital for the purposes of raising &lt;span id="xdx_903_eus-gaap--Capital_iI_c20210625_zHmKb77hr6Vk" title="Capital"&gt;$10,000,000&lt;/span&gt;
in equity financing in a proposed public offering and, in connection therewith, the Company filed a preliminary prospectus of Form
S-1 with the SEC on September 9, 2021. The Company believes that the afore expressed doubt about the Company&#x2019;s ability to
continue as a going concern will be fully mitigated if the financing were to close. There is no
assurance the offering will be completed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements included
in this Report have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities
and commitments in the normal course of business. The consolidated financial statements included in this Report do not include any adjustments
that may result from the outcome of any going concern uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There is no assurance that these events will be
satisfactorily completed. The issuance of equity securities in connection with the Offering (see Note 1), if accomplished, could cause
substantial dilution to existing stockholders. Any failure by the Company to successfully implement these plans would have a material
adverse effect on its business, including the possible inability to continue operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2386608</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">989888</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Liabilities contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">3675847</us-gaap:Liabilities>
    <us-gaap:Capital contextRef="AsOf2021-06-25" decimals="0" unitRef="USD">10000000</us-gaap:Capital>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zL6yBtq348Th" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 3 &#x2013; &lt;span id="xdx_822_zQmHd2l9WI91"&gt;Notes Payable&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s Notes Payable at September
30, 2021 consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A Note Payable dated December 31, 2018 having
a Face Value of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_c20181231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Face Value"&gt;136,744&lt;/span&gt; and accruing interest at &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20180101__20181231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_zEDMO8ip8aSf" title="Interest Rate"&gt;12&lt;/span&gt;% was due &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20180101__20181231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_zFkmxlZG1PGh" title="Maturity Date"&gt;December 31, 2019&lt;/span&gt;. On October 1, 2019, the holder of this note requested
to convert $&lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20190101__20191001__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, amount converted"&gt;30,000&lt;/span&gt; in principal amount into &lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20190101__20191001__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pdd" title="Debt converted, shares issued"&gt;1,500,000&lt;/span&gt; shares of Common Stock, leaving a principal balance $&lt;span id="xdx_909_eus-gaap--NotesPayable_c20191001__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Note payable balance"&gt;106,744&lt;/span&gt;. On December 31, 2019,
the Company renewed the remaining principal balance of this Note, together with accrued interest of $&lt;span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_c20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Interest accrued"&gt;15,509&lt;/span&gt; for a 12-month period. The
new Note has a Face Value of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Face Value"&gt;122,253&lt;/span&gt; and accrues interest at &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_zhdavqww6961" title="Interest Rate"&gt;12&lt;/span&gt;%. This Note matured on &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_z3fBHVcsw0mg" title="Maturity Date"&gt;December 31, 2020&lt;/span&gt;. On August 27, 2020, the holder
of this Note transferred all of its interest therein to RB Capital and in connection with a financing agreement with RB Capital, the Company
agreed to render the Note convertible at $0.001 per share. Through September 30, 2021, the entire principal amount of $&lt;span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, amount converted"&gt;122,253&lt;/span&gt; of this
Note and all accrued interest of $&lt;span id="xdx_90A_ecustom--DebtConvertedInterestConverted_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, interest converted"&gt;14,247&lt;/span&gt; was converted into &lt;span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pdd" title="Debt converted, shares issued"&gt;136,500,000&lt;/span&gt; shares of Common Stock valued at $&lt;span id="xdx_90F_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Debt converted, shares converted value"&gt;7,884,100&lt;/span&gt; resulting in a loss
of $&lt;span id="xdx_903_ecustom--GainLossOnDebtConversion_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2018Member_pp0p0" title="Gain (Loss) on debt conversion"&gt;7,747,600&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 17, 2020, the Company&#x2019;s Canadian
subsidiary received a CEBA Loan (Canada Emergency Business Account Loan) from CIBC (Canadian Imperial Bank of Commerce) in the principal
amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20200417__us-gaap--LongtermDebtTypeAxis__custom--CEBALoanMember__srt--CurrencyAxis__currency--CAD_pp0p0" title="Face Value"&gt;40,000&lt;/span&gt; Canadian ($29,352 US) as part of the Canadian government&#x2019;s COVID-19 relief program. The CEBA Loan is non-interest
bearing if repaid on or before December 31, 2022 (the &#x201c;Termination Date&#x201d;). The CEBA Loan is considered repaid in full if the
borrower repays 75% of the Principal Amount on or before the Termination Date. On June 15, 2021, the Company paid 75% &lt;span id="xdx_90C_eus-gaap--RepaymentsOfNotesPayable_pp0p0_c20210101__20210615__us-gaap--LongtermDebtTypeAxis__custom--CEBALoanMember__srt--CurrencyAxis__currency--CAD_zH9D8ZjO5so9" style="display: none" title="Repayments of notes payable"&gt;30,000&lt;/span&gt; of this loan and
the remaining 25% &lt;span id="xdx_90F_ecustom--GainLossOnDebtConversion_c20210101__20210615__us-gaap--LongtermDebtTypeAxis__custom--CEBALoanMember__srt--CurrencyAxis__currency--CAD_pp0p0" style="display: none"&gt;20,000&lt;/span&gt; was forgiven.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 27, 2020, the Company received a Paycheck
Protection Program loan ("PPP Loan") in the principal amount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_c20200427__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_pp0p0" title="Face Value"&gt;50,655&lt;/span&gt; from the US Small Business Administration (&#x201c;SBA&#x201d;)
as part of the US government&#x2019;s COVID-19 relief program. This loan accrues interest at the rate of&lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200427__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_zDviKoZhCJFf" title="Interest Rate"&gt; 1&lt;/span&gt;% per annum. The Company is obligated
to make payments of principal and interest totaling $&lt;span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20200101__20200427__us-gaap--LongtermDebtTypeAxis__custom--PPPLoanMember_pp0p0" title="Periodic Payment"&gt;2,133&lt;/span&gt; each month commencing on November 27, 2020, with any remaining balances due
and payable on or before April 27, 2022. The proceeds derived from this loan may only be used for payroll costs, interest on mortgages,
rent and utilities (&#x201c;Admissible Expenses&#x201d;). In addition, the Paycheck Protection Program provides for conditional loan forgiveness
if the Company utilizes at least 75% of the proceeds from the loan to pay Admissible Expenses. On December 15, 2020, the Company applied
to the funding bank for forgiveness of this loan per SBA guidance. On December 18, 2020, the Company received notification that the funding
bank has approved forgiveness of the loan in its entirety and that it has submitted a request to the SBA for final approval. On February
22, 2021, the funding bank informed the Company that the SBA has fully forgiven the loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 7, 2020, the Company received monies in
exchange for a Note Payable having a Face Value of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20200707__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Face Value"&gt;48,000&lt;/span&gt; with interest accruing at &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200707__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_zNhXvJ1X394" title="Interest Rate"&gt;8&lt;/span&gt;% is due &lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200707__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_zjVedKQLOiF7" title="Maturity Date"&gt;July 7, 2021&lt;/span&gt;. The Note is convertible after
180 days from issuance into Common Stock at a price 35% below market value. On January 5, 2021, the Company paid off the entire principal
balance of this Note, together with accrued interest and prepayment penalties of $&lt;span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210105__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Interest accrued"&gt;15,271&lt;/span&gt; by issuing cash payment of $&lt;span id="xdx_90E_eus-gaap--RepaymentsOfNotesPayable_c20210101__20210105__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Repayments of notes payable"&gt;63,271&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 27, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_c20200727__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Face Value"&gt;102,000&lt;/span&gt; with interest accruing at &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200727__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_zXOVBslYiu7g" title="Interest Rate"&gt;8&lt;/span&gt;% is due &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200727__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_zqGr6wMovZ99" title="Maturity Date"&gt;July 27, 2021&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price 30% below market value. On January 29, 2021, the entire principal amount of
$&lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Debt converted, amount converted"&gt;102,000&lt;/span&gt; of this Note plus accrued interest of $&lt;span id="xdx_90A_ecustom--DebtConvertedInterestConverted_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Debt converted, interest converted"&gt;4,171&lt;/span&gt; was converted into &lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pdd" title="Debt converted, shares issued"&gt;5,044,456&lt;/span&gt; shares of Common Stock valued at $&lt;span id="xdx_909_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Debt converted, shares converted value"&gt;484,268&lt;/span&gt; resulting
in a loss of $&lt;span id="xdx_902_ecustom--GainLossOnDebtConversion_c20210101__20210129__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Gain (Loss) on debt conversion"&gt;378,097&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 14, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20200814__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Face Value"&gt;67,000&lt;/span&gt; with interest accruing at &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200814__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_zb0YDi5pLNdc" title="Interest Rate"&gt;8&lt;/span&gt;% is due &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200814__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_z1ioZeBy69qb" title="Maturity Date"&gt;August 14, 2021&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price 30% below market value. On February 22, 2021, the entire principal amount of
$&lt;span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Debt converted, amount converted"&gt;67,000&lt;/span&gt; of this Note plus accrued interest of $&lt;span id="xdx_900_ecustom--DebtConvertedInterestConverted_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Debt converted, interest converted"&gt;2,680 &lt;/span&gt;was converted into&lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pdd" title="Debt converted, shares issued"&gt; 542,173 &lt;/span&gt;shares of Common Stock valued at $&lt;span id="xdx_90C_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Debt converted, shares converted value"&gt;119,169&lt;/span&gt; resulting in
a loss of $&lt;span id="xdx_90E_ecustom--GainLossOnDebtConversion_c20210101__20210222__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Gain (Loss) on debt conversion"&gt;49,489&lt;/span&gt;.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 14, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zs5dKGZ08bDg" title="Face Value"&gt;250,000&lt;/span&gt;
with interest accruing at &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zrSJ8YXNqKnb" title="Interest Rate"&gt;5&lt;/span&gt;%
which was due &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zw3piTPyZD2g" title="Maturity Date"&gt;September
14, 2022&lt;/span&gt;. The Note was convertible after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20200914__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pdd" title="Conversion Price"&gt;0.30 &lt;/span&gt;per
share. On June 2, 2021, the entire principal amount of $&lt;span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Debt converted, amount converted"&gt;250,000&lt;/span&gt;
of this Note plus all accrued interest of $&lt;span id="xdx_905_ecustom--DebtConvertedInterestConverted_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Debt converted, interest converted"&gt;8,850&lt;/span&gt;
converted into &lt;span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pdd" title="Debt converted, shares issued"&gt;862,833&lt;/span&gt;
shares of Common Stock valued at $&lt;span id="xdx_90B_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Debt converted, shares converted value"&gt;170,841&lt;/span&gt;
resulting in a gain of $&lt;span id="xdx_90D_ecustom--GainLossOnDebtConversion_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Gain (Loss) on debt conversion"&gt;88,009&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 24, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zF0hLsrNrVKh" title="Face Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0718"&gt;50,000,&lt;/span&gt;&lt;/span&gt; with interest accruing at &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zLWpTfKngd3" title="Interest Rate"&gt;5&lt;/span&gt;%, which due &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zJTUbHnCYINg" title="Maturity Date"&gt;September 24, 2022&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20200924__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_pdd" title="Conversion Price"&gt;0.30&lt;/span&gt; per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date on March 23, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 20, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zhwwbKzxfcUg" title="Face Value"&gt;250,000&lt;/span&gt;
with interest accruing at&lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zIcfQDfqiTZh" title="Interest Rate"&gt;
5&lt;/span&gt;% whic was due &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zNX9IYNIpRC3" title="Maturity Date"&gt;October
20, 2022&lt;/span&gt;. The Note was convertible after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20201020__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zZpLGSmSXbRb" title="Conversion Price"&gt;0.30&lt;/span&gt;
per share. On June 2, 2021, the entire principal amount of $&lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Debt converted, amount converted"&gt;250,000&lt;/span&gt;
of this Note plus all accrued interest of $&lt;span id="xdx_90A_ecustom--DebtConvertedInterestConverted_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Debt converted, interest converted"&gt;7,600&lt;/span&gt;
was converted into &lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pdd" title="Debt converted, shares issued"&gt;858,666&lt;/span&gt;
shares of Common Stock valued at $&lt;span id="xdx_909_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Debt converted, shares converted value"&gt;170,016&lt;/span&gt;
resulting in a gain of $&lt;span id="xdx_902_ecustom--GainLossOnDebtConversion_c20210101__20210602__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Gain (Loss) on debt conversion"&gt;87,584&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 19, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20201119__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Face Value"&gt;250,000&lt;/span&gt;
with interest accruing at &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201119__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_zZzH4B4mDPHe" title="Interest Rate"&gt;8&lt;/span&gt;%
which was due &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201119__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_zi1TN5bx1fg" title="Maturity Date"&gt;August
19, 2021&lt;/span&gt;. The Note was convertible after 180 days from issuance into Common Stock at a price 35% below market value. On May
19, 2021, the Company paid off the entire principal balance of this Note, together with accrued interest and prepayment penalties of
$&lt;span id="xdx_90D_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210519__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Interest accrued"&gt;126,881&lt;/span&gt;
by issuing cash payment of $&lt;span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20210101__20210519__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Repayments of notes payable"&gt;376,881&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 24, 2020, the Company received
monies in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20201124__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Face Value"&gt;260,000&lt;/span&gt;
with interest accruing at &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201124__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_z6xvrFpjEuA5" title="Interest Rate"&gt;8&lt;/span&gt;%
which was due &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dp_c20200101__20201124__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_zjeTo3APb0Lj" title="Maturity Date"&gt;November
24, 2021&lt;/span&gt;. The Note was convertible after 180 days from issuance into Common Stock at a price 30% below market value. On June
1, 2021, the entire principal amount of $&lt;span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Debt converted, amount converted"&gt;260,000&lt;/span&gt;
of this Note plus all accrued interest of $&lt;span id="xdx_90B_ecustom--DebtConvertedInterestConverted_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Debt converted, interest converted"&gt;10,428&lt;/span&gt;
was converted into &lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pdd" title="Debt converted, shares issued"&gt;3,865,841&lt;/span&gt;
shares of Common Stock valued at $&lt;span id="xdx_906_ecustom--DebtConversionConvertedInstrumentSharesIssuedValue_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Debt converted, shares converted value"&gt;695,078,&lt;/span&gt;
resulting in a loss of $&lt;span id="xdx_901_ecustom--GainLossOnDebtConversion_c20210101__20210601__us-gaap--LongtermDebtTypeAxis__custom--NotePayable8Member_pp0p0" title="Gain (Loss) on debt conversion"&gt;424,650&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 25, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_c20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_pp0p0" title="Face Value"&gt;250,000&lt;/span&gt; with interest accruing at &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_zIjbvs9zAeka" title="Interest Rate"&gt;5&lt;/span&gt;% is due &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_zDD7Pz9RCw13" title="Maturity Date"&gt;November 25, 2022&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201125__us-gaap--LongtermDebtTypeAxis__custom--NotePayable9Member_pdd" title="Conversion Price"&gt;0.30 &lt;/span&gt;per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date on May 24, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 2, 2020, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_pp0p0" title="Face Value"&gt;104,215 &lt;/span&gt;with interest accruing at &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_z9JyVfukcBtj" title="Interest Rate"&gt;5&lt;/span&gt;% is due &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_zhjs9KC1ryjb" title="Maturity Date"&gt;December 2, 2022&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201202__us-gaap--LongtermDebtTypeAxis__custom--NotePayable10Member_pdd" title="Conversion Price"&gt;0.30&lt;/span&gt; per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date on May 31, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 12, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_c20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_pp0p0" title="Face Value"&gt;150,000&lt;/span&gt; with interest accruing at &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_zXelRL6xjDuc" title="Interest Rate"&gt;5&lt;/span&gt;% is due&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_zKWE5c44uBH9" title="Maturity Date"&gt; January 12, 2023&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210112__us-gaap--LongtermDebtTypeAxis__custom--NotePayable11Member_pdd" title="Conversion Price"&gt;0.30 &lt;/span&gt;per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date of July 11, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 27, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pp0p0" title="Face Value"&gt;300,000&lt;/span&gt; with interest accruing at &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_znz9M9nvZNUj" title="Interest Rate"&gt;5&lt;/span&gt;% is due &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_zBqsSnh4HJAi" title="Maturity Date"&gt;January 27, 2023&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210127__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pdd" title="Conversion Price"&gt;0.50&lt;/span&gt; per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date of July 26, 2021, which is 180 days after the issuance date, and determined
that there was no beneficial conversion feature on September 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 12, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_c20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pp0p0" title="Face Value"&gt;700,000&lt;/span&gt; with interest accruing at &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_zQhol8cn6FEf" title="Interest Rate"&gt;5&lt;/span&gt;% is due&lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_zpKD0yK1wejh" title="Maturity Date"&gt; February 12, 2023&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210212__us-gaap--LongtermDebtTypeAxis__custom--NotePayable12Member_pdd" title="Conversion Price"&gt;0.60&lt;/span&gt; per share. The Company analyzed the conversion feature of the
note for a beneficial conversion feature on the commitment date of August&#160;11, 2021, which is 180 days after the issuance date, and
determined that there was no beneficial conversion feature on September 30, 2021.&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 5, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_pp0p0" title="Face Value"&gt;330,000 &lt;/span&gt;with interest accruing at &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_zykLR6I8qgJe" title="Interest Rate"&gt;10&lt;/span&gt;% is due &lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_zK2C7oNzGGVd" title="Maturity Date"&gt;January 5, 2022&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210405__us-gaap--LongtermDebtTypeAxis__custom--NotePayable13Member_pdd" title="Conversion Price"&gt;0.30&lt;/span&gt; per share or 35% below market value, whichever is lower. The Company
will analyze the conversion feature of the note for a beneficial conversion feature on the commitment date on October 2, 2021, which is
180 days after the issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 20, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_pp0p0" title="Face Value"&gt;500,000 &lt;/span&gt;with interest accruing at &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_z2IDWSem2fh8" title="Interest Rate"&gt;5&lt;/span&gt;% is due &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_z3K0qdJwCsU4" title="Maturity Date"&gt;April 20, 2023&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable14Member_pdd" title="Conversion Price"&gt;0.30&lt;/span&gt; per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date of October 17, 2021, which is 180 days after the issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 6, 2021, the Company received monies in
exchange for a Note Payable having a Face Value of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_pp0p0" title="Face Value"&gt;900,000&lt;/span&gt; with interest accruing at &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_zV64WnpCfgng" title="Interest Rate"&gt;5&lt;/span&gt;% is due &lt;span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_zhgHSKYFk69a"&gt;July 6, 2023&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable15Member_pdd" title="Conversion Price"&gt;0.30&lt;/span&gt; per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date of January 2, 2022, which is 180 days after the issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 18, 2021, the Company received monies
in exchange for a Note Payable having a Face Value of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_pp0p0" title="Face Value"&gt;500,000&lt;/span&gt; with interest accruing at &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_zfVrqpxjwz1i" title="Interest Rate"&gt;5&lt;/span&gt;% is due &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_zGJlX1iOlaxh" title="Maturity Date"&gt;August 18, 2023&lt;/span&gt;. The Note is convertible
after 180 days from issuance into Common Stock at a price equal to $&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable16Member_pdd" title="Conversion Price"&gt;0.30&lt;/span&gt; per share. The Company will analyze the conversion feature of
the note for a beneficial conversion feature on the commitment date of February 14, 2022, which is 180 days after the issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At September 30, 2021 and December 31, 2020, total
accrued interest on Notes Payable was $&lt;span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20210930_zDOg3t4z8jpf" title="Interest accrued"&gt;84,945 &lt;/span&gt;and $&lt;span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20201231_zR7erHBKJVKl" title="Interest accrued"&gt;24,320&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2018-12-31_custom_NotePayable2018Member"
      decimals="0"
      unitRef="USD">136744</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2018-01-012018-12-31_custom_NotePayable2018Member"
      decimals="INF"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2018-01-012018-12-31_custom_NotePayable2018Member">2019-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2019-01-012019-10-01_custom_NotePayable2018Member"
      decimals="0"
      unitRef="USD">30000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2019-01-012019-10-01_custom_NotePayable2018Member"
      decimals="INF"
      unitRef="Shares">1500000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:NotesPayable
      contextRef="AsOf2019-10-01_custom_NotePayable2018Member"
      decimals="0"
      unitRef="USD">106744</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2019-12-31_custom_NotePayable2018Member"
      decimals="0"
      unitRef="USD">15509</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-12-31_custom_NotePayable2018Member"
      decimals="0"
      unitRef="USD">122253</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2019-01-012019-12-31_custom_NotePayable2018Member"
      decimals="INF"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-01-012019-12-31_custom_NotePayable2018Member">2020-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-01-012021-09-30_custom_NotePayable2018Member"
      decimals="0"
      unitRef="USD">122253</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-09-30_custom_NotePayable2018Member"
      decimals="INF"
      unitRef="Shares">136500000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-04-17_custom_CEBALoanMember_currency_CAD"
      decimals="0"
      unitRef="USD">40000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-012021-06-15_custom_CEBALoanMember_currency_CAD"
      decimals="0"
      unitRef="USD">30000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-04-27_custom_PPPLoanMember"
      decimals="0"
      unitRef="USD">50655</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-04-27_custom_PPPLoanMember"
      decimals="INF"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2020-01-012020-04-27_custom_PPPLoanMember"
      decimals="0"
      unitRef="USD">2133</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-07-07_custom_NotePayable1Member"
      decimals="0"
      unitRef="USD">48000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-07-07_custom_NotePayable1Member"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-07-07_custom_NotePayable1Member">2021-07-07</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-01-05_custom_NotePayable1Member"
      decimals="0"
      unitRef="USD">15271</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-012021-01-05_custom_NotePayable1Member"
      decimals="0"
      unitRef="USD">63271</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-07-27_custom_NotePayable2Member"
      decimals="0"
      unitRef="USD">102000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-07-27_custom_NotePayable2Member"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-07-27_custom_NotePayable2Member">2021-07-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-01-012021-01-29_custom_NotePayable2Member"
      decimals="0"
      unitRef="USD">102000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-01-29_custom_NotePayable2Member"
      decimals="INF"
      unitRef="Shares">5044456</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-08-14_custom_NotePayable3Member"
      decimals="0"
      unitRef="USD">67000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-08-14_custom_NotePayable3Member"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-08-14_custom_NotePayable3Member">2021-08-14</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-01-012021-02-22_custom_NotePayable3Member"
      decimals="0"
      unitRef="USD">67000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-02-22_custom_NotePayable3Member"
      decimals="INF"
      unitRef="Shares">542173</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-09-14_custom_NotePayable4Member"
      decimals="0"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-09-14_custom_NotePayable4Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-09-14_custom_NotePayable4Member">2022-09-14</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-09-14_custom_NotePayable4Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-01-012021-06-02_custom_NotePayable4Member"
      decimals="0"
      unitRef="USD">250000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-06-02_custom_NotePayable4Member"
      decimals="INF"
      unitRef="Shares">862833</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-09-24_custom_NotePayable5Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-09-24_custom_NotePayable5Member">2022-09-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-09-24_custom_NotePayable5Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-10-20_custom_NotePayable6Member"
      decimals="0"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-10-20_custom_NotePayable6Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-10-20_custom_NotePayable6Member">2022-10-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-10-20_custom_NotePayable6Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-01-012021-06-02_custom_NotePayable6Member"
      decimals="0"
      unitRef="USD">250000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-06-02_custom_NotePayable6Member"
      decimals="INF"
      unitRef="Shares">858666</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-11-19_custom_NotePayable7Member"
      decimals="0"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-11-19_custom_NotePayable7Member"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-11-19_custom_NotePayable7Member">2021-08-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-05-19_custom_NotePayable7Member"
      decimals="0"
      unitRef="USD">126881</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-012021-05-19_custom_NotePayable7Member"
      decimals="0"
      unitRef="USD">376881</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-11-24_custom_NotePayable8Member"
      decimals="0"
      unitRef="USD">260000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-11-24_custom_NotePayable8Member"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-11-24_custom_NotePayable8Member">2021-11-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-01-012021-06-01_custom_NotePayable8Member"
      decimals="0"
      unitRef="USD">260000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-06-01_custom_NotePayable8Member"
      decimals="INF"
      unitRef="Shares">3865841</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-11-25_custom_NotePayable9Member"
      decimals="0"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-11-25_custom_NotePayable9Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-11-25_custom_NotePayable9Member">2022-11-25</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-11-25_custom_NotePayable9Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-12-02_custom_NotePayable10Member"
      decimals="0"
      unitRef="USD">104215</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-01-012020-12-02_custom_NotePayable10Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-12-02_custom_NotePayable10Member">2022-12-02</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-12-02_custom_NotePayable10Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-01-12_custom_NotePayable11Member"
      decimals="0"
      unitRef="USD">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-01-012021-01-12_custom_NotePayable11Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-01-12_custom_NotePayable11Member">2023-01-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-01-12_custom_NotePayable11Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-01-27_custom_NotePayable12Member"
      decimals="0"
      unitRef="USD">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-01-012021-01-27_custom_NotePayable12Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-01-27_custom_NotePayable12Member">2023-01-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-01-27_custom_NotePayable12Member"
      decimals="INF"
      unitRef="USDPShares">0.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-02-12_custom_NotePayable12Member"
      decimals="0"
      unitRef="USD">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-01-012021-02-12_custom_NotePayable12Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-02-12_custom_NotePayable12Member">2023-02-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-02-12_custom_NotePayable12Member"
      decimals="INF"
      unitRef="USDPShares">0.60</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-04-05_custom_NotePayable13Member"
      decimals="0"
      unitRef="USD">330000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-01-012021-04-05_custom_NotePayable13Member"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-04-05_custom_NotePayable13Member">2022-01-05</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-04-05_custom_NotePayable13Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-04-20_custom_NotePayable14Member"
      decimals="0"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-01-012021-04-20_custom_NotePayable14Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-04-20_custom_NotePayable14Member">2023-04-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-04-20_custom_NotePayable14Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-07-06_custom_NotePayable15Member"
      decimals="0"
      unitRef="USD">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-01-012021-07-06_custom_NotePayable15Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-07-06_custom_NotePayable15Member">2023-07-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-07-06_custom_NotePayable15Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-08-18_custom_NotePayable16Member"
      decimals="0"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-01-012021-08-18_custom_NotePayable16Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-08-18_custom_NotePayable16Member">2023-08-18</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2021-08-18_custom_NotePayable16Member"
      decimals="INF"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">84945</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">24320</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">128269</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-01-012019-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">2020-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">15392</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">143661</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-01-012020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember">2021-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-08-24_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">12929</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-012021-08-24_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">156590</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zmsPrI6Gxbac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 5 &#x2013; &lt;span id="xdx_822_zpR8R5juXnz"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the nine months ended September 30,
2021, the Company issued a total of &lt;span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_zJNb1u7s8cg" title="Debt converted, shares issued"&gt;103,673,969&lt;/span&gt;
shares of Common Stock valued at $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueOther_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_z4aneKSlkvne"&gt;11,981,072&lt;/span&gt; for the conversion of outstanding notes payable, reducing the debt by $&lt;span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_pp0p0" title="Debt converted, amount converted"&gt;1,233,028&lt;/span&gt;
and interest payable by $&lt;span id="xdx_908_ecustom--DebtConvertedInterestConverted_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_pp0p0" title="Debt converted, interest converted"&gt;38,201&lt;/span&gt;
and generating a loss on conversion of $&lt;span id="xdx_906_ecustom--GainLossOnDebtConversion_c20210101__20210930__us-gaap--DebtConversionByUniqueDescriptionAxis__custom--OutstandingNotesPayableMember_pp0p0" title="Gain (Loss) on debt conversion"&gt;10,709,843&lt;/span&gt;.
In addition, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pdd" title="Common stock issued for services, shares"&gt;60,000,000&lt;/span&gt;
shares of Common Stock valued at $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_pp0p0" title="Common stock issued for services, amount"&gt;918,000 &lt;/span&gt;to
its Officers and Directors as compensation for their services to the Company. The fair value of the stock was based on the closing price of the stock
on the date of the transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company declared &lt;span id="xdx_906_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_pp0p0_do_c20210930_z4MGShsO4Uua" title="Dividends Payable"&gt;no&lt;/span&gt; dividends through September
30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2021-01-012021-09-30_custom_OutstandingNotesPayableMember"
      decimals="INF"
      unitRef="Shares">103673969</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_custom_OutstandingNotesPayableMember"
      decimals="0"
      unitRef="USD">11981072</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2021-01-012021-09-30_custom_OutstandingNotesPayableMember"
      decimals="0"
      unitRef="USD">1233028</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Shares">60000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember"
      decimals="0"
      unitRef="USD">918000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember"
      decimals="0"
      unitRef="USD">130000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2020-01-012020-09-30_custom_OfficersAndDirectorsMember"
      decimals="0"
      unitRef="USD">255927</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember_custom_TrtPharmaMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember"
      decimals="INF"
      unitRef="Shares">60000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-09-30_custom_OfficersAndDirectorsMember"
      decimals="0"
      unitRef="USD">918000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zHfPRvbLECvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 7 &#x2013; &lt;span id="xdx_824_zwejI9ctrvmg"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 13, 2021, the holder of a Note Payable
dated April 5, 2021 elected to convert a total of $330,000 in principal and $16,500 in accrued interest into 5,250,000 shares of Common
Stock leaving a principal balance of $-0-.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>34
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,>+0U0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #'BT-4Q1[W3NT    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L0@$(9?I7A/QACH0;)>6GKJPD(76GH3G=V5QD1T2K)O7V-WLY3V 0I>G/G]
MYANP,T&:,>(NC@$C.4QWL^^')$W8L!-1D #)G-#K5.?$D)N',7I-^1J/$+3Y
MT$<$P?D]>"1M-6E8@%58B4QUUD@34=,8+WAK5GSXC'V!60/8H\>!$C1U TPM
M$\-Y[CNX 1888?3INX!V)9;JG]C2 79)SLFMJ6F:ZJDMN;Q# V_;YY>R;N6&
M1'HPF%\E)^D<<,.NDU_;A\?]$U.""U'Q?-J]$++EDHOWQ?6'WTW8C]8=W#\V
MO@JJ#G[]"_4%4$L#!!0    ( ,>+0U297)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MQ?:$<WLCL[P\)'S*I,R2\G+-V9(7R@#>KS+8)U4WZMRQ/F<>_@U02P,$%
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M"'F:,R[-=O;Q^==[XP?4'&,'<-2L0Q@TA,$@X4:D*;[2,-C#UT\D9Y*\L:2
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M LS_UU+JYQO;P>%KX?6_4$L#!!0    ( ,>+0U3[C/YZ308  / 7   8
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M*RL _U])B+S]ASV@>^1?_@]02P,$%     @ QXM#5*9+2K"Z!P   2\  !@
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MWERN69RP2@+$[_>EJ$'M!_D&\?ZM]_'_4$L#!!0    ( ,>+0U1Y(FGQBA,
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M&2167MQ1:UU XD<2&R(CH+F5#O%\FF(;A1:#4'RYRJ=B5ZNBYDF@MAK8/HI
M.]-#6; #TGM"1E;-JQ@$'5GPHE9RH[0*BOR$=Q2V:50X<(P!AON%QDKG/'',
MIO,X*N^/_Z-6\3>MI05V."P+]EV6?Z!+Q+!)J&5 <]A#CT=7$I6S322$;@R:
MD0K'O+2FXT= _P[[R,^10$9CV8;.@1R)" P@J*''R'"GM(;K$P_3?(6/P3JE
M]VQ&JPFZ>J4*"!$ B0E5AAKS5'0NNL?BP,$,_7FG0AW)?J@J<DSP*T\D8OE.
MOTZ% O<BXBNTNS)E>S7LEYT'C0[?I#2!?2R5[B)BL(*>E ^,A49:/-16E^1P
M"E<PH9+8!ZV;_8LZ1I#OB@*'574:BA0+BF??ZT?5&,B/N6/I23@>0%CJB2P?
MB4^<H* (7(8*5AT./QW.C>EPQM9ZKS8:+IF^HF)RKDUE.EC6DHL5";[_U&BR
M9TV_(;>-5YMG5TSH^_\X.]Z>5_VE\6E[?_6^EVZKH$I3A=#\^/PT$:Z_SOI!
ML&V\0C8VX$**KS5^ 9#C#5BO+$YI&'""\3?%^B]02P,$%     @ QXM#5-$R
M.W81!0  %!$  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6R]F%MOVS84
M@-_]*PZT85@!(1:IJ],D@.VT6(NU-=JM>QCV0,NT+40B79*.FW^_0^IBV;ET
MR."\6!1Y+M\Y/*1(7^RDNM%KS@U\KTJA+[VU,9OSX5#G:UXQ?28W7.#(4JJ*
M&7Q5JZ'>*,X63JDJAS0(DF'%"N%=7;B^F;JZD%M3%H+/%.AM53%U-^&EW%UZ
MQ&L[/A>KM;$=PZN+#5OQ+]S\N9DI?!MV5A9%Q84NI #%EY?>F)Q/(BOO!+X6
M?*=[;;"1S*6\L2_O%I=>8(%XR7-C+3!\W/(I+TMK"#&^-3:]SJ55[+=;ZV]=
M[!C+G&D^E>5?Q<*L+[W,@P5?LFUI/LO=;[R))[;V<EEJ]PN[6I:F'N1;;635
M*"-!58CZR;XW>>@I9,$C"K11H(Z[=N0HKYEA5Q=*[D!9:;1F&RY4IXUPA;"3
M\L4H'"U0SUQ]E(9KF+$[-B_YQ="@23LPS!OU2:U.'U$?P0<IS%K#&['@BT/]
M(:)T/+3EF= G#7[AFS,( Q]H0,D3]L(NOM#9"Q^Q=\WG!JX+G9=2;Q6'O\=S
M;136PC]/&(\ZXY$S'CTW>4^JV_5VKC<LYY<>+BC-U2WWG$T(X9>?,DK(:SAP
M 7^L.4QEM6'BS@FDK_61!#. *32\FG,U:/,(N<15I U?@%R"02-+6>)R+,3J
M',;.0F=@P:S8-<^="0B)-4$R6+-;%!\P>(O \)656VZ-_0PD3/PTBH#0>UHC
M.Y-!$ #QXZ!I!8UTC%TC5*(^C<,'E&FP'XQ\&J7.46LF];,L\HEKI5'J)]CZ
M)&"\444))*T-^"[4XWQ-F6"+@HF!WLYU@2UUA[M+SG%S6 "#Z9O)&'Z73,"O
M3I+!FXJK%1?Y'4RV&J=0:QCGN=P*X^1>P5+)"J;O)M-&!8W#NVK#5<%*F#!Q
M8Q.%&&@GYZ^@$(X+445>;%@Y8)4SYK(9U?$U>:/UHXN,/A19GQYG$;?M_&8P
M4SBI]<:'S95B%90N*&\VFSEN[SX)]$GBP$_B& A0GX2A97B_+>_@:8)*B@*K
ML1 #_CU?,[&RI:80[*#&ZEJ"^[4492[>K.^*V%JA*8$D=(\6Y >YJ$D&&.*S
M2$A ^RBT8VGZL?B0)?:#*/*C.$%R+-(D@S#%$$:IF[+M"O=O6[TGY$S2!O/0
M&VD'J)]D <013F***XF,?)*,(!KY43:RD-UF\0/.03>SS^.D<5W*<6][:CQ2
M",["H)/(_"S&WX3Z&98=20,_BPADMC*.B.E),UOC^'WBUF-#C#"?<B/=0/ "
MR1O$K;]!X^\H=?4^F,69GR2)2UU $LA2/\XB2_M1WC9S/7J)N6Z+<M"XP]5#
M$]RX":Z2^MEG>GHV_S=3TC*U#@>T72KM& G\B.(2]K,D=D67C'"!XX*&"&63
M.#CDC4]9??OU<NQP7WS=%Y.>=B?$G8W$2'+D;P_RGHFM_8R2>H"<"*1+R9&_
M\!Y(NUV?!B0,CD$:?Q:DKI*W?*Y>("5I1W+LT*(DO9-#?-*$M,>\H,O(<:TV
MYY?@E!AQEXT#;[WRL)_RY#\@//L ,]J7QM[7'J#]2&<OE(8#=PW&N'=#Z&Y:
MP,2]0[_;4*2Q!]0\5UL$*X3A>%'! Z(XNG;LF$;/> 8:1;'=R4,\OC]TP1KV
M;JKN6&WOXQK<:;J^M':]W95_7-]T]^+U_P4?F%H50D/)EZ@:G*6Q!ZJ^@]<O
M1F[<O7<N#=ZB77/-V8(K*X#C2XDA-"_60?='R-6_4$L#!!0    ( ,>+0U1%
M 7TD>P,  $(,   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;+57VV[;
M.!!][GX%(72!7:!KB=0E5F ;2'S!!MAT@P3=?2CZ0,LC6Z@D>DG*3H#]^)*4
M(CN.Q+IH^V*)EW/FS' T'(_VC'\6&P")'HN\%&-G(^7VTG5%LH&"B@';0JE6
M4L8+*M60KUVQY4!7!E3D+O&\R"UH5CJ3D9F[XY,1JV2>E7#'D:B*@O*G:\C9
M?NQ@YWGB/EMOI)YP)Z,M7<,#R _;.ZY&;LNRR@HH1<9*Q"$=.U?X<H%]#3 [
M_LE@+X[>D79ER=AG/;A9C1U/*X(<$JDIJ'KL8 IYKIF4CO\:4J>UJ8''[\_L
M"^.\<F9)!4Q9_F^VDINQ,W30"E):Y?*>[?^$QJ%0\R4L%^87[>N]%\IB4@G)
MB@:LQD56UD_ZV 3B"*!XN@&D 9!S 7X#\$\!00\@: #!*2#J 80-(#P7$#6
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M? TN]]7=LWH!*KGO+5W$[5$>-QA*Y'D#UODLV+RP@?8? %?_!5!+ P04
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M,T.BZ>/&; 74XY^Y:%3Q DCF;PI./8 BHH%L]/W#K_-H=*JLOS8;5."\@*[
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M>;-XD9;_6D_;9QUG8,TV:18O*W"NP7*^VOX?_EU-A0(@7 .@%8"^!.A&8!6
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MWTND2;9B,%N!D?:)M9"3I[6>(\G)@<D)"[1/"!X+-$=2F0.73UB@?4+P8I,
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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MBUVAX9[*N@8\-]UC3BN'(*E&](W.QZ/1+&] F>SD>#O7G<O#AO58>F4-![O
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MQV;V"5!+ 0(4 Q0    ( ,>+0U0'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ QXM#5,4>]T[M
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ QXM#5)E<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #'BT-4KCX" ?P#  ",#@  &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ QXM#5*C6H.8G!@  <Q8  !@              ("!/@P  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,>+0U2 Q9//;@,  "L,
M   8              " @9L2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #'BT-44N@[5L@&   Y'   &               @($_%@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ QXM#5/N,_GI-
M!@  \!<  !@              ("!/1T  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( ,>+0U2F2TJPN@<   $O   8              "
M@< C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #'BT-4
M>2)I\8H3  #<,P  &               @(&P*P  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ QXM#5,OTYD7W P  7P@  !@
M     ("!<#\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M ,>+0U31,CMV$04  !01   8              " @9U#  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #'BT-410%])'L#  !"#   &0
M            @('D2   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( ,>+0U1<[U0O:P(  #(%   9              " @99,  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ QXM#5/K8#F'' @
M^@<  !D              ("!.$\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #'BT-4/G* C6\"  !$!0  &0              @($V
M4@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,>+0U3C
M(Y\0IP8   P0   9              " @=Q4  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ QXM#5&*VK.J= P  [0D  !D
M     ("!NEL  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M  "+$   #0              @ &M<0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( ,>+0U27BKL<P    !,"   +              "  >5T  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( ,>+0U0Q)8E":0(  .4,   /              "
M <YU  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #'BT-4/P[=3!4!  "M
M"P  &@              @ %D>   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #'BT-404"D9EL!  #@#   $P              @ &Q
L>0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     &@ : .T&   ]>P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>131</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Unaudited Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Unaudited Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Unaudited Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Unaudited Condensed Consolidated Statement of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity</Role>
      <ShortName>Unaudited Condensed Consolidated Statement of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Going Concern and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/GoingConcernAndLiquidity</Role>
      <ShortName>Going Concern and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://sunshinebiopharma.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Face value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/FaceValue</Role>
      <ShortName>Face value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Salary and Wage, Excluding Cost of Good and Service Sold</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold</Role>
      <ShortName>Salary and Wage, Excluding Cost of Good and Service Sold</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Nature of Business and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies</Role>
      <ShortName>Nature of Business and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Nature of Business and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Going Concern and Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative</Role>
      <ShortName>Going Concern and Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/GoingConcernAndLiquidity</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/NotesPayable</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="sunshine_s1a2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Shareholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>Shareholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/ShareholdersEquity</ParentRole>
      <Position>18</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1/A" original="sunshine_s1a2.htm">sunshine_s1a2.htm</File>
    <File>sbfm-20210930.xsd</File>
    <File>sbfm-20210930_cal.xml</File>
    <File>sbfm-20210930_def.xml</File>
    <File>sbfm-20210930_lab.xml</File>
    <File>sbfm-20210930_pre.xml</File>
    <File>sunshine_ex107.htm</File>
    <File>sunshine_ex9901.htm</File>
    <File>sunshine_ex9902.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="476">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>40
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sunshine_s1a2.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 131,
   "dts": {
    "calculationLink": {
     "local": [
      "sbfm-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sbfm-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sunshine_s1a2.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sbfm-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sbfm-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sbfm-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 251,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 40,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 43
   },
   "keyCustom": 0,
   "keyStandard": 232,
   "memberCustom": 25,
   "memberStandard": 8,
   "nsprefix": "SBFM",
   "nsuri": "http://sunshinebiopharma.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://sunshinebiopharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Face value",
     "role": "http://sunshinebiopharma.com/role/FaceValue",
     "shortName": "Face value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2020-12-31_custom_NotePayableRelatedPartyMember_srt_ChiefExecutiveOfficerMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Shareholders\u2019 Equity",
     "role": "http://sunshinebiopharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-012021-09-30_custom_OfficersAndDirectorsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Salary and Wage, Excluding Cost of Good and Service Sold",
     "role": "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold",
     "shortName": "Salary and Wage, Excluding Cost of Good and Service Sold",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-012021-09-30_custom_OfficersAndDirectorsMember_custom_TrtPharmaMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Subsequent Events",
     "role": "http://sunshinebiopharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Nature of Business and Basis of Presentation (Policies)",
     "role": "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies",
     "shortName": "Nature of Business and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2019-01-012019-02-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Nature of Business and Basis of Presentation (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative",
     "shortName": "Nature of Business and Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2019-01-012019-02-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Going Concern and Liquidity (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative",
     "shortName": "Going Concern and Liquidity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2021-06-25",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Capital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Notes Payable (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative",
     "shortName": "Notes Payable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2019-12-31_custom_NotePayable2018Member",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueOther",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Shareholders\u2019 Equity (Details Narrative)",
     "role": "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
     "shortName": "Shareholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-012021-09-30_custom_OutstandingNotesPayableMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Unaudited Condensed Consolidated Balance Sheets",
     "role": "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets",
     "shortName": "Unaudited Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows",
     "role": "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Unaudited Condensed Consolidated Statement of Shareholders' Equity",
     "role": "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity",
     "shortName": "Unaudited Condensed Consolidated Statement of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Going Concern and Liquidity",
     "role": "http://sunshinebiopharma.com/role/GoingConcernAndLiquidity",
     "shortName": "Going Concern and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Notes Payable",
     "role": "http://sunshinebiopharma.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sunshine_s1a2.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 33,
   "tag": {
    "SBFM_CEBALoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "C E B A Loan [Member]"
       }
      }
     },
     "localname": "CEBALoanMember",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable10Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 10 [Member]"
       }
      }
     },
     "localname": "NotePayable10Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable11Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 11 [Member]"
       }
      }
     },
     "localname": "NotePayable11Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable12Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 12 [Member]"
       }
      }
     },
     "localname": "NotePayable12Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable13Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 13 [Member]"
       }
      }
     },
     "localname": "NotePayable13Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable14Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 14 [Member]"
       }
      }
     },
     "localname": "NotePayable14Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable15Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 15 [Member]"
       }
      }
     },
     "localname": "NotePayable15Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable16Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 16 [Member]"
       }
      }
     },
     "localname": "NotePayable16Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 1 [Member]"
       }
      }
     },
     "localname": "NotePayable1Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 2018 [Member]"
       }
      }
     },
     "localname": "NotePayable2018Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 2 [Member]"
       }
      }
     },
     "localname": "NotePayable2Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 3 [Member]"
       }
      }
     },
     "localname": "NotePayable3Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 4 [Member]"
       }
      }
     },
     "localname": "NotePayable4Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 5 [Member]"
       }
      }
     },
     "localname": "NotePayable5Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 6 [Member]"
       }
      }
     },
     "localname": "NotePayable6Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable7Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 7 [Member]"
       }
      }
     },
     "localname": "NotePayable7Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable8Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 8 [Member]"
       }
      }
     },
     "localname": "NotePayable8Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayable9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable 9 [Member]"
       }
      }
     },
     "localname": "NotePayable9Member",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_NotePayableRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable Related Party [Member]"
       }
      }
     },
     "localname": "NotePayableRelatedPartyMember",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_OfficersAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers And Directors [Member]"
       }
      }
     },
     "localname": "OfficersAndDirectorsMember",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_OutstandingNotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Notes Payable [Member]"
       }
      }
     },
     "localname": "OutstandingNotesPayableMember",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_PPPLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "P P P Loan [Member]"
       }
      }
     },
     "localname": "PPPLoanMember",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Notes [Member]"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_RBCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "R B Capital [Member]"
       }
      }
     },
     "localname": "RBCapitalMember",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SBFM_TrtPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trt Pharma [Member]"
       }
      }
     },
     "localname": "TrtPharmaMember",
     "nsuri": "http://sunshinebiopharma.com/20210930",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r361",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r46",
      "r48",
      "r96",
      "r97",
      "r177",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r96",
      "r97",
      "r177",
      "r212"
     ],
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r144",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33",
      "r291"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable &amp; accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r22",
      "r145",
      "r146"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued interest"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Equipment depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r50",
      "r51",
      "r52",
      "r329",
      "r343",
      "r344"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r243",
      "r291"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Capital paid in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r240",
      "r241",
      "r242",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r81",
      "r152",
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Patent amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r92",
      "r130",
      "r133",
      "r139",
      "r148",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r252",
      "r256",
      "r266",
      "r289",
      "r291",
      "r309",
      "r326"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r45",
      "r92",
      "r148",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r252",
      "r256",
      "r266",
      "r289",
      "r291"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation of Unaudited Financial Information"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Capital": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total capital as defined by regulatory framework.",
        "label": "Capital"
       }
      }
     },
     "localname": "Capital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r29",
      "r291",
      "r345",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash and Cash Equivalents at End of Period",
        "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r29",
      "r83"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r271"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r89",
      "r92",
      "r113",
      "r114",
      "r115",
      "r117",
      "r119",
      "r123",
      "r124",
      "r125",
      "r148",
      "r161",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171",
      "r210",
      "r211",
      "r214",
      "r218",
      "r266",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r42",
      "r159",
      "r315",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r291"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 510,093,265 and 346,419,296 at September 30, 2021 and December 31, 2020 respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income [Member]"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r64",
      "r317",
      "r336"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Stock issued for note conversions including interest"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r68",
      "r92",
      "r148",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r266"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt converted, amount converted"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt converted, shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Conversion [Line Items]"
       }
      }
     },
     "localname": "DebtConversionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionTable": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table that contains information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion [Table]"
       }
      }
     },
     "localname": "DebtConversionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r190",
      "r197",
      "r198",
      "r200",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r91",
      "r98",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r203",
      "r204",
      "r205",
      "r206",
      "r282",
      "r310",
      "r312",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r175",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r173",
      "r203",
      "r204",
      "r280",
      "r282",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Face value",
        "verboseLabel": "Face Value"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue",
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r39",
      "r193",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r39",
      "r202",
      "r280",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r39",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt stated rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue",
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r40",
      "r176",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue",
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41",
      "r91",
      "r98",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r203",
      "r204",
      "r205",
      "r206",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r41",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Periodic Payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r41",
      "r91",
      "r98",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r225",
      "r226",
      "r227",
      "r228",
      "r279",
      "r280",
      "r282",
      "r283",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue",
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r81",
      "r156"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r81",
      "r156"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r16",
      "r18",
      "r311",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r112",
      "r113",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r263",
      "r264",
      "r318",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and diluted (loss) per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r58",
      "r59",
      "r60",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r122",
      "r149",
      "r224",
      "r229",
      "r240",
      "r241",
      "r242",
      "r246",
      "r247",
      "r262",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r339",
      "r340",
      "r341",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r153",
      "r296"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Patents (net of $58,918 amortization and $556,120 impairment)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r81",
      "r207",
      "r208"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Debt release",
        "negatedLabel": "Debt &amp; interest release"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "totalLabel": "Total General\u00a0&amp;\u00a0Administrative Expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General &amp; Administrative Expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r67",
      "r92",
      "r130",
      "r132",
      "r135",
      "r138",
      "r140",
      "r148",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r266"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r81",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Patent impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r93",
      "r249"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "totalLabel": "Net (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r110",
      "r111",
      "r129",
      "r245",
      "r248",
      "r250",
      "r338"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "(Decrease) in Accounts Payable &amp; accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase in interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "(Increase) in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "(Increase) in prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InducedConversionOfConvertibleDebtExpense": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.",
        "label": "Loss on debt conversion",
        "negatedLabel": "Loss on debt conversions"
       }
      }
     },
     "localname": "InducedConversionOfConvertibleDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r61",
      "r128",
      "r278",
      "r281",
      "r319"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r75",
      "r78",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r37"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r314",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest accrued"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue",
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r44",
      "r291"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Stock issued for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r92",
      "r134",
      "r148",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r253",
      "r256",
      "r257",
      "r266",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Outstanding liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/GoingConcernAndLiquidityDetailsNarrative",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r92",
      "r148",
      "r266",
      "r291",
      "r313",
      "r331"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r92",
      "r148",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r253",
      "r256",
      "r257",
      "r266",
      "r289",
      "r290",
      "r291"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Long-term portion of notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue",
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative",
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r41",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue",
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative",
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Flows (used) in Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Flows (used) in operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r53",
      "r55",
      "r60",
      "r63",
      "r82",
      "r92",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r116",
      "r130",
      "r132",
      "r135",
      "r138",
      "r140",
      "r148",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r264",
      "r266",
      "r316",
      "r335"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net (Loss)",
        "totalLabel": "Net (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r17",
      "r312",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Note payable balance"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r32",
      "r95",
      "r286"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes payable - related party"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r130",
      "r132",
      "r135",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "(Loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r49",
      "r50"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Unrealized loss from foreign exchange translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Miscellaneous income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r291"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock value"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r150",
      "r151"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from notes payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherShortTermDebt": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from short-term debt classified as other.",
        "label": "Note payable to pay fees"
       }
      }
     },
     "localname": "ProceedsFromOtherShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Accounting"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r53",
      "r55",
      "r60",
      "r76",
      "r92",
      "r102",
      "r110",
      "r111",
      "r130",
      "r132",
      "r135",
      "r138",
      "r140",
      "r148",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r251",
      "r254",
      "r255",
      "r258",
      "r259",
      "r264",
      "r266",
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r158",
      "r291",
      "r321",
      "r332"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Equipment (net of $60,774 and $51,485 depreciation)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r232",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r232",
      "r284",
      "r288",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayment of notes payable",
        "negatedLabel": "Payments of notes payable",
        "verboseLabel": "Repayments of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/FaceValue",
      "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r244",
      "r294",
      "r349"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "R&amp;D"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r229",
      "r243",
      "r291",
      "r330",
      "r342",
      "r344"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated (Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r149",
      "r240",
      "r241",
      "r242",
      "r246",
      "r247",
      "r262",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r62",
      "r92",
      "r126",
      "r127",
      "r131",
      "r136",
      "r137",
      "r141",
      "r142",
      "r143",
      "r148",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r266",
      "r320"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenue:"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Begining balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r89",
      "r92",
      "r113",
      "r114",
      "r115",
      "r117",
      "r119",
      "r123",
      "r124",
      "r125",
      "r148",
      "r161",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171",
      "r210",
      "r211",
      "r214",
      "r218",
      "r224",
      "r266",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r43",
      "r58",
      "r59",
      "r60",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r122",
      "r149",
      "r224",
      "r229",
      "r240",
      "r241",
      "r242",
      "r246",
      "r247",
      "r262",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r339",
      "r340",
      "r341",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r122",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Common stock issued for services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Common stock issued for the reduction of notes payable and payment of interest, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r224",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Preferred stock issued for services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "verboseLabel": "Common stock issued for services, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SalaryAndWageExcludingCostOfGoodAndServiceSold",
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Common stock issued for the reduction of note payable and payment of interest",
        "verboseLabel": "Stock Issued During Period, Value, Other"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r229",
      "r238",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Preferred stock issued for management compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r92",
      "r147",
      "r148",
      "r266",
      "r291"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r229",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Going Concern and Liquidity"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/GoingConcernAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary Disclosure Of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Foreign exchange (gain) loss"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r112",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Common Shares Outstanding (Basic &amp; Diluted)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://sunshinebiopharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467568&loc=d3e6835-112609"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r351": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r352": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r353": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r354": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r355": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r356": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r357": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r358": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r359": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r361": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r362": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r363": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r364": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r365": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r366": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r367": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r368": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r369": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>41
<FILENAME>0001683168-22-000663-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-22-000663-xbrl.zip
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MK[QF$[CQ(:.H@5U:S9P@^/AY_VDA&76\+/%?:/^![/\-V)O_$K+_">Q_X9H
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M>7%'G[V1VUAJ+8@03@.&FOSH!9,&[*^!?Y-5J(AS- "[254/C6A [A)93VB
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M^AMZ)LZ& @\8_A-GI8W_-U!+ P04   (" #'BT-4%PI^-PXG  !)+@  #0
M &EM86=E7S P-RYJ<&?M>F587%NV[2ZJ\$(#! \:W-TA!*D0-+@%)P1W24@A
M@0#!"1[<@P1W@@:7H,%= @2WH/4JW;??ZW/.^[Z^K^^]_]ZN;_[:<^TUQY(Q
MQURK$-.(90#_B3Q,'@"!0( )\@<@Y@!9  ,-#1T-%0,='1T3$P,+2H0#Q<:&
MDA'>PR.B(G] 345.24G#P,E$0\=.3TG)+,3"SLW#S\__@$E$0IA7G)./G_?W
M1T"8F)A0;"@I#@XI+RTE+>__\X-H P@P0!!@$PRB U (0& "$*(+>   (%30
MWQ[@/QX0"AB"BH:.@8F%C72HP0=00& P"@2,B@J!(-_Z(M\#$ )40EH>&;1[
MZJ;H=,Y$O/XQ61CTCRK:B35&#QGXS%P",+%([I.2D3,^9&)F8>47$!02%A&5
M?2PGKZ (>_),4TM;1U=/W]S"TLKZA<U+5S=W#T\O;Y_ MT'![T)"PV+C/L0G
M)"8EIV3GY.;E%Q06?:JLJJZIK:MO:.SH[/K:W=/;US\V/C$Y]7UZ9G9E=6U]
M8W/KQ_;.T?')Z=GYQ:_+J]^X0  8](_G_XJ+ (D+!0(!0]!_XP*A>/YV(("@
MTO*@$<JHHYLZWZ/C]<<@>A235=&.2<^G<4ALYC**1<+ O\)X]!O:WY#]YX %
M_%O(_C>P_X-K%H""0<C) Q, 4L"YA+GN1*E[*A67TG@IYU9C7?I*RLY1IJ9N
M"F/;'$4L+,F#"D?A?(04_@U;%@&T#R[=O)?;NOD@07'7KH, K@3'&K& K;N9
M-;PKT OX+Y%4!!#SXMHZ7.H':A8"6-YTO),K"PC[;_"H.+-7.>_^H8!:":,P
M:/8/WO)MC_9M$P%XA-&92$DSL1" W=&[6Z!:ZH9R" 'T5OM6=3\X1?F&  Y=
MA1  W51"S!MW*A$'4M/ 9NL+NV36KZXU#89KPA*L9X#KOVC[74;N__O\DT^-
MJO;W9JV<%]]G\[K]<_A)M(\-%2MV"1-8PW3]4TWX_'?82LK@/?!C57$E!&!2
M_/F6: +T35V."#2R".^3'6W]20Q' #GV;)EE;T[NGE!'_'9" +<4-D:H@((S
M J >0P#U\'COTNJK$R^*3H)YFT8[#VJ'U-"U":J-GF3J\8TDZ;XU>CAU?@N_
MGPP$!4_MY8,*?=\4-L?*SG,OCTMG;_.7]C1EZ#(!:!(\TN/"8DT<K,]Q=LDW
MQCIO6^WY=^HR\:IEN%WH(B@.N% !::?V1JH>B:#3JWFG.2K1CHZ-&?@;SL_4
M2Z9MW0L5L/2[I+;==,9$^;'\2?I)QG&[]0DZ"O.F%T3]@>G@-1J75Q<"/OZ4
M"&!.W!0!2'/@(0!T/O@QAWQ*9+;[*S$N_!>-=MR+)='M BUKAIO233?YVD'<
M9(3R(_077N+Q(S#-,V5!*OWVTH<V^/=AA(J].)0A*Z/=,F3:6G;X,MT8]'1^
M[+(0[6\EW(]C'@=BA61IXIFP/ND=%1 K59#G$E?'T9BN:9FG^2 CZN3\L3+'
M:4>Q3T&^1T#1*^ P@F.6^9$J5,-P!89A89()CJFV^.@TTRV\*TW%2*2-VA.V
MMY<?'YGQYLH-USQ#X[$LY"DN!3T\25J<1)-5I&]Y&?RF\BSMQ0L$8"Y7WO0E
M?=\<JC:;U$E(\#'6PEV-NZ#EI7L9O*N1;5?'A]4,7M7N,39\?L$%SK[D9::-
MB?]RPKQ\<3H$V$X;*7N_J%(U=3:G92#E).==6^*IXI+2KS(<_,)^N.A?LIU^
MWU?=0*TAKC>2C//IF+R'([6M& E%998GX:"1$T8?E0! I"[W%R,>^75P!]L*
MA?\D=D< V2F-6%LWG@B X:2K]1RK$0&,*DM3H1*I2U/>_H&K(LR_DNC?#V&W
M.Q/;I: 02[7)/2G+)[ <S0')F*$KF$<VJWLC $8\>010KH4 [B*J2S'=1OBZ
M2&8+TJ+H9@W@;(Z+B[TSPZ_LMB-/04,S7K6[7:)IFQF91C:QD+2;IKW\50+"
MW,>'D4(5WA@K'P \#6Z/TR']E=(:R,3J@Y?CAKE[MO<J^P71<4-XYP,OT%9Q
MI3G:!1@.OTX@OU)<\-+&$2Z^*6U9>T(WW4=.Y [-:PCGIOT0N,.+FQ"55YM*
MW#GB>IXZ4/1Z-_G<#CJ-A5*F,@F2!C,LN\#Z:/JEYGR&MLBM@PNTI'B'BN;S
MJAW20C WGY2XX'Z/<.)+R[7GST_53==;;3FB% S&KX0YYNB26?O5>A2+IYM8
MMHE?*JJ +A7Z?6:'6L8BUA.A3--5/40J37SQ.NR=GX_0V/8.I"/O/YVJR5I[
MOX27090A:.#E<!KW25^6;M&@\O4Z@Q(V)O%H8RNK:E_WSJY4]6LE2P3P( 5Z
M_R@J&I9OS)6T=;W)$L#*TK[\9)T0?9"W,^K74O:BZHKM X)M%@1P3PIO@6/>
M!="+%8_H>HCUD;>[QZE-T\$GL'0%3MZY=@"H>N<O\(M6:\\YK-2I,03[-EQJ
M[E_J!E:?Q,QS"P/V6^_=(BBZ2.HN[L%R>[P0@-6$?0W&4*U%&R9OPJ4EL^;C
M(0+3VL=6]C%%I8+?JVV[_:LCJ.V=,Q\T)'3/B,>KAR=M1><J0(!'(B8*JA]6
M[>F4'_\*V-TS@W.\]4.#H=!H4W"K]L*>921"3/9'#K=W?/:CLKV?S\Z61KQ+
MR^#:\\0DN3$7GI=WCAF?4$-]19&!;V0L_UW?/2(BBE.FT:; -+"&[!$KO46
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MBB@B[XL3L@V<<85*$=ZH.]7>X1X&+02E]:/5MC36,J:YZ K''&$%2Z/A[A=
M8<3;#W#YTX14#SG?.5L6S!JH>N;KMPQ&=Q2."WW 1>YC$3,77]52]P^@DY[
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M!9AN&*XBW@6+\^ T-2<FICBE*X6R<W*%3H=&:].WLAN^7E\V.6/0T9]%2[B
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M27#Z,U,U$M#PA^4,LEFE6<S\",NTX7N&>%/2MI=BP!._@'=^!3.^U I5CI9
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M.I\.3"DH]HE5;YYF7NCIJ[CORQ1BXV2)Z@V+PAF#V3D/5>9B]S9MH047VS"
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MM>J)J2,\&#G,&2X"F-']+]KESO#N[CY\E#)3AQ3!3VUYC'28VZ7D)HG&BI'
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M:G!GS+ME6)S!EB[:!(([-,$);H$$=PO!@[L'M^#N%B T[AJ<--H$:=S=W2U
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M_XEK&8")B/!W\1#Q &* "U\%.X_:X$S42"8T>A1AC=_F]2^ 7*^.TV YJQ<
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M2S]W6_5"-0TX*_=1-XBIC.L?Z_[?R=O_X@Y+WKT 8/V_GYNJ+DKA)F?OI>Z
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MC^4*G7WB'W,SU0_C4V.?UA?KN18- (*)Y7.7$FN-X_9=EN4T58/CBMVU*E.
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MZ17V?@95>MH7^VUX"\329#1NL=+$E^9B9UQJ0USZ [N*@F5[Y3GM<SRM%@/
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M0EEUO=98L;7^-8Q&"I#TZ_).&]$,9N\P&O3GU0X"4L5(4MSG:^#?X!*#2F6
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MS%:3SSBNUOT!A3Q61FRZA>Q)1J4VFDOG*TH<]X^17%/1'UC.'=C*CTH.=R^
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M[0;SVD- C8X$VN[L_V\" %!+ P04   (" #'BT-46TV%G3XE  #7)0  #0
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M[V>@.>XS!AJG\SY\FPJF!%CYJOZ!9K;[F@:?>A#%>!F+MP&SY@$!(!D\&_+
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M&.ZPBFL5H/A0SC3+/(O0/54PGBAI,1:-(/R)\9S,D*O,6%X:BUJ" ^IOJ%R
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M^JQ9'0#I98ZHM^AXC:C!*7\WVXMHF:X@!V@1U+;IN0J\Y[U-7$*K#V)?]=L
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M[,V-=7'7[J'+?+LV<'1)+-WH7[\JX=CT CJN5#)3)=[V2I-A0&B2C*CF?N9
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M!98V-%7W5.^F:6_6_)W/-7C4<<_%>OY9!7DN_$UKFM9$O'+BP]C\*FN\9%A
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M9._-/%IPD5(.=H@H)O-07)8/V=!*5*+V,Z6E 3C<6,E<_O:M1%U)UE7NEE4
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MKU13QU)M9[?MG<X.34(RNQ2I!2G'NG]] ? ADGA2MH&3[LYN%/$[T ?B(W
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M>!>3EI:P&;$&46TP&#A97,8I9I/-_@L1'="+/ 2B4HDT*'@RZ5/32(5!^1)
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M(/H2) LQCGA.D*NLP/6BBVJD4L(='SVB)=T[@D2*!2,[ T%)<@P.+\-=4V8
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M_9JK;D_?ZU#J'@W%+X%I_RX?\8 !?M73 _4L05_@WI<8F4KCOW[Y+N*_VB^
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MZZXW2U%5,*I+1JVBN6SVZEZ8EN^ORZ7T<WR&RS\G:97E(&?9#RA;Q?MI&SM
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M?YK[O27A(67!+V_Z;T_>]$C@,H\&TU_>_'I_-+@?7E^_Z861$WB.SP+RRYN
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M_KDB0 I^M(6"BK:(+(P)ITP>FG, _A5A(/(?,9%7:(B.^67@01%_%@7;2/B
ME]1#A/N*AJ[CIZVZ$I^%>LAKQ*&PH]BFC6JB0_\_Q.%@X'/"4-A1S-4&%1%
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MC2I!3PX(IXBUU](JDM<YB1I7VXH@>K; MF0I5#:?;#^FDVT@K)0HDT5>2F5
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MU^6Q:"WDM=NV]:$'#5FQ?$$PMV0?7#>G%AY&%]"9K4W5TNC!2<AKE I/2[H
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M,NZAVZ*%\I<4H+]F)52M5HN56KU:/R@LZ(8FGM#H!RAE];.,4_T[#?5SCO\
M4$L#!!0   @( ,>+0U1]O(?XG@(   L)   3    <W5N<VAI;F5?97@Y.3 Q
M+FAT;=566V^;,!1^CY3_<(2T:I-(2=I-6A.*E 2Z1LK2*-"'/AIP@B>PF6W:
M9K]^-H9FO:WMM$P:#YACG\OWG7.,[9Y'7^=>M^.>!V-?C: ?-YI%\\!S'3.J
M5:=9=B<7_A6$T=4\.+76C,HA#/JEA(@46, "W\"*%8C:9L*&$'.RMI2A,EVV
M=@7B&T*'T+>\X#8C,9%P<G(X<)WE\XH'-!;EZ+'*:S&,X,Z94NV/0.);V4,Y
MV:BI!%.)N>6Y$V_*J% 22 8QA@4J< I(  *?<)Q(QF'!"D(Q=IV)MV<X>^7\
MK1*2K+>6-Z.0,$H5.<(HW!"9@<PPK$E.Z ;B+805%9FB#!/"R@SQ MG=SHPF
MA\#6M>H*;XB0'-4.0HDD+G0*E7#&>&%8A+W!SG>(DXH3211T1%,(;I,,T0V&
M*2L*(H1V4]$4\X?*XT3JF(.3XV.[KHJ*D^*TVWFO%0_R]'O%1O?U#W@]^<$V
M,&:088X5J<34V8:RXJ)"IN*K*L=&[^/QYV<AV*8Y=';HKC^H:8MN1RUJFY@A
MGFJT:=,X0@M/Y!)T*@G]729UDA#=FC'/#6^]8O(GJK+,L9&EYB?9H:J04A6L
M)0H-K*:L=>6(N%O5%"C@9C<J75$EV8MP=C#:L/MNUG^S)7S%-!V:6.9]AF->
M(;X%U7A'_:.C_XSG(X?1>#(/8!K,Y^%R/)TMOIQ:?:N6EV/?;^4FZ U)9::C
M]M^-X/4(8L;5!NHE+,]1*;#ZKS5?5GW.N-&J#7"-N20)RMLT2%9:S5GD1OX#
M&)]:%#U!?F #9<<O\M]HZ)Y=+*)?T]M;HX+DV^%+]!Y[NO0<X8"/KDFJ3@Z)
MJ.M<JC-"!_!J9.JU^C/N;^*[1X[WR#U%S*D[R]M'S_YUAXZ^S)C;C;X$_010
M2P,$%   " @ QXM#5!^^WL6H @  P@@  !,   !S=6YS:&EN95]E>#DY,#(N
M:'1MO59;;]HP%'Y'XC\<15JU24!HNTDKI)& T!:-4432ASXZR8%X2NS,=M:R
M7S\[E[+UMG8JRT.<8Y_+]YUS[-BY"+[.W7;+N9B./#V">9Q@%LRGKF-7HUZU
MZV5G?.E=@Q]<SZ>GUIHS-8##?JX@H!E*6. -K'A&6*>:Z("/@JXM;:A-EXU=
M1L2&L@'T+7=ZF]"0*C@YZ1TY]O)IQ0,6RGSX4.6E&(9PYTRK]H>@\%9U24HW
M>BI"IE!8KC-V)YQ)+8'B$"(L2(8Q$ D$/"HP4ES @F>4(3KVV-TSG+UR_E9(
M1==;RYTQB#ACFASE#&ZH2D E"&N:4K:!< M^P62B*;=;8\KSA(B,=&#&HA[P
M=:FZP@V52I#2@:^(PLRD4 MG7&05"[][N//M8U0(JJB&3E@,T]LH(6R#,.%9
M1J4T;@H6H[BO/(I4NZ6#'IX<'W?*LNA L:[0>Z-XD,;?"S[\4_] E),?-&)(
M4*#F$U4E[D!>"%F0JMBK(L4*Z<?CST]&[VC5=BM$DQFVZPU6M83Q8VQ"3D1L
MDA/7/2.-T*01[F61LN>2:/)#V+8:T[3=*BF;I2IWLLCS%"M9&8**]S15DDK>
M$&U@U14MBT;EW:IAP #KC:AU91$ES\#1$ R>'8PF[+X;]?]L!T]3C0=5K.I]
MAJ$HB-B"[KFC_M$CY]1>>0:C\7P*D^E\[B]'D]GB_-3J6Z6\''E>(]=(;FBL
M$@.E_VX(+X<5<J$;OAOQ-"6Y1'T$U5]6^4MP@E43X <*12.2-J@5SZWZM^$$
MWCT8GQH474E_8@5EQR_P7FGHG%TN@M]SWEV3C*;;P=_H/?1TY=K2!D_T8,1B
MH>V^8)JB<.PK?:B;,&Z)3[]6_Y:!5['>(]-'*#Y&SRZ[S'V#IG[S??K H6WN
M(-6EQ-Q=?@%02P,$%  (" @ Z(M#5                !$   !S=6YS:&EN
M95]S,6$R+FAT;>Q]67/;6)+NNR+T'W UW3-V!"23U&Y7^88LV]6>]J*Q7%/=
M]\4!$H<BVB# PB*9_>MO+F?#1E(2-TF<GJJ2* )GRY-[?OG+__TY#)UKD:1!
M'/VZT]YK[3@BZL5^$%W]NI-G_=V3G?_[>GOKET$&WX/O1NFO.X,L&[U\\>+F
MYF;O9G\O3JY>M$]/3U_\Q._L\)=>_JS]7J?5:K_XQZ>/E[V!&'J[091F7M03
M^J$PB'XTOQ__JK_:3<*@\%7\1 VR_Z+R:OBK;QZPOWST@O]8^&I6^]5#_FJF
MOAJD\4&G?3QI'OP-_<#/IN^V<<ZP0O&/-U\_FJ]G]=\W7WV1)5Z4]N-DZ&5P
MAOBFP]U69[=S9+UD-Q6]PHO@][VK^'KJ>TYV]]OJ/97#*:X4_]SU4KWCOBAM
MMQH3_@!/=-I_'JBO)J+?^.*C%_!7]<4\W;WRO)'^<M]+N_1%^0=Z[VZK;<T:
M_I+$H4AKGZ&_U#SD9\EN-AZ)M'Y:\.<7^&=\LH5/=O23O3B/LF1<OW+Y1QI0
M/Y G"=RXIB?D7PN/I$E670U\6+.0RS?O/^GOIGF4#N"XNT$\&GAPT'N]>$@/
MM4[W6SMTS87GPW\=_+]?LB +Q>M?7O!_X:]#D7D.OFQ7_)D'U[_NG,=1)J)L
M]QMLQH[3X]]^W<G$S^P%<X,7^-P+^=I?_L_NKO,^$*'_TKD4V2OGLS<4+YV?
M_L]7SH>W],/W5N?L^^^7?^V\_>WL[ +^@]-S=G=G?7K_Z#NN^7OM6K^KM=[B
MA0=O^"GXWUT>/SS\+H#@82'P_^\BV,KQ.>Q1XH4?(E_\_+L8?V\!4SQH=?8[
M)W=][]E01#[\D[T/O:OO69*+V[QIO^Y-;T7:2X(1LH+O6>S '0Q%+W/RD>]E
M(KW%ZX_>P'&^_=[^+CDACP,?W>8=G>^7<(@B_=[Y3HR?7Y+29[=YSUN<RX5\
MUWYE2O=[^>GWBSP1WP_LMXS@$_F.;NR/G30;A^+7G3[<E)=.NS7*G&_!$(;Y
M+&Z<K_'0BUS^P(5QDJ!/=](/KM5S?I".0F_\THGB2- ?@Y\O\7*)!&\M_1;X
MOHCH#N.O\,7/^1#>U>/K^3/[BLSV?1(/%;=HM;.8?S[=!3;@1+ X&$H$+VOI
M=>>U(=A?7A2&N,^H+'E^W0%I];(; U_V(B1D>SH%,M]YC7^>XP1JQK$N 0Q7
MN043!G^?>#U\3+Y5BJ>7Y_%P&&3XZO0L\I%[@IX%_#T0Z4YAHF?IE[X]N<#_
M=0>HK!,@;;5:IZ<[3AX%_%T@7&#WZ<LH"('UXIZ]5C-3TUC U%J[[0X)FN+4
MVJW6W*?V58R\,<WL2_]S#!M_X8V];BAVZLZVQ6?+/]5MWO[1R=QG>)G%O1\?
MTC07_ML\@8V[ (*(_?_UPEQ\R08BJ9TJS/.8IRK/^;M\W_<+H#0!DM^G%W\2
MPRZ^HKB.@_;\=WK>ZP"B&B5B(*(TN!8?P*X8BJ;%M-=^,5]!^P&-PG_G)1&\
M+6U:26?N*[E(XGZ0?8S3]/;[/XRCB41TO#ZS/?/] -_GA1=>X'^(SKU1D'EA
MT\SG?XWO///9[NO\F?:=2;Q]CW4<'*W].F;G.P?SI_]Y+V9&OG.P7+%&2O0;
ML/=]W&S8:7(;+(+>#@\?WL)F)\##Y=ZFN:QN1HH\7(5L:3Z0*9+P:!5RNV&V
MMY.$1_OK,_.9;O31P9HPW9:6Z*V[K.-T7936YG7,SHA.YT__\U[,C'SG=/[W
M84XL=>(Y3>%/IVLKWYM7=3L^M@"OQC+.;;;[==A:+K.8R^IFNW"'K:6+SGM<
MI,/6TM62.5V0P];23=[["<C#UKJ8O!6OX.W6L;\N)F_S.F9G1/OK8O(V+V9&
MOK._SB*Q^9RF\*>#=59?&E9U.SYVL%S]?U[G-N/]6K)_;"ZKF_'"+<!;-ET
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M;DH_><B[+!>S1EI2D\?S(>]RZRZ[W%K.+K<?TR[?A6,L7.-OGSY(;FR$EUK
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MQX)2:YSVX5_593-\VCPXHSVE*K,*97#PH\>I]R0B;N BBR1U!MXUYPK%E'N
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M+0;M[:!:[PM!RZE:-1BTMX5HO3<$K>IX5\&@O2>^[NTA:+'?XHS0P7>"H"T
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M72?[KV[/E>=@M!RY^_O[^(\DL'JR*O]?.3A:3'2U5 ;ZHF&1"H2+6)]W=87
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MIP&J5 ,OWFWESD3LS#_$]A9=?FQ-Z5Q1W"N#TX0+@J+*(\JG#*(46P5ZO4$
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MH$//%XP-"IPGNJ+6--1R5'=2A</0/5#M6].-?6D$R+_]"S3WU \(HE7"FV9
M@.;*85_C#"6LW@#:)J4@&_[G@.X=BN@J&[!NC,8%G*"6T'.'+ET=JZJ_<F<I
M-=5&<\)%JF<@5^I;K64!=9GKH<UDB1;<+?@4Z(1[@_%]@Y]05HI42UKT P ]
MDVK*J+"26-^(GI>G&E4VRH%TXCQE$T3VD%9Z$AV_EZ8QT!9J%40R2+KX;B_!
M]F.1(7:;#X@^=H).:6V(;YM'2DF&BXDDQ"W \1IGJM>N!*^5"X%UW Q$A"_
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M%ZVU8D1K!-3"SF>R6-%=(;QL4$E:*B4[V2GR<MU$YNHIE2U&[PLQ[@\T@+;
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M2];>H4; A4)B2EW^%M(\\19%X7FZYYQK'BFA6;EA227ZY99QT"HPU?84N.R
M->$*<H1F&<RS3+Z-'W,,5*%V%!K6%EFF LVQ==X>6(0X0P)!UBQ+$1_W90-+
M2G%)V5RIU(:P& 358"'JW:9_R%DT-J4UO!*3]* 14*?U""6NIK_]KSA JT'A
MP>D[H,$<XT3G:Q1NDN*+KC/$)98!&!6_+T"TU-VP_[*D@1E++_KQWK\_9.<:
M4EXMA9610F=HAB85 MVMLF^18-.S04KY8$7&JN4)T5TJ5(=H@NX#$07VA$BX
MO8V%,>W*!X0"."&(N%"H# 5/ZKF:%)1%9<^X!\P7WPZKBK'[-,O WR/$>G0N
M,\Z>PZP=@J3:V][Z-M#9SF8M*?)S-OQBF4;%.<K*9K63FFV4+,6;>MZ(R*[8
MBC4=>,9.Y4'WG$O,0"%;+@5#%91 (Y:ZXXK>8;?BBJ;VDKYM+ZZ'?S5V%F[]
MF+0S23;:M%9:QO;6.8*Q[+9/+=A<H,1B H\TNLLGB+*2"42_1/H7L)<W.<3(
M"@C\)Y%/]K:T=@SYDG_$:N=>:D9&S**P@96-(Y&E_PSWOFA7P8V@,E/, BP
M]\.86*> Z:BD]%*-@,RC*9" ,Y4";*XA6T7I3LVFGUE6)#,R,_4;P>X4$A,K
MR.R6' N_R7P'%%4LAP;-O=-["UH?VQ@#,+T+&73;6]SM&F'O$-;YAJ $5$,+
MN^N9;C\Y6W.Y4KM[+3H7LQ?'>X?HX5Z3,VA0.P8@HY5/@5/]I<[&+0>Q)3VE
M^-#."79/7H5QU[XEA9,DJYS0HY-\Q'M-U7_4(J,W0(1)5W)+RS16LDT6B/82
M;.7M.02:3>+5.#+V')XTU:5;HQ &N<:ZQSQQV;P.[SYZ(D!73<:*)P0I:1L!
M-@?$!>>1U+ Q(QW4&^D,]G,F&#:329F0C=A53J,UA;G=W$F4L]H<12$;)+.0
MTWMA"<WR59.^+*/,2$1\JOVHP3N/H]VK6.4-2_U?C<.O[L$DXR$IFL! ?7*[
M2&!]JF1!Y#2EA9:# F2RH*_OAGI/I+*_M&+\YG!5_\"?1-RR9Z1L(LDV$_>5
M1&T,R%)"\6-'^W;[%8BY,#2=AECF*0M.=8;6Z,H25A<%XMXR_>:KD ";,1<W
M9F6T25'Y@TU4?J51^79K$Y9_)/=.1R)F0Q3FM%<*<96B6Y9+#42=<L(9\8C/
M8 0G#$&UR;EH$1O6*+^B:]3>:P:@U6I6XZ/;6](G*3OJR$985AE&L2.$Y8I[
M[-8KNL2EP])65*B7I2<#?@I46"H]-Y$."'-< 903T@F.7]5 8K!+MH^GRV$0
M=IU3UT-"Q_BO5 5"R)ME!3ED[C3G>XQ074WM0(QV;@4$RN:6/<.4+V$55L42
MO]H>@AV**CY#];W<D+[28I)LJ4(DT@0^9<V*=,T5M2#5,YU]_C^!-5_)MYDX
M*$;>9&NDSS&K[&E&J2W<=AFC %ZB4TZ0N?G9@,MGO  [#85A?,,QC.(<U9:C
MT2* PJ]D=:^I^CSK]6)Z-787Y')<]&M+78W36JH#LG-?U@VKT:EC%.,N4*_M
M/E4[#^#/(N(@@D;-X=HUM8'_I>;Y*!Q\S8:%0><V/G\9$;2!!PQWE6P+[#A-
M5*:'.1^40 01+C!_LN5/#PP>!NN\A6P7VP^2-.,^LC^$KH>.F U1P)[[7@A9
M8T@4 LR4W K,MBP>MP&A?-Q$T@]"47?L*M"4VN2SH87'0@N<@V7Z<A1;TJE4
M'!6<0]^/C59JIXU@']F<Z4;8#2GM+VWHYK'0#1ZPT@"#-,U9^<O36N!")B_=
MI<'I>J"%EO!7@-JN \[E-:%E>$R[)/'E5OORFER25*>PRO0)K2#*/NU67\4-
M)3X62IRBMBBL#=5-6Q*KI-T-&3P6,KC1T1#9N,I&53%F3T%DZ712I@;<^0U!
M/!:"R+3WA5-]2HI.<]I!R7_GQSK0_0H$S(8^'@E]D$NW( RLKNA6_4^>BGX>
M.F'0QQ28H<SB+8''H>JB@Z16J9&%^E0H=GI"\*O&GV0AIU(?^ZB//;HP<&QM
M7*D>0[GSS'=!B%/\6Z&_];!;IY7Z7M0^.?$>7E*YU[(XHBZ%GO.O,Y52:,L/
M>W#EI,2H-V94E^"F4NS#+2/]UJI4LH@45((SJ6239\Q.#,F:BFQOC?ZNDU.J
M_>][EWO6]IBZ NTMUQ4<DNQ^I\H&T]':";T;SD:A=YDW(#PHA_7)0\@[Q4!E
M.=4.7B68S0F<,XYT78#+:C7GC^EB ?3%ZU_D JU,+K,E%!! 3SVZIW%R<IY4
M@9F8W^ D\Q'F.1!,B@67B[A-,@T%ETE^_2#IY<.4,'G9D4^I-Z8"P\=DVR'R
M=7X35S$Q 8!UHM!7'Q=@X'GITFD@&FE;Z7HR&65CH:F@CQ68 0/24KXAUOZ$
M<:I*4!-L@YR*7B*R4D"E]@:I4I/*R_7E0V#'FK#;$PB?_4%%MF/*ZREL*^:6
MV>RI4(.)U["'(-]8((!<[T:#^V'/$7%M0E*&WZGL23@CJFU*9(2-\DMY!_X6
MWV"C(K<X%\Y'+67BT&N+I;W(4NEBQHV,M5R'A]BI:8K[>",W JLW8'FX(279
MP<1:']KU4LR-E#5716*GR@Q%\"YGSX<9\YDXSZ@#4TI* *96EEP:E&V'#"OF
M6AHN$X';8MT<=$T$&,,T=7ZIL*>A:-\J9&VX68T2,(H3R[HM])- 7%J]>.F=
MZ==ODUNXBMI3$QG\$L2_]344HJRUZ6.M-C>*_3<G+39,&:^QF;,.TW4)$8M1
MCBBFJK>F)$LM1E3R4,K:0[X)%?930#^UIN JF%CB^CU,LD8]A7)AB1D!Z249
MN9KLEZJHF>KTS4V+,=0L3_@=#L&-6SB>*:64([LUA!2CQ11=OF&"ZT0Q"I>J
M/(/B*N!/^GZYE);)0* 4Y@5&(XL^X&%3@@_$VT/E@X)[=JZXOHYZ9U$/RS%-
M0A%\M6)$IG^'*HXO"U+512Y,=T\AT%,9IIKCKIZC@Z#Q5TP%N@I BUI*#2#
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MCF>8(W;HA(%%I<Z?>4P>:!:"7[Z=.Q=!!(<OL=<QFB9;%"$^&XG(71^,7?3
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MO;=KR9/(9J5528;H:&*-8_((^E?*L0#)G<&-E>"+5-Q!UK@<I#!M<Y#N7+[
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M8'ZPJ\*D!KF=;;WV_N0W'NC]V6NI\HK-[M&7DTGBT0#0"[26O-YKG I%0=W
M2X$^>T?:$DL/IK93X8QEKF":[CD,+-[A2JO/N\QQ!H?QX#)6R)1%53$=Y@4,
M[ZMD!"("+E:)3:^[16=I3;AUUFF4.X&1=U_ R$\+1FZ_@)&_N[-U"S_'DX3&
M/+ /D^HHVF=9>"RRJMO6ETFTS)$+FV@9W2BOXUXV0Q<;,IEV"PX4.Y\)JOP5
MF)B[6G;3]IE\ 9+HWZ.Q?00N0MMG*8^'%UO*_Z9S<RVA333A B)4$;IA(T.I
M O@WC> UKM_?9\,Y<U5;1GV/!*FU*WZ?62:V?*0@%6.YL  -YP)-!2]%IE6O
M':&3H*-D@C51_B@]]7C1_K;F=HSV/$)*#!+)B.8J<9*H;_<JC\<@QW=A167S
M'4CYM? MB V";Y8Z04[(_QXE8OSER<?W!UN]*!>CW5!(%%8# 4W/O>NQ$6:"
MF4QF-)J-]7?U&F^W:T7D&1$E/@+V70T;@7UAY;MGCL%K)B^?D%P:<N!\.AL8
MIOYEA!!P.;$:QN/4ZMV(#DHJ/%+78J.(:L"C*J@1S"+I9ZV37:#<PJM-KGB6
MM.M<:$EV9I_;Q')7N,(ZDE6<LIB75H=VT"Z.>%;L('\&40:'G'0.H5*$&'Y_
M^><LL^T>..Y$JY6.>L /3:7?63+FEH=^),./W/)2NF?*B6+Z-#((/4X0^[#J
MI5"68 [X2.#& ?C[VCE\D$2]F/M"7,6 \4\3L;O9?YN@IIH<A2SE2N7"R@F'
M=<$]H/7Z9Y)YA_[$2*&:[M:M/H E/-@BOWE"PLWZ2RK&-?KH>1ZDM*9;@Q2K
MS91?2IQ=V?G[%<CG<\3\AN0C)I'Z-_2Y5X?!(9L O%+'GV'VF /PV\D__WIP
M<G1F#VCI32$>0DC8+"4!:*Y[3>:5GXWM;Q-+SQPJ903'/B<2F?(L^W^1 AZC
M>;>O/SFD3I/C8\T;43KD<W49S/0>[C,$S\9E>.J\E:(:ZS4+:[P]9>7X=?02
M#I%T$"R@4GO;ZUOS5^:RK4I:D39@,>$83NGV5_?3?+W()=@B[Y$O;WI,*PS>
MP9N4MUAY?=N$E[O'0_  )2@!&LZ-3"[<Y/A-2<OG*BM0:$R15*##D6O1)?B<
M$>(.BF&2=>K)K:YCT@W=I L<3H92U./<%:9L/")F4A:Z$=T,](J,<;&3/A_'
MLPS:CY-%/6;$+%P!&CJ%MC64T-[CQ91"V NQS$],;HAV#Q4SU7N?KTP$1;5+
M+?K47Z;3)/*)Q0OQ;W]/U0P"2937G%";,A46BV[<&-U+2*T-S>>*740<XX<_
M2S$61K3)G*<:EW)TCDRX0%?,M[F)-/IWF=O3J_D@PRVFL[77)?YU24HRY_2*
M;5MD;!*/.[@LW/$U^<7,4Z)I*O1M1B\(MI<GX'.<C9D](PSZS),U\+;3:X)4
M2 $72*1HRW,77/5>N*3UA=!X-N:TF<YF@D"6OJAAHVH47H)^-> 7J-?X@KPU
M?CR[N(B&J3+TC(-CNANF&9]"KO4@#3'#)>?;MD<VL(8$2R/XL6BBGNY2$?0*
M&4$.?ZRW"D27+]Y;%+TX9;ZNE[XS($^2JZ+T_=E$<\P@:DM$ 9<Z9#"KC<M:
M9[#RQ_ZHUIXH.I_6T50Z)]?GU[1;(0$3WE81<7EG15XH0>W!/Y6?EJXZI1>:
M(IH[#\BH(O-;^FY,M$D7FIZ:>T@.!C/J#LD0'*2Z."3237,!TL_;H3^VO?]L
MJ91RP<&LI3LL1L^B6,+09;!X&)PV#ANA6(VD]>$!FK&1>\;<+I)L9#3E?SB7
M15=,)FP]]'?OOD*6,=>L&FEA4/EJW#_J_WN6Z(TH>LCH\K[B$&)M0JUN@> .
M*H@)?;65(_TIRA6#86Z767J#-@X>U(2=;I3FNKYM9W(C%53^<.Y7_GY$5XB(
M:\Y ;4V:9LCHAI-IA ^^BS\G_32TC=_.2%7])\[D,V]BV/US96@25U+R&DP?
MG[&?^YN+.X#G/E.:''R"[!C==_P>/TRD+;:WZ=9YB(+?T;$C.&+?P>071,W.
M2<3@@WJ:EC:7!F(9>RMRU^KN=64Y(INRD)@_>N/)X]Y%E^,H.)R-Z$NS01P*
M,:)&'R8IJ)OZM./B_4ROHGYD!Y(1=OB%V<Z$*PJJ0S$T!8]P%-,MGCEZZO-T
M@NDQ7Z(23\M'@M.48PX(G>QLT7]U[:J05^-.M5^6+>9L<7GOX"'P>7DL%^'9
MW2>LVQG*7Z]Y6/ZG4.U3-5J]7D2/IM[QUMXYC9P&/X3IS.W93D57'4ASB$C5
MKU/&--]_O#T(3@]+:O9#:-!ZTE."%6WH-'[;*@FUAF$.B:XHKF^%EN!Y>SK"
M/]BOC+HN-5GU5<>'JR2M2#UJKIU6XMVK@\(7CN+3:+:8K=QO\4MP',\N7=\N
M7>36C#[N+IY_X!XA*186_M?TZP2M6]\AHXU7L]OKK=[W$@UXGD>=P0+%.HG
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M>&NFQN9)2X>L3QT:D7?:IK[9: %4#'1#1S%@N!8 IQELT?8687ND\3U"O7%
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MT>]9\=,UA6_C[$+;&@TWV)3S8,5U0H_A *>.!^S=W@KX"Z#+U(RP=?2!42Z
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MEA"W92T)*C1WH>0VF:C-UMR3'1<9*&^^#D^#;Y+RKI4*R[O0WVO(QD)_KU/
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M_#JU)U&5"7%S=L[](;A^ )T%,]D5#",J#5XDC1_TXI/%140%H>WM_K$Q,-Q
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M='W-.Y GNM'N-"SC9D?/RTNQ3QM03C4RJ7/(!E"C5A?<S'$]!_!7T8IN8N-
M[]CC+;#>W"TH8Z::M<]*/W3*#K;)_D@)[CUR&;8)$H1FJ(.=RN,P"ALLDGYO
MTS6(":_8#LNH&7W? E<@R3UDG00^YLGXW%L&C%&ILC95'P3#QZT?=[JQN7=@
M1&B1$,(^>RQTF%]3.;GF#V._S3:D0D]'6F,BXA0*UR0(M5KU^P/XH\8,HN#
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M63JVNK<[7X92RRMJW7 Y.A.Z$3B6?1^V8#3D:/9" P ;((0&P,B>!%UBMDF
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MDBMB<6UOW1-..NR%OX:A;_>+[Q][MT^]9GI;,GT#=Z5V<,NP6AR^/713' E
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M72RSJ62VR:*:K+E68)"PM=M;XA!M6?("Q+SHE2T=*TZQDD)&A\+;BW";[T0
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M7BD5G5W/L1B^(*P@;$T(2YY)'C2M@CJC3AM5>B.J4DY]K 963<L^=ZD]$.>
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M=!_NB)OL;>\[Z?)Q2!?7LK6.T7TGG5!%Q5AP8L%F5\0O_>5]"_X2]_[RZ\2
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MO237U8R5X9+&X1:]#T4U>D%4051!5$'49A.5C.*+9@.K6C@8V?169.E$K-?
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M)3F.A0$X^[K3 R@P#")#,X&->-'!P497<&"3%J@%"F+'!?,']@1?"0#'!<R
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MG(_*52ICN0RE(@^I#%>(BCM\#<#V)T&I25G[KJ6C@WM$KZL*5YYK\Z0PO'(
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MLD4D"P,=?P]'UL4<%9T-,Z0%UW[&W(GT+@>7&$U9#;X'IQVYC8K-GH)+FEA
MY5=9<P@ O9L  /KRD8IG3'*SHF(6V/8#LS[9CG;8#@J9@783?*=(XFGG"GLP
M1S-]5.K)2,.JQ(FG'ZO#$_=76:G?YW7=9.Y@;#DU&"L_//_3?]>6#?7KI2J]
MX@.!;[0A*M9=#;_>)_AJL8-CX[+ .]S?"T)2?KE,<&FA8V%#!>"?OW<#,@TF
MWWPP,%4V$H23ZBAG6$L]X4(#:?HEZ*,X>X<W?+!!+Q?0*2QU&FZ:M2<;;I+O
M$9_E#<_BP:IP9_.U80LWEA0OD>HLVNIW5TO<R?+Q/*E<%6N*DA93874.K9;M
M!?D\WFYOL19[9[33(!NKS7OK2?5@+DX6N'D^/_MT7=<'=>VN$Z#(WX)PNU2S
MO.CN7R5H \"9/W@G0^Q-Z8TGR>G-\6@M,G#,I+!T_+B?>.,\+/%Y:+?S0-#%
MS_YOX_M;Z>9M+T"0_UI:6C3+B*-E((W"AEZ):&M#3#\3,TE))\/DU9M1(:6F
MS"6AX=Y@!')T<!(SQH)L-MXFH)<)B./RAJZ\"&%<S*DCB OK/-A/L$"D+245
M+M+H\"GP];,5@+3LI.6_7^17N<)/9F&X60Z2R'+165<2#O+)66"6)\:@:5L-
M5A!+9[=10-!X_B@F:_-@DO6S9E70N>"SW4[%)F_VS(J0ED9E["2K0RB5H0$B
MV29 =(J5R2F%E&%*(K80>J3Y@PBV_:LB$YF66G_\% R1F;,C-:P&W+#BFYJ&
MM^BV$JV1U3"75)IHC5"1.B9_>:8V[$=FTOG9+"[CCV(=1Y,O?O$HV)D_VH23
M6CRD'1H\229GU$?SK00.DU-63=TPVU>6R4NK.;:SMCX#TX;O>1JF9]AI&@&L
MPARM $NJJ>S(KFK!1J(W&GEQ*K9]HZ3/^K!/\1?2+: 1?R%[C.7D+ZP(0;(L
MRI7R='^!.!/=A=+"[D)4\V5@C8(1^/CKZ:FJ5J65NPLQ5;=^=X%/#*!,1!MH
MLU#X[*A+<AXR1E>Y<_+N2\MY*O6[BSL/R\ ]4^=!+DUR'E@YN"#'9G4PYX'>
MW@W4%YMFSSMS\8['NAMA0)?W\@([-#*-@)41CX6B([,,1NM.PH=CQ1%\Y$&;
M#:NF,X!I.SG<6K2>&N3 'Z5CL'?B4RI88^GQPBSV#JRQMLFX59TDU<\6=(]D
M*9@U.MKI?[O=(S\^/=[$?TWZ@9,M7CER68<">E5]%GNK$?8T"D%" <$>"CY8
M.4:#;4=P*BFBC%5R[-@8B G^F.P0-I9R"+,^[^8XA/F0<(I#6*XNZ!*R$3]M
M*N(2;,UQPIT!'-'ZZ=41LQ,,'./4^LA,U9I8KRNBA)!A@& IXJ#&SK <AZJE
ML?.7P_._!7<,+SA>FW%(Y'Y*?+%P@*^FK0C:X:'Q]7BZFE(3J\'I=N3J63#^
M-7'@5]@9EC?K9^EDVC\TUMC[]/RD(7RT *L'O'_H>=!VZ\1O <5O@=+O';+*
M@=/+DU/^"!T%T!^PZX8GFOG3YR </7,8WB?D6AXO@J:J>7E&YPT'ATNUF>D(
M3XF;]^?V.+8+'U*?N#7TO\I^@\\;9ROQZ]A(<C@%%WHCF_0W] #[65Y[*Y-%
M7X#(@S]D52Q79.'SW2$=Y1T9A!-\J1NT> OIS!_9AD6T!$>'6%U;Z_-RV(#(
M^ @V7ZUBMS"--<'NX-U>3:=^B64+K.)JK'A?CG4AN:?74EEQ#EKA\5$NL;?Z
M@^;HO0+Z'KQAZ(&%PBID82>6;5M/[(ZQ-G2$6N7/< *0;Z$V..E&]XC?&-U)
M6!$N)?9*ISO -XPRP&F$ 6YQ([1\Y[H3BRY2ZAP3K%6IDA]#/+]3S^K??UQ7
M'$L-^"+<H$!;#M$I=7ZHD4N]MNX,#&WX-^)]*ONDG7BZ]5 ]@M.O@I&F9 E\
MY\U NJ.]F^/12CD!YQ<+:-%<D<VE7S(&90Z T/SMX$201V+NFF:5$T=I1I0G
M4&>K1UH_]_=NPDD3-TSR,0HXH'VS;VYNJ""BOXQKQ$E^[^D<"E&>72'"CB(4
ML3IM)P?:+K:#Y=FR4A*KE=1A<F&UX^<[X0Y[242,FS:V-H!#,.GMWV*_.PGF
MVN#%B)@BA$7F4X&!0$B(GU+YP+I@3,LDSAQ*!6KP1<4R=/%\]JA_L+[W3M]?
MI%9<"'G%4)%@N'S/@'2FQ4YG&$,X=I7=:AKLE@W-[/>UGS0Y%^C#"'^;D0 (
MO5"(JF",UY54=#,HZ:T;MGR&*(ZSOO\>@;]H/@$PLLO\D3KQ&J]43H]5$9S-
MRS)-6*--6$@4CG<%;,UZ=06RGT5.J>#WE3A/--(*'%;I[2=E8X9A3(OPGC"T
MK0IICS42]"4$5FA;IH%7QP3/X3T,877;HIV)'=>)!*6PC[%ENWB7T*&S#TTV
MJ<)S_<NL04^.-NWBAUL\_SW 25^1*:QC,[M]O28DJ+6@[Q=K9VGZ]W#9]GU3
M@&#$0(_?I*6[>J;S,S'+#ON/F-@!7 ))3=?CTSD3MA_/&(<]*F(==+ ?&6=/
M6FK)FUTWT4FE[3G"[<8M-V1ZT "1IF2QMR6.# X, S"$]8[?!RVX^<=?#HX&
MOIVF,NGD'8;C^#;XZ756:\WBY.Z07SO0:-L?7 !<>M;?@W9*IF5&?@\WW#QK
M0(*X\6?\T&/XC:WV]V0YZIO$H,/Z89)8&^OP++@Z;H"5D_O;#S:^.X;@>P_.
M-]D,!#&B\PYYQ.^:R;+9L3K8GE]6,B5]/5H?/L'@JY5FE_J12)JT8JNO!O^7
M$-B5LA+U2GVB1T;EMQZKI:"(R+#0-::+E\3*\U7OV^-[Z5M955:=M8XKYTS0
M-L7L2FT4\2?:5TGUK>DF<4**.E.\_/A"VA_^^7BM7]06SD\O#N'EDM,1,2:E
MYJ7O_<2N[L1SN]@/:G]/JI>$-@;&J(8.KD'1C%<L7P*<I?$)8F50\$UB6$\H
M;W\2EV4<6'",3Z--#X_A2.ZD-#%JT 4*O5C34C_ Q.=U\X8?$XN(9JP H^&9
MV8,R4P7RBLJ_>!BMDJ>$!NM,KJ6Z6'A;#<F)WCO$WC ^BJ;=!DF-CXX&RS+%
MRZ2@9V[AS;PQ5"U/PM".V7-3XGK,H&,]1S(PZ.IS&'1SN/'1U.C*#3HY26_)
MV=4*RQE9=.G1T[DLNN70\OSM^LN)8_RK>[7NNDVZ#!"7N4E77=RD6Q(QO][:
MU:=/UN-W5<W,I)L=PAF8=/*"-MW^'FORN9!-5YIJT\GJ;&5^^WMCTG*NRS-I
M=7Z2K&8G1S>GR$\Z@G.M4>[&"E,'!DZAR[>Z+U<\)I7V*:*$5M#,E7W+7?7*
M]*R;6M:7"=$FU_15Q)*BB$JEFF%%GYII15^N!)Q6SJ?4%5&NUL>*^:A%RZKY
MTFJOYBY#R/2 TRKYRK6Z6%)K.^>4\-L DK)*MV2T*'F"6U*7E$607%ZQ6U(_
M@GV.2YIR9CYR+2.O)#W$/X]7LB16GINE?\_TRN#C5;NU7J\D$[QE[I54%O9*
MED6,I%O?R<FPJOYJ9N25S /AY;R2N"C;%+\D'.4C+^R8C%8F+^28R+*<G23=
M',=$/H)SK4_R+NB7E!;V2W)%8Y)?(HM5X A^WG&_9-H]SB7<DF6/.KM;,D,A
M699^228TF^*7*#+XD>/51SX"Y_=*3C/U2G(EWS2O1))44:JJ25>,L E8JE=R
MOH!7DND!IWDEBBHJ=77,*4GKU2H_/-]VM?/SIGG1^;5)'9C+#\__/KYKO+/+
MER=$V:"-J0_/%:)=].6S7_+W=72W3=M8X^&YYWTX<WK]][5N7AM;KF=UO>A9
MO;:>U6K1LWH"\YP^/#\]/IG?A]VN5EU'B_S\XCEAOX/)(1V<_LAK!S,)Z:2W
M[XB$=/3+R/6Q4DE=S%E5?&?5J;0_O/U>JC?/NBL(\:C)CJR26=5X9<H<DMF#
M/*,-*Q8+\BR+'OON??W?;U>_/IC-]09Y,L'<E"!/ZO6?/P%QM+U[)ETS,T70
M4WF@W]\,OY_)BW>]61S2RP5[(NV-N:"3IP=\(MYK6%VX4, '%*IF8+W[U"1R
M>(#3\,VA_W"#RTG9",2HPQN^0:"OF(_7)FPU5_$8]VE!+-[X?FWIN#PN&GVG
M=H!DP!O_!-.P%NWV,QI\72C85BTMY 4J&QYLPWG;:]6!">&V61O]5!8.N>6*
MS*206UVL5TK!F:?4 <Q%KY,#;LL>=%/K #(AV^1X6[TJB_7TVWY<+,T5<#O)
M-."6*_&F!MQJ);&N2 $01IKZ=#&LE=)I;?YN!%D><%K K8[W?<8#;MM>!1!Z
MC?)*"P%FNG VZC7*"QE)E:!1?*GWT;&O["\?>LE>XVS#0&M2G=[\Q_&1\4$C
M<V3CTV]=S^6H+0F1CU\']YT/9K==7K>?)B>9D)75^&G^&*XD'RV]8&6JC[8D
M;M[??VZ^,T__O;S*SD>;'<H9^6B^5)G!1<LN)Y_NHHV..YC+15L.GVMVT;+B
MK]E=-%\FQEJS1F[)FYHQ?.97O4-%*W0([13,;Z3O[]%I%DS1-(E).CH=39?T
M@,F7\J??T2% ^/$GS0;NELN^7\BX'>@M("Y&:VYTT!H^S":#MXE+^VS1*_W\
M+KK-0@JF-7U3XWUH=\=Z\,>1R*551IS3BZ12;0<)_BW"O=6@K??34_/#\^].
MZ_,*(LY2Z4A.ZDI:77_$.9> \]+8N6QU_CGK_-+OO_?2#!F6%,K=E,D&=0N;
M,E2VI0:<Y^JTGBF"KKZIE_]>70YN3\O9&#-SP7DY8X8+N?T]+N4V)-R<SGF3
M;!D0B]D(Q.^#CV_O^G??FK?-M=DU&3+;W';-_E[$L%DZ])S)!;0%XR'5[0P]
MKTX9+A%Z7OP66J[(3 H]1[M5@P&PTFMHRQYVR\+/R\BG(/Q<J8O5:NHEM$7"
MS]G>0LN5@">%GTM2=>[P\R*WT#(]X-3P<TVLU)6="S\'G0\E=94>Y*S3NL!.
MDJ2%[AK65GL-39*.I*0+K[7U>XQC>B.]V_X\+N.2>'G^_OQ..5'Z9S?OR%IC
MW]E@;N&+:--JE!:^D+8T@G3I_JK2_"UU,@I_SP7H+.ZC[>]QH3;#A;3L',8)
MS<\^:<-P3W.T/EMLQ.6$SF<)%]W.%FI]5LE2.*^P]5DE9VDMR56Q7D_MK+6_
M-T_S,VF1YF>98F8MS<_RQE&Y-A%'.VCC3:XPR-K&F[W5@"0MEMI;Y3A6IL 2
MLWB9S=J3JYG9>)FT0%L6+\_5WX_VQ>#'N=>HK-O&RP!SN=EXZ5GQN(V7/8)^
MD'NKW+AIEC[^R,S(FQW2RQEYOEC;WY-G[CN0H9DWH1^:9Q*P\Q8-18]2PX*A
MZ(4F\V[ZP--J\LCZU4G@)4+1B<6E,X:B<T1FXJS3DJC(]7EBT:/=')>*12]W
MV@V.12]/N\FQZ+)8KU98V6]VT>AJQM'H'&DX+1I=52MBJ587T\+1J>T'I(7"
MT1F><&K[ =!YU<KN#3<-?97$T2[K[]8,)M="7<75U?LJ2:W#U17%H^>HQ$ZW
M?N=S599"R_/EC^:CHSXWR$]M[:[*\HA;O'XII2_:PE=EET;,V5GMYEF]/7V2
MLJI<F@?"V;@HOC3;D"KL)2[*+BW^UEB%G2%K+711=NU5V$,_ EC48&=HL@3S
MX>3-;.2*4F^A.2BE%9LL<G*QCK^/+#J=*Z(LC2N_H,7>:F^/+8V89_7]\$O'
M^]DZ<7^LUVC)!G696RWEA:V6I5'3^^&H'TXE>_@CHW:N\\%X.;ME1*1MB-FR
M6,%U1C)PG79+AMRUG=?'AD)9*@R7S*=B\;DMDIQ4D9*7X9(^]V?$<)'0V5B(
M:5<ZZI3&>*5$_LQPDEY6P9;%F]#'YC\LB9CG;\2X_5C]_>/,6WT7^I$Y)5F@
M;EG#9;EH2Z:8^?#UO-)2%._D7>IP+&&ZX;(XC)<<CQ47:>7-,%S2?;5IADL&
M,G!MADNVW+5]$9<.&SLI%99+;I:+/PAO-9:+-(?ELMB(0FFE,SW9F*[$6=29
M#9<KE[*R7-+MQKDLER41\VP^JY]4\_'[U>?5AUQ&)ZQE@+K,0RZSUK(EC?U;
M$C4GOYP[LZ>\>]_0%P^Y+ [C;"P7+M(VQ'))CW/.8+DL*P/7:[EDQETIEDME
M<T,NW'*1JX7EDK7E$LRD6FW0)9V/QTP7>4&'8]6FBYSB6V1FNM0R,UT6SQ;%
MQMLLB9CG?WJ646^9U8OSSGI-EVQ0EW70);T&;)KELC1F!A_.2L,/TA/YT<LJ
MZ#(7C)<S749EVH;8+NGXG&Z[+"T$UVF[9,A>*;9+=9-M%W;YEVGT18,O^WNA
M#2-D;,),F,15ZGW[7OWWZ^^+?RL;-/"J\O#\2S%NC ^E7OMM=X,V!A"[:-_>
MNT^/[W[\6,<PH0D0^U'7W@^[AO7QPMC($6%J,2)L;2/"I%(Q(VP"]T@/SZ;]
MOM5N_]LQO[9W:D98 XP60ZAL:-1:*2U4VRNM=.0[&#C*42FICE?*;/)PN9SL
M^LU?*)A>@3:/Z[<L8IZ'/S_>5B_KO[KO5]]L)^:69(.Z*:Z?E&J>IH:MTTOB
MISE_2^/F@WQ:LZZ>W[[]TLXH;#T7D+,)6Z_A?L-\<:[I/M_2TF^=/E^&?+5$
MB:  :BJY_Q%WP @<!DD _DSLF(>(S2WP)C7S$R>[B4(&185!Y_11!W%_;YJ'
MN#O1:&:.\+;**[)'TC7BN#VR6(MD*7G 4)[V2&(79'\?R]LCE910]/SVR.+M
MXF,Z;TG$/,N79U_O2%_N].KKMD>R0-V:+RYDBIKRA]*O]ONG4^>SDIDY,@>,
MEVS\%Q5H&Q*'3B]<F<$F658"KM<FR8RW,KNV,)N1@6GK#*R,3F!E2+6YX]"[
M8V708H+J##8&<-C^WLJ&VS$.JP%_+L)AE17;&+4CV&@",\TW0FJ"C:%FENY.
M;UD[CXVQ+&*>OU25K^;@M-,UN^NU,;)!7>8VQOG"-L;2J.EUW]U]^/?B9U75
MYK8FYH+FDL&-4'!MB"V1CK/IML32DFZ=MD2&/+2MMD10(<I";2_2E&"Y?3CP
M*B,6,XV[8SQ6E^H+\5CR3(K\K(GZ$6PT@9TRF^F3%K&8WYI(GYDVCS6Q+&*>
M.U_L7X/?/YZ>)7V]UD0VJ,O<FDAO.#S-FE@:-6_?&]\D_=K0?J=6S\UI8\P%
MXRQ&%?@2;4/,C,7']&8@ M=I9F3(7-MJ9H35G,I+-30:;D(!'[W9$#1&X?TH
ML-F3Y6H&L.%8"V"3\JL3F!M8.SC&:5&Q.<O8C=A47:FDEDL/SV?7W;*K/-=_
M#!+JNO.?I:$>E4O+&PQU1525]-9,"/R)I2US P]D/58:W=:(_>[DP_LO'XR5
M X^V=BE+&33C5,2RG"I81+",G0&!SQZ),5PUCXXJM+#2JS[:$OM,=UJ&Y8!\
MNB4&B)/VN0D8&=[#6TX,4%X/SX^/_=-O)XWOY,N/O*HJFV\8F?'5Z9< "9:M
M(4S_!LBWB6WH)FWO"")3$?[S/W59DEZ/F$1UN?;P7&U_?"Y;WV],M\V^'HJ#
M(X$?$CZQW2''5?"?YIO=D*77GNNXP+UHW<<!H"5)V?V]'C':0A.].0:= 4!'
M9\V='9VU5D>]T[$,PWJ"5?_>#3@UXKYIFYY]1-U(JL"AP[3]Z?FU#P[?6)C5
MITVO=XK[M))*Q>0"!AVG;DK<W+1[<&SWZ.@>A>QUYQ)HXE%O@PG*EJ!_.^WI
MI'/^&Z0""JOK#A@PQ$[WC1^S]HTEE8GD!!LPX3RPY8<).\YBC%1=E*OJ1*T8
M^,ZA-[WH#;3S3H=I"?!%L<)9ZQ+4F<R=WB!*>-;O'[OJVV]O6U\2YLK82SGC
M"3#8%$*95O4HISOM_N29,?N5#BQ9Z@Z_I/J^_"91R(7LMA\[/<<*^TO1H0'A
M441AWA@!X)S'"'+$?D:-&WW\IL031';;*HR<FN2)7\ZB:FC*:,%I&F76 8*E
MC2&8]4PB+&V6MJF(9355B/"P FR8DB=&*W2KS4(50#V,;GH@9S2A,]GV2$]B
MC;<NWDCRR,?VV#1J4,IBM9HZ44;DO$'3+.F&QVSUAA,-CPTB@^>/MXU/_S3<
M^^?(1>W5&A[KH)(E# ^,:6HFK,PZ@S#YT/<5+X\YSEXQ-[5M\Z80RJ=NYZ+_
M7KIT;W[,;(#,<,5_I"'T%E@@Z4/YPG1N.)5@YI'(^WL+S42>-ONGP1[XJ&M-
MW= Q[G :FW=<7VS>8L[ZJ#%RS&E"*/64Z6F1Q*&.ZW&)154>]XA](V6>N<K1
MS/+,<Y4WDP*"[:]P/O,F$46E*E;4U #XJD/>LR:;72N:02%PN@%&G($W1R4N
MS=WV+*--;.?\EP?2%B$>QLN#$/FK>( ]*MMF7N/AN>_<V)?5M[^;6FM3PNR5
MU#"[_/ \N*W?5GYXW\SG5V]HJI4?DSY2>RVPX^YJB)W5C["+<0 P@2IO!U1F
M&W1"+,2^OS>N9MDP3+#*:"(3Y<>TTHXPF7XZ[VQ/S%<^I"QV,OQLZK\\<@:,
M8.L#)(.X.(VD$J*2RC>YWE\U):_FU%O=N,75VI#YG\CEOKR<>)2E1H%*)7#;
M:F5130@;+S$,=$R0L&-'2Y>HPW^-QM=*T:YH)OEP9_Q\-*?JNJD;7ST2QU69
M)*IU22S5)@=B1NI  )-6)-$6LP P_=OV6KZ(:"-/@)DT]=+$1-I/FSN=(Z8W
M=29U#B21:N>(<KDLEN344?/[>^AE!^X.IX!$=-<7'D>]-APGC:HNUT7P^V/'
M[Q*3H!E!\Z!LQ*\YPBR3AAW///!W97"8-@Q8*HFUDBK6E;)O\.[O79H"-ES"
M%R?J^TFU-"ER,JKO+BP;+)1',.*=*7")^@/WMF8ZC&*=DV'T+R/ 8>Z!TS#;
M9^#VMUS+=A++ ZGR<JCRXN="X>CPG?D*?T&]D'+>.25"ZE&64O-L3OWD6?7S
M:_G:C%I^W300XX[I5,!TPS+6P;J)8-*]/:D^L3> :^WOZ:XC^'M@=8S^+@0-
M*VOZ P(XH3#AQH4>P@\KA","A&5\.AI\X]%/\>"?&?PQT=S4'$"!7V$* A@E
M<="S)?CN_A[_BE]YBC^[(77L2#%IM)07$&H 3XY+WUC$&P-!X+PYD[*G02EC
MVXJ6@BJ?WM[UG&OELQ=.L0[6\XN+III&,VQ@YF+0(X>TD*Z?++OM8"AY)J(V
MK53KMQT<Q^W9EM?MA2[N_MZZ&H9/*G*,&%J?-%/K$E:;'O)<8@CFIJIU/I0O
MC%8MK\:6\X9@]O>JJ3&8QL-SOVZTNY^TZJ<2!J%&_@ZDV;R[T?K=]ZWOM<ZK
M-R$@A"@D1B,T.Q:HN1_-;DR0RS1Z'9/,-#Z#HG2RVM9 PNC$^0KP17WC+Q\%
M\SJU-=W?D!X6MR@*Y[3S(I[KU&(9FK>6U:9?X,I6N+.,J?[<+.?>'*4MI308
MC/DQ$R\BSHSG2'KT1>,YFCI=&9[E2D54Y5JJ<0;K\XL[DP.WX0T4=NDD5M /
M(@1M)X=P0Q>$TACIR!LM(GBZ"S=/;"SX'F++W/CC][9[ PY-7]L.<EM K/C?
M&#GI"L:':@[31V#I-]J/FFGU]98#@+,'W!@0#DSK:7_O)_Q_$UV&^]M[@>U1
MN#1;QX?@8U%EA9H-@6%;AD%H&7]RG?JQ,"4^,2D'L<GAB6?G^X_/CY]*-_<M
M=8$XA? " Q5"$*>@!:DS!2KDA0,5T=MSJZ()0[EN=^K?WRK74A&UF!RU\&D"
M)-$$X[@]<\9SE=Y@_E4 7M.AO>+=\T>LV$C+^D>++E.?>7A^U[FY?6Q^/#]]
MU#?$Q11JJ1ZF\O#\1'Y<JBW7?NQW7[T)SR6P@^VJTW@=]JJ5RM$Z.5;C@(HU
MWM=D?X]='HOUFA>( ;Q#J(KGV9-HRO\/WO%<T,VPQHXRW1]25:RP/XQ5T]'N
M A519N:%,!IOWM]C<MP@_J6T<.E(]=X?1Z6CXUDB*=+%P[/Z]MNI_N7$^%!;
M>D)*Y@C,?<%<ELQDT;R9(%A_PD@3.%4QTF1M(TVD%SC29/N52_&6&=_B<T=@
MT:!6ZCA2Z>=#J22]\LV.6P(>,XTV7()E,T"#% R46]+5'=29;>'&:QI@#39:
M+33N05CL[UWH=C]'<\7?^8I"W"Q7Z$2*,*D9@1\V+<W&BGZA[1OR^WOPVYUG
M.CVTXD]T:T!C"B(-*NS(Q7Z@F.N!;M+"$Y;OO-!-L'VP,<^=BW<MF/6Z*_;J
M5]I8CPB:U]9=?J<4+$<6W:%U^>!)H[Y%(S6\QN'T"'&I\9A&#\(!+O6?_RDK
MKWFLB/Y\B/$H>&SLZBL/ETHJ,Y?]?A+1UP,$? 104K0&A'DFC&AQTT#&Q'3T
M1^RE!;\3X0 KB@[%&(G_+_;2TMTAN^1$4S<=PWIRJ$=/M%8O2&\_60+>J<%6
MQ_0#=HN2>Z[^$?;WPO9"/O/XVV>E?0=H1O@!8/A;A]@V,^XU1PC U D(+3PG
M@QF-OUD>> ^,-!F(DKZ_OP<@<%"*8<K?&(K4$S ,O,0%>X?O\EBT,[K&P')H
M>&^T1<5T=(5G=CR#$85.,11'#P8(EH9UI).33JO$,+*!=[+\"T1<3ON^BX$W
M'EF%F0&@AR]@N*'MO^.S28F>,K:3>]P!9(O/U/F+#WC96XL%U(%A;1/."O]Q
M-? "A[LCONY'Q5424S )UR3$I.PQH#4=FN-X?1:68O-"XQW<, "DFQX1Z!7(
MKL5%(4+R6&@XH!2=EN<XC)2H/U_V*V^2MA /FO<TH$K'ZW2HD0':U;-IA QE
M%>%- 4>XAUW%-(D+/#30,0[0IOWBP&P?LB/8FNZ 8/::6*CHXNO;EM=T!:UI
M>2[E/G9_;,B#"O1X^WL)YV.H"Y/^_%Z&(PQ ^%/^M$D7C0-V8'@K2!>7V@XV
M ,QP+-@<%E(VH^#AE4A)^&E;=)0LRFP<ZR=0N=-&)+._T_/UT>'@0H:!"$$*
M9Z-RWK]7Z(54OG/\?*(Y.A.<W$39*3YV4H@#:8JKEP$VE6)$3 V "$_]KP/O
M\0GV6+@&91E_ !LB KV2WZ@@D:=\9>K;>>%"B=L(RN10#U-KR3D6OB(#(<T+
M ^8I1#10!QP%9!3?EZ :"E_$G0I?&(3.A7!-:X21S$^H\7T0TT^'P@$U!VY.
M&]<GOC&%+85LV(6-)@TW*IIH_83^#'TQ5_LCU8$\3FC9;6K5!5O\?'QW+'1(
M&]6FX*!\HO=.!4-["AT$;3" <]#PBNV!HF63F.'$GL$%%T?17;@ /GON-WG&
MN*/NT")O?TUZMATI)?Q*[WRT/1K(#:DF!>:@$+# '- >P(T! \2FA8(]^"M'
M-9.*3X1*90I T!AH#C'DX+L0VU83I2$\I#F6R3JY@>:SZ;N9:GCJL3O8,=U%
MMQ-EP8Y-J)0-#$E$G?\5,5@$VQ8AF]DVB"GXOXX-.XEW2-5Q*+<K1"D6%;0(
MG]IP'IS;C3?(N\#,0$_P5WXNM#3YN9B)R4+;)FN9BDELP<*!=2'[VM2_!\ZB
M*ALK%=C5FP 5\"(\6W0K'%[P*IKM\*O^J;R9^7U"$^"*A_0O_PP\>X!8A$6X
M!*(A]C$A1/RV$B8*J;B(\]4P;^$QX[DII<&/Z L@7+G\,RTP%=#Z9N_?$9:[
MCG(9M24"KF!.@=4B;<]F5=(:&EL.*^BQ=>>GDTK>01?#1,MN(NF+4<X<W0,U
MVZB68H3N4DZG>SD&QQK0$_EV<"#R6X.58"T1J48#2#@NJB<=]D)HM6V+< O-
M3[OR2B.ZEW90OQJX6DGG.M[?BT"3&G7A#C#7SZ[L^/&",;=+\%!?X@M!HYDZ
MV*I@E0JP51U!C-JZ36\ZA5I;1%O[B6#[9"?R"H8@I'#T8[E[JT5=U<3M@V[&
MP98Z>>22,L+V %6$$\ N(A:;@745\;2WC2]6Q6A_.7\))\(%V"EV%PW_TYL&
MJ*NM.X8?_<(R#NH3CEB"E%ZPS .HFN!U;*F<.T5\U'Z2)\L"R7%ZG?>[/FDV
M"!F_\&(M=1<;3BHKB<<'Z8I9\J92D3==7]Y4+O*FN1!\WE*@:1GM.59E,"TE
MP)0"+RWG,?[V:;R8Q^[&,YYRD/$\C:933G@RYXXF<Y)K3 (H1Y UEVB8':%-
M@$W7!DNRC8+$LO\6OO9T%^A\-NGRBM+P!('"@/3*)W7@O"@3QG\-OA.KA8L)
MHOC#2=_CK)Y%P4XS*)%;9+5QUIN5E)JQ#G'^'H2,CS0!ADFP+A"U%8A"M38O
M2_I?Y((E.*0T2$7DM*_.LG:2H9'\MFD"/:4*A35W;HY!<,:]C&0:9@# ^!.+
MPF'BNQ<&AZ0N 8YEJ>Q-X^[N_/XN;WDR_8NKE&Z+[&9FX"9I;[O;/)"QX0O[
M=YC YN-OY[?7A8;C@$WR]R8"9;-VLQ2*J(&5@!=N5E6K?R:QWRE6<02E,Q@[
M?]0,5A:5Z /)?TX6R+X1E_BR/U(6E5(<*[6NBO5Z/>VIQ'<DPWT=NU=*8@7[
M(RVX^=7S*\]>.GR<*WH&>7.))*I2=5-85L$)@6OCUS>7)MZFL>QAWN>4RV*M
M-D:8ZX*Z5 $:6"7@%^*-&ZPUTC%A@Y>/B9,[C@!%8X)O;2@2Y4IE U19HG5\
M1FBYXYC"FMN7F,?^S<JMX "NL1[*2QO0+_OT>4N%&;=T3Z_VQ8W?;4:/))9D
MD-'8XO"%$FBU(E;K8V;*JBETS&#87$=FLW:S>FL!NYX/:+7) 9;YXE7;BB0J
M]0J[V%NNB5))%=ID ):VKK%.'-'&,H>Y:W15K)0WQ@0LRZ)2F=,-6)6!D<32
M-YI+:^E"Y-;!AJUC:0[LX)D5M%!,5RI549)+@MX'Z]%&BCC<9D'(6P2\6$60
MW?GSDDD;+(8W:S<KD1_R<27%1KR^;WP4XJ'KB8LLP!+T.7IQQ" SQ;/F7"4T
M#Y6*J-24F<ZQN%S8<#"H=5%2Y$Q@4,B&79(-;SY>-DXN/U[>7YX76:JUV>H;
M?.3-VDTN>C$]-QB9A%<D"#?0D[V*SK-9$"1C&C8!&G6Y!#[@F V1,7)FV4FE
M7A7+I=I&<DT,&\)1T)J -F[-/6;@CR7>#/Z19%64Y]W.&I.J/M;^H_4'KX..
M;JO*)U5EL5Z;,\N6WV[4JEBOCQG+&^"PI7CNER-CG;8YAB$K8EE^N<DF&2>\
MC4GW#8K@+)5MBIA3VXPDP%%% BT\EG1^,61:+Y?%BKQV.BUR3AMJJ<]("#@E
M^PC'9 OT%CF[9VLFV?3;R"2JHHJE4A:)V>T\_X:D(PHAL=U"@B4C$L*4V\@3
M,AUZ4);&',,7(Q4*TZ&0"G->U+C^].GR_M/YU?V=T+@Z$TZOK^XOK]Z>7YT6
M.8N5IXLV]YR;M9O5L\G=N\;M^;OKCV?GMW?_*YS_\_GR_E_AX.S\XO+T\C[W
MDJT7CK&"3S:,3_!*!&]^3(>-L#O'X%B>"'^4CJ42)B7XG.(!L5G3YM="PW-[
MEJT_PU.2/YY*8!.K-A)ZF[6;_-),.NTO^;=P)-%[Z;ZQB%M@-\T3P^)L>!96
M.EJ>Z[?7BR 6_U(IQ6;4:&Y* ^J13[$;=;0D-F]T2/ZHM,V@CLH"NREJ)W:)
M/=]$)_*)*%-+)6FB0"W[?%<(U4U@F]SD:UFIB@K(1UFMTK^5*V(9?E75TL9*
M5[;EC;G0B! ;SX$6UNOF[28WG7;*6^^S:?"F0'ZW>)O>P&[-W>2HBUCV5!Z_
M6;>VFIJJ6(5_BKS.RS@;3(V;M9NU%#-Y?<^?YC,^HB=O*!U@%=,,)5^Y!V-@
M(XHZPY7XPX(_=I<_9LRH1)GFX(Q.>MGN6X 'H+1D4%ZUA9-,VWU\J28J946L
MEA>M/"BD0B$56-)]MI3"5G*)6E'$>OEE2H@:.ICU1:L7"_'P@L3#E"O"D:H<
MFII/$AC3R&S#;\X6%XASNT#,&]%OT="3Y#:S=X30Z4?!:$AV$<JU!#9L+FFN
M[XL?]Y+#@C,-M9"+H1;\B34,M2@70RTRXI:\)B/D-  !U\&Q$/_?*S6VJZ,G
M@@AE@RDFC;N8R_B9\N)91F6,;&Q\TD4Y>=+%7722VW5\LNYI+"9YR<>&?\2Q
MX8L?<"9C-0""_"K)S@SZI1=C"68;2U  ?1+0$Z&4 6W/[VPGH&"A.0);C:)P
M(L3X7(U<IE^L$>K+P&E]^/%'5"R G[P# F%_?M#.FC%^<7<=O>MKDJB,-^7>
MDL;[LB1*\IH:[\_5NOK4<J@5XR2A?9L"GG)%K"M9W#C:SN-+>%]]ASI8O[7!
M8L;)NAW=W6:\*!6Q4GVY;:NEDE@:KY8H[@$6F8B4M[\E)D[FYBV*&FT<3>ZX
MZ&"#-WW..Q45;=KRQ=P8OS2"D>QYG[4NB14Y[QYLL^]&%>7*G*61^96+6J;C
M&:M @E01R]6-N8=24\"6GI,D,FZ?2KJ:L0):J]3G[/F7(PF4:J*DKK(&=Q+I
M7W<Z>BOWTD[ 0$F>LR5<KF2OEM9)]NFO9.BPN9)NZS9IN98MV*3OF3P8GC=T
MY)HDJO,.2\MS.S70%*ML)SB)76XI8L[R/G2U)*K*QERH :4E;P2_I(T("P:M
M;+5#IXBEZLMM=R7AW,*I54+;$V9AK1MG<KJV&6U561:5A0M!MY]LJQ5)K(TW
ME"[B,"_!F\].6L2J&82.;?4CU0_;S!\'E5I5K"\LV+>[4KRJ2,5%DD(NS!:?
MO79[X/CY@H#;!H=%0'937',4S8)E"FW2=(669<([G*ATS@LD![)8JM3$BC1#
MM#3_J[%E<%-JL[CC64BOA?CHPK()_(IW_GN:V25"5]--X< (ZP3S X\BUM6-
MF:%Q 'Y[2557@ZK9^2@8M\"G8^0/AFI=E,:[S:^#>R1 B5J:_8[[ZKGGD^Y@
M%;1F$LMS5G3QO[Q)O;E2VFYOA HZ0]5C$X-H^;--3:R.6^UKB]B+:G650YNR
M=.RXM.M8=E=_)"9QMMJ?D\7ZP@[-]D=[)+$\3H?KCO4L%)A,]C:V&3=@)\NE
MFBA++_-6NE).;,*VPEA#T61R:WS9*^)RVXX[1@*[V^=_Z&J_\Y]:!PQ;JRO@
MHFQ$SR><'%8'3WL&FV=%QOF,K'MC6X\Z1B+0Q$A$X#;*L^RFW[ST\Z]-I- L
M1LO"XD8/K_5;8PF-0K)LM&091RF&/W6'XY2T$U#ZLGEM.\]_4*F#[;QL-Z>5
M^#2I'5*05A.NA$]9:0&4K*AA3+H(FQDD6P\"2:Q62Z*\/ @*MV87W9H9Q=-G
MTR;P ?;0CV2"F'72&<T5N;9F.L;6UQ*6:R\Y1B>/]]S>@CK"5"$VM>_)]DIX
M5')EL29-;::XTTJNHHJE\6KOE2JYHDYH'9JM,"TVU+08?^6)YNBMF0,<=(9/
MBXWXH:-\%H3<F)!)DB"EXSDJ"O+:PG@_D<(:W]3=K)ME4D)(JV0:G+>5,PIG
MY=T5#9HH&&>K&>?E*92"+UXF7[SY2EN'@FIHP"+8!=:?E<AFC%Z'P_+RAH5<
MP@AL52R7-^<N;DE4R[)8GZ4:/!%%+ZYK^/Y>T39\[6W#RT7;</[$&MJ&*T7;
M\*)M>'17V]LV7)FA;?BIYO2$"\-Z<A8_P$S:_,5VJ"[:@N\HT(LNXYO093PG
M3,^*F0*)BR,Q;$6^;B3FG;X>4]>)J>M %<=Z6H"WUL#9]+JK%RU'UQ5W#%O3
M+U1/MX[>[^E%<1-?LQE[3ZUFFV7O:Y@&WL:@!HV:8%#%)BW+;.G@_9AC5<'P
M9_RPA<SN.6".ZZ:?U@%.UPI.W[@,0[1G'IVMI/4M>,OS2AI,)C>Z6UM -;'O
MW'I+P\;?/M;4X@!K&0\%9,"\(70P8U>+W&]2S-K/8@T,=>=:8-SJCH,I;;R'
MY1#[46_E?XFN4MJDY@ER%;2<.N=V5L]-8]@::$,:/=+Y;?V\X:3@?8LY,S@Y
M\A4VI%YE>X6EFR[E3L>SMUQ:#8IF;KNT7L9ZBP7V@"Z?CZAM07&7T/XBQQ1I
M999RM-5@[D 5R^457?U;@*]T9V Y.K4#<5:5UW3TMJ[9P_R-XP7:[.2H1I-O
MP&T:?QV 2VYC]Y]#]+$T-CO$0>>,Z(^8F\J=FB51J<]@N^=_JU:9I47]:IDJ
M@ITV83\AFG306J9KY<]3!S6Q7MT$0QT[SZD;4!$\*R.!,SS0]+;?D2Y_CPI'
M\6Q$.T?L\C4[.Z^>CW0T_:B&RATI&Z:15M^';C%&.B,17#5\C72C#6FI!.M[
M#XK*1E=K9?Q5KH@E:?8FI7ER>AT<XA6U2UWRHJS/=4QG<0-^P! Y>H!MNA!:
MSNA"Z':>7I+$VKC%M@7W8>F69LHR8JXJDFD\^.R0-A5'.])"OUJIB?)XX/-E
MM+53*V)-76=;N^)J[#IR67E5(%R",^84%0@;FI=LM!\UL\7*^*<TFMHHNSM/
M U(1%6E%+MIB6OK5FQO/;O70<K0Z OGEZ0-,IFRUVI%$:7K;H9U4N/7Q\;0;
MV <L ^,P21-L->9>+LWB@,J%.QX5ET@W8S>YR(V%;$1^=;"P$3?+WA]_^XUM
MM0AI<[29] +H2, JMR0SCL<0965CZM@410+ K;+T9G:S_H:5USAH'ZX42P=2
MJ2I69ZF/RC\27)EQS,W:<F)X@=I'C' 4AH!7-*=)*0&FYLS Y[<;&<-.,[2@
MR)V;9NW5'$4>+<(&%QI^I_PF6' J4&JTS*-#MMO.?>G=FN5ZDIS?Y8 ^G7#0
M!I)N#A-MLVW&)M@1)8!@Y>4FJ!0LAJU,[0!:3-#>T-UL3I@?BTWI#^>_//U1
M,ZC)J;G""0'E9](.C1WAAMBZU5Z!,5.9I8G6:M"*8R?E68+(:_ -^$5#5GD0
MJ2:Y-(4 J?1F&0F1FC>\5$45:]6-*?X^J-;%NK2B0:Y+74]J>;9-S-8PVD==
MT(*;A+D#*J'O^5I</;&NKKFJ+J5[]/+"]!P^'Q.C$]^Z@.6QHN;;:ET5Z_7%
M.V_/9GQM.!"25=5","ABZ-MLBRT50[_S!@.#MF#2[*%PICLMPW(\F\0:,H%2
M[UAVGZJ%(J"^=LMZ]@D4B$!:(<]&#,8O26ZIW)-+HCINX[TLV3]C+"U_X;_T
M_*]1$IU]"N8+0E$!A$V2JF.WT&FH/KSDO.V4*XL5[-BPQ'"?G:#=FE03:_+4
MZI3Y:/?%=7$6BB;.:V_BK!1-G/D3:VCB7"F:.+_T)L[E\J0NSJQ9<O3OC-SK
MO#EE>I?GIM]3>4X#:=HF%^[XG'Z(\8[0E<2.T)&F_QB!H*,C>O &L*S^ET8T
MW6$FYYZ\89_P(B^9_Y$$&,M3 )7)>XNM%ELMMEIL=3NVNJK:NT4.D^5RB]8'
M+K[K!4IZ,G)(5MN^>XKE<>5A0WX&_EG_!W,?L=E5ES38$[,\%NP4OO@Y9VLF
MGM*>/4O:S^05\_/#\F=956/[W&C9/UV,##=JAXQMYN,V&D\M>*O@K?QQO%&L
MH@UT%\?<S<,K-Y@ITTWA_'>+=N1<)]-,.9_5F?=H-@M3%J*@$ 4O2Q0L:*/>
MV*1#;'O=ANFT^"4UH><[7&%O%X)@ TAW\^WM0 04)G?!7@5[Y>#.#FS2(Z:C
M/Y(Y51@M92MXK."Q@L<F[K#1:GE]SV#9WWDX[(QT]);N%BRVVRPV^Q8VB:HW
MG^_N+5<SLF">I S0O/2Z6+(KVXOCJ\RR\D>RS/<EY?,R66S1C170*:!30*>
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M.D7X;>0<C?8/SW%I! VC;K<$MNR0H[N!H>]6'$U.NTE7L$4A- KH%- IH%-
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MB8,A!!-DJ/#)\DQ7TTWA*W'< (;"G65X"%B'OPI W/"ZL"-.AZ4JK$I7H9R
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MX8?6B,S9WQO8%E(KLHO_,I17Q'#(4P_)6;,9F<#"3Y9MM",BGG^_!\+, 7C
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MLBA7%<$! F>TSZ>5W=&6+X\8,@'&TUSACSK.UE45NGGP?OI@O[I<B8P9#L?
M>PCOJLB53!_$(T*&+LC5,3S@ PK-'!UP@LA@,MM'D8[VSQ.:&:@BP KP8)E$
MY9ZFT^$Y>!IVVAS&W[HC)'X-4E0S/9"% K7^I?H$(K<Z8)_!'SF%(RXMST4]
M10DW)(.&"W) N&'R-"9(Z5]\\8DD%TCE 562!.1UCQBXN&8,N9'6(WW0AK!%
M;JX=[^\QS6P#<2)*0+J1@ /X-I JSC'P RK4;.,1+BR@ZB/VV7W/\AP\P!D:
M"[8#%*K4,4,7;NC@CVJM*M:4NO#Y[M"W!6)O!._+\-I(XBW-Z45'[?V!^;Y*
M?+4Z\'M=Q<5 K((A+OB@I.4Z\!!K.! !8P01U#.NO7:2. Q+??[ PB+,_"+?
MH^X#P0U <ZC1CLYU# $@UIJ!?1Y88Z"T6OH  *[UT76DYU#XIB+G*%?JHE*J
ML8-0Z\H?+!@.'G09H=A<4)3_!.F&\L/T^L=1PP?>:7#"&_&6;'*$K@]5<8SV
MJ(7)FTF9G,2PT K-*7S2=XNIOK>CPHNK.63SX/0,H7B/CMO\0EMW0(?KS&B$
M;_U1 8Q)<@6T+R$"BU# 5IL@.IZ8.!3Z%FCK-@$O&RU"\AO4GZF%+@Z(G\BB
M.R(Q0#9_TH -$H0%-[RNKK]QWO=M'@?($L6 .&*4!9$%H14J(BI71G&?Q H!
MV7$"1AF>),(I?0"/A-(C88=43 5+(^MP@Q^>AI<0/+(H<,U!MPC+]8F-,4/]
M&;G' F(&4@"&H[85EPXH&'WELCL4$#6+1HC T#RSU>..>D>W'9 %J$./X$M'
M+10L\!@W@47AW''0HP*N50'X2EU^C31B>JY->08=/6\P,*A=0!%HZ^B"<XHP
MT20^4 \%$BRC@6EA@=K2VP[#.GZOAT[4_E[3:@_1D 6!" ?]28ZCKQ_/4#YJ
M-D@\ )S3!RH\:FD#Y]4;M\^CD-0&;Q("].JY/1 ^S[R]'8#P)Z$1![ 9WA'-
M  G)S79JT@'YW5R![52JJ]5J>4=H(I3I%Z1I1^R)$;'.HT#4+(0_(W=)02#(
MP:D:OJ2/*CJ13;GU U)3[8^8DJ0VKR36I+)84JJBK,CXUGI%K%9D4&0E<(PC
M8:P+I%A_S@=?@4[[",-9]PFR*$(#0">ZJQEC^V!V+(OD#3#J 18("$(08!J/
MJ5!3N>P7<$6,@1TA$A <&"+Q!<>8QF\1(* VYQGNL(,X'X"T $N'ZUR,5IYJ
M1DOW^D=? -# [\)91$H<C_ <)Q;.<VI9*0/^>^!A=WN@BW109$!S$?1%MP1T
M D?U.EK+]6S"3"N'@$:BPF?*1B+Q^*:-3]*H92AQQIZ=5P+M"%6,FH-5E@U+
MEQL@OGN4@E8H/22U#/:\)*IR!=]:4<5JK2(J4BTN/>X(AB(+\5&\)8NRDVI1
M=K*^LI-:47:RA7QUC=[I4)#E)"72H6ZZQD-X:%CXF1V:-\*O?C9UC$O2M) 3
ML3C"&#E^=FK9X)L\ZK:';AY57Y;I)(OV\9>QF*+#HK(\X.!XS1^PS/Y>7W.I
M@P0LPJ.>H&ZH^A?ZED%:GL'WI9L]O:E'\ZFH'V); [O))1BN.O@$/V*XS12(
M^3S$Y"FZ1IC."LP17!,>@Y]L$FS5C[2-GZ''TJFV#FK+!9>71WJBP-\1M8,A
M4@_\3*DV@:; "P3J:".%T*PZVB -E'(&LRDNS6B$(VHR-/SG@G@<C:DE%F"(
M2 S$T%GXG'T'#@*O\!?SDX-!^_7]O3MFV&#UA>Y0OQ16C$=&T1:ZT#N QR N
M>E!GD;]#;D.(F!3@$?@_2L=2B4;TZ-]8.H.&T A&;=@9T48C5D=D1O;^GA^6
MQ0273<">1EN&A^XPA>11.*'-S-; SO&!219VDZ?&$,T0H*X*RP0",&+<!7-8
MW)0W6>X%U@AM+(!)#&HG8U 3.-"H]7>!MJD/JA! O#'U(1[B&NCCDVX8%+G!
M%9S#W;*_&H9C8;!T C=PVQHAMK\W 60A9J=CPH_X=K1'BR+RS#Z&3\'$%J[@
M!T,W-$Q6)0;+SZ]%7A( Q-\FG/W\:/#I]9?+LR-)C4AWE[1Z)G!;%],0?KC/
M3RO-NE=',"T33"23&CJ@ZT7Z 7R#@!&/O^_OL0]<&UQ+%C('^#"9"AXD0;$J
M&/HO#\L3<<M!ZFN$]XZ%<PU<6/KS/. ,"QFHN*(D*SS2TLC(VO<8P@Y2%$WJ
M-+.(FFNACQ(RUXSOI:F=YI"AD&%.\%^/_WPQL2,< ZKCC@Q<PM._"0Q#?H-*
M=ZE5TF$EJ)B@##+Y3!?<G@BGW"N\T6S7!..!U3F)PD=->(\&N"B<-E#46HR(
M\'DJ73%T H0?K]'#-34!E(C>]_J4J&3XC4DOQBP^X6*NM.F&6Q/0<N'1C]](
M"? >:J#HO\$\,=V>@SDRI!?7E^V8[75XP-QD$ML),F?X.IL8Y!$?N E35JQ(
M-ZHFPS_N[]&_QAWJL6>?X#RTBBU,$_!@L)^4JD224G1__!&AXV&"(@(%7,**
MR"SV$ZUZFIJB@Y=J?"V:46"90_ F )D<0BQ@',MN3UZ3)ZRX.4;1%'D#,\5L
ME!3EF):FBI@FPX&KNRCRB#T)>CT-1"S0">CFF(WG/EG"D&#2E*I'JOC9GUCQ
M VL_  #M8U7I*$ Q>F_B_IB'PR$0>44\A8_D3+%&#98@I.8D;!K)7<,*+M@'
M31LA<H>TF,$'Z]@SB!X,] %K4[ZP/!<+,33#'1X+#8KML3KM. ?C!H/0I<8%
M(TT!B^4*%VJHO3P69O)/H#MAO<Z.2+OQ0MC$4!YURUFI'BT_O>79M;  )&X?
MC]:3AO9QO&SO+;%@CY'U:+$=KVV)%2%\?MNXO0B*$/;WP.'!%)_I^B'"Y(4C
MC\>%#Z_^"FI)@G.P]&&?],'N9&G"4"+&&1T+B'Y2V>]:74+CF_28\"Y<@A<X
M<LG; J\-,RQ^7I(R6[2H!>&*13XMDBA,&G#2HZBC:!"M'10) <Y/+CX=W7Q4
M]O<.@(?:0?FBXQOUAT$$'2/48-VA!=]EPC%:I!G9$SH)>C]2N$DU@O]%%^'C
M3/*MF2,:@K9K:UC[$ZM5B98X!P59?MTN<^;#;#*J!0,<:M>C!:M8)XP"R+?X
MT$H!X*/49.C0#,M$N;J_]\."9XUA2(=\ SO"QA'I^[^.K_HIXOR+,4!X'80<
M]KOIL4H/EC9#G*:'P%'N8XV9:UL:DQ--S=$9)00L2 ':BE[-H=_EK#BIX!L$
M"A:(^,6=2&,'4\H[\<UIM0"' M(Z+R=F<LU EN/V++(8([^Q:QH[0@=G7N0&
M "#7?2(&X(R:>0)U46+)LOT]U(2\S(X!R-9TASY AH' &"UZBII9[: N9RP_
MPFB R@VP&7BTC%F>75/O8+V'"S:"\]-A63H/RS\P@H;/B)%:C(ZF&WY4#4QO
MK+;E<02,@7$E#7_D]P;P8U]NCT7V1DH^8B(8_@@BJL]VPQ)6P468\#0[0BIS
M7_62@ZM>=UZ_CP!$YHZ@$N]+>U0A[^_=@"AHZ63WKG]1]]H) 1"E92T @##X
M_]O[UN>VK23?[ZK2_X#*=?9*NY ,@.]DQE6T+#M,9$DCR<GD?MD"24A$# (,
M $KF_/6W'^< !R! 00^*%,VMFHU,@CBO/OW\=;=8/VK7FF"3D@.A2T^@9.TA
MH]YHKY.P9GPO-^<;EV&YA4R?0MBH- --DP]/3,5FDRZKS\!8L"F@$[#L%X%V
ME!S1!'TQ>-V%&\9E$^V&# "Z+72YB><?BA3Y@MW &2/@C/P7GQ#B3AEQ0#AH
M<0\5"@*MGY"-GM ZR*XAY([PB3HDSLF<8I.4X9 .6 ZVZF OW+W-(,5_N.]Z
MG\^[1U?:V4?MZ.SB[+3[>^_BRZ6V)YUD^]IY]_3#\>?>T3_>NAMR 14LH[12
M_D"]44)(SL(;T%K_PT0 _,RSR7!1550D*-0[X"H&0!I(>4.0>G8$!K?<.H2T
MW7A!'Q5->-X9NZ!['*7>D&@:4L9'>E_3]X-!2@%!DGO.;>#=XE.A/7&'WHRE
MRPTZ97R2.L+'+01E-HN$Z=X="W@* E;'3GCC8#KF&"8\#=F&'L//;V1X(9H@
M8Y$7@*;$_"*=%VI>,G% _!:W*WDE#3NRAZF/12H).%KJ9'!"PN\-66]$0/\@
MEJX.7@!JEF"_BVN<Y392N,*6I-)5Z\7LC05Y'$09KJ-B?&"-0U=85\.IO/.(
MY -^#.9*8MG)R2F>+/&-NAW,U'9W'+*'$WQQ7GU(U &T2_J@E; OE)4FU$1@
M_J=HR"&Y,@M..=?8'CK2?\1P;>2MDX#\*ZZ?W9S=G6*&SAFEF,*7X)4Y_+@A
M3&V31JD$&&EM 2.K XRTMX"1UWBOW'?G%[W3H][YR?$E*S^GEV<GO0_=J][9
MZ>:H.BBS;;4(U;T*/SIH*4K#0H;5Z3F_I=1_,FD=JA/F4.N"R*<@C,RV3]Y%
MPC)-^%<%7()R&"8!7)[MYF32 .E]N3Q&FCN^O.I][EX=7VX6O>5,J$(EA,\6
M#3G0?W9WV.E]6=V@"QU*4%3-389M?W40&^N."<@E4HJFXPG3&<&?;-+/A/4L
M5">A2U%L#W[@""+U7-;0I.X)*O[ "U"_%3XLG!8IX"6_B=4P6:DQF>BU<CZ@
MS8Z3:X= 9]":^2GGVP2]VA$JK-)NX%^1D4SN.=;4*4E-=2V4;PMIE?V9NI=H
M=F!D4L#D8!JXX3&6GHGB<$K3QKPH=/N[R5$G_G2:*OP@B0%@H$*Z4.UOO%_I
M , LV"$O*DO UDX]W&[,J9?AQ@ KERB+8#?L (PHG+ P$@::XX.Y$K!=A*[)
M+"YHZ& H@2%'TE6(BT*GKR]3RJ(%-+0Y3.BH>_F+!K:]1G\<_^M+[_?NR?'I
MU09QHX_"Z)/%\2]'CKRF:;TO0MK9T6AWYZ,7W,$ &"T:@4X&7(BQ.$ 6MXXT
MQHA5)9%K^&W'@ L^(WO.(S<O5R8AX!'[Z_I81R$:T8T FD^];VDP&6/(]$R?
MITI7[DVGW=';[39-^$T=4XM-I/NBZ#0]D_L471#H>9-A#+AF,<6\T?<P&&4&
M1"XPPYER BT9J,2Q8%L^](XTE,N<&VR)W&"QM^FBTL(6FW-)SB_.SH\OKOZD
MBX)WY/PS7)'-N2'GA1R;7;:B0 ]Z3H#+H[=)^"M 7H]05[OEZQ.*(DTLU=UP
M,!VC'WI 'PP1.2R!Q\C9[3"<I54=D.B0W'"<*69;H1\;I"PEC Z90EW_&B]F
M$3 #:Y$I%?3R$ WR7&LN]AL2U;3@8R)]+AS!B6,7#O[-; '!U+'C,Y8%+_((
M-I%O<1(:0JW70<@4R9ZA"$*.$7.ER'.0)\X=1A7I-8SC0A3JAMR-$L*A,%W,
M 5S,W(U@?S\H6@(%,\"D'TS9<\CEMQ@,'-IH"!]@O$@;.R#PF?92C4E1=&3A
M'9+.H"IZ#A?#X]\QI  5#?D@\5LW3.0ZG-@T<JZG'C"V6Q%>M/%G'I+:3R]\
M1JEG1?6DY#TM#YZ)XFCYX;X>-N1;>50#&S%*O?UC&1LM*0+-_IZSZVN$QAU+
M$OII855M,5C#>MQ@C8.6]B=BV![:ZZQD>Q8V.GO8U$[2<GL5]^(QZW_6U5<@
MCD?,\7=G1/D3+[OXI.KXZV;+H+(<=R].>Z>?+C507+3+7[H7QYNCKN0AHO8P
MF,B"4FDM7Q5%<(D1<3L$D? ^@/]H>Q^[E^_WM>[ED7853,!>M)J&AK6M0HK#
M 8%@]E6DO>4B,7D<K416LX21@DR8OP(HB/"F@83"HX 2GP]=#S'?XANP9<O&
M.@2#)4)3MNP!":3&&)=&KY4%5%S.+R-L.5CT0Q<FB^OR'<J0"<:.?)E]:[L>
MHX@):4A 8WH[U@[%1#6N?:5Q$S(4Z*@!WCB99Z-,,G52%T_X(3[PBA<L1$+*
MR-"8!+'(2DO6A/ (Q.NP/T74<T'?@-P'MD'D^]%]XW.. RAZ8+)X=HBZ&T.1
MA_=-9T-TLTT:I5( K+T-@*TN -;9!L!>X[URW_5.C\X^'VM7W7]O4@0"4T1!
M_H=#LN')6X?"OE4W$O!ACP7AE?W-P1)E#/L"L1[)+$$A*6-\("-24W.5/=BJ
MPW\FC$]18B[W:0J,21SAF5'ZB.J93#SRC3B^/:!,6$R0)9,@)%\T^N8X>B$B
M"\)Y!]++@=E0G$&@0]AW[I 7IN_$=QA<HRP$,(H9?UT:ZF!X$4/T\A$2B6HI
M1Q2R"Q]7,>_Q9R>I$B!) W^,=Q$ 8E8*=G<4OQ*^P[/OI-]_I@4#4 L.M6X:
M14#';7!'^T&(25+4AL)90SXMBHEX[E>$=(,NX9-[B(-"1?$)0BW!([L[?4):
M;I+_1M6D,:B$B"7:^D%PXTOH<W+*NSO),<-Q^<XU^X)M/PVCL+M%%C8(?(16
M7L=<@I5\X?+FP,'T$^ 3[SUMN<"P84X,*7@P4UN",@-9)QY+Y:.#VJ8H,86.
M/DI7CW@(CMGA0FPV@_3QU _XU _PU _@2.D+2F2,4-W5%425\-@G.Y$ JXIV
M(\DXY.LHMH8W-''^2]+1IE@1'R@K]I0T3WDKDPTH6A+5KA/+HA\D,\><XJ+K
MF$R&?+ER+:79;06>TY*SS<4NDG<3<D#F7')A8]L3.'PDE9F>%!J.2]^-U_N&
M@\#LVQMBOBKZ!BES1(8_LU,0,4"/;4(_V-VY=H;TBB#D#:%!%*K!IT(.#\8"
MI#C3YGZ4^0%P?F0L%+O&T#31WE5 3'<^-9#\SL)!C/QTEN:CRK.5V[,A# 5I
M-BD7BT?WY3+C@2U,U4?_O=E*LD30AT\_XCQ3KGV%CG<6R\IY2.-4O3@H4)1F
M*$&(>6>4JWR [Q/2E(*_%,VR-RR@^_'+Z1&BE[HGVM&7BXOCTZ,_-T>MP_O^
MY?#R4!M2Y6;*L1P18'8@LGB8"PQF2;WJ),=29B&D34&*ROXP3REZ80X[_'\C
MK:"I@)Q1\A5/=$/(2V6W!-WR6"&-"_>B%'M,N;_*,48K#+HLVV'Q(&]!]3E4
M\RN@*_[AC@0. ^3M=>.PX?H9\[SL.4L\V&FV.IDGWW5+ %)8"4"2$U<R)'^>
M;#] 11L4JR=: */B*@*J6__1&U"PUGL^6LZ(\_LH3-=TT2FH,K>5J:DZY\#-
M;F_.:9M9SFOOQ5K(OQ+GN=PNLAV5? L$G('Q*=E_LET2IB>H$4%QF9V4YBK5
M4U& KQFL*YI-FA?X-P=8$$"!%FF^30 (K@;$$$HJ\3$&JT$T&%#]\T*'$L \
MDEZA "TD^C H\0\:7">]&.=,O8G(7 _@ZB(_1Q2>CYV4D'TGFZ.^?D-D'6+C
MSDZ/CD^O+@@-3O#PB^,/O2OMHG?YVP;YRM*0F0+K9*,\B<5XL[1*82Z!"BQ[
M]!U+5 Q"8C&EBC.R999EVF#"([A<'@DGT>!#1]1308Z3,_ FGCT0VL: D'KJ
M[\F(1KR>'!V+[* ?X3JS.C>>;AB1?NR==D^/>J#N]TXOKRZ^(#+MDH!J'[N]
M"^WW[LD7@IDGS^WN* ]N#A6KE,+9O)%T-+%/E_F>$A2^P0)K0+NZAM%@$0A&
M+W';:NA*(+F7WHI#^7T*/4><*(4:7<Z@%.APX3JSW3"M[71==-%T;$V -;F*
M=2/% 25RL-6/A!\VXP#6298GU<W)"8JLF8I%40U)@7Y29J<S?&WH7&-68F[:
M=N'$)?1:N,N 6?"07%XE>8KCM/U4W1ARHTN)V%8;7@H/-28">!YWPPHYE;/,
M796%_&6GC3Q"3S6CE*VDR>S*A\J3HI$-=M,9#,*ID^+M&</.!1W$4Q&7J/_&
M>+(\L'$X35SQT2@(XPQD.+M3\/*_IP&AU[@D&!4+BZCH3.(UX@  ;_2U-T6X
M?.Q(,#+]BIYX;=SM-;RP4@BZLPU!KRP$;1G;$/2:W)8*(KI U-A28+L#AHJ#
M()#2(RFR1Z5[/(^*+E-XCHH)PJ:[7% 8Q0FF"]E*[)7#170-O%F1Q$E8+LH;
MU%))(V4OA(C8<G'G^1*%JJK!+BQ1:$BN:N2"N1T.1K,4.T9ELS%6(D3 9(H=
M'R->G1A/?07YR[C<IH=5AD1LMF]'XA4(KK_!\L9VTO56^#:3T3GJ1/6<@CL4
M)?0FZIB!XVNR)G@"""-1IV:."3FFS$O9&E&B+1WN1I:,(Z7<80N (WL4]TDB
MO4+H"6F'1\7EP?A(1+ESPNYCK;CB /+>"2W&5&<4[2<1;+GD[ R"?N2$K!"(
M(Q"OJ65?\]J$Z=8C^0"/I"0<"0J1_Q84@7X4)E#LW$L4NI?2[OXCR35I39:F
M,@BPHBQXJI0$P;R&: $WVG!7)Q^(E3L@2ST@_G-WA_5R0G3DF8HH."P8HSQD
MQAU@&F_*"J0?-!$NB1C1-<>E$89@]PW0KT88(?FO0ZTG,N7F?RJ+>T^< 6<@
M[6'6,%IE4]O;IYJ@6"8HL[:D@&YN<AA?P>;@[)3AZ!<VI4)/GJQ4@Q. _5!F
M\'V022U')C653%2.CR85?5%^W'BW$XLV)# 1?!RCI2B!#$)K2&I4+GC9_/4M
M"%1L2/8!593+VL$9YT<9W@S]&N&0<\94[2>2VS:41431>4 %R4/T1:?_)DC;
MH>*Z*7&J9-_'U?C%.W9W1%U2JD[-?AS!)51PFC(_0I;9V23[6_+4(S:M(,<W
M@]0IEA"X?2YC1H;SL\TM>%$5@(?O1O[E-O:^J[83#G8CP,SBC,LHC5)Q!<,)
MUE';%*7*?7=Z=G5\J9UW_^R^/]F@')OW01B2+<-7(8.#<X7PR=Q3A* Y7$M,
M,; P]S-*,%"'6NZU*,S(3D=Q*HB>RK*/D8JI(QZ\X&>*1:58U@R4=1(&F#@,
MBAD/#\2:'W]?*:TQ=+B$0\I<YB%^;CZ\FC0^$)5OA9SMIXM)XZR.+(2NN.T$
M)'@S* -HOGMT=/;E]*IW^DG[>':A?3B^Z/W>O>K]#A?AI-=]WSOI7?4V"4V>
M@<DRTMB1[<@#K@BBBW_> 1';7$0F%)YBJ>MQ>,!!30V3F]UK(6#2[Q'=-NX[
MPZ$C*K+[3E)U*?LD1;>N9^@SR91H)Z2I#!M[2;4E%"6HG:3 N*3Q1N2D4>$T
M'ZYM-@[JAJY]2%ZNAD'H/OWB#&'C;G["8I9B5G!_CLF02>H<GMWYE,@J0M,"
M%RZZ9Z!T2>OZI'UXDIA!8BA5"D@@1-_#JKB<Y!\1G#N9OAJYX!0Y4M^&!W%P
MP(H< 4](AA4 ZCF97RHHD>I?HH94=/5ON8;Y_*0%FRGX,4<N!'Z &AUA]<CY
M7PG6I/"D:[46 6)BB-@$[TJ(3X0N-H3W?)D$LD5-).IT.M^P#WLD"*/PP$5V
M1Y94^/1S&HR=E*#/-%01XL/GLYT[UY3H,+HFJ+TPJHX3$3I4*D:S1"LJ+-%S
M?8<%45KQ/!U-M.+C&YV_N%)F9V:F4!V%MF3<;OZ"Y79+. [GQI[WAB;<;<@+
M\*EM0G%7&P5(K^(.$-_.AQ"Z5!:6S"KE7!66L:@*#H8%-X3J,9W[7U]Z5W]F
M0OR]R\LOQQ^TJS.>A';\^?SD[,_CX\O='9#)IV>G!\DG)*6[\(H+%-F?SLX^
M7&KPR>7QQ>^]HTT3U"2'#_I4[ N%*+ _)E?!"HF>N'D%Z()>,'-D1-@_2#^X
MHVQQ-\E#\&:YN+N=JU4BTJEN$_D*]S@""M;0YX 1C:SN2 /0Y<&2TKG2B.3G
M*5L&\A@QS5P%O323) MZ2+E#RVSKHBO'>WKSD?+F0\R3KS)HMINDJ@;)SBPL
M+6&#W('2RW'.D%@DTL@03R .P)U2%C574H]&S<5EU+V<KUHGFQ7"NM1S%P&(
M3.)@+C6P:$=YIDF$!6=ZD&&FW )AQJ!S.8G7QIU>PPNK1.E;QC9*O[HHO;F-
MTJ_);2G7-MYW+WM'A"'\T#OY<@5:QNGQE?:IVSO5]D[.+B_W-[VJC$CUCN8K
MKBC2012L15E@-<%6/I8%1?#Y2R[A(KY,X8)JWQ24#H3]HUHQHK9LKCA).K;L
M0'=\?IETPV.! [:]/5 4]ZSWZK6)F3*').V14L%F#\]F7ST<M:8<J ^YPC?B
M^5P]FX-[Z]FD!6R4P4M&+:FV0Y-YV*BJ4U]HCJF/$5TET32<"=U+U!80T:?X
M+C@@0TU\KO3^I+I[E/[.I75N'8)6JH#NI)XASIY1_TE<B_(G'1_=$?,VEQ]D
MT.)R +5P#[7_EL%8RN)F\$JF?-*"&R""XZ(["&.#E-H!V-@P6==F$#UE<Z#
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M#DQK=T>(1+7:E[8G?'=U8_\G[1*[XL&;);DKK490&*@_/)0RDYIW)CP;KDN
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MG9HE\MH6VX\J6+VIU^&W5J?)BA58L_#/3L>8,WZES@(?"O"?1]X^GF0"!18
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MTH60^@Y^6G8(X?X'7S*@L9W-\\[FA? 6=6,1WB+KEGQ19$+^<1G*>Q2HHO@
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M8-1FW:A"O+5F0V^U6Z7$6S-,O=/:(/;[T>F'1"R-95)OK:77&Q6I-_'"&\_
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ML"3)&DEB^ =2=&&988(R:NXU_))5<(*B,OW-B4Y+V\.9X+"6\?.50!"B+/D
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MF+\B&I)]46K*V[Z$2A9,/^>):A2:H),)$&$*WKR>2J8%LAWGKTPWL1!I7"1
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M^(4V&#EC3 Y%.Q8;,*GR.#-2DE":S2"?3,,!6'*.<#+*]CMB >2&:@OLOY)
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MR2("  (8% !02P$"%  4   (" #'BT-4)I"T>JL;  #@'   #0
M            :6UA9V5?,# Q+FIP9U!+ 0(4 !0   @( ,>+0U07"GXW#B<
M $DN   -                 -8;  !I;6%G95\P,#<N:G!G4$L! A0 %
M" @ QXM#5,641MB,*   FC0   T                 #T,  &EM86=E7S P
M."YJ<&=02P$"%  4   (" #'BT-4O0I^O6!#  "02   #0
M  #&:P  :6UA9V5?,# Y+FIP9U!+ 0(4 !0   @( ,>+0U1;386=/B4  -<E
M   -                 %&O  !I;6%G95\P,3 N:G!G4$L! A0 %   " @
MQXM#5+=1';H<!P  RSP  !$                 NM0  '-B9FTM,C R,3 Y
M,S N>'-D4$L! A0 %   " @ QXM#5)YK2[<I"P  .HD  !4
M    !=P  '-B9FTM,C R,3 Y,S!?8V%L+GAM;%!+ 0(4 !0   @( ,>+0U3W
M4C)5]1(  *TN 0 5                 &'G  !S8F9M+3(P,C$P.3,P7V1E
M9BYX;6Q02P$"%  4   (" #'BT-4]'[@[)HL  !.= ( %0
M  ")^@  <V)F;2TR,#(Q,#DS,%]L86(N>&UL4$L! A0 %   " @ QXM#5/!(
MJ9];'P  "@$" !4                 5B<! '-B9FTM,C R,3 Y,S!?<')E
M+GAM;%!+ 0(4 !0   @( ,>+0U3(W?J!C@8  -4Q   2
M .1& 0!S=6YS:&EN95]E>#$P-RYH=&U02P$"%  4   (" #'BT-4?;R'^)X"
M   +"0  $P                "B30$ <W5N<VAI;F5?97@Y.3 Q+FAT;5!+
M 0(4 !0   @( ,>+0U0?OM[%J (  ,((   3                 '%0 0!S
M=6YS:&EN95]E>#DY,#(N:'1M4$L! A0 %  (" @ Z(M#5$ \OR/)(@(  A@4
M !$                 2E,! '-U;G-H:6YE7W,Q83(N:'1M4$L%!@     .
-  X <P,  %)V P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
